---
document_datetime: 2023-09-21 20:12:32
document_pages: 150
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-3726-ii-0035-epar-assessment-report-variation_en.pdf
document_name: lynparza-h-c-3726-ii-0035-epar-assessment-report-variation_en.pdf
version: success
processing_time: 172.295796
conversion_datetime: 2025-12-24 06:15:32.535264
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

17 September 2020 EMA/523504/2020 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Lynparza

International non-proprietary name: olaparib

Procedure No. EMEA/H/C/003726/II/0035

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                                                        | 9                                                                                                         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                                                          | ..................................................................................................9       |
| 1.2. Steps taken for the assessment of the product                                                                                                              | ........................................................9                                                 |
| 2. Scientific discussion..............................................................................                                                          | 10                                                                                                        |
| 2.1. Introduction ......................................................................................................                                        | 10                                                                                                        |
| 2.1.1. Problem statement                                                                                                                                        | .......................................................................................... 10             |
| 2.1.2. About the product ...........................................................................................                                            | 12                                                                                                        |
| 2.2. Non-clinical aspects............................................................................................                                           | 14                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                                                       | 14                                                                                                        |
| 2.2.2. Discussion and conclusion on non-clinical aspects................................................                                                        | 14                                                                                                        |
| 2.3. Clinical aspects                                                                                                                                           | .................................................................................................. 14     |
| 2.3.1. Introduction....................................................................................................                                         | 14                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                                                         | ............................................................................................ 16           |
| 2.3.3. Pharmacodynamics..........................................................................................                                               | 20                                                                                                        |
| 2.3.4. Discussion on clinical                                                                                                                                   | pharmacology................................................................... 23                        |
| 2.3.5. Conclusions on clinical pharmacology.................................................................                                                    | 25                                                                                                        |
| 2.4. Clinical efficacy                                                                                                                                          | .................................................................................................. 25     |
| 2.4.1. Dose response study........................................................................................                                              | 25                                                                                                        |
| 2.4.2. Main study                                                                                                                                               | ..................................................................................................... 25  |
| 2.4.3. Discussion on clinical efficacy............................................................................                                              | 81                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy                                                                                                                     | .................................................................... 88                                   |
| 2.5. Clinical safety                                                                                                                                            | .................................................................................................... 89   |
| 2.5.1. Discussion on clinical safety............................................................................                                                | 136                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................                                                 | 141                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                                                               | ................................................................................................... 141   |
| 2.6. Risk management plan                                                                                                                                       | ..................................................................................... 141                 |
| 2.7. Update of the Product information......................................................................                                                    | 143                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                                                              | 144                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................                                              | 144                                                                                                       |
|                                                                                                                                                                 | 144                                                                                                       |
| 3.1.1. Disease or condition ...................................................................................... 3.1.2. Available therapies and unmet medical | need..................................................... 144                                             |
| 3.1.3. Main clinical studies.......................................................................................                                             | 144                                                                                                       |
| 3.2. Favourable effects............................................................................................                                             | 145                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                                                          | 145                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................                                              | 146                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                                                                   | ....................................... 146                                                               |
| 3.6. Effects Table....................................................................................................                                          | 147                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                                                      | 148                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                                                            | 148                                                                                                       |
| 3.7.2. Balance of benefits and risks                                                                                                                            | .......................................................................... 149                            |
| 3.7.3. Additional considerations on the benefit-risk balance                                                                                                    | ......................................... 149                                                             |
| 3.8. Conclusions                                                                                                                                                | ..................................................................................................... 149 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations  ............................................................................... 150

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ACMG

American College of Medical Genetics and Genomics

ADR

Adverse drug reaction

AE(s)

Adverse event(s)

AESIs

Adverse events of special interest

ALT

Alanine aminotransferase

ARCAGY

Association de Recherche sur les Cancers dont GYnécologiques

AST

Aspartate aminotransferase

AUC

Area under plasma concentration-time curve

AUCss

Area under plasma concentration-time curve during any dosing interval at steady

state

BCRP

Breast Cancer Resistance Protein

bd

Twice daily

BICR

Blinded independent central review

BRCA

Breast cancer susceptibility gene

BRCAm

gBRCA or sBRCA mutated/mutation

BRCA wt/VUS

gBRCA and sBRCA wild type/variant of uncertain significance

CA-125

Cancer antigen-125 (tumour biomarker)

CDS

Core Data Sheet

CDx

Companion diagnostic

CHMP

Committee for Medicinal Products for Human Use

CI

Confidence interval

CLIA

Clinical Laboratory Improvement Amendments

Cmax (Cmax,ss)

Maximum plasma concentration (at steady state)

Cmin (Cmin,ss)

Minimum plasma concentration (at steady state)

CR

Complete response

CrCL

Creatinine clearance

CRF

Case report form

CSR

Clinical study report

CTCAE

Common Terminology Criteria for Adverse Events

CTD

Common technical document

CYP

Cytochrome P450

DCO

Data cut-off

<div style=\"page-break-after: always\"></div>

| DDI         | Drug-drug interaction                                                                                         |
|-------------|---------------------------------------------------------------------------------------------------------------|
| ECOG        | Eastern Cooperative Oncology Group                                                                            |
| eCRF        | Electronic case report form                                                                                   |
| EMA         | European Medicines Agency                                                                                     |
| ENGOT       | European Network for Gynaecological Oncological Trial groups                                                  |
| EORTC       | European Organisation for Research and Treatment of Cancer                                                    |
| EU          | European Union                                                                                                |
| FAS         | Full Analysis Set                                                                                             |
| FDA         | Food and Drug Administration                                                                                  |
| FIGO        | Fédération Internationale de Gynécologie Obstétrique (International Federation of Gynaecology and Obstetrics) |
| gBRCA       | Germline BRCA                                                                                                 |
| gBRCAm      | Germline BRCA mutated                                                                                         |
| gBRCAwt/VUS | Germline BRCA wild type/variant of uncertain significance                                                     |
| GCIG        | Gynecologic Cancer InterGroup                                                                                 |
| GCP         | Good Clinical Practice                                                                                        |
| Gmean       | Geometric mean                                                                                                |
| GOG         | Gynecologic Oncology Group                                                                                    |
| h           | Hours                                                                                                         |
| HER2        | Human epidermal growth factor receptor 2                                                                      |
| HR          | Hazard ratio                                                                                                  |
| HRQoL       | Health-related quality of life                                                                                |
| HRR         | Homologous recombination repair                                                                               |
| HRRm        | Homologous recombination repair gene mutated/mutations                                                        |
| IC50        | Half maximal inhibitory concentration                                                                         |
| IC90        | 90% inhibitory concentration                                                                                  |
| ICH         | International Council for Harmonisation                                                                       |
| IDMC        | Independent Data Monitoring Committee                                                                         |
| IDS         | Interval debulking surgery                                                                                    |
| ILD         | Interstitial lung disease                                                                                     |
| INCa        | Institut National du Cancer                                                                                   |
| IND         | Investigational new drug                                                                                      |
| ITT         | Intention-to-treat                                                                                            |
| iv          | Intravenous                                                                                                   |

<div style=\"page-break-after: always\"></div>

| IVD    | In vitro diagnostic                                    |
|--------|--------------------------------------------------------|
| IVIVc  | in vitro-in vivo correlation                           |
| IVRS   | Interactive voice response system                      |
| Ka     | Absorption rate constant                               |
| LOH    | Loss of heterozygosity                                 |
| MATE   | Human Multi-Drug and Toxin Extrusion Transporter       |
| MCV    | Mean corpuscular volume                                |
| MDS    | Myelodysplastic syndrome                               |
| MedDRA | Medical Dictionary for Regulatory Activities           |
| MTP    | Multiple testing procedure                             |
| NCCN   | National Comprehensive Cancer Network                  |
| NDA    | New Drug Application                                   |
| NE     | Not estimable                                          |
| NED    | No evidence of disease                                 |
| NR     | Not reported                                           |
| OAT    | Organic anion transporter                              |
| OATP   | Organic anion-transporting polypeptide                 |
| OCT    | Organic cation-transporter                             |
| ORR    | Objective response rate                                |
| OS     | Overall survival                                       |
| PARP   | Polyadenosine 5'diphosphoribose polymerase             |
| PBPK   | Physiologically-based pharmacokinetic                  |
| PBRER  | Periodic benefit-risk evaluation report                |
| PD     | Pharmacodynamic                                        |
| PFS    | Progression-free survival                              |
| PFS2   | Time from randomisation to second progression or death |
| P-gp   | P-glycoprotein                                         |
| PK     | Pharmacokinetic                                        |
| PR     | Partial response                                       |
| PRO    | Patient reported outcomes                              |
| PSR    | Platinum-sensitive relapsed                            |
| PT     | Preferred term                                         |
| QC     | Quality control                                        |

<div style=\"page-break-after: always\"></div>

| QLQ-OV28    | Quality of Life Questionnaire for Ovarian Cancer                                                                                  |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------|
| QLQ-C30     | Quality of Life Questionnaire Core 30 item module                                                                                 |
| QSR         | Quality Systems Regulation                                                                                                        |
| QT wave     | ECG interval measured from the beginning of the QRS complex to the end of the                                                     |
| QTc         | QT interval corrected for heart rate                                                                                              |
| QTcF        | QT interval corrected for heart rate using Fridericia correction                                                                  |
| QTcI        | QT interval corrected for heart rate using individual-specific correction                                                         |
| RECIST      | Response Evaluation Criteria in Solid Tumours                                                                                     |
| SAE         | Serious adverse event                                                                                                             |
| SAP         | Statistical analysis plan                                                                                                         |
| SAS         | Safety Analysis Set                                                                                                               |
| sBRCA       | Somatic BRCA (BRCA variant found in the tumour but not in the germline)                                                           |
| sBRCAm      | Somatic BRCA mutated/mutation                                                                                                     |
| sBRCA VUS   | Somatic BRCA variant of uncertain significance                                                                                    |
| sd          | Standard deviation                                                                                                                |
| SmPC        | Summary of Product Characteristics                                                                                                |
| t1/2        | Half life                                                                                                                         |
| tBRCA       | Tumour BRCA (mutations detected in the tumour)                                                                                    |
| tBRCAm      | Tumour BRCA mutated/mutation                                                                                                      |
| tBRCAwt/VUS | Tumour BRCA wild type/variant of uncertain significance                                                                           |
| TDT         | Time to discontinuation of treatment or death (defined as time from randomisation to discontinuation of study treatment or death) |
| TEAE        | Treatment emergent adverse event                                                                                                  |
| TFST        | Time from randomisation to start of first subsequent therapy or death                                                             |
| TIM-1       | TNO Intestinal Model                                                                                                              |
| tmax        | Time to reach maximum concentration                                                                                               |
| TOI         | Trial outcome index                                                                                                               |
| TSST        | Time from randomisation to start of second subsequent therapy or death                                                            |
| UGT         | UDP-glucuronosyltransferase                                                                                                       |
| ULN         | Upper limit of normal                                                                                                             |
| US/USA      | United States/United States of America                                                                                            |
| USPI        | United States Prescribing Information                                                                                             |
| VEGF        | Vascular endothelial growth factor                                                                                                |

<div style=\"page-break-after: always\"></div>

vs Versus VUS Variant of uncertain significance wt Wild type

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AstraZeneca AB submitted to the European Medicines Agency on 21 November 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected     |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|----------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II, IIIA and IIIB |

Extension of indication to include the use of Lynparza tablets in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy with bevacizumab. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC are updated. The PL is updated accordingly. In addition, sections 4.4 and 4.8 of the SmPC for Lynparza hard capsules are revised based on updated safety data analysis. Furthermore, the PI is brought in line with the latest QRD template version 10.1. The RMP version 19 has also been submitted.

The variation requested amendments to the Summary of Product Characteristics, Annex II, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0262/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0262/2018 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

Co-Rapporteur:

Koenraad Norga

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 21 November 2019  |
| Start of procedure:                                  | 28 December 2019  |
| CHMP Co-Rapporteur Assessment Report                 | 21 February 2020  |
| CHMP Rapporteur Assessment Report                    | 21 February 2020  |
| PRAC Rapporteur Assessment Report                    | 28 February 2020  |
| PRAC Outcome                                         | 12 March 2020     |
| CHMP members comments                                | 16 March 2020     |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 20 March 2020     |
| Request for supplementary information (RSI)          | 26 March 2020     |
| CHMP Rapporteur Assessment Report                    | 5 June 2020       |
| PRAC Rapporteur Assessment Report                    | 29 May 2020       |
| PRAC Outcome                                         | 11 June 2020      |
| CHMP members comments                                | 15 June 2020      |
| Updated CHMP Rapporteur Assessment Report            | 19 June 2020      |
| Request for supplementary information (RSI)          | 25 June 2020      |
| PRAC Rapporteur Assessment Report                    | n/a               |
| CHMP Rapporteur Assessment Report                    | 4 September 2020  |
| CHMP members comments                                | 7 September 2020  |
| Updated CHMP Rapporteur Assessment Report            | 11 September 2020 |
| Opinion                                              | 17 September 2020 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The initially applied indication is for Lynparza in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of firstline platinum-based chemotherapy in combination with bevacizumab.

<div style=\"page-break-after: always\"></div>

## Epidemiology

Ovarian cancer is the leading cause of death from gynaecological cancers in the US and Europe, ranking as the fifth most common cause of cancer death in women (American Cancer Society 2019, Ferlay et al 2013). In 2019, it is estimated that there will be 22,530 newly diagnosed ovarian cancer cases in the US and approximately 13,980 women will die from ovarian cancer (American Cancer Society 2019). Across Europe, the estimated age standardised rate of newly diagnosed ovarian cancer cases in 2020 is 15.5/100,000 and the mortality is 10.3/100,000 (ECIS 2020).

The disease is predominantly diagnosed in post-menopausal women over 50 years of age (&gt;80%) and the aetiology is unknown although family history and a woman's reproductive history are important risk factors (Ledermann et al 2013). Family history (patients having 2 or more first degree relatives with ovarian cancer) including linkage BRCA1 and BRCA2 genotypes is associated with early-onset disease.

Ovarian cancer remains one of the most difficult cancers to diagnose at an early curable stage; 75% of patients present with advanced disease at initial diagnosis (Stage III or IV) (Hennessy et al 2009). Most patients die from their disease, with 5-year survival rates of only 29% for advanced stages (American Cancer Society 2019, Siegel et al 2019).

## Biologic features

More than 90% of malignant ovarian tumours are of epithelial origin, designated epithelial ovarian cancer (EOC). The most common and most lethal EOC is high-grade serous carcinoma (HGSC).

High grade epithelial ovarian cancers have two principal phenotypic characteristics that suggests PARP inhibitor sensitivity. Firstly, epithelial ovarian cancers are highly responsive to platinum-based chemotherapy. Underpinned by a similar dependence on HRR for the repair of platinum-induced DNA damage, in the relapsed setting, platinum sensitivity has been demonstrated as a useful biomarker of PARP inhibitor sensitivity (Gelmon et al 2011, Ledermann et al 2012). Secondly, using known measures of HRR-deficiency, approximately 50% of high grade serous ovarian cancers are expected to be HRRdeficient at diagnosis (Konstantinopoulos et al 2015). HRR-deficiency in ovarian tumours can arise through a number of different mechanisms including loss of function mutations in genes that encode proteins with essential roles in HRR (including BRCA1 and BRCA2) as well as epigenetic silencing of HRR genes (Kondrashova et al 2018).

## Clinical presentation, diagnosis and stage/prognosis

Ovarian cancer is often asymptomatic in the early stages and is, therefore, first detected in advanced stages, when prognosis is poor. For women who do experience symptoms in the early stages, ovarian cancer is sometimes misdiagnosed because the majority of symptoms are nonspecific. These symptoms may overlap those of gastrointestinal and other diseases, and as a result, many patients may be treated incorrectly for months or years.

The 5-year overall survival (OS) rate in advanced ovarian cancer patients decreases from 42% for Stage IIIA, 32% for Stage IIIC, and 19% for Stage IV.

## Management

Cytoreductive surgery and platinum-based chemotherapy are considered treatments of choice for patients with newly diagnosed advanced ovarian cancer (NCCN Ovarian 2019, Karam et al 2017, Ledermann et al 2013). Even though most newly diagnosed advanced ovarian cancer patients achieve complete response

<div style=\"page-break-after: always\"></div>

at the end of first line treatment, approximately 70% relapse within the first three years of diagnosis (Ledermann et al 2013). Once ovarian cancer relapses, the disease becomes largely incurable.

The vascular endothelial growth factor (VEGF) inhibitor bevacizumab, given in combination with carboplatin and paclitaxel followed by bevacizumab as maintenance, is the first biological treatment to be approved in the first line ovarian cancer treatment setting. The approval of bevacizumab in EU was based on the primary analysis of the GOG-0218 (Bevacizumab SmPC 2018, Burger et al 2011) and ICON7 (BO17707) (Perren et al 2011, Oza et al 2015) studies.

Most recently, results of the SOLO1 trial led to the approval of olaparib as first targeted maintenance treatment for newly diagnosed advanced BRCAm ovarian cancer patients in the EU in June 2019. The results from SOLO1 demonstrated a substantial 70% reduction in risk of disease progression or death (HR 0.30; 95% CI 0.23 to 0.41).

## 2.1.2. About the product

Olaparib,  is  a  potent  oral  human  PARP  inhibitor  that  exploits  deficiencies  in  DNA  repair  pathways  to preferentially target cancer cells carrying such deficiencies. Dysfunctional HRR in tumour cells results in reliance on error-prone repair pathways, leading to an accumulation of DNA damage and cell death in tumour cells.

Lynparza is approved in EU for the treatment of ovarian cancer, breast cancer and adenocarcinoma of the pancreas.

Lynparza presented as tablet formulation is currently indicated in the following indications for the treatment of ovarian cancer:

-As monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-  mutated  (germline  and/or  somatic)  high-grade  epithelial  ovarian,  fallopian  tube  or  primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinumbased chemotherapy.

-As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed highgrade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

The recommended dose of Lynparza in monotherapy is 300 mg (two 150 mg tablets) taken twice daily, equivalent to a total daily dose of 600 mg. The 100 mg tablet is available for dose reduction.

The  initially  claimed  indication  was  for  olaparib  (300  mg  twice  daily  [bd],  tablet  formulation)  for  the following indication:

'Lynparza in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in  response  (complete  or  partial)  following  completion  of  first-line  platinum-based  chemotherapy  with bevacizumab'.

Pre-clinical data have suggested a potential clinical synergistic benefit may be achieved when combining VEGF and PARP inhibitors, as there have been multiple observations around the impact of hypoxia on cell stress, including the DNA damage response and specifically inhibition of HRR.

The clinical rationale for investigating the role of the combination of olaparib/bevacizumab in the PAOLA-1 trial was based on available non-clinical and clinical data to combine two effective targeted treatments in ovarian cancer after completion of platinum based chemotherapy, in the first line maintenance setting

<div style=\"page-break-after: always\"></div>

where  improvement  in  clinical outcomes  can  be  most  impactful  to  patients  with  significant  delay  in progression and relapse and potentially improvement in cure rates.

## The recommended indication by CHMP is as follows:

Lynparza in combination with bevacizumab is indicated for the:

- maintenance  treatment  of  adult  patients  with  advanced  (FIGO  stages  III  and  IV)  high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial)  following  completion  of  first-line  platinum-based  chemotherapy  in  combination  with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).

Before Lynparza with bevacizumab treatment is initiated for the first-line maintenance treatment of EOC, FTC  or  PPC,  patients  must  have  confirmation  of  either  deleterious  or  suspected  deleterious  BRCA1/2 mutation and/or genomic instability determined using a validated test.

The recommended dose of Lynparza in combination with bevacizumab is 300 mg (two 150 mg tablets) taken twice daily,  equivalent  to  a  total  daily  dose  of  600 mg.  The  100 mg  tablet  is  available  for  dose reduction.

When Lynparza is used in combination with bevacizumab for the first-line maintenance treatment of highgrade  epithelial  ovarian,  fallopian  tube,  or  primary  peritoneal  cancer  following  completion  of  first-line platinum-based therapy with bevacizumab, the dose of bevacizumab is 15 mg/kg once every 3 weeks. Please refer to the full product information for bevacizumab (see section 5.1).

Patients can continue treatment with Lynparza until radiological disease progression, unacceptable toxicity or for up to 2 years if there is no radiological evidence of disease after 2 years of treatment. Patients with evidence of disease at 2 years, who in the opinion of the treating physician can derive further benefit from continuous Lynparza treatment, can be treated beyond 2 years. Please refer to the product information for bevacizumab for the recommended overall duration of treatment of a maximum of 15 months including the periods in combination with chemotherapy and as maintenance (see section 5.1).

## Detection of BRCA1/2 mutations

Genetic testing should be conducted by an experienced laboratory using a validated test. Local or central testing of blood and/or tumour samples for germline and/or somatic BRCA1/2 mutations have been used in different studies. DNA obtained from a tissue or blood sample has been tested in most of the studies, with testing of ctDNA being used for exploratory purposes. Depending on the test used and the international classification consensus, the BRCA1/2 mutations have been classified as deleterious/suspected deleterious or pathogenic/likely pathogenic. Homologous recombination deficiency (HRD) positive status can be defined by detection of a BRCA1/2 mutation classified as deleterious/suspected deleterious or pathogenic/likely pathogenic. Detection of these mutations could be combined with positive HRD score (below) to determine HRD positive status.

## Detection of genomic instability

HR deficiency-associated genomic alterations that have been investigated in Paola-1 include genome-wide loss of heterozygosity, telomeric allelic imbalance and large scale transition, which are continuous measures with pre-defined criteria and score. Composite genomic instability score (GIS, also called HRD score) is determined when the combined measures and respective scores are used to assess the extent of specific genomic aberrations accumulated in tumour cells. Lower score defines lower likelihood of HR deficiency of tumour cells and higher score determines higher likelihood of HR deficiency of tumour cells

<div style=\"page-break-after: always\"></div>

at the time of the sample collection relative to exposure to DNA damaging agents. Validated cut-offs should be used to determine GIS positive status.

HRD positive status can be defined by a composite GIS score for HR deficiency-associated genomic alterations tested by an experienced laboratory using a validated test.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP (see discussion on non-clinical aspects).

## 2.2.1. Ecotoxicity/environmental risk assessment

The risk of an adverse environmental impact from the use of the drug substance olaparib has already been evaluated and approved by the EMA (EMEA/H/C/003726). The present submission seeks approval for a change to the ovarian cancer indication, to register Lynparza, in combination with bevacizumab, for the maintenance treatment of adult patients with advanced, high-grade epithelial ovarian, fallopian tube or primary  peritoneal  cancer  who  are  in  response  (complete  response  or  partial  response)  to  first  line platinum-based chemotherapy with bevacizumab.

Although the indication has been amended, potentially increasing the patient population contributing to environmental exposure, the dose has not changed, and the indication and patient population used in the original  environmental  risk  assessment  (ovarian  cancer)  is  considered  sufficiently  broad  to  cover  the proposed indication change for this variation. The approval of this variation will have no significant effect on the predicted environmental exposure concentration presented in the original indication. Therefore, in accordance with the European Medicines Agency guidance (CHMP 2006 and CHMP 2016), an environmental risk assessment for olaparib has not been provided with this variation.

## 2.2.2. Discussion and conclusion on non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP. Both olaparib and bevacizumab have an indication in the first line maintenance treatment of ovarian cancer patients. The contribution of olaparib in the combination is assessed as add-on therapy to bevacizumab used in both arms concurrently with chemotherapy and in maintenance setting as indicated in the SmPC.

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of olaparib.

Considering the above data, olaparib is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were

<div style=\"page-break-after: always\"></div>

carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

<!-- image -->

| Type of study                                                          | Study identifier                                                       | Location ofStudy Reportin Module5                                      | Objective(s) of the study                                                                                                                                                                                                                                                                                                                                                     | Study Design and Type of Control                                                 | Test Products, Dosage Regimen, Routeof Administration                                 | Number of Subjects randomised/ treated                                 | Healthy Subjects or Diagnosis of Patients                                                                                                                                                                                                                                                                                                                                                          | Duration of Treatment                                                                                                                                                                                                                                                                                                                                                                                                                              | Study Status; Type of Report                                            |
|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication                                                                                                                                                                                                                                                                                                        | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication           | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication                | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication                                                                                                                                                                                                                                                                                                                             | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication                                                                                                                                                                                                                                                                                                                                                                             | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication  |
| Efficacy, Safety                                                       | D0817C00003 (PAOLA-1)                                                  | 5.3.5.1                                                                | To determine the efficacy ofolaparibvs placebo added to bevacizumabbyPFS, progression byRECIST timetoearliest or CA-125 or death, TFST, PFS2, TSST, and OS. Tocompare the effects ofolaparib maintenance compared with placebo on HRQoL and PROs, withconsideration of patient preference. To assess the safety and tolerabilityofolaparib maintenance compared with placebo. | Phase III double-blind, randomised, placebo-controlled|Bevacizumab15 multicentre | Olaparib 300 mg bd tablet (oral) mg/kg ofbody weight every3 weeks for 15 months (iv). | 806/802                                                                | Patients with newly diagnosed, advanced (FIGO Stage IIB-IV) or high grade highgrade serous endometrioid ovariancancer, primary peritoneal cancer and/orfallopian tube cancer who are in CR or PR following completion of first line platinum-taxane chemotherapy based and bevacizumab. Patientswith other epithelial non-mucinous histologywere also eligible provided they had a gBRCA mutation. | Patients were to starttreatment with olaparib or matching placebo tablets at least3weeks andno more than 9weeks after theirlast dose of chemotherapy. Patients could continue olaparib or placebo for2 years or until disease progression as per modified RECIST 1.1 as assessed by the investigator. Patients who in the opinion of the investigator, in discussion with the Sponsor, could derive further benefitfrom continued treatment, could | Ongoing, full CSR (Final PFS analysis and interim PFS2 and Os analysis) |

| betreated  beyond 2years.  Bevacizumab  was tobedosed  foradurationof  15months in  total/22 cycles in  total (including  combination  with platinum-  based  chemotherapy)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PatientPKandInitialTolerabilityStudyReports   | PatientPKandInitialTolerabilityStudyReports   | PatientPKandInitialTolerabilityStudyReports   | PatientPKandInitialTolerabilityStudyReports                                                                                                                                                                                                                 | PatientPKandInitialTolerabilityStudyReports                                                                                                                                             | PatientPKandInitialTolerabilityStudyReports                                                                                                                                                                                                         | PatientPKandInitialTolerabilityStudyReports   | PatientPKandInitialTolerabilityStudyReports   | PatientPKandInitialTolerabilityStudyReports                                                                                                | PatientPKandInitialTolerabilityStudyReports   |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| PK, safety                                    | D0810C00022                                   | 5.3.3.2                                       | To determine the safety andtolerability of twice daily oral doses of olaparib when administered in combinationwith bevacizumab to patients with advanced solid tumours. Tocompareexposure to olaparib when given alone and in combination with bevacizumab. | Phase I study to assess the safety and tolerability of olaparib when used in combinationwith bevacizumab (Avastin) in patients with advancedsolid tumours.Open label dual-centre study. | Cohort 1: olaparib 100 mg capsule bd (2 x 50 mg) starting on Day 1 (oral); bevacizumab10 mg/kg iv every 14 days (cycle) starting onDay8 Cohort 2: olaparib 200 mg capsule bd (4 x 50 mg) starting on Day 1 (oral); bevacizumab 10 mg/kg iv every 14 | 12/12                                         | Patients with advanced solid tumours          | Olaparib capsule bd starting on Day 1; bevacizumab 10 mg/kg iv every 14 days (cycle) startingonDay8 and continued for a minimum of2 cycles | Complete, full CSR                            |
|                                               |                                               |                                               |                                                                                                                                                                                                                                                             |                                                                                                                                                                                         | days (cycle) starting on Day 8 Cohort 3: olaparib 400 mg capsule bd (8 x 50 mg) starting on Day 1 (oral); bevacizumab 10 mg/kg iv every 14 days (cycle) starting on Day 8                                                                           |                                               |                                               |                                                                                                                                            |                                               |

## 2.3.2. Pharmacokinetics

## Introduction

The proposed application is mainly based on data from the pivotal study, PAOLA-1. In addition to the original package, one additional phase I clinical study (study D0810C00022) has been submitted to support the proposed indication with the aim to assess the safety and tolerability of olaparib in combination with bevacizumab and to compare exposure to olaparib when given alone and in combination with bevacizumab.

## Main PK properties of olaparib (ADME)

Olaparib  is  a  biopharmaceutics  classification  system  class  IV  compound  possessing  low  solubility  and moderate permeability. The commercial tablet dose and strengths are 2 x 150 mg tablets for 300 mg bd with the 100 mg strength tablet available to support dose reductions. It is also recommended that olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided.

PK parameters associated with rich PK sampling data, fasting conditions, olaparib as monotherapy and in normal renal and hepatic function groups are summarized below.

- Olaparib  was  rapidly  absorbed  following  oral  dosing  in  fasting  conditions,  with  peak  plasma concentrations observed typically after 1.5 hours post-dose and declined in a biphasic manner. After 300 mg single dose, the arithmetic mean values of elimination half-life (t1/2) and apparent clearance (CL/F) were respectively 14.9 hours (SD of 8.2 hours) and 7.40 L/h (SD of 3.9 L/h). The pooled tablet population PK analyses characterised the absorption phase of olaparib as a sequential zero- and first-order absorption and showed a significant impact of olaparib tablet strength on the absorption rate constant.
- Co-administration of olaparib tablet formulation with a high fat meal showed minimal impact on AUC (8% increase), the observed effect was a result of decrease in absorption rate: olaparib median time to reach maximum concentration (tmax) was 4 hours and mean Cmax was reduced by 21% compared to fasted  data.  These  changes  are  not  considered  to  be  clinically  relevant,  therefore  the  olaparib  tablet formulation can be given with or without food.
- Olaparib exhibited a high apparent volume of distribution (Vz/F) of 158 L (SD of 136). The plasma protein binding in vitro was moderate (81.9% at clinically relevant concentrations of 10 μ g/mL).

<div style=\"page-break-after: always\"></div>

· Following  single  dosing,  exposure,  measured  by  the  area  under the  plasma  concentration-time curve (AUC), increased approximately proportionally with dose for the tablet single dose range 25 to 450 mg; maximum observed plasma concentration of olaparib (Cmax) increased slightly less than proportionally for the same dose range.

· Following a single 100 mg dose of radiolabelled olaparib capsule, unchanged olaparib and oxidised metabolites were detected in plasma, urine and faeces. Metabolite profiles of plasma indicated that olaparib was the major component (70% of the circulating radioactivity). There were three major drug derived components in plasma M12 (AZ14102299, ring-open piperazin-3-ol), M15 (AZ14102296, 4-fluorophenol (hydroxy)methyl) and M18 (AZ14102567, piperazin-3-ol); each of them accounted for 9-14% of the plasma radioactivity. Drug-related material was eliminated in the urine (44% mean recovery) and in the faeces (42% mean recovery), predominantly as metabolites.

## Dose proportionality and time dependencies

Exposure, measured by area under plasma concentration-time curve from zero to infinity (AUC), increased approximately proportionally with dose for the single dose tablet range 25 to 450 mg; maximum plasma concentration (Cmax) increased slightly less than proportionally for the same dose range.

Following bd dosing, an AUC mean accumulation ratio of 1.8 was observed at steady state. At the 300 mg bd  dose,  olaparib  PK  appeared  to  be  time  dependent,  with  mean  temporal  change  parameter  (TCP calculated as AUC during the dosing interval at steady state [AUCss]/AUC single dose) of 1.53 (SD 0.59).

## Special populations

The key observations related to the intrinsic factors impacting olaparib PK are summarised below.

· The latest population PK analysis pooling PK data from studies with the tablet formulation did not identify  gender,  race,  tumour  location,  age  or  body  weight  as  significant  covariates  (Olaparib-MS-08). BRCA1/2 status was not identified as a significant covariate either, but there were 36% of missing values for this covariate. In addition, no race difference in the PK of olaparib was shown from the phase I Japanese PK studies with the tablet or capsule formulations (respectively D081BC00001 and D0810C00001 [Study 01]) or from the phase I Chinese PK study using the tablet formulation (D081BC00002). Therefore, dose adjustment based on race, gender, age or body weight is not required. The PK of olaparib in prostate cancer patients was similar to other cancer patients supporting the dose regimen of 300 mg bd in these patients.

· In patients with mild hepatic impairment (Child-Pugh Classification A), AUC increased by 15% and Cmax increased by 13%. In patients with moderate hepatic impairment (Child-Pugh Classification B), AUC increased by 8% and Cmax decreased by 13%. The changes in AUC and Cmax of olaparib in patients with mild  or  moderate  hepatic  impairment  were  not  considered  to  be  clinically  relevant.  No  olaparib  dose adjustment is warranted in patients with mild or moderate hepatic impairment. In the absence of safety and PK data, olaparib is not recommended for use in patients with severe hepatic impairment (Child-Pugh classification C).

· The effect of renal impairment on exposure to olaparib has been studied. In patients with mild renal impairment (creatinine clearance [CrCL] 51 mL/min to 80 mL/min), there was a small increase in mean olaparib exposure compared to patients with normal renal function; 15% for Cmax and 24% for AUC. This was not considered to be clinically relevant. No olaparib dose adjustment is warranted in patients with mild renal impairment. In patients with moderate renal impairment (CrCL 31 mL/min to 50 mL/min), Cmax and AUC values increased by 26% and by 44% compared to patients with normal renal function. Patients with moderate renal impairment are recommended to take an olaparib tablet dose of 200 mg bd (equivalent to

<div style=\"page-break-after: always\"></div>

a total daily dose of 400 mg). Olaparib is not recommended for patients with severe renal impairment or endstage renal disease (CrCL ≤30 mL/min) since there are no data in such patients.

- No  studies  have  been  conducted  to  investigate  the  pharmacokinetics  of  olaparib  in  paediatric patients.

## Pharmacokinetic interaction studies

## Study D0810C00022

The potential for drug-drug interaction of the co-administered drugs, olaparib and bevacizumab, has been investigated in the formal PK study D0810C00022 performed in the early development of olaparib. This investigation was conducted with the hard gelatin capsule formulation. This study is described below.

## Study dates:

First patient enrolled: 13 June 2008

Last patient last visit: 25 March 2009

## Objectives

The primary objective of this study was to determine the safety and tolerability of twice daily (bd) oral doses of olaparib (also known as AZD2281, KU-0059436) when administered in combination with bevacizumab to patients with advanced solid tumours by assessment of adverse events (AEs), vital signs, electrocardiograms (ECG), clinical chemistry, haematology, urinalysis and physical examination.

The secondary objective was to compare exposure to olaparib when given alone and in combination with bevacizumab, by assessment of appropriate derived pharmacokinetic (PK) parameters.

## Study design

Successive cohorts of 4 to 6 patients received increasing doses of olaparib (100, 200 and 400 mg bd) continuously in combination with intravenous (iv) bevacizumab at a fixed dose of 10 mg/kg given every 14 days (1 cycle). A safety review of the data was performed at the end of each cycle of bevacizumab to determine if any dose-limiting toxicity (DLT) would prevent escalation to the next dose of olaparib. Dosing with bevacizumab started on Day 8 and continued for a minimum of 2 cycles. To be evaluable for PK assessment and potential dose escalation, patients had to complete at least 1 cycle of bevacizumab, and have a full PK profile for olaparib taken both in the monotherapy setting (on Day 4) and on the day of first administration of bevacizumab.

## Target patient population and sample size

Up to 18 patients with histologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent, with a life expectancy of at least 12 weeks and Eastern Co-operative Oncology Group (ECOG) Performance status 0 to 2.

## Investigational product and comparator: dosage, mode of administration and batch numbers

Olaparib 50 mg capsules given orally bd at doses of 100, 200 and 400 mg.

## Duration of treatment

A minimum of two 14-day cycles of bevacizumab. Patients could continue combinational study treatment indefinitely until they met a withdrawal criterion if, in the investigator's opinion, they were receiving some benefit.

<div style=\"page-break-after: always\"></div>

## Criteria for evaluation - pharmacokinetics (main variables)

Maximum and minimum plasma concentrations at steady state (Cmax,ss, and Cmin,ss), time to Cmax (tmax) and area under the plasma concentration-time curve during the dosing interval at steady state (AUCss).

## Criteria for evaluation - safety (main variables)

AEs, vital signs, ECG, haematology, clinical chemistry, urinalysis, physical examination.

## Statistical methods

There was no formal statistical analysis of PK variables or of safety and tolerability data. Data have been listed and summarised.

## Patient population

Twelve patients (4 in each treatment group) with a mean age 49.7 years (range 22 to 71 years) were enrolled and received study treatment (olaparib and bevacizumab). Most patients (11/12) were White and 10/12 were female. Three patients were still receiving their initial treatment (olaparib and bevacizumab) at data cut-off (Last patient last visit: 25 March 2009). No patients experienced dose-limiting toxicity and so each dose of olaparib was received by 4 patients. Three patients were excluded from the PK analyses due to protocol deviations.

## Summary of pharmacokinetic results

A summary of the PK parameters of olaparib for 200 and 400 mg bd, alone and in combination with bevacizumab, is presented in Table 1.

For both the 200 mg and 400 mg bd groups, the geometric mean (Gmean) AUCss, in combination with bevacizumab, were similar to that when given alone (26.57 ng.h/mL compared to 25.79 ng.h/mL for the 200 mg bd group, and 50.33 ng.h/mL compared to 58.08 ng.h/mL for the 400 mg bd group), with similar inter-patient variability (%CVs).

Similar results were observed for the Gmean Cmax,ss. The mean ratios of olaparib AUCss and Css,max (olaparib in combination with bevacizumab to olaparib alone) for both the 200 mg bd and 400 mg bd groups were both near to 1.0, at 1.030 and 0.867 for AUCss and 1.105 and 0.889 for Cmax,ss, respectively. Of the 7 assessable patients, 4 patients had AUCss values in combination with bevacizumab that were within 10% of those values for olaparib alone, and 3 patients had values that were within 20%. These results were reflected in the data for the individual ratios of Cmax,ss. For the 2 patients administered 100 mg olaparib bd that had Cmax,ss data, 1 patient had a Cmax,ss value in combination with bevacizumab that was within 15% of that for olaparib alone. The other patient showed approximately an apparent 40% decrease.

Table 1: Pharmacokinetic parameters of olaparib: PK analysis set, Study D0810C00022

| PK                | Summary statistics   | Olaparib dose (mg bd)   | Olaparib dose (mg bd)   | Olaparib dose (mg bd)   | Olaparib dose (mg bd)   | Olaparib dose (mg bd)   |
|-------------------|----------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| parameter, units  |                      | 200 alone               | 200 bevacizumab         | 400 alone               | 400 + bevacizumab       |                         |
| n                 |                      | 3                       | 3                       | 4                       | 4                       |                         |
| C ss,min , μ g/mL | Gmean (CV%)          | 0.544 (191.2)           | 0.612 (158.6)           | 1.602 (46.05)           | 1.254 (43.94)           |                         |
| C ss,max , μ g/mL | Gmean (CV%)          | 4.739 (35.56)           | 5.237 (49.04)           | 9.078 (27.18)           | 8.067 (17.15)           |                         |

<div style=\"page-break-after: always\"></div>

| t max , h        | median (range)   | NC            | NC            | NC            | NC            |
|------------------|------------------|---------------|---------------|---------------|---------------|
| AUC ss , μ .h/mL | Gmean (CV%)      | 25.79 (70.02) | 26.57 (78.12) | 58.08 (29.37) | 50.33 (23.05) |
| AUC ss ratio a   | Mean (range)     | N/A           | 1.030 (11.96) | N/A           | 0.867 (6.082) |
| C ss,max ratio b | Mean (range)     | N/A           | 1.105 (22.06) | N/A           | 0.889 (12.21) |

a

Ratio of AUCss = AUCss for olaparib in combination with bevacizumab to AUCss for olaparib alone.

b

Ratio of Css, max = Css, max for olaparib in combination with bevacizumab to Css, max for olaparib alone. AUCss Area under the  plasma  concentration-time  curve during  any  dosing  interval  at  steady  state;  bd  Twice  daily;  Cmax,ss  Maximum plasma (peak) concentration in plasma during dosing interval; Cmin,ss Minimum plasma (trough) concentration in plasma during dosing interval; CV Coefficient of variation; Gmean Geometric mean; N/A Not assessable; PK Pharmacokinetics; tmax Time to reach peak or maximum concentration or maximum response following drug administration.

## 2.3.3. Pharmacodynamics

## Mechanism of action

No new study was submitted.

Olaparib is a potent inhibitor of human poly (ADP ribose) polymerase enzymes (PARP 1, PARP 2, and PARP 3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies.

PARPs are required for the efficient repair of DNA single strand breaks and an important aspect of PARP induced repair requires that after chromatin modification, PARP auto modifies itself and dissociates from the DNA to facilitate access for base excision repair (BER) enzymes. When olaparib is bound to the active site of DNA associated PARP it prevents the dissociation of PARP and traps it on the DNA, thus blocking repair. In replicating cells this also leads to the formation of DNA double strand breaks (DSBs) when replication forks meet the PARP DNA adducts. In normal cells, homologous recombination repair (HRR) pathway is effective at repairing these DNA DSBs. In cancer cells lacking critical functional components for efficient HRR such as BRCA1 or 2, DNA DSBs cannot be repaired accurately or effectively, leading to substantial homologous recombination deficiency (HRD). Instead, alternative and error prone pathways are activated, such as the classical non homologous end joining (NHEJ) pathway, leading to a high degree of genomic instability. After a number of rounds of replication, genomic instability can reach insupportable levels and result in cancer cell death, as cancer cells already have a high DNA damage load relative to normal cells. HRR pathway may be compromised by other mechanisms, although the causative aberrancy and penetrance are not fully elucidated. Absence of fully functional HRR pathway is one of the key determinants of platinum sensitivity in ovarian and possibly other cancers.

In BRCA1/2 deficient in vivo models, olaparib given after platinum treatment resulted in a delay in tumour progression and an increase in overall survival compared to platinum treatment alone that correlated with the period of olaparib maintenance treatment.

## Primary and secondary pharmacology

No new study was submitted.

<div style=\"page-break-after: always\"></div>

## Evaluation of biomarkers associated with homologous recombination deficiency in PAOLA-1

Prospective tBRCA testing was conducted in all screened patients at recommended institutions in France. Patients  were  stratified  based  on  their  screening  laboratory  tBRCAm  result.  Note  patients  classified  as 'absence of deleterious mutation (tBRCAwt/VUS/unk)' also included patients who failed testing. gBRCA testing was not mandatory in the study; however, information regarding gBRCA status was requested for all randomised patients.

A blood sample collection for central germline BRCA testing of all patients was not included in the PAOLA1 study. All sites were requested, but not required, to enter local gBRCA test results in the CRF (negative, positive  or  inconclusive,  and  where  available,  the  mutation  name).  The  laboratories  that  carried  out screening tBRCA testing, also carried out gBRCA testing for patients enrolled at study sites in France. Of the 806 patients randomised into PAOLA-1, 404 (50.1%) patients reported a gBRCA result and 402 (49.9%) did not have a gBRCA result reported in the CRF. Out of the 404 patients with gBRCAm results in the CRF, 120 patients were reported to carry gBRCA mutation (29.7%).

Available tumour samples from PAOLA-1 patients were retrospectively tested post-randomisation (but prior to database lock) using the Myriad myChoice HRD Plus test in order to investigate efficacy in pre-defined biomarker subgroups. HRD positive status was determined as either tBRCAm and/or a genomic instability score (GIS) ≥ 42.

The Myriad myChoice CDx test has been developed using BRCA mutant breast and ovarian tumours. The GIS score is a continuous variable composed of an assessment of three different tumour measures of genomic instability (loss of heterozygosity, telomeric allelic imbalance and large-scale transition) and the 42-threshold is based on the 5th percentile of genome instability scores (GIS) observed in BRCA mutant tumours (i.e. 95% of ovarian BRCAm tumours have a GIS ≥42; Telli et al 2016). The ability of the myChoice test to discriminate patients that benefit from maintenance PARP inhibitors has been explored across a number of ovarian cancer studies, as well as the data from PAOLA-1. The 42-theshold has been evaluated prospectively  in  the  NOVA  (Mirza  et  al  2016)  and  PRIMA  (Gonzalez-Martin  et  al  2019)  studies  and retrospectively in Study 19 (Hodgson et al 2018).

Considering the patients that had a local gBRCA result available in the CRF and had a germline/somatic status available from Myriad (n=91); this excludes patients with co-occurring BRCA mutations (one patient had  2  gBRCA1  mutations),  the  concordance  between  the  CRF  result  and  the  Myriad  prediction  was considered high (91.0% PPA; 95.8% NPA).

Based on the local gBRCA status available in the CRF and the Myriad germline/somatic prediction, patients were allocated an overall tBRCAm classification of germline, somatic or not determined: 160 patients in PAOLA-1  were  determined  to be gBRCAm  and  51  sBRCAm.  For  38  Myriad  tBRCAm  patients, somatic/germline status could not be determined, which included 7 cases where somatic/germline status was discordant based on local germline results and Myriad predictions. For the subset of patients that have a GIS/HRD score available, somatic and germline BRCAm patients have a similar distribution of GIS/HRD scores.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note: only patients with an HRD score available can be displayed on the plots. HRD = homologous recombination deficient; gBRCAm = germline BRCA mutated; sBRCAm = somatic BRCA mutated.

Figure 1: Histograms showing HRD score distribution for patients classified as sBRCAm or gBRCAm in PAOLA-1

Table 2: PAOLA-1 PFS subgroup analyses by germline and somatic BRCAm status as determined by CRF and Myriad predictions

|                              | Olaparib/bevacizumab (n=537)   | Placebo/bevacizumab (n=269)   |
|------------------------------|--------------------------------|-------------------------------|
| Myriad tBRCAm                |                                |                               |
| No. events/total no. pts (%) | 44/158 (27.8)                  | 52/77 (67.5)                  |
| Median PFS (95% CI) months   | 37.2                           | 18.8                          |
| HR (95% CI)                  | 0.28 (0.19-0.42)               | 0.28 (0.19-0.42)              |
| gBRCAm                       |                                |                               |
| No. events/total no. pts (%) | 29/103 (28.2)                  | 34/57 (59.6)                  |
| Median PFS (months)          | 37.2                           | 22.2                          |
| HR (95% CI)                  | 0.38 (0.23-0.63)               | 0.38 (0.23-0.63)              |
| sBRCAm                       |                                |                               |
| No. events/total no. pts (%) | 6/33 (18.2)                    | 15/18 (83.3)                  |
| Median PFS (95% CI) months   | Not reached                    | 14.4                          |
| HR (95% CI)                  | 0.10 (0.04-0.25)               | 0.10 (0.04-0.25)              |

BRCA = Breast cancer susceptibility gene; BRCAm = BRCA mutated; CI = confidence interval; gBRCAm = germline BRCA mutated; HR = hazard ratio; PFS = progression free suvival; sBRCAm = somatic BRCA mutated; tBRCAm = tumour BRCA mutated.

Source: Table 2253.

<div style=\"page-break-after: always\"></div>

## BRCA1 vs BRCA2 mutations and large genomic rearrangements

The proportion of BRCA1 and BRCA2 mutated patients, expressed as a fraction of total BRCAm patients, in PAOLA-1 (67.7% BRCA1m, 31.9% BRCA2m and 0.4% BRCA1m and BRCA2m) was consistent with the SOLO1 study (72.8% BRCA1m, 26.4% BRCA2m and 0.8% BRCA1m and BRCA2m) and across recent first line ovarian cancer maintenance studies (GOG-218, Norquist et al 2018, and VELIA, Coleman et al 2019) with  65.5-69.2%  of  BRCAm  patients  carrying  a  BRCA1  mutation  and  30.8%-34.5%  carrying  a  BRCA2 mutation.

In PAOLA-1 (tBRCA) and SOLO1 (gBRCA), the proportion of large rearrangement in BRCA1 and BRCA2 were 4.2% and 5.7% respectively.

## BRCA-locus specific loss of heterozygosity (LOH) data

BRCA-gene specific LOH was reported by Myriad using RUO methodology as part of the myChoice HRD plus assay. Of 235 Myriad tBRCAm patients, 193/235 (82.1%) were evaluable for determination of BRCA-locus specific LOH status. Bi-allelic loss of BRCA was determined in 183/193 (94.8%) of evaluable tumours. In 10/193 (5.2%) samples, BRCA loss was heterozygous, of which 9 were BRCA2m (5 gBRCA2m, 2 sBRCA2m and 2 somatic/germline status unknown) and 1 was BRCA1m (gBRCA1m).

## TP53 mutations

Sequencing  data  for  TP53  was  available  for  the  PAOLA-1  tumour  samples  analysed  using  the  Myriad myChoice HRD Plus assay. It has been previously shown that TP53 mutations are present in almost all cases of high-grade serous ovarian cancer (Ahmed et al 2010) and 697/755 (92.3%) of PAOLA-1 tumour samples sequenced at Myriad harboured a mutation in TP53 predicted to affect protein function. Using the same classification schemes as described for Study 19 (Molina-Vila et al 2014; Poeta et al 2007), 350/697 (50.2%)  of  TP53  mutations  in  PAOLA-1  were  predicted  to  be  disruptive  and  340/697  (48.9%)  nondisruptive in nature. For 7/697 (1.0%) patients the disruptive vs non-disruptive status of the mutation could not be determined.

## 2.3.4. Discussion on clinical pharmacology

Olaparib tablets as monotherapy, is already approved in adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. Olaparib PKs (ADME) as well as the influencing intrinsic factors have been fully characterized and already evaluated with the hard gelatine capsules and the tablets.

The variation under review consists of the use of olaparib tablets in combination with bevacizumab in the same indication. The claimed dose of olaparib for the combination is identical to that approved in the monotherapy indication. The combination indication is not claimed for the hard gelatine capsule.

No  new  clinical  PK  investigations  pertaining  the  claimed  variation  was  submitted.  No  PK  investigation (sparse sampling or formal PK) have been included in the pivotal PAOLA-1 study.

The results of Study D0810C00022, an open label, dual-centre, Phase I study to assess the safety and tolerability of olaparib when used in combination with bevacizumab in patients with advanced solid tumours were presented. The design of the study is far less than optimal to pertain to the claimed variation. The tested formulation is hard gelatin capsule and the tested doses were 200 and 400 mg. While the variation under review concerns the tablets and the daily dose is 600 mg. Bearing in mind that the absolute bioavailability of the capsule is much lower than that of tablets, the olaparib dose tested in this DDI interaction study is too low. Also, the very limited number of patients enrolled in each arm of the study (n=3-4) is an additional pitfall in the study., Although. no firm conclusion can be drawn due to

<div style=\"page-break-after: always\"></div>

study limitations, the study did not indicate significant difference in the systemic exposure to olaparib when co-administered with bevacizumab.

Furthermore, as bevacizumab is not a cytokine modulator, it is not expected to have any effect on CYP450 enzymes (Kenny et al 2013) and on the PK/exposure of olaparib.

The impact of co-administration of olaparib on the PKs of bevacizumab was neither investigated nor discussed. The MAH argued that at the therapeutic dose of 15 mg/kg Q3W in PAOLA-1, the clearance of bevacizumab is predominantly mediated by catabolism and not by TMDD. Therapeutic mAbs which are cleared primarily by TMDD, typically exhibit dose-dependent PK (Betts et al 2018). Therefore, olaparib is unlikely to affect the clearance of bevacizumab via the TMDD pathway or via any other putative or plausible mechanisms. It is agreed that TMDD elimination pathway is plausibly saturated. Thus, the absence of interaction investigation is acceptable.

No investigation of Exposure-Safety Relationships for olaparib and bevacizumab has been carried out. This is mainly justified by the difficulty in deriving an unbiased and predictive multivariate ER model based on available data from PAOLA study. Therefore, no supportive data are available and the safety should be appreciated solely on the observational safety data collected in the PAOLA study. No investigation of Exposure-efficacy Relationship has been carried out as well.

Several biomarkers have been used to date to assess the extent of homologous recombination deficiency (HRD) in tumours. Based on mechanistical rationale, mutations in BRCA1 and BRCA2 genes (of germline and somatic origin) have been associated with HRD and have been largely used in clinical studies to inform on HRD status, although mutations in these genes might neither be necessary nor sufficient for response to PARPi. Homologous recombination deficiency (HRD) positive status can be defined by detection of a BRCA1/2 mutation classified as deleterious/suspected deleterious or pathogenic/likely pathogenic. Other biomarkers can be used to inform on the extent of HRD in tumour cells. Detection of BRCA1/2 mutations could be combined with positive HRD score to determine HRD positive status.

HR deficiency-associated genomic alterations that have been investigated in Paola-1 include genome-wide loss of heterozygosity, telomeric allelic imbalance and large scale transition, which are continuous measures with pre-defined criteria and score. Composite genomic instability score (GIS, also called HRD score) is determined when the combined measures and respective scores are used to assess the extent of specific genomic aberrations accumulated in tumour cells. Lower score defines lower likelihood of HR deficiency of tumour cells and higher score determines higher likelihood of HR deficiency of tumour cells at the time of the sample collection relative to exposure to DNA damaging agents. HRD positive status can be defined by a composite GIS score for HR deficiency-associated genomic alterations tested by an experienced laboratory using a validated test.

With regards to the evaluation of gBRCAm status, the concordance between the CRF result and the Myriad prediction was considered high (91.0% PPA; 95.8% NPA). The bi-allelic LOH was reported in the majority of tumours (95%). The OS data are currently too immature in PAOLA-1 to conduct a subgroup analysis for OS based on TP53 status. Submission of subgroup analyses is expected when final OS data become available (REC). The MAH is also recommended to submit additional exploratory analyses of tumour samples at progression upon finalisation in 2023. (REC)

Overall, there are no PK/PD data provided in support for the claimed dose of the combination in the applied indication. The currently approved doses of each drug in ovarian tumours was selected for the development of the combination (Study PAOLA-1). As discussed above, it is not expected that bevacizumab could have any effect on the PK/exposure of olaparib and vice-versa.

<div style=\"page-break-after: always\"></div>

## 2.3.5. Conclusions on clinical pharmacology

The currently available PK data have been correctly summarised. The currently approved doses of each drug in solid tumours was selected for the development of the combination (Study PAOLA-1).

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No new dose response study was provided as part of this application (see discussion on clinical efficacy).

## 2.4.2. Main study

## Study D0817C00003 (PAOLA-1)

A Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance (PAOLA-1).

Figure 2: Overall study design - Study PAOLA-1

<!-- image -->

## Methods

## Study participants

## Key inclusion criteria:

- 1) Patients must have been ≥18 years of age.
- 2) Patient with newly diagnosed:

<div style=\"page-break-after: always\"></div>

- Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer,

- Histologically confirmed (based on local histopathological findings): high grade serous or high grade endometrioid or other epithelial non mucinous ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation.

- At an advanced stage: FIGO stage IIIB, IIIC, or IV of the 1988 FIGO classification.

- 3) Patients who had completed first line platinum-taxane chemotherapy prior to randomisation:

-The platinum-taxane based regimen must have consisted of a minimum of 6 and a maximum of 9 treatment  cycles;  however,  if  platinum-based  therapy  was  discontinued  early  as  a  result  of  nonhaematological toxicity specifically related to the platinum regimen, (i.e., neurotoxicity, hypersensitivity etc), patients must have received a minimum of 4 cycles of the platinum regimen.

-Intravenous,  intraperitoneal,  or  neoadjuvant  platinum-based  chemotherapy  was  allowed;  for weekly therapy, 3 weeks was considered to be 1 cycle.  Interval debulking surgery was allowed.

4) Patients must have received prior to randomisation a minimum of 3 cycles of bevacizumab in combination with the last 3 cycles of platinum-based chemotherapy.  Only in case of interval debulking surgery, it was allowed to realize only 2 cycles of bevacizumab in combination with the last 3 cycles of platinium-based chemotherapy.  Bevacizumab treatment was to be administered at a dose of 15 mg/kg Q3W for up to a total of 15 months.

5)  Patient  must  be  prior  to  randomization  without  evidence  of  disease  (NED)  due  to  complete surgical resection or in complete response (CR) or partial response (PR) from first line platinum-containing chemotherapy and bevacizumab. There should be no clinical evidence of disease progression (physical exam, imagery, CA 125) throughout the first line treatment and prior to study randomization.

6) Patients must have been randomised at least 3 weeks and no more than 9 weeks after their last dose of chemotherapy (last dose is the day of the last infusion) and all major toxicities from the previous chemotherapy  must  have  resolved  to  CTCAE  Grade  1  or  better  (except  for  alopecia  and  peripheral neuropathy).

7)  Patients  must  have  normal  organ  and  bone  marrow function,  serum  creatinine  ≤  1.25  x institutional ULN and creatinine clearance &gt; 50 mL/min, normal blood pressure or adequately treated and controlled hypertension.

8) ECOG performance status 0 to 1.

9) A formalin fixed, paraffin embedded tumour sample from the primary cancer must have been available for central BRCA testing and the test result must have been available for stratification.

## Key exclusion criteria:

- 1) Patients  whose  tumours  were  of  non-epithelial  origin  of  the  ovary,  the  fallopian  tube  or  the peritoneum (i.e., germ cell tumours).
- 2) Patients with ovarian tumours of low malignant potential (e.g., borderline tumours) or mucinous carcinoma.
- 3) Patients with synchronous primary endometrial cancer, unless both of the following criteria were met:

-Stage &lt;II

-Less than 60 years old at the time of diagnosis of endometrial cancer with Stage IA or IB Grade I or II, or Stage IA Grade III endometrial carcinoma OR ≥60 years old at the time of diagnosis of

<div style=\"page-break-after: always\"></div>

endometrial cancer with Stage IA Grade I or II endometrioid adenocarcinoma.  Patients with serous or clear cell adenocarcinoma or carcinosarcoma of the endometrium were not eligible.

- 4) Patients with another malignancy within the last 5 years except: adequately treated non melanoma skin cancer, curatively treated in situ cancer of the cervix, and ductal carcinoma in situ.  Patients with a history of localised malignancy diagnosed over 5 years ago may be eligible provided they completed their adjuvant systemic therapy prior to randomisation and they remain free of recurrent or metastatic disease.  Patients with a history of primary triple negative breast cancer may be eligible providing they completed their definitive anticancer treatment more than 3 years ago and they remain breast cancer disease free prior to the start of study treatment.
- 5) Patients with a history of myelodysplastic syndrome/acute myeloid leukaemia.
- 6) Patients who experienced for at least 1 cycle a delay &gt;2 weeks during first line chemotherapy due to prolonged haematological recovery.
- 7) Patients who received radiotherapy within 6 weeks prior to study treatment.
- 8) Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
- 9) Any previous treatment with a PARP inhibitor, including olaparib.
- 10) Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or antineoplastic  hormonal  therapy,  or  simultaneous  radiotherapy  during  the  study  treatment  period (hormonal replacement therapy is permitted as are steroidal anti emetics).
- 11) Prior history of hypertensive crisis (CTCAE Grade 4) or hypertensive encephalopathy.
- 12) Clinically significant (e.g., active) cardiovascular disease, including:

-Myocardial infarction or unstable angina within ≤6 months of randomisation.

-New York Heart Association ≥Grade 2 congestive heart failure.

-Poorly  controlled  cardiac  arrhythmia  despite  medication  (patients  with  rate  controlled  atrial fibrillation are eligible), or any clinically significant abnormal finding on resting electrocardiogram.

-Peripher al vascular disease Grade ≥3 (eg, symptomatic and interfering with activities of daily living requiring repair or revision).

- 13) Previous cerebro-vascular accident, transient ischemic attack or sub-arachnoid haemorrhage within 6 months prior to randomisation.
- 14) History or evidence of haemorrhagic disorders within 6 months prior to randomisation.
- 15) Evidence of bleeding diathesis or significant coagulopathy (in the absence of coagulation).
- 16) History  or  clinical  suspicion  of  brain  metastases  or  spinal  cord  compression.    Computed tomography/magnetic resonance imaging (MRI) of the brain is mandatory (within 4 weeks prior to randomisation) in case of suspected brain metastases.  Spinal MRI is mandatory (within 4 weeks prior to randomisation) in case of suspected spinal cord compression. History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy (e.g. uncontrolled seizures).
- 17) Non-healing wound, active ulcer or bone fracture.  Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require 3weekly wound examinations.

<div style=\"page-break-after: always\"></div>

- 18) History  of  VEGF-therapy  related  abdominal  fistula  or  gastrointestinal  perforation  or  active gastrointestinal bleeding within 6 months prior to the first study treatment.
- 19) Current,  clinically  relevant  bowel  obstruction,  including  sub-occlusive  disease,  related  to  the underlying disease.
- 20) Patients with evidence of abdominal free air not explained by paracentesis or a recent surgical procedure.
- 21) Pregnant or lactating women.
- 22) Patients who are unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
- 23) Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
- 24) Immunocompromised patients, e.g., with known active hepatitis (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids or patients who are known to be serologically positive for human immunodeficiency virus.

tBRCA testing and HRD testing is described under clinical pharmacology.

## Treatments

- Olaparib tablets per os 300 mg twice daily,
- Placebo tablets per os twice daily.

It was recommended that patient begins study treatment as soon as possible after randomization, within 7 days and ideally concomitant with bevacizumab administration.

Bevacizumab, as standard of care therapy, was administered in both arms as followed:

· 15 mg/kg, d1, q3w, for a total duration of 15 months / 22 cycles (including combination with platinumbased chemotherapy).

Patients continued bevacizumab in the maintenance setting and started treatment with Lynparza after a minimum  of  3  weeks  and  up  to  a  maximum  of  9  weeks  following  completion  of  their  last  dose  of chemotherapy.  Treatment  with  Lynparza  was  continued  until  progression  of  the  underlying  disease, unacceptable toxicity or for up to 2 years. Patients who in the opinion of the treating physician could derive further benefit from continuous treatment could be treated beyond 2 years.

## Objectives

## Primary objective:

To determine the efficacy by progression free survival (PFS1) investigator based according to modified Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) of olaparib maintenance compared to placebo in high grade epithelial ovarian, fallopian tube, or peritoneal cancer that are in clinical complete response or partial response following first line platinum-taxane based chemotherapy plus bevacizumab, and planned to pursue bevacizumab in the maintenance phase up to a total of 15 months.

Secondary objectives:

1. To determine:

<div style=\"page-break-after: always\"></div>

- -time to earliest progression by RECIST or Cancer Antigen-125 (CA-125) or death,
- -time from randomization to first subsequent therapy or death (TFST),
- time from randomization to second progression (PFS2),
- time from randomization to second subsequent therapy or death (TSST),
- overall survival (OS).

2. To assess the safety and tolerability of olaparib and bevacizumab maintenance compared to bevacizumab alone.

3. To compare the effects of olaparib maintenance compared to placebo on Health-Related Quality of Life (HRQoL) and patient reported outcomes (PROs), with consideration of patient preference.

4. To evaluate the impact of treatment and disease on resource use.

Exploratory objectives:

1. To explore pre planned subgroup analyses of efficacy (including PFS1 and OS) based on relevant potential prognostic factors, including, but not limited to stratification factors, clinical characteristics and tumour HR deficiency status (BRCAm, mutations in other HR genes and Myriad HRD scar status)

2.  Explore  the  time  to  next  severe  toxicity  (grade  4  neutropenia  lasting  &gt;  7  days,  grade  ≥3  febrile neutropenia, grade 4 thrombo cytopenia with bleeding or platelet transfusion, grade ≥ 3 non -hematological toxicity) in both arms.

3. To explore the correlation between geriatric assessment and efficacy and tolerance of olaparib versus placebo for patients &gt; 70 years old.

4. To explore the efficacy of olaparib by assessment of overall survival (OS) adjusting for the impact of spontaneous switching (outside of study design) to Polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerization (PARP) inhibitors or other potentially active investigational agents.

5.  Biological  biomarkers  analysis:  to  determine  the  frequency  of  somatic  BRCA  mutation  (sBRCAm)  in tumour samples and to compare this with germline BRCA mutation (gBRCAm) status. To determine a HR deficiency signature correlated with olaparib efficacy combined with bevacizumab.

6. To explore whether resistance mechanisms to olaparib can be identified through analysis of tumour and blood samples - archival tumour and blood sample at baseline (mandatory), tumour biopsy and blood sample on progression (optional).

7. Future exploratory research into factors that may influence response to study treatment (where response is defined broadly to include efficacy, tolerability or safety) and may be performed on the collected and stored archival tumour samples that were mandatory for entry onto the study or on optional tumour biopsy samples collected during the course of the study.

8. To collect and store DNA (according to each country's local and ethical procedures) for future exploratory research into genes/genetic variation that may influence response (i.e., distribution, safety, tolerability and efficacy) to study treatments and or susceptibility to disease (optional).

## Outcomes/endpoints

Primary endpoint:

PFS was defined as the time from randomization until the date of the first objective radiological disease progression according to investigator assessment of RECIST version 1.1 or death (by any cause in the

<div style=\"page-break-after: always\"></div>

absence of progression) regardless of whether the patient withdraws from randomized study treatment or receives another anti-cancer therapy prior to progression.

## Secondary endpoints:

1. OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

2.  Time  to  earliest  progression  by  RECIST  v.  1.1  or  CA-125  or  death  was  defined  as  the  time  from randomization to the earliest date of RECIST or CA-125 progression or death by any cause. Progression according to CA-125 was assessed according to GCIG

3.  PFS2.  Time  from  randomization  to  second  progression  is  defined  as  the  time  from  the  date  of randomization to the earliest of the progression event subsequent to that used for the primary variable PFS1, or date of death. The date of second progression will be recorded by the investigator and defined according  to  local  standard  clinical  practice  and  may  involve  any  of;  objective  radiological,  CA-125  or symptomatic  progression  or  death.  Second  progression  status  will  be  reviewed  regularly  following  the progression event used for the primary variable PFS (PFS1) and recorded. Patient alive and for whom a second disease progression has not been observed should be censored at the last time known to be alive and without a second disease progression, i.e. censored at the latest of the tumor assessment date if the patient has not had a second progression or death).

4. TFST is defined as the time from the date of randomization to the earliest of the date of anti-cancer therapy start date following study treatment discontinuation, or death.

5.  TSST  is  defined  as  the  time  from  the  date  of  randomization  to  the  earliest  of  the  date  of  second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.

6. Patient reported outcomes (PROs) variables (EORTC QLQ-C30 and OV-28), with consideration of patient preference.

7. Geriatric assessment will be performed using the Geriatric Vulnerability Score (GVS).

## Sample size

The  study  was  calibrated  to  detect  a  treatment  effect  hazard  ratio  (HR)  of  0.75,  translating  in  an improvement in median PFS1 from 15.8 months (control arm) to 21.1 months (olaparib arm), (Herzog et al., 2014) with a 2:1 randomization, allowing patients to have only 1 chance out 3 to get placebo. A total of 458 events in the study would have approximately &gt; 80% power to show statistically significant PFS1 at a 2-sided alpha. Considering a recruitment duration of 24 months and a 21-month follow-up for the last included patient (estimated total duration from first randomized patient to PFS1 assessment: 45months), assuming a common exponential dropout rate of 1%, 762 patients will be randomized in the study (508 patients in the olaparib arm and 254 patients in the placebo arm) so that maturity of the PFS1 data is approximately 60%.

Approximately 24 patients were planned to be randomized in Japan by the Gynecologic Oncology Trial and Investigation Consortium of North Kanto (GOTIC) in addition to the 762 randomized patients. The patients randomized in Japan were to be included in the Full Analysis Set provided there are no clinical data from the  ongoing  olaparib  program  suggesting  different  efficacy  or  safety  with  olaparib  tablet  in  Japanese patients with high grade epithelial ovarian cancer.

<div style=\"page-break-after: always\"></div>

## Randomisation

Approximately 762 patients were planned to be randomized in a 2:1 ratio to the treatments with olaparib or placebo.

Stratification was to be done by:

- First line treatment outcome at screening as defined below:
1. No Evidence of Disease (*) with complete macroscopic resection at initial debulking surgery,
2.  No  Evidence  of  Disease/  Complete  response  (*)  with  complete  macroscopic  resection  at  interval debulking surgery,
3. No Evidence of Disease (*) / Complete Response at screening, in patients who had either incomplete resection (at initial or interval debulking surgery) or no debulking surgery (Debulking surgery considered as not feasible),
4. Partial Response.

(*) Patients without assessable disease after initial debulking surgery will be considered to have NED at the end of first-line chemotherapy and surgery strategy if the disease has not progressed. Those with measurable or assessable disease after initial surgery or at the start of neo-adjuvant chemotherapy and whose disease is no more detectable at the end of the chemotherapy and surgery strategy will be considered to have achieved a complete response (CR).

Table 3:  Stratification categories by first line treatment outcome at screening

<!-- image -->

| Surgery with maximal debulking effort (initial, interval, none): Presence or not of residual disease   | Disease status before randomization (CTScan /MRI)                                                                       | Strata                          |
|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| Initialsurgerywithoutintervalsurgery Complete macroscopic resection Incomplete resection               | NED* Presence of disease NED or Complete Response** Partial Response Stable or Progressive disease                      | Not eligible 3 4 Not eligible   |
| Interval surgery Complete macroscopic resection Incomplete resection                                   | Complete Response or NED Presence of disease*** Complete Response or NED Partial Response Stable or Progressive disease | 2 Not eligible 3 4 Not eligible |
| No debulking surgery                                                                                   | Complete Response or NED Partial Response Stable or Progressive Disease                                                 | 3 4 Not eligible                |

NED: No evidence of disease on CTscan or MRI (No measurable/assessable disease according to RECIST1.1

*+Complete response: Disappearance of all measurable/assessable disease which was present at the start of chemotherapy and normalization of cAi25 blood level

+++presence of disease on CTScan/MRI or abnormal CA125 level

- tBRCA status determined by prospective local testing (result of BRCA testing on tumor tissue):

-Deleterious mutation,

<div style=\"page-break-after: always\"></div>

-Absence of deleterious mutation.

## Blinding (masking)

This study is double-blind.

## Statistical methods

The primary endpoint is progression-free survival (PFS1) defined as the time from the date of randomization to the first documented disease progression (according to RECIST v1.1) or death from any cause, whichever occurs first.

Patients had RECIST 1.1 tumour assessments at baseline and every 24 weeks (CT/MRI at 12 weeks if clinical or CA 125 progression) for up to 42 months or until objective radiological disease progression.

PFS was to be estimated using the Kaplan-Meier method and to be described in terms of median PFS1 per arm, and hazard ratio for progression between the 2 arms. Associated 2-sided 95% CI for the estimates were to be provided. The HR comparing randomised treatments (and associated CI) were estimated from a stratified Cox Proportional Hazards model (with ties=Efron and the stratification variables as strata) and the CI was  calculated using a profile likelihood approach. The HR  (olaparib/bevacizumab vs placebo/bevacizumab) together with its corresponding 95% CI and p-value were presented.

PFS distributions were to be compared between the 2 study arms using a 2-sided Log-Rank test (significance level of 5%) stratified by response to first line treatment and tBRCA status, supported by a stratified Cox regression.

This analysis was to be performed when approximately 458 PFS1 events have occurred.

## Multiple testing procedure and hierarchical testing strategy

In order to strongly control the type I error at 5% 2-sided for key label claims, a multiple testing procedure (MTP) was to be employed across the primary endpoint (PFS1) and key secondary endpoints (PFS2 and OS).

A hierarchical testing strategy was to be employed where PFS1 is tested first using the full test mass (full test mass = alpha) and key secondary endpoints of PFS2 and OS will then be tested using a MTP with a recycling strategy (i.e., the MTP will recycle the test mass to the endpoint not yet rejected in the hierarchy). The hierarchical testing strategy is detailed below.

PFS2 was to be only be tested if statistical significance was shown for PFS1. OS was only to be tested if the null hypothesis (of no difference) was rejected for PFS2.

## PFS2 analysis

An interim PFS2 analysis (IA) was to be performed at the time of the PFS1 analysis. Final PFS2 analysis was  planned  to  be  performed  when  the  PFS2  data  were  approximately  53%  mature  (approximately 411 events) OR after a maximum duration of 1 year following the PFS1 analysis, whichever occurred first.

## OS analysis

An interim OS analysis (IA) was to be performed when statistical significance was shown for PFS2 (interim or  final  PFS2  analysis).  Final  OS  analysis  was  planned  to  be  performed  when  the  OS  data  were approximately 60% mature OR after a 3-year duration from the main PFS1 analysis, whichever occurred first.

<div style=\"page-break-after: always\"></div>

The complete multiple testing procedure accounting for the inclusion of interim PFS2 and OS analyses is detailed below.

Figure 3: Complete MTP including PFS2 and OS interim analysis in the hierarchical testing strategy

<!-- image -->

## Adjustment for interim PFS2 analysis

If statistical significance was shown for PFS1, the full test mass (alpha) was to be carried forward to PFS2. In  order  to  adjust  for  the  inclusion  of  an  interim  PFS2  analysis,  the  Lan  and  DeMets  approach  that approximates the O'Brien and Fleming spending function was to be used (Lan and DeMets 1983). The 1sided  significance  level  at  the  interim  analysis  was  to  be  calculated  based  on  the  information  fraction observed at this time; the information fraction was defined as the ratio between the number of events observed at the time of the interim analysis and the total number of events required for the final analysis. As an example, if 358 PFS2 events have occurred at the interim analysis, translating in an information fraction of 87%, then the significance level will be 1.6% at the interim analysis.

If the null hypothesis for PFS2 was not rejected at the first analysis time point, then accounting for the expected correlation between the proportion of events at the interim and at the final analysis, the 1-sided significance level at the final PFS2 analysis was to be approximately 2% (final significance level was to be determined once the exact correlation between the interim and final PFS2 analyses was known).

## Adjustment for interim OS analysis

If PFS2 was significant at either the interim or final analyses, the full test mass (alpha) was to be carried forward to OS. Statistical significance was to be declared at the interim analysis for OS if the null hypothesis for PFS2 was rejected and the observed p-value for OS was p&lt;0.0001. This allows the significance level at the final analysis for OS to be controlled at the 2.5% level (1-sided) (Haybittle J L 1971)).

## Analysis

PFS2 and OS were to be analyzed using the same methodology as described for the PFS1 analysis, taking into account the MTP described above. Should PFS1 not be statistically significant, the study would still continue to final OS timepoint for descriptive/research purposes.

<div style=\"page-break-after: always\"></div>

## Patient reported outcome analysis

Quality of Life (QoL) were to be analysed descriptively. Descriptive statistics, graphs and listings were to be reported to evaluate the effect of olaparib maintenance on symptoms, HRQoL and PROs. The relationship between patient-reported outcomes, progression and AEs was to be assessed.

## Exploratory endpoints analysis

Subgroup analyses of PFS1 and OS were to be conducted to assess consistency of treatment effect across predefined subsets, and to identify predictive factors of olaparib efficacy as maintenance therapy.

Subgroups considered were to include, but may not be limited to:

Stratifications factors:

- tBRCA status as per randomisation (tBRCAm vs tBRCAwt/VUS/unk)
- First line treatment outcome

Tumour characteristics as assessed by Myriad MyChoice HRD plus assay:

- Tumour BRCA mutation status (tBRCAm vs non-tBRCAm)
- Tumour HRR associated including BRCAm (HRRm* vs non-HRRm)
- Tumour Myriad HRD status cut off 42 (HRD positive vs HRD negative).
- Tumour Myriad HRD status cut off 33 (HRD positive vs HRD negative)
- Tumour HR deficiency status (tBRCAm or HRRm or HRD (42) + vs absence of HR deficiency biomarker)
- Tumour HR deficiency status (tBRCAm or HRRm or HRD (33) + vs absence of HR deficiency biomarker)

Main clinical characteristics:

- Age at randomisation (&lt;65 vs. ≥ 65)
- FIGO stage at disease (FIGO III vs IV)
- Histological subgroups (HGSOC vs others)
- ECOG performance status at baseline (0 or 1)
- Baseline CA125 value (≤ ULN vs &gt; ULN)
- BRCA mutation type (BRCA1, BRCA2 or BRCA1/2 (both)
- Cytoreductive surgery outcome (no residual disease vs residual disease)
- Timing of cytoreductive surgery (upfront vs interval debulking)
- Duration of chemotherapy plus bevacizumab before randomization
- Region (Europe vs Japan)
- Other exploratory molecular subgroups
- QoL, safety

## Response rate, best objective response rate and duration of response

For patients, in partial response at the randomization, the objective response rate (complete or partial response) was to be presented in each treatment arm by a proportion together with its 95% confidence interval and will be compared between the two arms using a Fisher exact test.

<div style=\"page-break-after: always\"></div>

## Primary endpoint Supportive (sensitivity) analysis

If  the  primary  PFS1  analysis  according  to  investigator  assessment is positive, a sensitivity analysis for progression free survival as measured by central review assessment might be performed to support primary PFS1 results.

No adjustment to the significance level for testing was to be made since this analysis was only to be considered as supportive of the primary analysis of PFS1.

## Results

## Participant flow

<!-- image -->

- Informed consent received.
- Percentages are calculated from mumber of patients randomised.
- b Percentages are calculated from number of patients not randomised.
- P Percentages are calculated from mumber of patients who received treatment.
- Includes patients who never received study treatment.
- Includes events reported as symptomatic deterioration.

Data derived from Table 14.1.1.

Figure 4: PAOLA-1: Patient disposition (All patients)

<div style=\"page-break-after: always\"></div>

Figure 5: Routes to randomisation and stratification by tumour BRCA1/2 status

<!-- image -->

## Recruitment

The first patient was enrolled into the study on 10 July 2015 and the last patient on 31 August 2017. Patients were randomised in 137 study centres in 11 countries worldwide (97% in Europe and 3% in Japan): Austria (6 centres), Belgium (3 centres), Denmark (1 centre), Finland (2 centres), France and Monaco (44 centres), Germany (51 centres), Italy (9 centres), Japan (7 centres), Spain (13 centres) and Sweden (1 centre). 24 patients were randomised in Japan centers and are included in the FAS. The majority of patients were randomised in France (327 patients), Germany (251 patients), Italy (85 patients) and spain (55 patients).

The DCO date for the primary analysis was 22 March 2019, 44 months after the first patient enrolment.

## Conduct of the study

## Protocol amendments

The original study protocol (Version 1.1) is dated 18 December 2014). The last protocol version 7.0 is dated 28 Feb 2019. Additional amendments to the protocol have been done and one SAP version issued by AstraZeneca and dated 14 May 2019, after the DCO in March 2019, has been provided.

<div style=\"page-break-after: always\"></div>

Table 4: Protocol amendments and other significant changes to study conduct

| Protocol number (date of internal approval)        | Key details of amendment (Section of this report affected)                                                                                                                                                                                   | Reasonforamendment                                                                                                                                                                   | Person(s)/ group(s) responsible for amendmenta     |
|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| Amendmentsmadebefore thestart ofpatientrecruitment | Amendmentsmadebefore thestart ofpatientrecruitment                                                                                                                                                                                           | Amendmentsmadebefore thestart ofpatientrecruitment                                                                                                                                   | Amendmentsmadebefore thestart ofpatientrecruitment |
| Version 1.2 (12 March 2015)                        | Clarification of inclusion criteria to allow for inclusion of patients with other (non-high-grade serous or non-high-grade endometrioid histology) epithelial non-mucinous ovarian cancer only for patients cairying gBRCAm (Section 9.3.1). | Inclusion criteria updated following publication showing that patients with gBRCAm ovarian cancer have higher rates of platinum sensitivity and improved OS (Pennington et al 2014). | ARCAGY- GINECO Research                            |
| Version 1.2 (12 March 2015)                        | Clarification that collection of QoL questionnaires and pharmaco-economic information was restricted to the first 2 years of treatment (calculated from 1t study drug administration) (Sections 9.8.4.8, 11.1.3 and 11.1.4)                  | To have the same period of data collection for pharmaco-economic informationasfordose administration.                                                                                | ARCAGY- GINECO Research                            |

| Amendmentsmadeafter thestartofpatientrecruitment   | Amendmentsmadeafter thestartofpatientrecruitment                                                                                                                                                                                                                                                                                                                                                                                                    | Amendmentsmadeafter thestartofpatientrecruitment                                                                                 | Amendmentsmadeafter thestartofpatientrecruitment   |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| Version 2.0 (14 January 2016)                      | Pneumonitis added to the list of AESIs (Sections 9.1 and 12.2.3).                                                                                                                                                                                                                                                                                                                                                                                   | Pneumonitis had been missed off the list of AESIs in error.                                                                      | ARCAGY- GINECO Research                            |
| Version 2.0 (14 January 2016)                      | Clarification that blood samples for exploratory biomarker analysis would only be taken from patients recruited at study centres in France (change also covered in local amendment version 3.0 in France; Section 11.6).                                                                                                                                                                                                                            | Due to sample importation regulations, only samples collected from sites in France could be analysed for exploratory biomarkers. | ARCAGY- GINECO Research                            |
| Version 3.0 (15 February 2016)                     | Modification of selection criteria to allow patients having IDS to have only 2 cycles of bevacizumab in combination with the last 3 cycles of platinum-based chemotherapy (instead of the protocol requirement for a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of platinum-based chemotherapy) and to clarify that patients on a stable dose of oral anticoagulants could be recruited to the study (Section 9.3.1). | To bring the CSP in line with standard clinical practices for patients having IDS.                                               | ARCAGY- GINECO Research                            |

<div style=\"page-break-after: always\"></div>

|                               | Modification of the CT/MRI schedule to require collection of data for a minimum of 42 months or until the date when total number of PFS events was reached (Sections 9.1, 9.8.3 and 11.1)                                                                                             | The imaging (CT or MRI scans) were scheduled for each randomised patient until PFS. Thereafter, patients were followed according to thelocalproceduresofthe investigator site. It was expected that the total number of PFS events (n=372) would be reached when the first patient had been followed for 42 months. For patients whose disease would not be expected to progress during the treatment phase, imaging would be performed according to the CSP until 42 months or until the number of PFS events (n=372) was reached.   |                 |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Version 4.0 (06 January 2017) | An increase of the number of randomised patients from 612 to 762 patients and prolongation of recruitment period from 18 to 24 months (Sections 9.8 and 11.1).                                                                                                                        | Amendmentmade due to expanding knowledge of the benefit of PARP inhibitors in treating patients with ovarian cancer, with emerging evidence that different levels of benefit may be achieved depending on the genetic pre-disposition of an individual patient. The plannedsamplesizewas increased to be able to detect a significant difference in the                                                                                                                                                                               | ARCAGY Research |
| Version 4.0 (06 January 2017) | Addition of an exploratory objective: \"Explore the time to next severe toxicity (Grade 4 neutropenia lasting >7 days, Grade ≥3 febrile neutropenia, Grade 4 thrombocytopenia with bleeding or platelet transfusion, Grade ≥3 non-haematological toxicity) in both arms.\" (Section 8). | To explore whether olaparib when compared with placebo can delay the occurrence of a severe toxicity during study andsubsequenttreatment administration.                                                                                                                                                                                                                                                                                                                                                                              | ARCAGY Research |
|                               | Modification of guidance for management of AEs of anaemia (only olaparib or placebo treatment was to be interrupted until haemoglobin levels returned to ≥10 g/dL) (Section 12.1).                                                                                                    | Clarification that bevacizumab treatment could be maintained during AEs of anaemia unless CTCAE Grade 3 or worse, with onset of neutropenia and/or thrombocytopenia.                                                                                                                                                                                                                                                                                                                                                                  |                 |
|                               | Modification of Sponsor's name from ARCAGY GINECO toARCAGY Research (Section 6.1 and throughout CSR).                                                                                                                                                                                 | Administrative purposes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                 |

<div style=\"page-break-after: always\"></div>

| Version 5.0 (22 December 2017)   | Removal of the planned interim efficacy analysis (after 229 PFS events) (Sections 9.8 and 11.1).                                                                                                                                                | The interim efficacy analysis was due to occur shortly after studyrecruitment was completed and was considered of limited value at that point as all patients were already recruited and undisputable efficacy could not be declared with such a short follow-up.   | ARCAGY Research   |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Version 5.0 (22 December 2017)   | Modification of the frequency of haematology testing during Month 6 to Month 12 on study (Sections 9.8.6 and 12.4.1).                                                                                                                           | To bring haematology testing requirements in line with olaparib labelling recommendations.                                                                                                                                                                          | ARCAGY Research   |
| Version 6.0 (03 October 2018)    | Expansion of the exploratory objective exploring pre-planned subgroup analyses of efficacy to include clinical characteristics and tumour homologous recombination deficiency status (Sections 8, 9.8.3 and 11.1.5).                            | Emerging data from the NOVA trial on the importance of different HR deficiency subgroups on efficacy of PARPinhibitors with different levels of benefit observed according to the genetic profile of the tumour (BRCAm, HRD positive/negative; Mirza et al 2016).   | ARCAGY Research   |
| Version 6.0 (03 October 2018)    | Clarification that olaparib or placebo treatment should be stopped after 2 years of exposure unless the investigator considered that the patient could get a clinical benefit by prolonging the experimental treatment (Sections 9.5 and 12.1). | Amendment made to bring the CSP in line with olaparib labelling recommendations.                                                                                                                                                                                    | ARCAGY Research   |
|                                  | Clarification that an exploratory analysis of efficacy (PFS and OS) by region (Europe vs Japan) would be performed Note the Japanese cohort were to be included in the FAS per protocol (Sections 9.8 and 11.1).                                | An analysis by region was not originally planned, but was subsequently considered to be useful.                                                                                                                                                                     |                   |

<div style=\"page-break-after: always\"></div>

| Version 7.0 (28 February 2019)   | Modification of statistical methodology to add an IA of PFS2 and OS at the same time as PFS analysis (Section 9.8).                                                                       | Interim analyseswerenot originally planned, but were subsequently considered tobe required for regulatory puposes.                                                    | ARCAGY Research   |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Version 7.0 (28 February 2019)   | Addition of visits during the follow-up of patients (Section 9.1).                                                                                                                        | Additional visits added for follow-up of patients whose last visit occurred more than 12 weeks prior to any DCO date for data analysis, to update the disease status. | ARCAGY Research   |
| Version 7.0 (28 February 2019)   | Addition of clarification for the definition of an SAE (excluding planned hospitalisations or hospitalisations without other related seriousness criteria) (Sections 9.8.6 and 12.3.1.1). | Accurate reporting of SAEs.                                                                                                                                           | ARCAGY Research   |
| Version 7.0 (28 February 2019)   | Addition of details regarding the data protection methodology (Section 5.2).                                                                                                              | Compliance with EU data protection regulations.                                                                                                                       | ARCAGY Research   |

All protocol amendments were approved by ARCAGY Research before being submitted to a regulatory authority and/or an IRB/IEC.

## Protocol deviations

Table 5: Important protocol deviations (FAS)

|                                                                                                                                                                                               | Number (%) of patients        | Number (%) of patients       | Number (%) of patients   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|------------------------------|--------------------------|
|                                                                                                                                                                                               | Olaparib/ bevacizumab (N=537) | Placebo/ bevacizumab (N=269) | Total (N=806)            |
| Number of patients with at least 1 important deviation?                                                                                                                                       | 35 (6.5)                      | 13 (4.8)                     | 48 (6.0)                 |
| Inclusion criterion not met (platinum-taxane based regimen must have consisted of a maximum of 9 treatment cycles)                                                                            | 0                             | 1 (0.4)                      | 1 (0.1)                  |
| Inclusion criterion not met (patients must have been randomised nomore than9weeks after their last dose of chemotherapy)                                                                      | 2 (0.4)                       | 1 (0.4)                      | 3 (0.4)                  |
| Inclusion criterion not met (histologically confirmed high- grade serous, endometrioid, or other epithelial non mucinous ovarian cancer in a patient with gBRCAl or 2 deleterious mutation).b | 1 (0.2)                       | 0                            | 1 (0.1)                  |
| Baseline RECIST scan >28 days (+14 days window) beforerandomisation                                                                                                                           | 5 (0.9)                       | 3 (1.1)                      | 8 (1.0)                  |
| GCP violation: SAEreporting                                                                                                                                                                   | 8 (1.5)                       | 0                            | 8 (1.0)                  |
| Lack ofRECIST scans on >2occasions beforeevidence of disease progression according to RECIST                                                                                                  | 1 (0.2)                       | 1 (0.4)                      | 2 (0.2)                  |
| Other malignancy within the last 5 years except history as described in protocol                                                                                                              | 1 (0.2)                       | 0                            | 1 (0.1)                  |
| Patients randomised but who did not receive olaparib/matching placebo due to site error                                                                                                       | 2 (0.4)                       | 2 (0.7)                      | 4 (0.5)                  |
| Patientsrandomisedwhoreceived atreatmentbottleother than that to which they were allocatedd                                                                                                   | 15 (2.8)                      | 5 (1.9)                      | 20 (2.5)                 |

a Important protocol deviations before the start of treatment and during treatment. b Patient with clear cell histology with no evidence of gBRCA mutation. c Late reporting of an AESI for olaparib or Suspected Unexpected Serious Adverse Reactions. d The majority of patients received 1 incorrect bottle. The maximum number of incorrect bottles

<div style=\"page-break-after: always\"></div>

received was 6. Note: No patient had more than 1 important protocol deviation (see Appendix 16.2.2.1). Data derived from Table 14.1.2.

Patients who missed two or more consecutive RECIST assessments were 7 (1.3%) and 3 (1.1%) in the olaparib-bevacizumab  and  placebo-bevacizumab  arms,  respectively,  whereas  patients  who  missed  one RECIST  assessment  were  112  (20.9%)  and  44  (16.4%)  in  the  olaparib-bevacizumab  and  placebobevacizumab arms, respectively. There were 229 (42.6%) and 66 (24.5%) patients censored less than or equal to one scheduled tumour assessment interval (+ 2 weeks) before DCO in the olaparib-bevacizumab and placebo-bevacizumab arm, respectively. There were 28 (5.2%) and 9 (3.2%) patients censored more than one scheduled tumour assessment interval (+ 2 weeks) before DCO in the olaparib-bevacizumab and placebo-bevacizumab arm, respectively.

## Baseline data

Table 6 : Selected demographics and baseline characteristics (FAS)

|                                  | Olaparib/bevacizumab (n=537)   | Placebo/bevacizumab (n=269)   |
|----------------------------------|--------------------------------|-------------------------------|
| Demographics                     |                                |                               |
| Age (years)                      |                                |                               |
| Mean (SD)                        | 60.8 (9.4)                     | 59.2 (10.1)                   |
| Median (range)                   | 61.0 (32-87)                   | 60.0 (26-85)                  |
| Age group (years), n (%)         |                                |                               |
| <50                              | 67 (12.5)                      | 47 (17.5)                     |
| ≥50 to <65                       | 265 (49.3)                     | 135 (50.2)                    |
| ≥65                              | 205 (38.2)                     | 87 (32.3)                     |
| Disease characteristics          |                                |                               |
| ECOG Performance status, n (%)   |                                |                               |
| (0) Normal activity              | 378 (70.4)                     | 189 (70.3)                    |
| (1) Restricted activity          | 153 (28.5)                     | 76 (28.3)                     |
| Missing                          | 6 (1.1)                        | 4 (1.5)                       |
| Tumour characteristics           |                                |                               |
| Primary tumour location, n (%)   |                                |                               |
| Ovary                            | 456 (84.9)                     | 238 (88.5)                    |
| Fallopian tubes                  | 39 (7.3)                       | 11 (4.1)                      |
| Primary peritoneal               | 42 (7.8)                       | 20 (7.4)                      |
| FIGO Staging, n (%)              |                                |                               |
| IIIB                             | 43 (8.0)                       | 17 (6.3)                      |
| IIIC                             | 335 (62.4)                     | 169 (62.8)                    |
| IV                               | 159 (29.6)                     | 83 (30.9)                     |
| CA-125 status at baseline, n (%) |                                |                               |
| CA- 125 levels ≤ULN              | 463 (86.2)                     | 234 (87.0)                    |
| CA-125 levels >ULN               | 74 (13.8)                      | 34 (12.6)                     |
| Missing                          | 0                              | 1 (0.4)                       |
| Histology type, n (n%)           |                                |                               |
| Serous                           | 519 (96.6)                     | 253 (94.1)                    |
| Endometrioid                     | 12 (2.2)                       | 8 (3.0)                       |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                        | Olaparib/bevacizumab (n=537)                                                         | Placebo/bevacizumab (n=269)                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Clear cell                                                                                                                             | 2 (0.4)                                                                              | 0                                                                                    |
| Undifferentiated                                                                                                                       | 1 (0.2)                                                                              | 6 (2.2)                                                                              |
| Other                                                                                                                                  | 3 (0.6)                                                                              | 2 (0.7)                                                                              |
| Type of surgery and outcome                                                                                                            |                                                                                      |                                                                                      |
| Any surgery, n (%)                                                                                                                     | 499 (92.9)                                                                           | 248 (92.2)                                                                           |
| Residual macroscopic disease                                                                                                           | 176 (35.3)                                                                           | 88 (35.5)                                                                            |
| No residual macroscopic disease                                                                                                        | 323 (64.7)                                                                           | 160 (64.5)                                                                           |
| Patients with initial debulking surgery, n (%)                                                                                         | 271 (50.5)                                                                           | 138 (51.3)                                                                           |
| Residual macroscopic disease                                                                                                           | 111 (41.0)                                                                           | 53 (38.4)                                                                            |
| No residual macroscopic disease                                                                                                        | 160 (59.0)                                                                           | 85 (61.6)                                                                            |
| Patients with interval debulking surgery, n (%)                                                                                        | 228 (42.5)                                                                           | 110 (40.9)                                                                           |
| Residual macroscopic disease                                                                                                           | 65 (28.5)                                                                            | 35 (31.8)                                                                            |
| No residual macroscopic disease                                                                                                        | 163 (71.5)                                                                           | 75 (68.2)                                                                            |
| Patients without surgery, n (%)                                                                                                        | 38 (7.1)                                                                             | 21 (7.8)                                                                             |
| First line treatment outcome at screening (obtained from the randomisation schedule)                                                   | First line treatment outcome at screening (obtained from the randomisation schedule) | First line treatment outcome at screening (obtained from the randomisation schedule) |
| NED with complete macroscopic resection at initial debulking surgery                                                                   | 170 (31.7)                                                                           | 86 (32.0)                                                                            |
| NED/CR with complete macroscopic resection at interval debulking surgery                                                               | 166 (30.9)                                                                           | 84 (31.2)                                                                            |
| NED/CR at screening, in patient who had either incomplete resection (at initial or interval debulking surgery) or no debulking surgery | 82 (15.3)                                                                            | 40 (14.9)                                                                            |
| Partial response                                                                                                                       | 119 (22.2)                                                                           | 59 (21.9)                                                                            |
| First line treatment outcome at screening (obtained from the eCRF)                                                                     | First line treatment outcome at screening (obtained from the eCRF)                   | First line treatment outcome at screening (obtained from the eCRF)                   |
| NED with complete macroscopic resection at initial debulking surgery                                                                   | 158 (29.4)                                                                           | 83 (30.9)                                                                            |
| NED/CR with complete macroscopic resection at interval debulking surgery                                                               | 158 (29.4)                                                                           | 75 (27.9)                                                                            |
| NED/CR at screening, in patient who had either incomplete resection (at initial or interval debulking surgery) or no debulking surgery | 80 (14.9)                                                                            | 36 (13.4)                                                                            |
| Partial response                                                                                                                       | 134 (25)                                                                             | 73 (27.1)                                                                            |
| Not applicable as per eCRF                                                                                                             | 7 (1.3)                                                                              | 2 (0.7)                                                                              |
| Screening laboratory tBRCA status (obtained from the randomisation schedule)                                                           | Screening laboratory tBRCA status (obtained from the randomisation schedule)         | Screening laboratory tBRCA status (obtained from the randomisation schedule)         |
| Deleterious mutation                                                                                                                   | 161 (30.0)                                                                           | 80 (29.7)                                                                            |
| Absence of deleterious mutation b                                                                                                      | 376 (70.0)                                                                           | 189 (70.3)                                                                           |
| Screening laboratory tBRCA status on tumour tissue (obtained from the eCRF)                                                            | Screening laboratory tBRCA status on tumour tissue (obtained from the eCRF)          | Screening laboratory tBRCA status on tumour tissue (obtained from the eCRF)          |
| tBRCAm                                                                                                                                 | 157 (29.2)                                                                           | 80 (29.7)                                                                            |
| Non-tBRCAm                                                                                                                             | 380 (70.8)                                                                           | 189 0.3)                                                                             |

a  Stage III combined. b Includes test cancelled/failed patients (i.e., inconclusive and unknown groups).  26 patients on the olaparib/bevacizumab arm and 7 patients on the placebo/bevacizumab arm.

In the HRD-positive subgroup, 65% of patients had complete cytoreduction and 35% of patients had residual microscopic disease.

<div style=\"page-break-after: always\"></div>

Table 7: Previous treatments for ovarian cancer (FAS)

|                    |                             | Number (%6) of patients       | Number (%6) of patients      | Number (%6) of patients   |
|--------------------|-----------------------------|-------------------------------|------------------------------|---------------------------|
| Treatment category | Previous treatment modality | Olaparib/ bevacizumab (N=537) | Placebo/ bevacizumab (N=269) | Total (N=806)             |
| Platimm            | Carboplatin                 | 536 (99.8)                    | 268 (99.6)                   | 804 (99.8)                |
|                    | Cisplatin                   | 5 (0.9)                       | 3 (1.1)                      | 8 (1.0)                   |
| Taxane             | Paclitaxel                  | 533 (99.3)                    | 265 (98.5)                   | 798 (99.0)                |
|                    | Docetaxel                   | 14 (2.6)                      | 8 (3.0)                      | 22 (2.7)                  |
|                    | No taxane                   | 0                             | 1 (0.4)                      | 1 (0.1)                   |
| Bevacizimab        | 91                          | 537 (100)                     | 269 (100)                    | 806 (100)                 |

FAS Full Analysis Set.

Data derived from Table 14.1.10.1.

The study randomised 806 patients (2:1 randomisation: 537 olaparib/bevacizumab: 269 placebo/bevacizumab) who had no evidence of disease (NED) due to complete surgical resection, or who were in complete response (CR), or partial response (PR) following completion of first-line platinumcontaining chemotherapy and bevacizumab. Patients had completed a minimum of 4 and a maximum of 9 cycles, with the majority (63%) having received 6 cycles of first line platinum-taxane based chemotherapy, including a minimum of 2 cycles of bevacizumab in combination with the 3 last cycles of chemotherapy. The median number of bevacizumab cycles prior to randomisation was 5.

<div style=\"page-break-after: always\"></div>

Table 8: Number of cycles of previous first line treatment prior to randomisation (FAS)

|                    | Nunber (%) of patients        | Nunber (%) of patients       | Nunber (%) of patients   |
|--------------------|-------------------------------|------------------------------|--------------------------|
| Number of cycles   | Olaparib/ bevacizumab (N=537) | Placebo/ bevacizumab (N=269) | Total (N=806)            |
| Platinum/taxane    |                               |                              |                          |
| <4                 | 1 (0.2)                       | 2 (0.7)                      | 3 (0.4)                  |
| 4                  | 1 (0.2)                       | 0                            | 1 (0.1)                  |
| 5                  | 18 (3.4)                      | 9 (3.3)                      | 27 (3.3)                 |
| 6                  | 341 (63.5)                    | 165 (61.3)                   | 506 (62.8)               |
| 7                  | 73 (13.6)                     | 41 (15.2)                    | 114 (14.1)               |
| 8                  | 61 (11.4)                     | 27 (10.0)                    | 88 (10.9)                |
| 9                  | 42 (7.8)                      | 23 (8.6)                     | 65 (8.1)                 |
| >9                 | 0                             | 1 (0.4)                      | 1 (0.1)                  |
| No platinum/taxane | 0                             | 1 (0.4)                      | 1 (0.1)                  |
| Platinum           |                               |                              |                          |
| <4                 | 0                             | 0                            | 0                        |
| 4                  | 0                             | 0                            | 0                        |
| 5                  | 4 (0.7)                       | 2 (0.7)                      | 6 (0.7)                  |
| 6                  | 341 (63.5)                    | 164 (61.0)                   | 505 (62.7)               |
| 7                  | 78 (14.5)                     | 48 (17.8)                    | 126 (15.6)               |
| 8                  | 63 (11.7)                     | 28 (10.4)                    | 91 (11.3)                |
| 9                  | 51 (9.5)                      | 26 (9.7)                     | 77 (9.6)                 |
| >9                 | 0                             | 1 (0.4)                      | 1 (0.1)                  |
| No platinum        | 0                             | 0                            | 0                        |
| Bevacizumab        |                               |                              |                          |
| 1                  | 0                             | 0                            | 0                        |
| 2                  | 21 (3.9)                      | 12 (4.5)                     | 33 (4.1)                 |
| 3                  | 87 (16.2)                     | 41 (15.2)                    | 128 (15.9)               |
| 4                  | 100 (18.6)                    | 56 (20.8)                    | 156 (19.4)               |
| 5                  | 120 (22.3)                    | 42 (15.6)                    | 162 (20.1)               |
| >5                 | 209 (38.9)                    | 118 (43.9)                   | 327 (40.6)               |
| No bevacizumab     | 0                             | 0                            | 0                        |

Patients were counted as to have received a cycle of therapy as soon as the infusion had started. Platinum-taxane based regimen must have consisted of a minimum of 6 treatment cycles and a maximum of 9. However, if platinumbased therapy was discontinued early as a result of non-haematological toxicities specifically related to the platinum regimen, (i.e., neurotoxicity, hypersensitivity etc), patients must have received a minimum of 4 cycles of the platinum regimen. Patients must have received, prior to randomisation, a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of platinum-based chemotherapy. Only in cases of interval debulking surgery, was it permitted to receive only 2 cycles of bevacizumab in combination with the last 3 cycles of platinum-based chemotherapy.

<div style=\"page-break-after: always\"></div>

Table 9: Allowed concomitant medications during study treatment (FAS)

|                                                            | Number (9b) of patients       | Number (9b) of patients      | Number (9b) of patients   |
|------------------------------------------------------------|-------------------------------|------------------------------|---------------------------|
| Medicaion class                                            | Olaparib/ bevacizumab (N=537) | Placebo/ bevacizumab (N=269) | Total (N=806)             |
| Number of patients with amy allowed concomitamtmedlication | 433 (80.6)                    | 193 (71.7)                   | 626 (77.7)                |
| Antibiotic                                                 | 244 (45.4)                    | 116 (43.1)                   | 360 (44.7)                |
| Antibypertensive dnug                                      | 142 (26.4)                    | 110 (40.9)                   | 252 (31.3)                |
| Continuous or intenmittent antiemetic agent                | 192 (35.8)                    | 45 (16.7)                    | 237 (29.4)                |
| Auticoaguant                                               | 85 (15.8)                     | 33 (12.3)                    | 118 (14.6)                |
| Red blood cell trausfusion                                 | 100 (18.0)                    | 4 (1.5)                      | 104 (12.9)                |
| Erythropoietin                                             | 30 (5.6)                      | 3 (1.1)                      | 33 (4.1)                  |
| Gramulocyte-colony stimulating factor                      | 7 (1.3)                       | (s1) +                       | 11 (1.4)                  |
| Platelet transfnsion                                       | 5 (0.9)                       | 1 (0.4)                      | 6 (0.7)                   |

Includes medication with an onset date on or after the date of first dose and up to and including 30 days followingthe date oflast dose ofolapanib orplacebo.Alsoincludesmedicationwith an onset datepriorto the date of first dose but contiuued after the date of first dlose.

FAS Full Amalysis Set.

Data derived from Table 14.1.14.1.

Table 10: Disallowed concomitant medications during study treatment (FAS)

|                                                             | Number (9o) of patients       | Number (9o) of patients      | Number (9o) of patients   |
|-------------------------------------------------------------|-------------------------------|------------------------------|---------------------------|
| Mledication class                                           | Olaparib/ bevaicizumab (=537) | Placebo! bevacizumab (N=269) | Total (N=80.0)            |
| Nummber of patientswithany dlisallowedcomcomitamtmedication | 4 (0.7)                       | 3 (1.1)                      | 7 (0.9)                   |
| Antibiotic                                                  | 4 (0.7)                       | 2 (0.7)                      | 6 (0.7)                   |
| Clarithromycin                                              | 4 (0.7)                       | 2 (0.7)                      | 6 (0.7)                   |
| Antihypertensive dnug                                       | 0                             | 1 (0.4)                      | 1 (0.1)                   |
| Carmen                                                      | 0                             | 1 (0.4)                      | 1 (0.1)                   |

Includes medication with an onset date on or after the date of first dose and up to and including 30 days followingthedateoflastdoseofolapaniborplacebo.Alsoincludesmedicationwithanonsetdatepniortothe dateoffirstdlosebut coutimuedafterthhedateoffirstdlose.

FAS Full Amalysis Set.

Data deniwed fnom Table 14.1.14.2.

## BRCA mutation status

In the overall patient population enrolled, 30% of patients in both arms were tBRCAm (deleterious/pathogenic mutation) at screening by local testing and for 4% of patients the BRCAm status was unknown. Retrospective analysis of available clinical samples was conducted in 97% of patients to confirm tBRCAm status and investigate genomic instability score. Among non-tBRCAm patients, 29% (19% of the overall population) had positive GIS predefined in this study as composite score ≥42. When tBRCAm status and positive GIS were combined, patients with HRD-positive, HRD-negative and HRD unknown status in their tumours represented 48%, 34% and 18% of the overall patient population.

<div style=\"page-break-after: always\"></div>

Table 11: Deleterious and suspected deleterious tumour/germline BRCA1/2 mutations, tumour HRR mutation types and Myriad HRD Status (FAS)

|                                             | Number of patients (96)       | Number of patients (96)      | Number of patients (96)   |
|---------------------------------------------|-------------------------------|------------------------------|---------------------------|
|                                             | Olaparib/ bevaicizumab (=537) | Placebol bevacizumab (N=269) | Total (N=806)             |
| Myriad iBRCA status                         |                               |                              |                           |
| TBRCAm                                      | 158 (29.4)                    | 77 (28.6)                    | 235 (29.2)                |
| TBRCAIm                                     | 111 (20.7)                    | 48 (17.8)                    | 159 (19.7)                |
| TBRCA2m                                     | 46 (8.6)                      | 29 (10.8)                    | 75 (9.3)                  |
| tBRCA1momdtBRCA2m                           | 1 (0.2)                       | 0                            | 1 (0.1)                   |
| Mon-tBRCAm\"                                 | 346 (64.4)                    | 174 (64.7)                   | 520 (64.5)                |
| tBRcAtestcancelledfailed                    | 17 (3.2)                      | 10 (3.7)                     | 27 (3.3)                  |
| tBRCA missing                               | 16 (3.0)                      | 8(3.0)                       | 24 (3.0)                  |
| Myriad HRD) status (eBRCAm or≥42cut-ofm)    |                               |                              |                           |
| Myriad HRD stats posilive                   | 255 (47.5)                    | 132 (49.1)                   | 387 (48.0)                |
| Mfymiad HR.Dstahsposilive excludingtBRCAm   | 97 (18.1)                     | 55 (20.4)                    | 152 (18.9)                |
| Mymiad HRD status negative                  | 192 (35.8)                    | 85 (31.6)                    | 277 (34.4)                |
| Mymiad HRD status test cancelledfailed      | 74 (13.8)                     | 44 (16.4)                    | 118 (14.6)                |
| Myriad HRD status missing                   | 16 (3.0)                      | 8 (3.0)                      | 24 (3.0)                  |
| Myriad HRDistatus (oBRCAm or 233 cut-off)   |                               |                              |                           |
| Myriad HRD status positive                  | 292 (54.4)                    | 145 (53.9)                   | 437 (54.2)                |
| Mymiad HRD stahis positive excluding tBRCAm | 134 (25.0)                    | 68 (25.3)                    | 202 (25.1)                |
| MyniadHRDstahusuegalive                     | 155 (28.9)                    | 72 (26.8)                    | 227 (28.2)                |
| Myriad HRDstatus test cancelled/failed      | 74 (13.8)                     | 44 (16.4)                    | 118 (14.6)                |
| Myriad HRD status missing                   | 16 (3.0)                      | 8 (3.0)                      | 24 (3.0)                  |
| Myriad tumour HRRm statusb                  |                               |                              |                           |
| HRRm stahs positive including tBRCAm        | 192 (35.8)                    | 97 (36.1)                    | 289 (35.9)                |
| HRRm stahs positive exchuding tBRCAm        | 34 (6.3)                      | 20 (7.4)                     | 54 (6.7)                  |
| mon-HRRm                                    | 312 (58.1)                    | 154 (57.2)                   | 466 (57.8)                |
| HRR test caucelledlfailed                   | 17 (3.2)                      | 10 (3.7)                     | 27 (3.3)                  |
| HRR. missing                                | 16 (3.0)                      | 8 (3.0)                      | 24 (3.0)                  |

Non-tBRCAm=tBRC.wiVUS HRR genes of interest included in the panel are: BRCA1, BRCA2, A7f, BRIP1, PALB2, RAD5IC, BARD1, CDKI2,CHEK1,CHEK2,FANCL,PPP2R2A,RAD51B,RAD51D,RAD54L.

BRCA breast cancer susceptibility gene; eCRF elecmomic case report fonm; FAS Full Analysis Set; gBRCA homologousrecombination repair gene mutatedmutations; sBRcA somaticBRcd; sBRCAm somaticBRCA mmiated;tBRCAhumorBRCA:tBRCAmtumourBRc.mutated:wnktmkuown:VUSTaniamt ofumcertain sigwifcance; wt wild type.

Sowuce: Table 14.1.8.2.

<div style=\"page-break-after: always\"></div>

Table 12: Summary of BRCA mutation status by Screening laboratory tBRCA and Myriad tBRCA (Full analysis set)

Figure 6: tBRCA concordance in PAOLA-1

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 13: Analysis sets

|                                     | Number (%o) of patients   | Number (%o) of patients   | Number (%o) of patients   |
|-------------------------------------|---------------------------|---------------------------|---------------------------|
|                                     | Olaparib/ bevacizumab     | Placebo/ bevacizumab      | Total                     |
| Patientsrandomised                  | 537                       | 269                       | 806                       |
| PatientsincludedinFAS               | 537 (100)                 | 269 (100)                 | 806 (100)                 |
| PatientsincludedinSAS               | 535 (99.6)                | 267 (99.3)                | 802 (99.5)                |
| Combination Phase only              | 534 (99.4)                | 267 (99.3)                | 801 (99.4)                |
| Patients excluded from SASa         | 2 (0.4)                   | 2 (0.7)                   | 4 (0.5)                   |
| Did not receive olaparib or placebo | 2 (0.4)                   | 2 (0.7)                   | 4 (0.5)                   |

a  An individual patient could have been excluded for more than 1 reason. FAS: all randomised patients analysed on an ITT basis. SAS: all patients who received at least 1 dose of study treatment and had at least 1 safety follow-up. Combination phase was from the first dose of combination treatment (bevacizumab/olaparib or placebo) until the last dose of bevacizumab +21 days whilst on combination treatment. FAS Full Analysis Set; ITT intention-to-treat; SAS Safety Analysis Set.

## Outcomes and estimation

## Primary endpoint: PFS by investigator assessment

PFS (based on investigator assessment) was the primary variable for the study and was analysed based on the primary DCO (22 March 2019) using the FAS population.

At the time of PFS analysis, the median duration of treatment with Lynparza was 17.3 months and 15.6 months for placebo. The median duration of bevacizumab post-randomisation was 11.0 months on the Lynparza arm and 10.4 months on the placebo arm.

The progression status based on investigator assessment at the time of PFS analysis is presented below.

<div style=\"page-break-after: always\"></div>

Table 14: Progression status at the time of PFS analysis based on investigator assessment (FAS) (DCO 22 March 2019)

|                    |                                       | Number (%o) of patients      | Number (%o) of patients     |
|--------------------|---------------------------------------|------------------------------|-----------------------------|
| Progression status | Iype of event                         | Olaparib/bevacizumab (N=537) | Placebo/bevacizumab (N=269) |
| Progression        | Total                                 | 280 (52.1)                   | 194 (72.1)                  |
| Progression        | RECIST progression*                   | 274 (51.0)                   | 188 (69.9)                  |
| Progression        | Target lesionsb                       | 8 (1.5)                      | 6 (2.2)                     |
| Progression        | Non-target lesionsb                   | 47 (8.8)                     | 22 (8.2)                    |
| Progression        | New lesionsb                          | 250 (46.6)                   | 172 (63.9)                  |
| Progression        | Deathc                                | 6 (1.1)                      | 6 (2.2)                     |
| No progression     | Total                                 | 257 (47.9)                   | 75 (27.9)                   |
| No progression     | Censored RECIST progressiond          | 3 (0.6)                      | 0                           |
| No progression     | Censored death*                       | 2 (0.4)                      | 1 (0.4)                     |
| No progression     | Progression free at time of analysisf | 240 (44.7)                   | 69 (25.7)                   |
| No progression     | Lost to follow-ups                    | 2 (0.4)                      | 0                           |
| No progression     | Withdrawn consents                    | 10 (1.9)                     | 5 (1.9)                     |
| No progression     | Discontimued studys                   | 0                            | 0                           |

b Not necessarily mutually exclusive categories.

Does not include RECIST progression events that occurred after 2 or more missed visits or within 2 visits of baseline where the patient had no evaluable visits or did not have a baseline assessment.

Death in the absence of RECIST progression or death that occured within 2 visits of baseline where the patient had no evaluable visits or did not have a baseline assessment. Does not include deaths that occurred after 2 or more missed visits.

- Death which occured after 2 or more missed visits in the absence of RECIST progression.
- RECIST progression event occured after 2 or more missed visits or within 2 visits of baseline where the patient had no evaluable visits or did not have a baseline assessment.
- Patients known to be alive and without RECIST progression.

Patients at last evaluable RECIST assessment.

Table 15: Summary of analysis of progression-free survival by investigator (FAS) (DCO 22 March 2019)

|                                        | Olaparib/bevacizumab (N=537)   | Placebo/bevacizumab (N=269)   |
|----------------------------------------|--------------------------------|-------------------------------|
| n (%) of events                        | 280 (52.1)                     | 194 (72.1)                    |
| Treatment effect                       |                                |                               |
| Median PFS (95% CI), monthsb           | 22.1 (21.8, 24.1)              | 16.6 (15.4, 18.6)             |
| HR                                     | 0.59                           | 0.59                          |
| 95% CI°                                | 0.49,0.72                      | 0.49,0.72                     |
| 2-sided p-valued                       | c0.0001                        | c0.0001                       |
| Progression free at 6 months (%)b      | 88.8                           | 85.3                          |
| Progression free at 12 months (%)b     | 78.0                           | 65.6                          |
| Progression ftee at 18 months (%)b     | 62.3                           | 45.8                          |
| Progression free at 24 months (%)b     | 46.0                           | 27.7                          |
| Median (IQR) follow-up for PFS, months | 22.7 (18.0, 27.7)              | 24.0 (18.7,27.7)              |

PFS was defined as time from randomisation umtil the date of objective radiological disease progression according to modified RECIST 1.1 or death.

b Caleulated using KM techmiques

Estimated from a stratified Cox proportional hazards model stratified by first line treatment outcome and tBRCA status.

d Determined using log-rank test stratified by first line treatment outcome and tBRCA status.

CI confidence interval; FAS Full Analysis Set; HR hazard ratio; IQR interquartile range; KM Kaplan-Meier; PFS progression-ftee suvival; RECIST Response Evaluation Criteria in Solid Tumous.

Time from randomisation to date of censoring.

Data derived from Table 14.2.1.2.

<div style=\"page-break-after: always\"></div>

Figure  7:  Progression-free  survival  by  investigator,  Kaplan-Meier  plot  (FAS)  (DCO  22  March 2019)

<!-- image -->

## Secondary endpoints

## Time from randomisation to second progression or death

PFS2  events  were  based  on  radiological,  CA-125  or  symptomatic  progression  as  assessed  by  the investigator  or  death.  At  the  time  of  the  PFS  analysis,  the  interim  PFS2  data  were  39.1%  mature (315 events/806 patients).

<div style=\"page-break-after: always\"></div>

Table 16: Second Progression-free survival (FAS) (DCO 22 March 2019)

|                                                                       | Olaparib/bevacizumab (N=537)   | Placebo/bevacizumab (N=269)   |
|-----------------------------------------------------------------------|--------------------------------|-------------------------------|
| n (%) of eventsa                                                      | 196 (36.5)                     | 119 (44.2)                    |
| Treatment effect                                                      |                                |                               |
| Median PFS2 (95% CI), monthsb                                         | 32.3 (29.2, 39.8)              | 30.1 (25.7, 32.6)             |
| HR.6                                                                  | 0.86                           | 0.86                          |
| 95% CI                                                                | 0.69, 1.09                     | 0.69, 1.09                    |
| 2-sided p-valued                                                      | 0.2097                         | 0.2097                        |
| Second progression free at 6 months (%)b                              | 98.3                           | 97.3                          |
| Second progression free at 12 months (%)b                             | 88.7                           | 86.7                          |
| Second progression free at 18 months (%)b                             | 79.0                           | 80.1                          |
| Second progression free at 24 months (%。)b                            | 67.0                           | 64.6                          |
| Median (IQR) follow-up for second progression-free suuvival (months)- | 24.0 (19.8, 28.3)              | 24.8 (21.6, 28.2)             |

b Calculated using KM techmiques.

d

PFS2 was defined as time from randomisation to second progression or death.

Estimated from a stratified Cox proportional hazards model stratified by first line treatment outcome and tBRCA status.

Time from randomisation to date of censoring.

CI confidence interval; FAS Full Analysis Set; HR hazard ratio; IQR interquartile range; KM Kaplan-Meier; RECIST Response Evaluation Criteria in Solid Tumours. Data derived from Table 14.2.2.2.

The 2-sided sigmificance level at the interim PFS2 analysis was 0.02092 based on an infommation fraction of 0.766.

<!-- image -->

FAS Full Analysis Set; PFS2 time from randomisation to second progression or death.

Figure 8: Second progression-free survival, Kaplan-Meier plot (FAS) (DCO 22 March 2019)

## Overall survival

At the time of the primary analysis (DCO 22 March 2019), the interim OS data were immature (25.9% mature [209 events/806 patients]; HR 1.01; 95% CI 0.76 to 1.36) with similar proportions of deaths reported on each arm.

<div style=\"page-break-after: always\"></div>

At the time of the DCO for the updated OS analysis (30 September 2019), six months after the primary DCO (22 March 2019), the OS data maturity increased to 32% with 259 events (168 patients had died in the olaparib/bevacizumab arm and 91 patients in the placebo/bevacizumab arm).

Table 17: Summary of overall survival status (FAS)

|                             | DC022 March 2019              | DC022 March 2019             | DCO 30 September 2019         | DCO 30 September 2019        |
|-----------------------------|-------------------------------|------------------------------|-------------------------------|------------------------------|
|                             | Olaparib! bevacizumab (n=537) | Placebo! bevacizumab (n=269) | Olaparib/ bevacizumab (n=537) | Placebo/ bevacizumab (n=269) |
| n (96) of events            | 139 (25.9)                    | 70 (26.0)                    | 168 (31.3)                    | 91 (33.8)                    |
| Treatment effect            |                               |                              |                               |                              |
| Median OS (9596 CD), months | 39.4 (38.4, Not reached)      | Not reached                  | Not reached                   | 45.7 (37.4, Not reached)     |
| HR. (9596 CI)               | 1.01 (0.76, 1.36)             | 1.01 (0.76, 1.36)            | 0.94 (0.73, 1.21)             | 0.94 (0.73, 1.21)            |
| p-value (2-sided)           | 0.9270                        | 0.9270                       | Not caleuated                 | Not caleuated                |
| Alive at 6 months (96)      | 99.4                          | 99.2                         | 99.4                          | 99.2                         |
| Alive at 12 months (96)     | 94.7                          | 94.0                         | 94.7                          | 94.0                         |
| Alive at 18 months (96)     | 87.6                          | 86.7                         | 87.6                          | 86.7                         |
| Alive at 24 months (96)     | 79.1                          | 78.0                         | 79.8                          | 78.7                         |

CI = confidence intenval; CSR. = clinical shdy report; DcO =data cut-off; FAS = finll Analysis Set; HR. = hazard ratio:Os=overall sunvival.

Souwrce: Table 14.2.3.2, PA0LA-1 CSR. (DCO 22 March 2019): Table 14.2.3.2 (DC0 30 September 2019).

<!-- image -->

DCO= data cut-off; FAS =fill Analysis Set; KM =Kaplan-Meier.

Source: Figure 14.2.3.1 (DCO 30 September 2019).

Figure 9: Overall survival, Kaplan-Meier plot (FAS), DCO 30 September 2019

<div style=\"page-break-after: always\"></div>

## Time from randomisation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death

Table 18: Summary of TFST (FAS), DCO 22 March 2019

|                                   | Olaparib/bevacizumab (N=537)   | Placebo/bevacizumab (N=269)   |
|-----------------------------------|--------------------------------|-------------------------------|
| n (%) of eventsa                  | 275 (51.2)                     | 190 (70.6)                    |
| Treatment effect                  |                                |                               |
| Median TFST (95% CI), monthsb     | 24.8 (23.4, 27.9)              | 18.5 (17.2, 20.1)             |
| HR.c                              | 0.58                           | 0.58                          |
| 95% CIc                           | 0.48,0.70                      | 0.48,0.70                     |
| 2-sided p-valued                  | c0.0001                        | c0.0001                       |
| Mediam follow-up for TFST, months | 25.1                           | 25.1                          |

- b Calculated using KM techmiques.

TFST was defined as time from randomisation to first subsequent therapy or death.

- Estimated from a stratified Cox proportional hazards model stratified by first line treatment outcome and tBRCA status.
- d Determined using log-rank test stratified by first line treatment outcome and tBRCA status and not controlled for multiplicity.

BRCA breast cancer susceptibility gene; CI confidence interval; FAS Full Analysis Set; HR hazard ratio; KM Kaplan-Meier; tBRCA tumour BRCA.

- Time from randomisation to date of censoring.

Data derived from Table 14.2.4.1.

<!-- image -->

FAS Full Analysis Set; TFST time from randomisation to first subsequent therapy or death. Data derived from Figuue 14.2.4.1.

Figure 10: TFST, Kaplan-Meier plot (FAS), DCO 22 March 2019

<div style=\"page-break-after: always\"></div>

## Time from randomisation to the earlier of second subsequent therapy start date following study treatment discontinuation, or death (TSST)

Table 19: Summary of TSST (FAS), DCO 22 March 2019

|                                    | Olaparib/bevacizumab (N=537)   | Placebo/bevacizumab (N=269)   |
|------------------------------------|--------------------------------|-------------------------------|
| n (%) of eventsa                   | 194 (36.1)                     | 119 (44.2)                    |
| Treatment effect                   |                                |                               |
| Median TSST (95% CD), monthsb      | 33.8 (31.6, NC)                | 30.4 (26.5, 33.9)             |
| HR                                 | 0.79                           | 0.79                          |
| 95% CI                             | 0.63, 1.00                     | 0.63, 1.00                    |
| 2-sided p-valued                   | 0.0444                         | 0.0444                        |
| Median follow-up for TSST, months* | 25.2                           | 25.1                          |

b Caleulated using KM techniques.

TSST was defined as time from randomisation to second subsequent therapy or death.

- Estimated from a stratified Cox proportional hazards model stratified by first line treatment outcome and tBRCA status.
- Time from randomisation to date of censoring.
- d controlled for multiplicity.

BRCA breast cancer susceptibility gene; CI confidence interval; FAS Full Analysis Set; HR hazard ratio; KM Kaplan-Meier; tBRCA tumour BRCA.

Data derived from Table 14.2.5.1.

FAS Full Analysis Set; TSST time from randomisation to second subsequent therapy or death.

<!-- image -->

Data derived from Figure 14.2.5.1.

Figure 11: TSST, Kaplan-Meier plot (FAS), DCO 22 March 2019

<div style=\"page-break-after: always\"></div>

## Time from randomisation to discontinuation of treatment or death (TDT)

Figure 12: TDT, Kaplan-Meier plot (FAS), DCO 22 March 2019

<!-- image -->

Table 20: Analysis of time to study treatment discontinuation or death (TDT), FAS, DCO 22 March 2019

<!-- image -->

|                                                                                 | 0-4221           | (N-249) 中        |
|---------------------------------------------------------------------------------|------------------|------------------|
| Total owhnr of events (t) to)                                                   | 479 (01.2)       | 247(91.0)        |
| Hedian (loRi follov-up for eine to stody tseatsent dincontinuation (eonthni Ie] | 21.1 (20.0,22.4) | 21.5 (19.6,22.5) |
| Diseontinuaslon free as ( sonths (h) [b]                                        | 77.6             | 12.1             |
| 9St Condidence Interval                                                         | 73.0,00.9        | 77.0,06.2        |
| Dlusentinuatien fetl at ll eenths                                               | 41.1             | 41.9             |
| Sll Genfidenee Ieterwal                                                         | 07.7,45.9        | 41.0,07.0        |
| Dlncontinoatlon free at Il sonths () [9]                                        | 41.1             | 42.2             |
| PIk Confidenee Interval                                                         | 44.6,42.0        | 24.2,40.0        |
| Dlscontinuatlon free ae 2l sonths () [b]                                        | 25.1             | 21.0             |
| SSk Genfidhnee Intesva!                                                         | 25.4,11.0        | 17.1,20.2        |
| Piseonwinuawion free as so wnths ()                                             | 0.9              | 0.0              |
| S5l Confidence Interval                                                         | 0.3,2.3          | 0.0,0.0          |
| Diusentinuasion free as pl eentho () (b]                                        |                  | 9.0              |
| Sll Conlidanee Inteewal                                                         |                  | 0.0,0.0          |
| Blscontinuatlon free at ll sonths [b]                                           |                  | 0.0              |
| FSk Gonfidense Interval                                                         |                  | 0.0.0.0          |
| Xadian eisa te oeedy tstataint dioeentinuneien (eonthnl (b)                     | 17.4             | 14.0             |
| 9Wl Confldenee Interwal                                                         | 14.3,19.8        | 10.0,17.3        |
| 29oh gareenelle                                                                 | 6.9              | 0.0              |
| T9th Fareenelle                                                                 | 24.0             | 21.1             |
| Hasard ratio [d]                                                                |                  | 0.03             |
| 19k Cendidense Interval tdi                                                     |                  |                  |
| 2-nidhd p-valoe [el                                                             |                  | 0.0212           |

<div style=\"page-break-after: always\"></div>

## Best objective response (BoR)

Table 21: BoR (FAS - patients with evidence of disease at baseline) (DCO 22 March 2019)

|                 |                                    | Number (%6) of patients       | Number (%6) of patients     |
|-----------------|------------------------------------|-------------------------------|-----------------------------|
| Response status | Best objective response            | Olaparib/ bevacizumab (N=129) | Placebo/ bevacizumab (N=72) |
| Response        | Total                              | 39 (30.2)                     | 18 (25.0)                   |
| Response        | CR                                 | 32 (24.8)                     | 13 (18.1)                   |
| Response        | PR*                                | 7 (5.4)                       | 5 (6.9)                     |
| Non-response    | Total                              | 90 (69.8)                     | 54 (75.0)                   |
| Non-response    | Stable disease ≥24 weeks           | 54 (41.9)                     | 33 (45.8)                   |
| Non-response    | Progression                        | 34 (26.4)                     | 21 (29.2)                   |
| Non-response    | RECIST progression                 | 34 (26.4)                     | 21 (29.2)                   |
| Non-response    | NE                                 | 2 (1.6)                       | 0                           |
| Non-response    | No evaluable follow-up assessments | 2 (1.6)                       | 0                           |

Response did not require confirmation.

Patients with evidence of disease at baseline were considered evaluable for response.

This analysis is based on investigator RECIST assessment. Modified RECIST Version 1.1.

CR complete response; FAS Full Analysis Set; PR. partial response; NE non evaluable; RECIST Response Evaluation Criteria in Solid Tumouus.

Data derived from Table 14.2.8.3.1.

## Time to earliest progression by modified RECIST 1.1, CA-125 or death

Table 22: Summary of time to earliest progression by modified RECIST 1.1, CA-125 or death (FAS) DCO 22 March 2019

|                           | Olaparib/bevacizumab (N=537)   | Placebo/bevacizumab (N=269)   |
|---------------------------|--------------------------------|-------------------------------|
| n (%) ofeventsa           | 287 (53.4)                     | 198 (73.6)                    |
| Treatment effect          |                                |                               |
| Median (95% CD), monthsb  | 22.1 (21.4,25.1)               | 15.8 (13.8, 16.8)             |
| HRc                       | 0.58                           | 0.58                          |
| 95% CI                    | 0.48,0.69                      | 0.48,0.69                     |
| 2-sided p-valued          | -0.0001                        | -0.0001                       |
| Median follow-up, months* | 24.2                           | 24.4                          |

1.1, CA-125 or death.

Time to event was defined as time from randomisation to time of earliest progression by modified RECIST

b Calculated using KM techmiques.

Estimated from a stratified Cox proportional hazards model stratified by first line treatment outcome and tBRCA status.

d Detemmined using log-ramk test stratified by first line treatment outcome and tBRCA status and not controlled for multiplicity.

BRCA breast cancer susceptibility gene; CA-125 cancer antigen-125; CI confidence interval; FAS Full Analysis Set; HR. hazard ratio; KM Kaplan-Meier; RECIST Response Evaluation Criteria in Solid Tuumours; tBRCA tumouur BRCA.

Time from randomisation to date of censoring.

Data derived from Table 14.2.7.1.

<div style=\"page-break-after: always\"></div>

<!-- image -->

CA-125 cancer antigen-125; FAS Full Analysis Set; RECIST Response Evaluation Criteria in Solid Tuumours. Data derived from Figuure 14.2.7.1.

Figure 13: Time to earliest progression by modified RECIST 1.1, CA-125 or death, Kaplan-Meier plot (FAS)

## Health-related quality of life: EORTC QLQ-C30 and EORTC QLQ-OV28

Table 23: Change from baseline in QLQ-C30 global health status/QoL score, MMRM (FAS) (DCO 22 March 2019)

|                        | Olaparib/bevacizumab (N=537)   | Placebo/bevacizumab (N=269)   |
|------------------------|--------------------------------|-------------------------------|
| Average over 24 months | Average over 24 months         | Average over 24 months        |
| n                      | 446                            | 229                           |
| Adjusted mean          | 0.13                           | -0.46                         |
| Standard error         | 0.583                          | 0.824                         |
| 95% CI                 | -1.020, 1.271                  | -2.078, 1.159                 |
| Estimated difference   | 0.59                           | 0.59                          |
| 95% CI for difference  | -1.399,2.570                   | -1.399,2.570                  |
| p-valuea               | 0.5626                         | 0.5626                        |

Baseline was defined as the last evaluable assessment prior to dosing with olaparib or placebo.

Not adjusted for multiplicity.

The analysis was performed using an MMRM analysis of the change from baseline QLQ-C30 QoL score for all post-baseline visits (up to study treatment discontinuation) with treatment, visit and treatment by visit interaction baseline QLQ-C30 QoL score by visit interaction. Treatment, visit and treatment by visit interaction were fixed effects in the model, patient was included as a random effect.

CI confidence interval; FAS Full Analysis Set; MMRM mixed models for repeated measures;

QLQ-C30 quality of life questiomnaire Core 30 item module; QoL quality of life.

Data derived from Table 14.2.9.1.

<div style=\"page-break-after: always\"></div>

Figure 14: Mean (±SD) EORTC QLQ-C30 global health status/QoL score change from baseline across time points, by treatment group (FAS)

<!-- image -->

## Ancillary analyses

## Subsequent therapy

Of patients who received any subsequent therapy, PARP inhibitors were received by 49 (16.4%) of the 298 olaparib/bevacizumab-treated patients and 83 (43.0%) of the 193 placebo/bevacizumab-treated patients (DCO Sept 2019). Out of the 36 patients in the olaparib/bevacizumab arm who received a subsequent PARPi treatment, 34 patients receive it as maintenance treatment and 2 patients as a first subsequent treatment (DCO 22 March 2019).

<div style=\"page-break-after: always\"></div>

Table 24: Summary of subsequent therapies received (FAS)

<!-- image -->

## Sensitivity analyses

Table 25: Sensitivity analysis of progression-free survival (FAS, DCO 22 March 2019)

|                                                                          | Number of events:total number of patients (%)   |   Median PFS (months) |   HR | 95% CI     |
|--------------------------------------------------------------------------|-------------------------------------------------|-----------------------|------|------------|
| PFS by BICR                                                              | Olaparib/bev: 226:537 (42.1)                    |                  26.1 | 0.63 | 0.51, 0.77 |
| PFS by BICR                                                              | Placebo/bev: 146:269 (54.3)                     |                  18.3 | 0.63 | 0.51, 0.77 |
| Evaluation time bias                                                     | Olaparib/bev: 280:537 (52.1)                    |                  20.5 | 0.59 | 0.49, 0.71 |
| Evaluation time bias                                                     | Placebo/bev: 194:269 (72.1)                     |                  14.9 | 0.59 | 0.49, 0.71 |
| Attrition bias                                                           | Olaparib/bev: 279:537 (52.0)                    |                  22.2 | 0.6  | 0.50, 0.72 |
| Attrition bias                                                           | Placebo/bev: 189:269 (70.3)                     |                  16.6 | 0.6  | 0.50, 0.72 |
| eCRF stratification variables                                            | Olaparib/bev: 280:537 (52.1)                    |                  22.1 | 0.58 | 0.48, 0.70 |
| eCRF stratification variables                                            | Placebo/bev: 194:269 (72.1)                     |                  16.6 | 0.58 | 0.48, 0.70 |
| Informative censoring (using BICR)                                       | Olaparib/bev: 293:537 (54.6)                    |                  22.1 | 0.61 | 0.51, 0.74 |
| Informative censoring (using BICR)                                       | Placebo/bev: 203:269 (75.5)                     |                  16.6 | 0.61 | 0.51, 0.74 |
| Estimating HR using the stratified log rank test                         | Olaparib/bev: 280:537 (52.1)                    |                  22.1 | 0.57 | 0.47, 0.69 |
| Estimating HR using the stratified log rank test                         | Placebo/bev: 194:269 (72.1)                     |                  16.6 | 0.57 | 0.47, 0.69 |
| Programmatically derived RECIST visit response (using investigator data) | Olaparib/bev: 285:537 (53.1)                    |                  22.1 | 0.6  | 0.50, 0.72 |
| Programmatically derived RECIST visit response (using investigator data) | Placebo/bev: 194:269 (72.1)                     |                  16.6 | 0.6  | 0.50, 0.72 |

<div style=\"page-break-after: always\"></div>

|                                                         | Number of events:total number of patients (%)                     | Median PFS (months)                                               | HR                                                                | 95% CI                                                            |
|---------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
| Earliest of investigator/BICR assessment of progression | Olaparib/bev: 293:537 (54.6)                                      | 22.0                                                              | 0.58                                                              | 0.49, 0.70                                                        |
| Earliest of investigator/BICR assessment of progression | Placebo/bev: 203:269 (75.5)                                       | 16.0                                                              | 0.58                                                              | 0.49, 0.70                                                        |
| Deviation bias                                          | Analysis not performed as ≤10% patients with specified deviations | Analysis not performed as ≤10% patients with specified deviations | Analysis not performed as ≤10% patients with specified deviations | Analysis not performed as ≤10% patients with specified deviations |

Bev= Bevacizumab; BICR  Blinded Independent Central Review; BRCA Breast cancer susceptibility gene; CI  Confidence interval; CSR  Clinical study report; DCO  Data cut-off; eCRF  Electronic case report form; FAS Full Analysis Set; HR  Hazard ratio; PFS  Progression-free survival; RECIST  Response Evaluation Criteria in Solid Tumours; tBRCA Tumour BRCA. Source: Table 14.2.1.3, Table 14.2.1.4, Table 14.2.1.5, Table 14.2.1.6, Table 14.2.1.7, Table 14.2.1.16, Table 14.2.1.17, Table 14.2.1.18 and Table 14.2.1.19, PAOLA-1 CSR, Module 5.3.5.1.

BICR blinded independent central review; FAS Full Amalysis Set; PFS progression-free suvival. Data derived from Figure 14.2.1.6.

<!-- image -->

Figure 15: Progression-free survival by BICR, Kaplan-Meier plot (FAS) (DCO 22 March 2019 )

<div style=\"page-break-after: always\"></div>

Table 26: Disagreement between investigator and central reviews of RECIST progression (FAS) (DCO 22 March 2019)

|                                                                           | Number (%o) of patients        | Number (%o) of patients       | Difference                                   |
|---------------------------------------------------------------------------|--------------------------------|-------------------------------|----------------------------------------------|
|                                                                           | Olaparib/ bevacizumab (IN=537) | Placebo/ bevacizumab (69t=ND) | Olaparib/ bevacizumab - Placebo/ bevacizumab |
| RECIST progression* declared by:                                          |                                |                               |                                              |
| Investigator and central review                                           | 213 (39.7)                     | 137 (50.9)                    | NA                                           |
| Progression date agreement (within 2 weeks)b                              | 123 (57.7)                     | 85 (62.0)                     | NA                                           |
| Progression date ≥2 weeks earlier by central review than by investigatorb | 71 (33.3)                      | 44 (32.1)                     | NA                                           |
| Progression date ≥2 weeks earlier by imvestigator than by central reviewb | 19 (8.9)                       | 8 (5.8)                       | NA                                           |
| Imvestigator but not central review                                       | 67 (12.5)                      | 57 (21.2)                     | NA                                           |
| Central review but not investigator                                       | 13 (2.4)                       | 9 (3.3)                       | NA.                                          |
| No progression by both                                                    | 244 (45.4)                     | 66 (24.5)                     | NA                                           |
| Early discrepancy rate                                                    | 0.31                           | 0.34                          | -0.03                                        |
| Late discrepancy rated                                                    | 0.49                           | 0.45                          | 0.04                                         |

Progression events that occuured after 2 or more missed visits, were censored at the latest evaluable RECIST assessment, or Day 1 if there were no evaluable visits. Patients with a RECIST progression within 2 visits of baseline who did not have any evaluable visits or did not have a baseline assessment were censored at Day 1.

Percentages were calculated based on the muumber of progressions declared by both investigator and central review.

- Early discrepancy rate is the frequency of investigator declared progressions before central review as a proportion of all investigator progressions.

Late discrepancy rate is the frequency of investigator declared progressions after central review as a proportion of all discrepancies. Modified RECIST Version 1.1.

FAS Full Analysis Set; RECIST Response Evaluation Cniteria in Solid Tuumouurs. Data derived from Table 14.2.1.12.

<div style=\"page-break-after: always\"></div>

## PFS subgroup analyses

Figure 16: Forest plot of progression-free survival subgroup analysis (FAS), (DCO 22 March 2019)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 27: PFS subgroup analyses (FAS): Stratification factors (DCO 22 March 2019)

| Subgroup                                                                 | Olaparib/ bevacizumab (N=537)   | Placebo/ bevacizumab (N=269)   |
|--------------------------------------------------------------------------|---------------------------------|--------------------------------|
| First line treatment outcome at screening (as randomised)                |                                 |                                |
| NED with complete macroscopic resection at initial debulking surgery     |                                 |                                |
| Number of events/total number of patients (%)                            | 57/170 (33.5)                   | 50/86 (58.1)                   |
| Median PFS (months)                                                      | 39.3                            | 20.7                           |
| HR (95% CI)                                                              | 0.47 (0.32, 0.69)               | 0.47 (0.32, 0.69)              |
| NED/CR with complete macroscopic resection at interval debulking surgery |                                 |                                |
| Number of events/total number of patients (%)                            | 91/166 (54.8)                   | 60/84 (71.4)                   |
| Median PFS (months)                                                      | 22.1                            | 18.2                           |
| HR (95% CI)                                                              | 0.69 (0.50, 0.95)               | 0.69 (0.50, 0.95)              |
| NED/CR in patients with incomplete resection or no debulking surgery     |                                 |                                |
| Number of events/total number of patients (%)                            | 43/82 (52.4)                    | 35/40 (87.5)                   |
| Median PFS (months)                                                      | 21.8                            | 12.3                           |
| HR (95% CI)                                                              | 0.37 (0.23, 0.57)               | 0.37 (0.23, 0.57)              |
| PR                                                                       |                                 |                                |
| Number of events/total number of patients (%)                            | 89/119 (74.8)                   | 49/59 (83.1)                   |
| Median PFS (months)                                                      | 16.4                            | 11.2                           |
| HR (95% CI)                                                              | 0.76 (0.54, 1.08)               | 0.76 (0.54, 1.08)              |
| Screening tBRCA status (as randomised)                                   |                                 |                                |
| Deleterious mutation                                                     |                                 |                                |
| Number of events/total number of patients (%)                            | 44/161 (27.3)                   | 48/80 (60.0)                   |
| Median PFS (months)                                                      | 37.2                            | 22.0                           |
| HR (95% CI)                                                              | 0.34 (0.23, 0.51)               | 0.34 (0.23, 0.51)              |
| Absence of deleterious mutation                                          |                                 |                                |
| Number of events/total number of patients (%)                            | 236/376 (62.8)                  | 146/189 (77.2)                 |
| Median PFS (months)                                                      | 18.9                            | 16.0                           |
| HR (95% CI)                                                              | 0.70 (0.57, 0.86)               | 0.70 (0.57, 0.86)              |
| Screening tBRCA status (per eCRF)                                        |                                 |                                |
| Deleterious mutation                                                     |                                 |                                |
| Number of events/total number of patients (%)                            | 41/157 (26.1)                   | 49/80 (61.3)                   |
| Median PFS (months)                                                      | 37.2                            | 21.7                           |
| HR (95% CI)                                                              | 0.31 (0.20, 0.47)               | 0.31 (0.20, 0.47)              |
| Absence of deleterious mutation                                          |                                 |                                |
| Number of events/total number of patients (%)                            | 239/380 (62.9)                  | 145/189 (76.7)                 |
| Median PFS (months)                                                      | 18.9                            | 16.0                           |
| HR (95% CI)                                                              | 0.71 (0.58, 0.88)               | 0.71 (0.58, 0.88)              |

CI  Confidence interval; CR  Complete response; CSR  Clinical study report; DCO  Data cut-off; FAS  Full Analysis Set; HR  Hazard ratio; NED  No evidence of disease; PFS  Progression-free survival; PR  Partial response; tBRCA Tumour BRCA .

<div style=\"page-break-after: always\"></div>

Figure 17: PAOLA-1: Kaplan-Meier plot of PFS for patients with tBRCAm (as randomised) (44% maturity - investigator assessment)

<!-- image -->

## Other PFS exploratory biomarker subgroup analyses per Myriad myChoice HRD Plus

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 18 Forest plot of PFS subgroup analysis (FAS), (DCO 22 March 2019) Tumour characteristics as assessed by Myriad myChoice HRD Plus test

<!-- image -->

Subgroups in the figure and table below (tBRCAm, GIS positive, HRD positive) correspond respectively to subgroups 'Myriad tBRCAm', ' Myriad HRD positive excluding tBRCA' (with genomic instability score ≥42 ) and Myriad HRD status positive (with genomic instability score ≥42). Analyses only by GIS subgroups in the overall population are described in the section 'Post-hoc analyses in exploratory biomarker subgroups'.

Figure 19 Overlap Between GIS positive (score≥ 42) and tBRCA Mutation positive Within HRD Positive Status (tBRCAm and/or GIS) group of patients in PAOLA-1

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 28: PFS results for patients with homologous recombination deficiency (HRD) positive status defined by either tBRCAm and/or GIS in advanced ovarian cancer patients in PAOLA-1

|                                                                 | t BRCAm *, c (n=235)                                            | t BRCAm *, c (n=235)                                            | GIS positive *, d (n=152)                                       | GIS positive *, d (n=152)                                       | HRD positive * (n=387)                                          | HRD positive * (n=387)                                          |
|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                                                                 | Olaparib/ bevacizu mab                                          | Placebo/ bevacizu mab                                           | Olaparib/ bevacizu mab                                          | Placebo/ bevacizu mab                                           | Olaparib/ bevacizu mab                                          | Placebo/ bevacizuma b                                           |
| PFS, investigator assessment (46% maturity) DCO 22 March 2019 a | PFS, investigator assessment (46% maturity) DCO 22 March 2019 a | PFS, investigator assessment (46% maturity) DCO 22 March 2019 a | PFS, investigator assessment (46% maturity) DCO 22 March 2019 a | PFS, investigator assessment (46% maturity) DCO 22 March 2019 a | PFS, investigator assessment (46% maturity) DCO 22 March 2019 a | PFS, investigator assessment (46% maturity) DCO 22 March 2019 a |
| Number of events: Total number of patients (%)                  | 44/158 (28)                                                     | 52/77 (68)                                                      | 43/97 (44)                                                      | 40/55 (73)                                                      | 87/255 (34)                                                     | 92/132 (70)                                                     |
| Median time (months)                                            | 37.2                                                            | 18.8                                                            | 28.1                                                            | 16.6                                                            | 37.2                                                            | 17.7                                                            |
| HR (95%) CI b                                                   | 0.28 (0.19, 0.42)                                               | 0.28 (0.19, 0.42)                                               | 0.43 (0.28, 0.66)                                               | 0.43 (0.28, 0.66)                                               | 0.33 (0.25, 0.45)                                               | 0.33 (0.25, 0.45)                                               |

* Pre-planned subgroup

a  Based on Kaplan-Meier estimates, the proportion of patients that were progression free at 12 and 24 months were 89% and 66% for olaparib/bevacizumab versus 71% and 29% for placebo/bevacizumab.

b  A value &lt;1 favours olaparib. The analysis was performed using a Cox proportional hazards model stratified by first line treatment outcome at screening and screening laboratory t BRCA status.

c t BRCA m status by Myriad

d Genomic instability score (GIS) by Myriad ≥42 (pre -specified cut-off)

CI Confidence interval; HR Hazard ratio; NR not reached

<div style=\"page-break-after: always\"></div>

Figure 20: PAOLA-1: Kaplan-Meier plot of PFS for patients with advanced ovarian cancer defined as HRD positive in PAOLA-1 (46% maturity - investigator assessment)

<!-- image -->

Figure 21: PAOLA-1: Kaplan-Meier plot of PFS for patients with advanced ovarian cancer defined as Myriad HRD positive excluding tBRCA in PAOLA-1

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 22: PAOLA-1: Kaplan-Meier plot of PFS for patients with advanced ovarian cancer defined as HRD negative in PAOLA-1

<!-- image -->

## PFS-2 in exploratory biomarker subgroups

Table 29: PFS-2 results for patients with homologous recombination deficiency (HRD) positive status defined by either tBRCAm and/or GIS in advanced ovarian cancer patients in PAOLA-1

|                                                                        | t BRCAm *, c (n=235)                                                   | t BRCAm *, c (n=235)                                                   | GIS positive *, d (n=152)                                              | GIS positive *, d (n=152)                                              | HRD positive * (n=387)                                                 | HRD positive * (n=387)                                                 |
|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
|                                                                        | Olaparib/ bevacizu mab                                                 | Placebo/ bevacizu mab                                                  | Olaparib/ bevacizu mab                                                 | Placebo/ bevacizu mab                                                  | Olaparib/ bevacizu mab                                                 | Placebo/ bevacizuma b                                                  |
| Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 | Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 | Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 | Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 | Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 | Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 | Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 |
| Number of events: Total number of patients (%)                         | 29/158 (18)                                                            | 24/77 (31)                                                             | 31/97 (32)                                                             | 24/55 (44)                                                             | 60/255 (24)                                                            | 48/132 (36)                                                            |
| Median time (months)                                                   | NR                                                                     | NR                                                                     | 37.8                                                                   | 28.6                                                                   | NR                                                                     | 34.6                                                                   |
| HR (95%) CI b                                                          | 0.59 (0.34, 1.02)                                                      | 0.59 (0.34, 1.02)                                                      | 0.64 (0.37, 1.10)                                                      | 0.64 (0.37, 1.10)                                                      | 0.60 (0.41, 0.88)                                                      | 0.60 (0.41, 0.88)                                                      |

* Pre-planned subgroup

<div style=\"page-break-after: always\"></div>

b  A value &lt;1 favours olaparib. The analysis was performed using a Cox proportional hazards model stratified by first line treatment outcome at screening and screening laboratory t BRCA status.

c t BRCA m status by Myriad

d Genomic instability score (GIS) by Myriad ≥42 (pr e-specified cut-off)

CI Confidence interval; HR Hazard ratio; NR not reached

## Overall survival in exploratory biomarker subgroups

Exploratory  OS  analyses  in  HRD  subgroups  as  defined  by  the  Myriad  myChoice  HRD  plus  assay  were performed. OS analyses by subgroups have been pre-specified as such, but an update has been with DCO 30 September 2019, in addition to the analysis with primary endpoint analysis DCO, has been submitted during procedure. Analyses for main subgroups (tBRCAm at randomisation, tBRAm by Myriad analysis and HRD status as defined in PAOLA-1) are presented below.

Table 30: Updated OS analyses in exploratory subgroups (DCO 30 September 2019)

|                                                                                  | Olaparib/ bevacizumab (N=537)                                                    | Placebo/ bevacizumab (N=269)                                                     |
|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| FAS (n=806) (31.3-33.8% maturity)                                                |                                                                                  |                                                                                  |
| HR (95% CI)                                                                      | 0.59 (0.49, 0.72)                                                                | 0.59 (0.49, 0.72)                                                                |
| tBRCA status based on test at randomisation                                      |                                                                                  |                                                                                  |
| tBRCAm (n=241) (16.8-23.8% maturity)                                             |                                                                                  |                                                                                  |
| HR (95% CI)                                                                      | 0.66 (0.37, 1.21)                                                                | 0.66 (0.37, 1.21)                                                                |
| Non-tBRCAm (n=565) (37.5-38.1% maturity)                                         |                                                                                  |                                                                                  |
| HR (95% CI)                                                                      | 1.02 (0.77, 1.36)                                                                | 1.02 (0.77, 1.36)                                                                |
| Myriad tBRCA status                                                              |                                                                                  |                                                                                  |
| tBRCAm (n=235) (17.1-26.0% maturity)                                             |                                                                                  |                                                                                  |
| HR (95% CI)                                                                      | 0.61 (0.34, 1.09)                                                                | 0.61 (0.34, 1.09)                                                                |
| Non-tBRCAm (n=520) (37.9-39.9% maturity)                                         |                                                                                  |                                                                                  |
| HR (95% CI)                                                                      | 1.04 (0.77, 1.40)                                                                | 1.04 (0.77, 1.40)                                                                |
| Myriad tBRCA test cancelled/failed/missing (n=51) (30.3-27.8% maturity)          | Myriad tBRCA test cancelled/failed/missing (n=51) (30.3-27.8% maturity)          |                                                                                  |
| HR (95% CI)                                                                      | 1.02 (0.77, 1.36)                                                                | 1.02 (0.77, 1.36)                                                                |
| Myriad HRD status (tBRCAm and/or GIS cut-off 42)                                 | Myriad HRD status (tBRCAm and/or GIS cut-off 42)                                 |                                                                                  |
| HRD positive (tBRCAm or GIS ≥42) (n=387) (21.1 -27.3%                            | maturity)                                                                        |                                                                                  |
| HR (95% CI)                                                                      | 0.71 (0.47, 1.10)                                                                | 0.71 (0.47, 1.10)                                                                |
| HRD negative (GIS <42) (n=277) (43.2.1-43.5% maturity)                           |                                                                                  |                                                                                  |
| HR (95% CI)                                                                      | 1.11 (0.76, 1.65)                                                                | 1.11 (0.76, 1.65)                                                                |
| HRD status unknown (test cancelled/failed/missing) (n=142) (34.4-34.6% maturity) | HRD status unknown (test cancelled/failed/missing) (n=142) (34.4-34.6% maturity) | HRD status unknown (test cancelled/failed/missing) (n=142) (34.4-34.6% maturity) |
| HR (95% CI)                                                                      | 1.03 (0.58, 1.88)                                                                | 1.03 (0.58, 1.88)                                                                |

a  Non-tBRCAm = tBRCAwt/VUS

BRCA = breast cancer susceptibility gene; BRCAm = BRCA mutated; CI = confidence interval; CSR = clinical study report; DCO = data cut-off; FAS = full analysis set; HR = hazard ratio; HRD = homologous recombination deficiency; OS = overall survival; tBRCAm = tumour BRCA mutated.

Source: Table 14.2.3.2 PAOLA-1 CSR, Table 2160.1 (DCO 30 September 2019).

Subjects who are either lost to follow-up or who withdrew consent from further participation from the study were censored.

<div style=\"page-break-after: always\"></div>

The KM plots for the HRD positive and HRD negative subgroups are shown in the Figures below.

Figure 23: Overall survival, HRD positive subgroup (DCO 30 September 2019)

<!-- image -->

Figure 24: Overall survival, HRD negative subgroup (30 September 2019)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 31: OS results for patients with homologous recombination deficiency (HRD) positive status defined by either tBRCAm and/or GIS in advanced ovarian cancer patients in PAOLA-1

|                                                 | t BRCAm *, c (n=235)                            | t BRCAm *, c (n=235)                            | GIS positive *, d (n=152)                       | GIS positive *, d (n=152)                       | HRD positive * (n=387)                          | HRD positive * (n=387)                          |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                                 | Olaparib/ bevacizu mab                          | Placebo/ bevacizu mab                           | Olaparib/ bevacizu mab                          | Placebo/ bevacizu mab                           | Olaparib/ bevacizu mab                          | Placebo/ bevacizuma b                           |
| Interim OS (23% maturity) DCO 30 September 2019 | Interim OS (23% maturity) DCO 30 September 2019 | Interim OS (23% maturity) DCO 30 September 2019 | Interim OS (23% maturity) DCO 30 September 2019 | Interim OS (23% maturity) DCO 30 September 2019 | Interim OS (23% maturity) DCO 30 September 2019 | Interim OS (23% maturity) DCO 30 September 2019 |
| Number of events: Total number of patients (%)  | 27/158 (17)                                     | 20/77 (26)                                      | 27/97 (28)                                      | 16/55 (29)                                      | 54/255 (21)                                     | 36/132 (27)                                     |
| Median time (months)                            | NR                                              | NR                                              | NR                                              | NR                                              | NR                                              | NR                                              |
| HR (95%) CI b                                   | 0.61 (0.34, 1.09)                               | 0.61 (0.34, 1.09)                               | 0.88 (0.48, 1.67)                               | 0.88 (0.48, 1.67)                               | 0.71                                            | (0.47, 1.10)                                    |

* Pre-planned subgroup

b  A value &lt;1 favours olaparib. The analysis was performed using a Cox proportional hazards model stratified by first line treatment outcome at screening and screening laboratory t BRCA status.

c t BRCA m status by Myriad

d Genomic instability score (GIS) by Myriad ≥42 (pre -specified cut-off)

CI Confidence interval; HR Hazard ratio; NR not reached

## Post-hoc analyses in exploratory biomarker subgroups

## Analyses for GIS subgroups

Subgroups defined only by GIS have not been pre-specified and subgroup analyses in GIS positive (score ≥42), GIS negative (score &lt;42) and unknown GIS subgroups has been requested during procedure.

At cut-off 42, the GIS positive subgroup contains 60 fewer patients than the HRD positive subgroup:

- 19 tBRCAm patients that had a GIS score &lt;42 (these patients moved into the GIS score negative group)
- 41 tBRCAm patients that failed GIS score testing (these patients moved into the unknown group)

<div style=\"page-break-after: always\"></div>

Table 32: Summary of Key Efficacy Outcome Variables Using Only GIS at Cut off 42

|                                             | myChoice CDx GIS positive          | myChoice CDx GIS positive          | myChoice? CDx GIS negative         | myChoice? CDx GIS negative         | myChoice?CDx GIS unknown *         | myChoice?CDx GIS unknown *         |
|---------------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                             | Olaparib/ bevacizumab (n=216)      | Placebo/ bevacizumab (n=111)       | Olaparib/ bevacizumab (n=204)      | Placebo/ bevacizumab (n=92)        | Olaparib/ bevacizumab (n=117)      | Placebo/ bevacizumab (n=66)        |
| PFS (by investigator assessment)            | PFS (by investigator assessment)   | PFS (by investigator assessment)   | PFS (by investigator assessment)   | PFS (by investigator assessment)   | PFS (by investigator assessment)   | PFS (by investigator assessment)   |
| Numberofevents/totalnumber of patients (%)  | 70/216 (32.4)                      | 77/111 (69.4)                      | 153/204 (75.0)                     | 72/92 (78.3)                       | 57/117 (54.7)                      | 45/66 (68.2)                       |
| Median PFS (months)                         | 39.3                               | 16.7                               | 16.6                               | 16.6                               | 24.0                               | 16.0                               |
| HR (95% CI)                                 | 0.30 (0.22-0.42)                   | 0.30 (0.22-0.42)                   | 1.01 (0.76-1.34)                   | 1.01 (0.76-1.34)                   | 0.63 (0.43-0.94)                   | 0.63 (0.43-0.94)                   |
| PFS2                                        | PFS2                               | PFS2                               | PFS2                               | PFS2                               | PFS2                               | PFS2                               |
| Numberofevents/totalnumber of patients (%)  | 46/216 (21.3)                      | 40/111 (36.0)                      | 89/158 (56.3)                      | 38/73 (78.2)                       | 43/117 (36.8)                      | 28/66 (42.4)                       |
| Median PFS (months)                         | Not reached                        | 34.6                               | 22.5                               | 26.4                               | 32.3                               | 35.1                               |
| HR (95% CI)                                 | 0.55 (0.36-0.84)                   | 0.55 (0.36-0.84)                   | 1.10 (0.79-1.55)                   | 1.10 (0.79-1.55)                   | 0.91 (0.57-1.47)                   | 0.91 (0.57-1.47)                   |
| Updated OS (DC0 30 September 2019)          | Updated OS (DC0 30 September 2019) | Updated OS (DC0 30 September 2019) | Updated OS (DC0 30 September 2019) | Updated OS (DC0 30 September 2019) | Updated OS (DC0 30 September 2019) | Updated OS (DC0 30 September 2019) |
| Numberofevents/total number of patients (%) | 41/216 (19.0)                      | 28/111 (25.2)                      | 89/204 (43.6)                      | 40/92 (43.5)                       | 38/117 (32.5)                      | 23/66 (34.8)                       |
| Median PFS (months)                         | Notreached                         | Not reached                        | 37.8                               | 36.8                               | Not reached                        | 42.3                               |
| HR (95% CI)                                 | 0.69 (0.43-1.12)                   | 0.69 (0.43-1.12)                   | 1.13 (0.78-1.65)                   | 1.13 (0.78-1.65)                   | 0.93 (0.56-1.59)                   | 0.93 (0.56-1.59)                   |

CDx = companion diagnostic; CI = confidence interval; DCO = data cut-off; HR = hazard ratio; GIS = genomic instability score; ITT = intention-to-treat; PFS = progression-free survival; PFS2 = time from randomisation to second progression or death; OS = overall survival.

Analyses presented for GIS unknown patients to cover the totality of the ITT.

<!-- image -->

Figure 25: KM Plots for PFS at GIS Cut-offs 42 (DCO 22 March 2019)

Figure 26: KM Plots for PFS2 at GIS Cut-offs 42 (DCO 22 March 2019)

<!-- image -->

Figure 27: KM Plots for OS at GIS Cut-offs 42 (DCO 30 September 2019)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 33: Baseline Patient characteristics by Myriad HRD status

<!-- image -->

|                                                                                                                                 | FAS                                                             | FAS                                                             | HRD positive                                                    | HRD positive                                                    | HRD negative                                                    | HRD negative                                                    | HRDunknown                                                      | HRDunknown                                                      |
|---------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                                                                                                                                 | Olaparib/ bevacizumab (m=537)                                   | Placebo/ bevacizumab (m=269)                                    | Olaparib/ bevacizumab (m-255)                                   | Placebo/ bevacizumab (n=132)                                    | Olaparib/ bevacizumab (n-192)                                   | Placebo/ bevacizumab (m=85)                                     | Olaparib/ bevacizumab (m=90)                                    | Placebo/ bevacizumab (m=52)                                     |
| First linetreatment outcome at screening(obtainedfrom the eCRF)                                                                 | First linetreatment outcome at screening(obtainedfrom the eCRF) | First linetreatment outcome at screening(obtainedfrom the eCRF) | First linetreatment outcome at screening(obtainedfrom the eCRF) | First linetreatment outcome at screening(obtainedfrom the eCRF) | First linetreatment outcome at screening(obtainedfrom the eCRF) | First linetreatment outcome at screening(obtainedfrom the eCRF) | First linetreatment outcome at screening(obtainedfrom the eCRF) | First linetreatment outcome at screening(obtainedfrom the eCRF) |
| NEDwithcompletemacroscopic resection at initial debulking surgery                                                               | 158 (29.4)                                                      | 83 (30.9)                                                       | 88 (34.5)                                                       | 47 (35.6)                                                       | 57 (29.7)                                                       | 27 (31.8)                                                       | 13 (14.4)                                                       | 9 (17.3)                                                        |
| NED/CRwithcompletemacroscopic resection at interval debulking surgery                                                           | 158 (29.4)                                                      | 75 (27.9)                                                       | 75 (29.4)                                                       | 32 (24.2)                                                       | 36 (18.8)                                                       | 18 (21.2)                                                       | 47 (52.2)                                                       | 25 (48.1)                                                       |
| NED/CRatscreening,inpatientwho had either incomplete resection (at initial orinterval debulkingsurgery) or no debulking surgery | 80 (14.9)                                                       | 36 (13.4)                                                       | 39 (15.3)                                                       | 18 (13.6)                                                       | 35 (18.2)                                                       | 14 (16.5)                                                       | 6 (6.7)                                                         | 4 (7.7)                                                         |
| Partialresponse                                                                                                                 | 134 (25.0)                                                      | 73 (27.1)                                                       | 50 (19.6)                                                       | 33 (25.0)                                                       | 60 (31.3)                                                       | 26 (30.6)                                                       | 24 (26.7)                                                       | 14 (26.9)                                                       |
| Not applicable as per eCRFb                                                                                                     | 7 (1.3)                                                         | 2 (0.7)                                                         | 3 (1.2)                                                         | 2 (1.5)                                                         | 4 (2.1)                                                         | 0                                                               | 0                                                               | 0                                                               |

Stage Ill combined.

Notapplicable asunabletoassigntooneofdetailedcategories.

BRCA = breast cancer susceptibility gene; CR = complete response; CSR = clinical study report, ECOG = eastem cooperative oncology group; eCRF = electronic case report form;FAS=fullanalysis set;FIGO=internationalfederation ofgynaecology andobstetrics;HRD=homologousrecombination deficiency;NED=noevidence of disease. Source: Tables 14.1.8.1, 14.1.12.1, PAOLA-1 CSR; Table 1860.2, 1860.3 (DCO 22 March 2019).

## Myriad HRD status 'unknown' subgroup

Although not a protocol-specified subgroup, to account for the remaining patients in the FAS, a post-hoc analysis of OS was conducted in the subgroup of patients with Myriad HRD unknown status (see table with updated OS analysis at DCO 30 September 2019 above).

The  HRD  biomarker  positive  and  negative  subgroups  considered  the  Myriad  testing  results  only,  and therefore  the  HRD  unknown  subgroup  included  a  subset  of  patients  that  were  tBRCAm  by  screening laboratory  testing.  In  total,  there  were  21  Myriad  HRD  status  unknown patients  who  were  tBRCAm  at randomisation with 9 (10%) on the olaparib arm and 12 (23.1%) on the placebo arm. The KM plot for the HRD unknown subgroup is shown in Figure below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

DCO = data cut off; HRD = homologous recombination deficiency. Source: Figure 2181.8 (DC0 30 September 2019).

Figure 28: Overall Survival, HRD unknown subgroup (DCO 30 September 2019)

## Subsequent therapies for HRD subgroups

Subsequent PARP inhibitor treatment was generally balanced within arms across the HRD positive, HRD negative, and HRD status unknown subgroups (

<div style=\"page-break-after: always\"></div>

Table 34). Cross over to a PARP inhibitor in the placebo arm as subsequent treatment varied between 24.7% and 36.4%.

<div style=\"page-break-after: always\"></div>

Table 34: Summary of subsequent therapies received by subgroup (DCO 30 September 2019)

<!-- image -->

DCO = data cut-off; HRD = homologous recombination deficiency; PARP = polyadenosine 5'diphosphonbose

<div style=\"page-break-after: always\"></div>

## Subgroup OS analysis by disease evaluation

Table 35: OS subgroup analyses by overall disease evaluation (DCO 30 September 2019)

<!-- image -->

| Subgroup                                       | Olaparibl bevacizumab (N=537)   | Placebo! bevacizumab (N=269)   |
|------------------------------------------------|---------------------------------|--------------------------------|
| Overall Disease Evaluation (eCRF)              |                                 |                                |
| NED                                            |                                 |                                |
| Number of events/total mumber of patients (9o) | 60/290 (20.7)                   | 38/141 (27.0)                  |
| Median OS (months) *                           | NR.                             | 45.7                           |
| HR (95% C1) b                                  | 0.76 (0.51,1.15)                | 0.76 (0.51,1.15)               |
| CR.                                            |                                 |                                |
| Number of events/total mumber of patients (9o) | 33/106 (31.1)                   | 18/53 (34.0)                   |
| Median OS (months) a                           | NR.                             | 42.3                           |
| HR (95% C1) b                                  | 0.87 (0.50, 1.58)               | 0.87 (0.50, 1.58)              |
| PR.                                            |                                 |                                |
| Number of events/total mumber of patients (%o) | 75/141 (53.2)                   | 35/75 (46.7)                   |
| Median OS (months)                             | 31.6                            | 36.8                           |
| HR (95%6 C1) b                                 | 1.23 (0.83, 1.86)               | 1.23 (0.83, 1.86)              |

Calculated using KM technigues.

Estimated fom a Cox proportional hazards model including treatment, subgroup of interest and subgroup of interest by treahment interaction temms.

CI = confidence interval; CR. = complete response; DCO = data cut-off; eCRF = electomic case report form; HR. = hazard ratio; NED = no evidence of disease: OS = overall swvival; PR. = partial response. Souwce: Table 2322.1.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 36: Summary of Efficacy for trial PAOLA-1

Title: A Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.

Study identifier

PAOLA-1 D0817C00003

Design

Randomized, double-blind, phase III study, placebo controlled

Duration of main phase:

Until objective radiological disease progression, or up to 2 years if patient had NED.

<div style=\"page-break-after: always\"></div>

|                                                            | Duration of Extension phase:                               | Duration of Extension phase:                               | Duration of Extension phase:                               | Duration of Extension phase:                               | Patients who in the opinion of the treating physician could derive further benefit from continuous treatment, could be treated beyond 2 years.                                                                                                                                                                 | Patients who in the opinion of the treating physician could derive further benefit from continuous treatment, could be treated beyond 2 years.                                                                                                                                                                 |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                            |                                                            |                                                            |                                                            |                                                            | Hypothesis                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                |
| Treatments groups                                          | Superiority Olaparib/bevacizumab                           | Superiority Olaparib/bevacizumab                           | Superiority Olaparib/bevacizumab                           | Superiority Olaparib/bevacizumab                           | Olaparib 300 mg BID 2 years, N=537 Bevacizumab 15mg/kg q3weeks, in the maintenance phase up to a total of 15                                                                                                                                                                                                   | Olaparib 300 mg BID 2 years, N=537 Bevacizumab 15mg/kg q3weeks, in the maintenance phase up to a total of 15                                                                                                                                                                                                   |
|                                                            | Placebo/bevacizumab                                        | Placebo/bevacizumab                                        | Placebo/bevacizumab                                        | Placebo/bevacizumab                                        | months. Pb 300 mg BID 2 years, N=269 Bevacizumab 15mg/kg q3weeks, in the maintenance phase up to a total of 15 months.                                                                                                                                                                                         | months. Pb 300 mg BID 2 years, N=269 Bevacizumab 15mg/kg q3weeks, in the maintenance phase up to a total of 15 months.                                                                                                                                                                                         |
| Endpoints and definitions                                  | Primary endpoint                                           | Primary endpoint                                           | PFS                                                        | PFS                                                        | the time from randomisation until the date of objective radiological disease progression according to modified RECIST 1.1 or death (by any cause in the absence of progression) regardless of whether the patient discontinued randomised therapy or received another anticancer therapy prior to progression. | the time from randomisation until the date of objective radiological disease progression according to modified RECIST 1.1 or death (by any cause in the absence of progression) regardless of whether the patient discontinued randomised therapy or received another anticancer therapy prior to progression. |
|                                                            | Secondary endpoint                                         | Secondary endpoint                                         | PFS2                                                       | PFS2                                                       | time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death.                                                                                                                                                                    | time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death.                                                                                                                                                                    |
|                                                            | Secondary endpoint                                         | Secondary endpoint                                         | OS                                                         | OS                                                         | time from the date of randomisation until death due to any cause.                                                                                                                                                                                                                                              | time from the date of randomisation until death due to any cause.                                                                                                                                                                                                                                              |
|                                                            | Secondary endpoint                                         | Secondary endpoint                                         | TFST                                                       | TFST                                                       | time from randomisation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death.                                                                                                                                                                             | time from randomisation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death.                                                                                                                                                                             |
|                                                            | Secondary endpoint                                         | Secondary endpoint                                         | TSST                                                       | TSST                                                       | Time from randomisation to the earlier of the second subsequent therapy start date following study treatment discontinuation, or                                                                                                                                                                               | Time from randomisation to the earlier of the second subsequent therapy start date following study treatment discontinuation, or                                                                                                                                                                               |
|                                                            | Secondary endpoint                                         | Secondary endpoint                                         | TDT                                                        | TDT                                                        | death. Time from randomisation to study treatment                                                                                                                                                                                                                                                              | death. Time from randomisation to study treatment                                                                                                                                                                                                                                                              |
| Database lock                                              | 22 March 2019; 30 September 2019 (OS analyses)             | 22 March 2019; 30 September 2019 (OS analyses)             | 22 March 2019; 30 September 2019 (OS analyses)             | 22 March 2019; 30 September 2019 (OS analyses)             | 22 March 2019; 30 September 2019 (OS analyses)                                                                                                                                                                                                                                                                 | 22 March 2019; 30 September 2019 (OS analyses)                                                                                                                                                                                                                                                                 |
| Results and Analysis Analysis description Primary Analysis | Results and Analysis Analysis description Primary Analysis | Results and Analysis Analysis description Primary Analysis | Results and Analysis Analysis description Primary Analysis | Results and Analysis Analysis description Primary Analysis | Results and Analysis Analysis description Primary Analysis                                                                                                                                                                                                                                                     | Results and Analysis Analysis description Primary Analysis                                                                                                                                                                                                                                                     |
| Analysis population and                                    | Analysis population and                                    | Intent to treat: FAS                                       | Intent to treat: FAS                                       | Intent to treat: FAS                                       | Intent to treat: FAS                                                                                                                                                                                                                                                                                           | Intent to treat: FAS                                                                                                                                                                                                                                                                                           |
| time point description Descriptive statistics and          | time point description Descriptive statistics and          | All patients who were randomized Treatment group           | All patients who were randomized Treatment group           | Olaparib/bevacizumab                                       | Olaparib/bevacizumab                                                                                                                                                                                                                                                                                           | Placebo/bevacizumab                                                                                                                                                                                                                                                                                            |
| estimate variability                                       | estimate variability                                       | Number of subject                                          | Number of subject                                          | 537                                                        | 537                                                                                                                                                                                                                                                                                                            | 269                                                                                                                                                                                                                                                                                                            |
|                                                            |                                                            | Median PFS (months)                                        | Median PFS (months)                                        | 22.1                                                       | 22.1                                                                                                                                                                                                                                                                                                           | 16.6                                                                                                                                                                                                                                                                                                           |
|                                                            |                                                            | 95% CI                                                     | 95% CI                                                     | 21.8; 24.1                                                 | 21.8; 24.1                                                                                                                                                                                                                                                                                                     | 15.4; 18.6                                                                                                                                                                                                                                                                                                     |
|                                                            |                                                            | Median PFS2 (months)                                       | Median PFS2 (months)                                       | 32.3                                                       | 32.3                                                                                                                                                                                                                                                                                                           | 30.1                                                                                                                                                                                                                                                                                                           |
|                                                            |                                                            | 95% CI                                                     | 95% CI                                                     | 29.2; 39.8                                                 | 29.2; 39.8                                                                                                                                                                                                                                                                                                     | 25.7; 32.6                                                                                                                                                                                                                                                                                                     |
|                                                            |                                                            | Median OS (months)                                         | Median OS (months)                                         | NR                                                         | NR                                                                                                                                                                                                                                                                                                             | 45.7                                                                                                                                                                                                                                                                                                           |
|                                                            |                                                            | 95% CI                                                     | 95% CI                                                     |                                                            |                                                                                                                                                                                                                                                                                                                | (37.4, NR)                                                                                                                                                                                                                                                                                                     |
|                                                            |                                                            | Median TFST                                                | Median TFST                                                | 24.8                                                       | 24.8                                                                                                                                                                                                                                                                                                           | 18.5                                                                                                                                                                                                                                                                                                           |
|                                                            |                                                            | 95% CI                                                     | 95% CI                                                     | 23.4; 27.9                                                 | 23.4; 27.9                                                                                                                                                                                                                                                                                                     | 17.2; 20.1                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                | Median TSST                                                                                                              | 33.8                                                  | 30.4                                                       |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------------|
|                                | 95% CI                                                                                                                   | 31.6; NC                                              | 26.5; 33.9                                                 |
|                                | Median TDT                                                                                                               | 17.4                                                  | 16.3                                                       |
|                                | 95% CI                                                                                                                   | 16.3; 19.5                                            | 13.8; 17.3                                                 |
| Effect estimate per comparison | Primary endpoint                                                                                                         | Comparison groups                                     | Olaparib vs placebo                                        |
|                                | PFS                                                                                                                      | HR                                                    | added to bevacizumab 0.59                                  |
|                                |                                                                                                                          | 95% CI                                                | 0.49; 0.72                                                 |
|                                | Secondary endpoint                                                                                                       | P-value Comparison groups                             | <0.0001 Olaparib vs placebo added to bevacizumab           |
|                                | PFS2                                                                                                                     | 95% CI                                                | 0.86 0.69; 1.09                                            |
|                                |                                                                                                                          | HR                                                    |                                                            |
|                                | Secondary endpoint                                                                                                       | P-value Comparison HR                                 | Olaparib vs placebo added to bevacizumab 0.94 (0.73, 1.21) |
|                                |                                                                                                                          | groups                                                | 0.2097                                                     |
|                                | OS                                                                                                                       | 95% CI P-value                                        | Not calculated                                             |
|                                | Secondary endpoint                                                                                                       | Comparison                                            | Olaparib vs                                                |
|                                | TFST                                                                                                                     | groups                                                | placebo added to                                           |
|                                |                                                                                                                          | HR                                                    | bevacizumab 0.58                                           |
|                                | Secondary endpoint                                                                                                       | Comparison                                            | Olaparib vs placebo                                        |
|                                | TSST                                                                                                                     | groups HR                                             | added to bevacizumab 0.79 1.00                             |
|                                | Secondary endpoint                                                                                                       | 95% CI P-value Comparison groups                      | 0.63; 0.0444 Olaparib vs placebo added to bevacizumab      |
|                                | TDT                                                                                                                      | HR                                                    | 0.83 0.0232                                                |
| Analysis description           | Subgroup analysis PFS, investigator tBRCAm by Myriad*                                                                    | CI assessment (46% maturity) (n= Olaparib/bevacizumab | DCO 22 March 2019 a Olaparib/placebo                       |
|                                |                                                                                                                          | 95% P-value                                           | 0.71; 0.98                                                 |
|                                | Number of events/total number of patients Median PFS (months) HR (95% CI) GIS positive* b (n=152) Number of events/total | 44/158 (28) 37.2 0.28 Olaparib/bevacizumab 43/97 (44) | 52/77 (68) 18.8 (0.19, 0.42) Olaparib/placebo 40/55 (73)   |
|                                | Median PFS (months)                                                                                                      |                                                       |                                                            |
|                                | Median PFS                                                                                                               | 37.2                                                  | 17.7                                                       |
| Notes                          | NR: Not reached                                                                                                          |                                                       |                                                            |
|                                |                                                                                                                          | 28.1                                                  | 16.6                                                       |
|                                | HR (95% CI)                                                                                                              |                                                       |                                                            |
|                                |                                                                                                                          | 0.43 (0.28,                                           | Olaparib/placebo                                           |
|                                |                                                                                                                          |                                                       | 0.66)                                                      |
|                                | HRD positive* Number of number of patients                                                                               | (n=387)                                               | 92/132 (70)                                                |
|                                | events/total                                                                                                             | Olaparib/bevacizumab 87/255 (34)                      |                                                            |
|                                | (months)                                                                                                                 |                                                       |                                                            |

<div style=\"page-break-after: always\"></div>

| HR (95% CI)                                                            | 0.33 (0.25, 0.45)                                                      | 0.33 (0.25, 0.45)                                                      |
|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 | Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 | Interim PFS2, investigator assessment (30% maturity) DCO 22 March 2019 |
| tBRCAm by Myriad* (n= 235)                                             | Olaparib/bevacizumab                                                   | Olaparib/placebo                                                       |
| Number of events/total number of patients                              | 29/158 (18)                                                            | 24/77 (31)                                                             |
| Median PFS (months)                                                    | NR                                                                     | NR                                                                     |
| HR (95% CI)                                                            | 0.59 (0.34, 1.02)                                                      | 0.59 (0.34, 1.02)                                                      |
| GIS positive* b (n=152)                                                | Olaparib/bevacizumab                                                   | Olaparib/placebo                                                       |
| Number of events/total number of patients                              | 31/97 (32)                                                             | 24/55 (44)                                                             |
| Median PFS (months)                                                    | 37.8                                                                   | 28.6                                                                   |
| HR (95% CI)                                                            | 0.64 (0.37, 1.10)                                                      | 0.64 (0.37, 1.10)                                                      |
| HRD positive*                                                          | Olaparib/bevacizumab                                                   | Olaparib/placebo                                                       |
| Number of events/total number of patients                              | 60/255 (24)                                                            | 48/132 (36)                                                            |
| Median PFS (months)                                                    | NR                                                                     | 34.6                                                                   |
| HR (95% CI)                                                            | 0.60 (0.41, 0.88)                                                      | 0.60 (0.41, 0.88)                                                      |
| Interim OS (23% maturity) DCO 30 September 2019                        | Interim OS (23% maturity) DCO 30 September 2019                        | Interim OS (23% maturity) DCO 30 September 2019                        |
| tBRCAm by Myriad* (n= 235)                                             | Olaparib/bevacizumab                                                   | Olaparib/placebo                                                       |
| Number of events/total number of patients                              | 27/158 (17)                                                            | 20/77 (26)                                                             |
| Median PFS (months)                                                    | NR                                                                     | NR                                                                     |
| HR (95% CI)                                                            | 0.61 (0.34, 1.09)                                                      | 0.61 (0.34, 1.09)                                                      |
| GIS positive* b (n=152)                                                | Olaparib/bevacizumab                                                   | Olaparib/placebo                                                       |
| Number of events/total number of patients                              | 27/97 (28)                                                             | 16/55 (29)                                                             |
| Median PFS (months)                                                    | NR                                                                     | NR                                                                     |
| HR (95% CI)                                                            | 0.88 (0.48, 1.67)                                                      | 0.88 (0.48, 1.67)                                                      |
| HRD positive*                                                          | Olaparib/bevacizumab                                                   | Olaparib/placebo                                                       |
| Number of events/total number of patients                              | 54/255 (21)                                                            | 36/132 (27)                                                            |
| Median PFS (months)                                                    | NR                                                                     | NR                                                                     |
| HR (95% CI)                                                            | 0.71 (0.47, 1.10)                                                      | 0.71 (0.47, 1.10)                                                      |

* Pre-planned subgroup;  b Genomic instability score (GIS) by Myriad ≥42 (pre -specified cut-off) Note: HRD positive status was defined in this study by a combination of both biomarkers; tBRCAm (prospectively and retrospectively defined), GIS.

In the tBRCAm as randomised subgroup (241/806 patients) median PFS for the olaparib/bevacizumab arm was 37.2 months vs 22.0 months for the placebo/bevacizumab arm (HR=0.34, 95% CI 0.23,0.51) and for OS the HR was 0.66 (95% CI 0.37, 1.21).

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

In  support  of  the  submitted  application,  the  MAH  provided  the  results  of  PAOLA-1  study  which  is  an institutional sponsored, pivotal Phase III, randomised, double blind, placebo controlled, multicentre study investigating the efficacy and safety of olaparib vs placebo when added to bevacizumab as maintenance treatment  for  patients  with  newly  diagnosed  advanced  (FIGO  stage  IIIB-IV)  high-grade  serous  or endometrioid ovarian, fallopian tube, or primary peritoneal cancer who were in response following first line treatment with platinum-taxane chemotherapy and bevacizumab.

The study was designed to investigate a potential synergistic clinical benefit or at least additive benefit when combining bevacizumab (VEGF inhibitor) and olaparib (PARP inhibitor) in the maintenance setting in patients who are not selected by biomarker status.

No  PK/PD  modelling  was  performed  in  order  to  investigate  the  PK/PD  relationship  of  olaparib  and bevacizumab in the claimed indication. Empirically, the currently approved doses of each drug in solid tumours were implemented in the development of the combination (Study PAOLA-1).

Olaparib was approved on 12 June 2019 for maintenance treatment of newly diagnosed advanced BRCAm ovarian  cancer  patients  (EPAR  Lynparza).  The  results  from  SOLO1  demonstrated  a  substantial  70% reduction in risk of disease progression or death (HR 0.30; 95% CI 0.23 to 0.41; p&lt;0.0001) with olaparib compared to placebo with an improvement in median PFS for olaparib over placebo estimated to be in the region of 3 years.

In a population not selected on the basis on BRCA mutations, according to the results from study GOG218, a phase III multicentre, randomised, double-blind, placebo-controlled, three arm study evaluating the effect of adding bevacizumab to an approved chemotherapy regimen in patients with advanced ovarian cancer,  a  maintenance  treatment  with  bevacizumab  produced  a  significant  benefit  in  PFS  (15  months compared with 12 months without maintenance and with 11 months without bevacizumab at all (Avastin SmPC). Bevacizumab could not show a clear benefit for BRCAm patients. In the subgroup of patients with HRR  mutations (n=228) the HR for PFS was 0.95 (95%  CI 0.71-1.26) for bevacizumab + carboplatin/paclitaxel vs carboplatin/paclitaxel while the HR 0.71 (95% CI 0.60-0.85) in the subgroup of patients with no HRR mutation (n=581) (Norquist et al. 2018). In patients with BRCA mutations, HR was 0.82 (95% CI 0.55-1.21) and 1.10 (95% CI 0.61-2.0) in the BRCA1 (n=114) and BRCA2 subgroups (n=59) respectively.

Due  to  the  absence  of  olaparib  monotherapy  arm  and  suboptimal  stratification  factor  (tBRCAm)  to distinguish patients with or without the sensitive degree of HRD, it remains currently unknown what is the contribution of components of such VEGFi-PARPi combination therapy in maintenance phase. Bevacizumab is indicated in the first-line maintenance setting only after prior concomitant treatment with platinum-based chemotherapy, whereas olaparib is indicated in first-line maintenance after platinum-based chemotherapy in the subgroup of BRCA1/2-mutated (germline and/or somatic) patients. Only, the contribution of olaparib could be assessed as add-on therapy to bevacizumab used in both arms concurrently with chemotherapy and in maintenance setting for the total duration of treatment up to 15 months.

Inclusion and exclusion criteria are overall considered acceptable. Nevertheless, they define a heterogeneous population as patients were included regardless of their HRD status (mutations in HRR genes/ HRD genomic scar/unknown Pt sensitivity status). There is a priori biological rational and evidence indicating  that  biomarkers  associated  with  homologous  recombination  deficiency  can  be  a  plausible predictive factor of therapeutic response for olaparib in ovarian cancer, more particularly in the context of

<div style=\"page-break-after: always\"></div>

first line maintenance treatment when, in contrast to relapsed setting, platinum sensitivity has not yet been established according to usually used criteria (Pt treatment-free-interval&gt;6 months).

Eligible patients were those with newly diagnosed advanced (FIGO Stage IIIB, IIIC or IV) ovarian cancer, primary peritoneal cancer and/or fallopian tube cancer that was histologically confirmed as high-grade serous,  or  high-grade  endometrioid,  or  other  epithelial  non  mucinous  ovarian  cancer  in  a  patient  with gBRCA1 or 2 deleterious mutation. Prior to randomisation, patients must have had NED or be in CR or PR following first line treatment. There should have been no clinical evidence of disease progression (physical exam, imaging, or CA-125) throughout the first  line  treatment  and  prior  to  study  randomisation.  Any occurrence of discrepancy between investigator tumour assessment and BICR assessment at baseline in term of deviation from eligibility criteria (NED, CR and PR) and incorrect stratification by first line treatment outcome was requested to be discussed. The MAH argued that the eligibility criteria with regards to first line treatment outcome was assessed only by the investigator. The baseline overall response status was not a requirement for the BICR assessment. Patients were randomised at least 3 weeks and no more than 9 weeks after the last dose of chemotherapy and during this time bevacizumab could be continued as a single agent.

Bevacizumab  was  administered  for  up  to  15  months/22  cycles  in  total  (including  the  period  of  prerandomisation given with chemotherapy and post-randomisation given with olaparib or placebo) in line with the SmPC recommendations (SmPC Avastin). Patients were to receive olaparib or placebo 300 mg BID for up to 2 years or until objective radiological disease progression or unacceptable toxicity in line with the recently approved recommendations in the SmPC for maintenance treatment in newly diagnosed advanced BRCAm ovarian cancer (SmPC Lynparza). Patients who in the opinion of the treating physician could derive further benefit from continuous treatment, could be treated beyond 2 years. Upon progression, patients were able to access PARP inhibitors including olaparib outside of the study. OS and PFS2 analysis are thus diluted by cross-over and multiple subsequent lines of therapy. This is likely to hamper comparisons in terms of OS and PFS2.

PFS  by  investigator  is  the  primary  endpoint  in  PAOLA-1  study,  supported  by  PFS2,  OS  (adjusted  for multiplicity), TFST, TSST, TDT, BOR, PRO as secondary endpoints. The assessment of PFS2 is considered crucial in this setting in order to assess any possible negative effect on next line therapy and to outbalance tolerability and toxicity concerns related to maintenance therapy.

The primary analysis of PFS was based on site or investigator assessment of scans according to modified RECIST 1.1 criteria. The study was double-blinded, but investigator bias cannot be ruled out due to the known toxicity profile of olaparib. A blinded independent central review (BICR) of progression data was thus conducted. Nevertheless, after investigators confirmed progression, no further scans were sent for central review. In this regard, bias due to informative censoring (patients had progressed according to investigator but not according to BICR) may be likely. PFS2 events were defined by investigator according to local standard clinical practice, without considering scheduled visits, and could involve radiological, CA125 or symptomatic progression. The variability in the methods and frequency of tumour assessments between treatment arms and different centres were discussed. There is no impact on the reliability and the accuracy of results.

Sample size calculation was driven by number of PFS events. 762 patients were planned to be randomised (2:1 ratio) so that maturity of the PFS data was approximately 60%, considering a recruitment duration of 24 months and a 21-month follow-up for the last included patient (estimated total duration from first randomized patient to PFS1 assessment: 45months) and assuming a common exponential dropout rate of 1%. In addition, approximately 24 patients were to be randomised in Japan. The patients randomised in Japan were included in the FAS provided that there were no clinical data derived from the ongoing olaparib programme that suggested a different efficacy or safety profile for olaparib tablets in Japanese patients with  high-grade  epithelial  ovarian  cancer.  It  is  noted  that  the  sample  size  was  increased  by  protocol

<div style=\"page-break-after: always\"></div>

amendment (Version 4) from 612 to 762 patients. The assumption of treatment effect was reduced for the calculation of the new sample size (from HR of 0.7 to HR of 0.75).

Patients were randomized in a 2:1 ratio. The randomisation was stratified by 2 prognostic factors: first line treatment outcome including 4 strata (NED with complete resection at initial surgery, CR with complete resection at IDS, CR with incomplete resection or no surgery and PR) and local tBRCA status with 2 strata (deleterious mutation, and absence of deleterious mutation) at screening.

A multiple testing procedure was employed across PFS and key secondary endpoints (PFS2 and OS). An interim OS analysis was planned to be performed when statistical significance was shown for PFS and PFS2 (interim or final PFS2 analysis). Accordingly, only a descriptive OS interim analysis (25.9% maturity) was performed at the primary analysis of PFS (DCO 22 March 2019). An updated descriptive interim OS analysis (33% maturity) has been provided during procedure (DCO 30 September 2019).

Seven amendments to the original study protocol version were made. Most of the amendments and changes to the design of the study were for administrative or clarification purposes. In the protocol version 3, the amendment allowed patients having IDS to have only 2 cycles of bevacizumab in combination with the last 3 cycles of Platinum-based chemotherapy, in line with standard clinical practices for patients having IDS.

Under protocol amendment 6, additional PFS and OS subgroup analyses have been pre-specified, including analyses in biomarker-defined subgroups defined based on retrospective post-randomisation analysis of tumour tissue samples by Myriad myChoice HRD Plus test.

Important protocol deviations have been reported in 6% of patients. These were generally balanced between treatment arms (6.5% for the olaparib/bevacizumab arm and 4.8% for the placebo/bevacizumab arm) and no patient have had more than 1 important protocol deviation.

The applicant reported that the sponsor of the study, one CRO and 10 investigator centres (France 1 site, Germany 1 site, Italy 1 site and Japan 7 sites) were independently audited by a third party, on behalf of the MAH and no critical findings were identified across the five audits conducted. However, one outcome of the sponsor audit was that the process for assessing, documenting and managing protocol violations was not considered robust to ensure compliance with GCP and integrity of trial results. In fact, sponsor grading and assessment of the majority of protocol violations has not been completed (violations dated from 2015 and included violations to eligibility criteria, dispensing errors and incorrect randomisation). This was a serious concern that could have substantially affected the integrity and the robustness of the study data. Accordingly, a retrospective re-review and formal grading of all the protocol non-compliance prior to June 2018 has been undertaken. Feedback from the Sponsor with regards to the non-compliance review is that there are 20 additional major deviations. The number of patients with at least one major protocol deviations has thus increased from 6% to 8.4%. The newly identified major deviations are considered unlikely to have influenced the overall efficacy and safety conclusions of the study.

## Efficacy data and additional analyses

Of the 1222 patients enrolled into the study, 416 patients were not randomised, with 324 patients not meeting the eligibility criteria; the most common reason being that patients had not received a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of platinum-based therapy. 806 patients were randomised in 137 study centres in 11 countries worldwide (97% in Europe and 3% in Japan). 24 patients were randomised in Japan centers and are included in the FAS. The DCO date for the primary analysis was 22 March 2019.

Of the 806 patients randomised into the study, 535 olaparib patients and 267 placebo patients received study treatment in addition to bevacizumab; 2 patients randomised to the olaparib/bevacizumab arm and

<div style=\"page-break-after: always\"></div>

2 patients randomised to the placebo/bevacizumab arm did not receive olaparib or placebo. A higher proportion of patients in the olaparib/bevacizumab arm (27.7%) completed the protocol-specified 2 years of treatment than in the placebo/bevacizumab arm (19.9%). 61.9% patients in the olaparib/bevacizumab arm discontinued olaparib, and 72.7% patients in the placebo/bevacizumab arm discontinued placebo. The most common reason for discontinuation of olaparib or placebo was disease progression as per RECIST criteria; this was lower in the olaparib/bevacizumab arm (34.0%) than in the placebo/bevacizumab arm (58.1%). A higher proportion of patients discontinued olaparib due to AEs (20.4%) than placebo (4.9%). A similar and low proportion of patients in both arms discontinued olaparib or placebo for any other reason: for most of these patients in the olaparib/bevacizumab arm (13/19 patients) and all of the patients in the placebo bevacizumab arm (6/6 patients), the reason was patient decision.

Patients randomised were overall representative of the intended target population. Demographic and baseline characteristics were balanced between both arms in the ITT population and in the biomarkerdefined sub-groups by t BRCA m (prospectively and retrospectively defined), GIS and HRD status (defined in this study by a combination of both biomarkers).

Median age overall was 61 years, which is consistent with the expected median age of an advanced ovarian cancer patient population not selected for gBRCA mutation. The majority of patients were FIGO Stage IIIC, had high-grade serous histology, and had an ECOG performance status of 0 across both treatment arms. 30% of patients were Stage IV. The majority of patients had normal CA-125 at study entry.

In total, 747 patients (92.7%) underwent debulking surgery prior to randomisation. The timing and outcome of debulking surgery was well balanced across both treatment arms. Stratification factors, as randomised or per eCRF (occurrence of some discrepancies), were well balanced between treatment arms.

All randomised patients had a prior platinum-based chemotherapy and bevacizumab regimen at baseline. The majority of patients had received between 4 and 9 cycles of platinum/taxane-based chemotherapy, with 62.8% of patients having received 6 cycles. All patients received a minimum of 5 cycles of platinum chemotherapy; 1 patient received &gt;9 cycles of platinum chemotherapy. All patients had received a minimum of 2 cycles of bevacizumab prior to randomisation.

At study entry, approximately 29.4% of patients had local tBRCAm status and 70.6% of patients had non-BRCAm status (wild type or variant of uncertain significance or inconclusive/unknown status). Demographic and baseline characteristics in the biomarker sub-groups were consistent with those in the ITT population.

Post randomisation testing using the Myriad myChoice HRD Plus test was performed to determine Myriad tBRCAm status, HRRm status and Myriad HRD status. Genomic instability score (GIS) was also determined and considered with tBRCAm for determination of the positive Myriad HRD status (tBRCAm and/or positive GIS). In accordance with two GIS cutoffs (≥42 or ≥33), two different cut -offs (≥42 or ≥33) were used to assign HRD positive status in PAOLA -1 (Myriad HRD status 42 and 33 cut-offs). Myriad biomarker status was available for 97% of randomised patients (782/806 patients, for 24 patients no sample sent). 93.7% of patients (755/806 patients) had a Myriad tBRCA and HRR results available (for 27 patients test failed) and 82.4% (664/806 patients) had an available Myriad HRD status. The proportion of Myriad tBRCA mutations, HRR mutations and Myriad HRD status was well balanced between treatment arms. The overall agreement between screening tBRCA and Myriad tBRCA was 96.3% (701/728 patients). 29.2% of patients (235/806) were tBRCAm and 64.5% of patients (520/806) were non-tBRCAm by Myriad testing. Only a low proportion of patients (6.7% or 54/806) were Myriad HRRm excluding tBRCAm.

<div style=\"page-break-after: always\"></div>

Using the Myriad HRD status 42 and 33 cut-offs, 48.0% and 54.2% of overall patient population, respectively, were considered Myriad HRD positive. In addition to tBRCAm patients within these groups, measuring of GIS by Myriad test allowed to include patients with positive GIS (≥42 or ≥33). Therefore, 18.9% of overall patient population were defined as Myriad HRD (42) positive excluding Myriad tBRCAm patients (also called 'GIS positive' within 'HRD positive' group) and 25.1% were Myriad HRD (33) positive excluding Myriad tBRCAm patients. Hence, biomarkers of homologous recombination deficiency (tBRCAm and HR-associated genomic instability) can both define HRD status, which in PAOLA-1 was defined as by combining both detection of tBRCAm and positive GIS, resulting in about half of patient population defined as HRD-positive.

Central gBRCA testing was performed only for patients at study sites in France. gBRCA status was available for half of the patients (404/806 [50.1%]). Of these, 120/404 (29.7%) patients were gBRCAm. The proportion of sBRCAm (8.6%) is in line with that expected in first line ovarian cancer.

All efficacy and HRQoL data were analysed using the FAS on an ITT basis (FAS=806).

## Primary endpoint

The study met its primary objective. The investigator assessed PFS showed a statistically significant improvement in patients treated with olaparib compared with placebo when added to bevacizumab with a 41% reduction in the risk of disease progression or death (58.8% maturity, HR 0.59; 95%CI (0.49;0.72) p-value &lt;0.0001). The median PFS showed a difference of 5.5 months favouring olaparib/bevacizumab arm (22.1 months vs 16.6 months). Based on KM analysis estimations, 46.0% of the patients in the olaparib/bevacizumab arm remained progression free at 2 years compared with 27.7% of the patients in the placebo/bevacizumab arm. The majority of patients in both arms progressed due to developing new lesions.

The results of the BICR PFS analysis were consistent with the primary analysis. The estimates of median PFS were longer by BICR than by investigator (26 vs 22 months, respectively, for olaparib/bevacizumab; 18.3 vs 16.6 months, respectively, for placebo/ bevacizumab). However, HR and p values were similar (HR = 0.63, 95% CI: 0.51-0.77; p &lt;0.0001).

Overall, there was 82% concordance between investigator and central reviews in progression. Nevertheless, there was a difference in the rate of patients who had progressed by investigator but not according to BICR (67 patients (12.5%) in olaparib arm and 57 patients (21.2%) in placebo arm) between treatment arms (informative censoring). The potential impact of informative censoring was assessed through a sensitivity analysis based on BICR where informatively censored patients were assumed to have an event 24 weeks after time of censoring. Results were consistent with those of the investigator assessed PFS analysis.

Of note, differences in early discrepancy rate (-0.03) and late discrepancy rate (0.04) were observed between treatment arms. The negative discordance in EDR and positive discordance in LDR may indicate investigator bias in favour of olaparib/bevacizumab arm, however they did not reach the threshold of 0.075.

Evaluation-time bias analysis results for PFS were in line with those of the primary analysis. A descriptive analysis about compliance with scheduled evaluations by treatment arm was provided. The proportion of patients  with  at  least  one  visit  off-schedule  was  higher  in  the  olaparib  arm  than  in  the  placebo  arm (difference of 9%). The MAH have provided a detailed analysis of the timing of RECIST assessments to explain this difference (data not shown). This is likely due to the fact that the number of assessments per patient in the olaparib arm was higher than on the placebo arm due to longer PFS (19% difference).

The MAH also provided a sensitivity analysis censoring patients who missed at least one RECIST assessment at the time of the latest evaluable RECIST assessment without previous missed visits (data not shown). Results were consistent with the primary analysis.

<div style=\"page-break-after: always\"></div>

## Secondary endpoints

At  DCO of 22 March 2019, the investigator assessed PFS2 data  were 39.1% mature (315 events/806 patients)  with  63.5%  of  patients  in  the  olaparib/bevacizumab  arm  vs  55.8%  of  patients  in  the placebo/bevacizumab  arm  not  having  had  second  progression.  Median  PFS2  was  32.3  months  in  the olaparib/bevacizumab arm and 30.1 months in the placebo/bevacizumab arm (HR=0.86 [0.69; 1.09], pvalue=0.2).  In  both  treatment  arms,  the  majority  of  progression  events  were  based  on  radiological assessment. Symptomatic progression and progression by CA-125 events were a minority. The interim analysis  of  PFS2  indicates  a  slightly  better  outcome,  not  statistically  significant,  favouring  olaparib/ bevacizumab arm. Nevertheless, PFS2 analysis is considered immature, and results are not conclusive.

The interim OS analysis is considered extremely immature (209 events; 25.9% mature) with a similar proportion of patients in the olaparib/bevacizumab arm and in the placebo/bevacizumab arm (70.8% vs 71.4% respectively) in survival follow-up. The median OS was 39.4 months in the olaparib/bevacizumab arm and was not reached in the placebo/bevacizumab arm with a HR of 1.01 (95%CI 0.76, 1.36) p=0.9270. At the DCO of 30 September 2019, the updated OS analysis shows a HR of 0.94 (95% CI 0.73 to 1.21) in the ITT population.

PFS2 and OS were key secondary endpoints. The next planned analysis of PFS2 and OS was to be performed when the PFS2 data were approximately 53% mature (approximately 427 events) or after a maximum duration of one year post primary analysis PFS DCO, whichever occurs first. The DCO was set as 22 March 2020 which is one year post PFS analysis. The MAH is recommended to submit the updated data for PFS2 and OS estimated to be in December 2020 and the final OS data when available (planned in March 2022) (REC).

In the placebo/bevacizumab arm, 20.4% of patients received PARPi as a first subsequent therapy compared to 5.2% in the olaparib/bevacizumab arm. This may have a confounding effect on OS and PFS2 analysis. Additional analysis adjusting for impact of subsequent PARP inhibitor treatment will be provided with the updated and final analyses (REC).

No multiplicity adjustment was applied on secondary exploratory efficacy endpoints including TFST, TSST, and TDT. There was a delay in TFST in favour of olaparib/bevacizumab arm in line with the benefit observed in PFS (HR: 0.58, 95%CI: 0.48; 0.7, 2-sided p-value&lt;0.0001). The median value was 24.8 months in the olaparib/bevacizumab arm compared with 18.5 months in the placebo/bevacizumab arm. The numerical improvement obtained in TSST and TDT is considered limited. The 95% interval confidence of median values overlapped. It should be noted that, at the beginning of the treatment (up to 9 months), there was a higher rate of treatment discontinuation in the olaparib/bevacizumab arm compared to placebo/bevacizumab.

The main endpoint for HRQoL analysis in the study was EORTC QLQ-C30. Overall, there was no meaningful difference between the treatment arms in average change over the 24-month treatment period in QLQ-C30 global health status/QoL score using MMRM (estimated difference: 0.59, 95% CI-1.399, 2.57, p=0.5626). Although PRO assessment was a secondary endpoint, there was no multiplicity adjustment and this analysis is considered as exploratory. Therefore, the inclusion of PRO data in the SmPC is not accepted.

Patients  have  been  stratified  by  tBRCAm  status,  based  on  the  prospectively  conducted  tumour  tissue testing.  As  expected,  the  magnitude  of  treatment  effect  was  notable  in  the  subgroup  of  patients  with deleterious BRCA1/2 mutations, with HR (95% CI) of 0.34 (0.23, 0.51) and clinically relevant difference in median  PFS:  37.2  months  and  22  months  in  olaparib/bevacizumab  and  placebo/bevacizumab  arms, respectively. The extent of treatment effect was much lower in the non-tBRCAm patients compared to tBRCAm  patients  with  median  PFS  of  19  months  and  16  months  (HR  (95%  CI)  0.7  (0.57,  0.86))  in olaparib/bevacizumab and placebo/bevacizumab arms respectively. The subgroup analysis by tBRCA status by Myriad was consistent with this analysis.

<div style=\"page-break-after: always\"></div>

In the tBRCAm subgroup based on test result at randomisation, the OS HR point estimate was reported as 0.66 (95% CI 0.37 to 1.21), while in non-tBRCAm subgroup it was 1.02 (95% CI 0.77 to 1.36) (DCO 30 September 2019). In line with analysis in these prospectively defined subgroups, in exploratory subgroups by mutation status determined retrospectively by Myriad test, the OS HR point estimate was 0.61 (95% CI 0.34 to 1.09) in the Myriad tBRCAm subgroup while it was 1.04 (95% CI 0.77 to 1.4) in non-tBRCAm subgroup (DCO 30 September 2019).

Similarly, an inconsistency in treatment effect was observed in subgroup analysis based on retrospectively analysed samples to determine tumour Myriad HRD status combining tBRCAm status and HRD score (GIS, genomic instability score). This analysis is however pre-specified in the SAP. Patients were classified as having Myriad HRD positive or Myriad HRD negative tumours using a combination of positive or negative BRCAm status and Myriad GIS/HRD score (≥ 42/ 33 for positive, &lt;42/ 33 for negative). For the remaining patients,  such  combined  HRD  status  was  considered  unknown.  A  large  differential  benefit  in  PFS  was observed in the following subgroups: (1) Subgroup of patients classified as Myriad HRD positive at two cutoffs 42 and 33 (either tBRCAm or GIS/HRD score ≥ cut -off). With the GIS score cut-off 42, HR was 0.33 [0.25, 0.45]; median PFS 37 months in olaparib vs 17 months in placebo arm; (2) Subgroup of patients classified as overall tumour biomarker status positive (patients identified by biomarkers associated with HRD: tBRCAm or HRRm or Myriad HRD (≥ 42 or 33) tumours): HR of 0.38 [0.29, 0.50].

However, absence of effect on PFS was reported in the following subgroups: (1) Subgroup of patients classified as Myriad HRD negative at two cut-offs (HRD score&lt;cut-off in absence of tBRCAm): HR=1.00 [0.75; 1.35], median PFS 16.4 months in olaparib vs 16.5 months in placebo arm; (2) Subgroup of patients classified as overall tumour biomarker status negative (negative status for biomarkers associated with HRD: absence of tBRCAm and HRRm and Myriad HRD (≥ 42 or 33) tumours): HR of 0.94 [0.69, 1.27] median PFS 16.6 months in olaparib vs 16.2 months in placebo arm.

Consistently with data observed in patients without determined tBRCAm and supported by biological plausibility, the updated OS analysis do not allow to exclude a detrimental effect in the HRD-negative subgroup. In the 30 September 2019 DCO analysis, the OS HR point estimate was 0.71 (95% CI 0.47 to 1.10) in the HRD-positive subgroup and 1.11 (95% CI 0.76 to 1.65) in the HRD-negative subgroup. KM plots separate late in the HRD-negative subgroup in favour of bevacizumab/placebo arm. Though acknowledging limitations related to data immaturity, it cannot be excluded that treatment with the combination bevacizumab+olaparib in the first line setting in ovarian cancer patients whose tumours are defined as HRD-negative may be associated with poorer OS.

Post-hoc analyses using only the Genomic Instability Score (GIS)/HRD score at cut-off 42, have shown results in the GIS positive subgroup consistent to those in the HRD positive subgroup.

It is noted that a GIS or HRD test is not available to date in Europe and different cut-offs are used across different PARPi studies. However, a greater treatment effect was consistently observed across several trials using predefined cut-off for GIS (42) as used for Myriad HRD test. There is also a biological rational supporting genomic instability as a biomarker predicting magnitude of PARPi activity.

Overall, efficacy can only be considered established in patients identified as HR deficient based on biomarkers associated with HRD (BRCAm, HR deficiency-associated genomic instability and combination thereof). In patients without defined positivity for combined biomarker (HRD-negative patients), the overall efficacy data do not support that benefits outweigh risks. The indication has been restricted to patient population whose tumour are associated with HR deficiency defined by biomarkers (tBRCAm and/or genomic instability).

<div style=\"page-break-after: always\"></div>

## 2.4.4. Conclusions on the clinical efficacy

PAOLA-1 met its primary objective, demonstrating a statistically significant improvement in PFS (HR 0.59 [0.49; 0.72] p&lt;0.0001) in the ITT population for olaparib vs placebo when added to bevacizumab in the maintenance setting in patients with newly-diagnosed ovarian cancer who are not selected by HRD biomarker status. However, patients defined as biomarker-positive (t BRCA m, GIS, HRD status positive defined as t BRCA m and/or GIS positive) derived most of the benefit.

The magnitude of treatment effect was large in the subgroup of patients with deleterious BRCA1/2 mutations and higher genomic instability scores with pre-defined cut-off (HRD-positive), with HR (95% CI) of 0.33 (0.25, 0.45); with a clinically relevant difference in median PFS: 37.2 months vs 17 months in olaparib/bevacizumab and placebo/bevacizumab arms, respectively. However, the treatment effect was absent in the HRD-negative patients with median PFS of 16.4 months and 16.5 months in olaparib/bevacizumab and placebo/bevacizumab arms respectively (HR (95% CI) 1.00 [0.75; 1.35]). Furthermore, there is an indication of detrimental effect on OS, observed in subgroups without defined positivity for biomarkers associated with homologous recombination deficiency, including HR deficiencyassociated genomic instability as a biomarker for predicting PARPi activity. It is noted that an HRD test is not available to date in Europe and different cut-offs are used across different PARPi studies for genomic instability score. However, a greater treatment effect in BRCAm and HRD-positive patients, was consistently observed across these trials using Myriad HRD test when considering a pre-defined cut-off (42).

Overall, efficacy can only be considered established in patients whose cancer is associated with HR deficiency defined by biomarkers (tBRCAm and/or genomic instability) and identified as biomarkerpositive.

Data for PFS2 and OS are still immature with no clear benefit reported in interim analysis. The MAH is recommended to provide updated and final analyses as soon as available (REC).

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

Across the entire clinical program, as of 15 June 2019, approximately 11919 patients are estimated to have received treatment with olaparib. The focus of this application is the PAOLA-1 study, where olaparib 300 mg (or placebo) bd was given in addition to bevacizumab as a maintenance treatment for patients with newly-diagnosed advanced (FIGO Stage IIIB-IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer and were in response following first line treatment, with platinum-taxane chemotherapy and bevacizumab.

Supportive safety data were provided from a pool of patients who were intended to receive olaparib 300 mg bd as a monotherapy in the MAH-sponsored studies.

Table 37: Number of patients in the 300 mg bd pool (as of DCO 15 June 2019)

<!-- image -->

| Study/pooled dataset                                                                                                                                                 | Number of patients intended for the 300 mg bd cohort and received olaparib (all tumour types)   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Total exposed                                                                                                                                                        | 1585                                                                                            |
| D0818C00001 (SOLO1): Phase II FIGO Stage III-IV ovarian cancer SOLO1 China cohort                                                                                    | 260 40                                                                                          |
| D0816C00002 (SOLO2): Phase Ill platimum-sensitive serous ovanian cancer SOLO2: China cohort                                                                          | 195 22                                                                                          |
| Study D0816C00010 (SOL03): Phase II gBRCAm_third line ovarian cancer patients                                                                                        | 178                                                                                             |
| D0819C00003 (OlympiAD): Phase II HER2-negative breast cancer patients with gBRCA1/2 mutation                                                                         | 205                                                                                             |
| Study D081DC00007 (PROfouud): Phase II HRRm metastatic castation- resistant prostate cancer (mCRPC)                                                                  | 256                                                                                             |
| Study D081FC00001 (POLO): Phase III gBRCAm metastatic pancreatic adenocarcinoma patients whose disease has not progressed on first-line platimum-based chemotherapy. | 91                                                                                              |
| Study 24: Phase I Relative Bioavailability (300 mg tablet bd patients only. Groups 4 and 6)                                                                          | 忆                                                                                               |
| Study 04: Phase I Food interaction & QT                                                                                                                              | 57                                                                                              |
| Study 06: Phase I Renal impainment study                                                                                                                             | 43                                                                                              |
| Study 07: Phase I CYP3A4 inhibition and QT                                                                                                                           | 56                                                                                              |
| Study 08: Phase I CYP induction                                                                                                                                      | 19                                                                                              |
| Shudy D081CC00001: Phase I anti-hommonal PK study                                                                                                                    | 69                                                                                              |
| Study D081BC00001: Phase I Japan Monotherapy study                                                                                                                   | 19                                                                                              |
| D0816C00005: Phase I hepatic impainment study                                                                                                                        | 31                                                                                              |
| D081BC00002: China PK study                                                                                                                                          | 20                                                                                              |

The patients in the China cohorts of SOLO1 and SOLO2 were reported separately to the main CSRs for these studies.

## Patient exposure

## Overall extent of exposure: PAOLA-1

All  except  4  of  the  806  randomised  patients  in  PAOLA-1  received  study  treatment  (2  patients  in  the olaparib/bevacizumab arm and 2 patients in the placebo/bevacizumab arm). At the DCO, the majority of

<div style=\"page-break-after: always\"></div>

patients in the safety analysis set (SAS) had discontinued olaparib or placebo treatment (331 [61.9%] of 535  olaparib/bevacizumab-treated  patients  and  194  [72.7%]  of  267  placebo/bevacizumab-treated patients). It should be noted that study treatment discontinuation reasons were only collected for olaparib or placebo and not for bevacizumab.

As per protocol, olaparib or placebo treatment was stopped after 2 years of exposure. The proportion of patients who had completed the maximum 2 year treatment period was higher in the olaparib/bevacizumab arm  (148  [27.7%]  of  535  patients)  compared  with  the  placebo/bevacizumab  arm  (53  [19.9%]  of 267 patients). At the time of DCO, 56 (10.5%) patients in the olaparib/bevacizumab arm and 20 (7.5%) patients in the placebo/bevacizumab arm remained on (olaparib or placebo) study treatment.

The most common reason for discontinuation in both treatment arms was disease progression, although the proportion of patients discontinuing due to disease progression was lower in the olaparib/bevacizumab arm (182 [34.0%] of 535 patients) compared with the placebo/bevacizumab arm (155 [58.1%] of 267 patients).

A higher proportion of patients in the olaparib/bevacizumab arm had discontinued for an AE, compared with the  placebo/bevacizumab  arm  (109  [20.4%]  of  535  patients  versus  153  [5.6%]  of  267  patients, respectively).

Table 38: PAOLA-1: overall extend of olaparib or placebo exposure (SAS)

|                         | Nunber (%) of patients Overall study duration   | Nunber (%) of patients Overall study duration   |
|-------------------------|-------------------------------------------------|-------------------------------------------------|
| Month (approximate)     | Olaparib/ bevacizumab N=535                     | Placebo/ bevacizumab N=267                      |
| ≥Day 1                  | 535 (100)                                       | 267 (100)                                       |
| ≥1 month (30.4 days)    | 506 (94.6)                                      | 265 (99.3)                                      |
| ≥3 months (91.3 days)   | 467 (87.3)                                      | 246 (92.1)                                      |
| ≥6 months (182.6 days)  | 415 (77.6)                                      | 219 (82.0)                                      |
| ≥9 months (273.9 days)  | 362 (67.7)                                      | 196 (73.4)                                      |
| ≥12 months (365.3 days) | 331 (61.9)                                      | 165 (61.8)                                      |
| ≥18 months (547.9 days) | 259 (48.4)                                      | 110 (41.2)                                      |
| ≥24 months (730.5 days) | 109 (20.4)                                      | 37 (13.9)                                       |
| ≥25 months              | 11 (2.1)                                        | 2 (0.7)                                         |
| ≥30 months              | 2 (0.4)                                         | 0                                               |
| ≥33 months              | 1 (0.2)                                         | 0                                               |

<div style=\"page-break-after: always\"></div>

Table 39: PAOLA-1: duration of olaparib or placebo exposure (SAS)

|                                   | Number (%) of patients            | Number (%) of patients            | Number (%) of patients            | Number (%) of patients            | Number (%) of patients            | Number (%) of patients            |
|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                   | Overallstudyduration              | Overallstudyduration              | Combinationtreatmentphaseonly     | Combinationtreatmentphaseonly     | Postcombinationtreatmentphase     | Postcombinationtreatmentphase     |
|                                   | Olaparib/ bevacizumab N=535       | Placebo/ bevacizumab N=267        | Olaparib/ bevacizumab N=534       | Placebo/ bevacizumab N=267        | Olaparib N=388                    | Placebo N=214                     |
| Totaltreatmentduration(months)    | Totaltreatmentduration(months)    | Totaltreatmentduration(months)    | Totaltreatmentduration(months)    | Totaltreatmentduration(months)    | Totaltreatmentduration(months)    | Totaltreatmentduration(months)    |
| Mean (Std)                        | 15.2 (8.7)                        | 14.9 (7.6)                        | 9.1 (4.1)                         | 9.5 (3.7)                         | 8.5 (5.2)                         | 6.8 (5.4)                         |
| Median (range)                    | 17.3 (0.0- 33.0)                  | 15.6 (0.1 -26.2)                  | 10.6 (0.3 -20.2)                  | 10.6 (0.7 -17.1)                  | 9.9 (0.0 -20.5)                   | 6.6 (0.0-23.0)                    |
| Total treatment days              | 8144.7                            | 3981.3                            | 4882.0                            | 2543.9                            | 3288.8                            | 1448.2                            |
| Actualtreatment duration(months)b | Actualtreatment duration(months)b | Actualtreatment duration(months)b | Actualtreatment duration(months)b | Actualtreatment duration(months)b | Actualtreatment duration(months)b | Actualtreatment duration(months)b |
| Mean (Std)                        | 14.6 (8.6)                        | 14.7 (7.6)                        | 8.7 (4.1)                         | 9.4 (3.7)                         | 8.3 (5.1)                         | 6.7 (5.3)                         |
| Median (range)                    | 16.8 (0.0-32.1)                   | 15.0 (0.1 -26.2)                  | 10.2 (0.3 - 20.1)                 | 10.4 (0.5 -17.1)                  | 9.6 (0.0 -20.5)                   | 6.6 (0.0-22.7)                    |
| Total treatment days              | 7815.6                            | 3924.9                            | 4647.9                            | 2509.8                            | 3201.3                            | 1424.9                            |

In general, toxicity observed during the course of the study could be managed by dose interruptions and reductions; reduction to 250 mg bd as a first step and further reduction to 200 mg bd as a second step, with no dose re-escalations allowed.

For patients who were able to stay on treatment (i.e., did not discontinue due to progression or other reasons), the majority received the 300 mg bd dose (throughout the duration of the study). For the majority of patients in the olaparib/bevacizumab treatment arm, olaparib dose reductions were not required (first dose reduction was to 250 mg bd [i.e., 500 mg total daily dose]; second dose reduction was to 200 mg bd [i.e., 400 mg total daily dose]) with AEs in most patients being managed through dose interruptions. The majority of dose reductions occurred in the first 3 months of treatment.

Table 40: PAOLA-1: dose reductions of olaparib by time period (SAS)

|                      | Number (%) of patients by time period   | Number (%) of patients by time period   | Number (%) of patients by time period   | Number (%) of patients by time period   | Number (%) of patients by time period   |
|----------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                      | Up to 3months (N=535)                   | >3 to ≤6months (N=460)                  | >6 to months (N=402)                    | >9 to ≤12 months (N=356)                | >12months (N=324)                       |
| First dose reduction | 183 (34.2)                              | 40 (8.7)                                | 4 (1.0)                                 | 2 (0.6)                                 | 1 (0.3)                                 |
| Seconddose reduction | 72 (13.5)                               | 56 (12.2)                               | 11 (2.7)                                | 10 (2.8)                                | 11 (3.4)                                |

## Overall extent of exposure: Olaparib 300 mg bd pool

<div style=\"page-break-after: always\"></div>

Table 41: 300 mg bd pool: overall extend of exposure (SAS)

| Month (days)             | Number (%) of patients Olaparib 300mg bd N=1585   |
|--------------------------|---------------------------------------------------|
| ≥Day 1                   | 1585 (100.0)                                      |
| ≥1 month (30.4 days)     | 1495 (94.3)                                       |
| ≥3 months (91.3 days)    | 1246 (78.6)                                       |
| ≥6 months (182.6 days)   | 977 (61.6)                                        |
| ≥12 months (365.3 days)  | 599 (37.8)                                        |
| ≥18 months (547.9 days)  | 417 (26.3)                                        |
| ≥24 months (730.5 days)  | 285 (18.0)                                        |
| ≥36 months (1095.8 days) | 22 (1.4)                                          |
| ≥48 months (1461.1 days) | 6 (0.4)                                           |

Compared with the olaparib/bevacizumab arm of PAOLA-1, treatment duration in the 300 mg bd pool was generally shorter. Of note, 27.6% of patients in this pool were recruited to Phase I studies.

## Demographic

## PAOLA-1

Key demographic and baseline characteristics are described in Table 6.

## Olaparib 300 mg bd pool

Summaries of the key demographic and baseline patient characteristics for the 15 studies contributing to the pooled dataset are provided in the Table below.

<div style=\"page-break-after: always\"></div>

Table 42: Key demographic and baseline characteristics by study: studies in olaparib 300 mg bd pool

| Study Number of Subjects randomised/ treated              | Age/sex/race                                                                                                                                          | Performance status                                     | Tumour type                                 | Prior anticancer treatment                                                                      | Genemutation status   |
|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------|
| SOL01 N=391/390 (260 n the pooled dataset)                | 29 to 84 years (mean age 53.5 years) All Female 320 (81.8%) White, 59 (15.1%) Asian 12 (3.1%) Black, Affican American and Other                       | ECOG PS ≤1 305 (78.0%) PS0 85 (21.7%) PS1              | Advanced (FIGO Stage II-IV) OvarianCancer   | All pre-treated Median number of prior chemotherapies was 1.0                                   | 389 gBRCAm 2 sBRCAm   |
| SOLO1 China cohort N=64/64 (444+ in the pooled dataset)   | 33 to 67 years (mean age 51.0 years) All Female 64 (100%) Asian                                                                                       | ECOG PS ≤1 33 (51.6%) PS0 31 (48.4%) PS1               | Advanced (FIGO Stage III-IV) Ovarian Cancer | All pre-treated Median number of prior chemotherapies was 1.0                                   | All gBRCAm            |
| SOL02 N=295/294 (195 in pooled dataset)                   | 28 to 83 years (mean age 57.0 years) All female 173 (88.3%) White 22 (11.2%) Asian 1 (0.5%) Black or African American                                 | ECOG PS ≤1 239 (81.0%)PS0 54 (18.3%) PS1               | PSRovariancancer                            | All treated patients had prior chemotherapy Median number of prior regimens = 2.0 (range 2 - 7) | All gBRCAm            |
| SOLO2 China Cohort N=32/32 (22 in pooled dataset)         | 33 to 67 years (mean age 49.6 years) All female 32 (100%) Asian                                                                                       | ECOG PS ≤1                                             | PSR ovarian cancer                          | All treated patients had prior chemotherapy Median number of prior regimens = 2.0 (range 2 - 4) | All gBRCAm            |
| D0816C00010 (SOL03) N=266/254 (178 in the pooled dataset) | 39 to 79 years (mean age 58.5 years) All Female 148 (83.1%) White, 24 (13.5%) Asian 6 (3.4%) Black, African American and Other                        | ECOG PS ≤2 198 (74.4%) PS0 67 (25.2%) PS1 1 (0.4%) PS2 | Advanced (FIGO Stage III-IV) Ovarian Cancer | All pre-treated Median number of prior chemotherapies was 3.0                                   | All gBRCAm            |
| OlympiAD N=302/296 (205 in the pooled dataset)            | 22 to 76 years (mean age 45.3 years) 295 (97.7%) Female, 7 (2.3%) Male 197 (65.2%) White, 94 (31.1%) Asian 11 (3.6%) Black, Afican American and Other | ECOG PS ≤1 210 (69.5%) PS0 92 (30.5%) PS1              | Metastaticbreastcancer                      | All pre-treated Median number of prior chemotherapies was 1.0                                   | All gBRCAm            |

<div style=\"page-break-after: always\"></div>

| D081FC00001 (POLO) N=154/151 (91 in the pooled dataset)                                                          | 36 to 84 years (mean age 57.5 years) 70 (45.5%) Female 84 (54.5%) Male 141 (91.6%) White, 6 (3.9%) Asian 5 (3.2%) Black, African American and 2 (1.3%) Other   | ECOG PS≤1 103 (66.9%) PS0 48 (31.2%) PS1 (data were missing for 3 patients)                 | Metastatic pancreatic adenocarcinoma                                                                                                                                                                                                                                                                                              | All pre-treated Median number of prior chemotherapiesfor metastatic disease was 1.0   | All gBRCAm                                    |
|------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-----------------------------------------------|
| D081DC00007 (PROfound) N=387/386 (256 in the pooled dataset):                                                    | 47 to 91 years (mean age 68.6 years) All male 248 (64.1%) White 105 (27.1%) Asian 8 (2.1%) Black, African American, 23 (5.9%) Missing and 3 (0.8%) Other.      | ECOG PS ≤2 186 (48.1%) PS0 183 (47.3%) PS1 17 (4.4%) PS2 (data were missing for 1 patient). | HRRmmetastaticcastration-resistant prostate cancer                                                                                                                                                                                                                                                                                | All pre-treated                                                                       | All HRRm                                      |
| Study 24 bioavailability (groups 4 and 6) N=197 in whole study/24 in groups 4 and 6 (24 in pooled dataset)       | 40 to 78 years (mean age 56 years) 23 (95.8%) Female, 1 (4.2%) Male 23 (95.8%) White, 1 (4.2%) Asian                                                           | ECOG PS ≤2                                                                                  | Breast or ovarian cancer                                                                                                                                                                                                                                                                                                          | All had prior chemotherapy Median number of prior regimens in groups 4 and 6 was 4.0  | All gBRCAm                                    |
| Study 04 Food effect (Part C) N=60/55 (57 in pooled  dataset, including 2 patients from Part B)                  | 36 to 79 years (mean age 60.0 years) 42 (76.3%) Female, 13 (23.6%) Male 54 (98.2%) White, 1 (1.8%) other                                                       | ECOG PS ≤2 (54 [98.2%] patients were ECOG PS ≤1 and data for1 patient was missing)          | Patients with advanced solid tumours. The most common primary tumour locations were: 0vary (19 [34.5%] lung (4 [7.3%] patients),colorectal (3 [5.5%] patients), peritoneum (2 [3.6%] patients), and prostate (2 [3.6%] patients))                                                                                                 | All pre-treated                                                                       | 5 BRCAm, 8 BRCAwt/VUS, 47 patients not tested |
| Study 06: renal impairment study (Part B only) N=44/43 (43 in pooled dataset)                                    | 32 to 76 years (mean age 61.9 years) 19 (44.2%) male, 24 (55.8%) female 42 (97.7%) White/ 1 (2.3%) Asian                                                       | 41 (95.3%) patients were ECOG PS ≤1; data for 2 patients were missing                       | Patientswithadvancedsolidtumours and normal renal function or mild or moderate renal impairment. Most common locations were ovary (12 [27.9%] patients),renal (5 [11.6%] patients) and breast (4 [9.3%] patients).                                                                                                                | All pre-treated                                                                       | 3 BRCAm, 4 BRCAwt, 35 patients not tested     |
| Study 07 itraconazole interaction study (Part C) N=59/54 (56 in pooled dataset including 2 patients from Part B) | 34 to 82 years (mean age 61.0 years) 38 (70.4%) Female, 16 (29.6%) Male 51 (94.4%) White, 1 (1.9%) each of Asian, Black or African American, and other race    | ECOG PS ≤2 (53 [98.1%] patients were ECOG PS ≤1; 1 patient was PS 2)                        | Patients with advanced solid tumours. Themostcommonprimarytumour locations were: ovary (20 [37.0%] patients), pancreas (6 [11.1%] patients), rectal (4 [7.4%] patients), breast, cervix, and head/neck, cervix (3 patients [5.6%] each), biliary tract, colon, colorectal, lung, peritoneum, and uterus (2 [3.7%] patients each). | All pre-treated                                                                       | 6 BRCAm, 8 BRCAwt/VUS, 45 patients not tested |

<div style=\"page-break-after: always\"></div>

| Study 08 rifampicin interaction study (Part B only) N=22/19 (19 in pooled dataset)           | 31 to 79 years (mean age 58.0 years) 16 (84.2%)Female, 3 (15.8%) Male 19 (100.0%) White                                                                      | ECOG PS ≤2 (16 [84.2%] patients were ECOG PS ≤1; 3 patients were PS 2)                                                                   | Patients with advanced solid tumours. The most common primary tumour locations were: breast and ovary (each with 6 patients [26.3%]); colon (2 patients [10.5%]).                                                                                                                                        | All pre-treated                                                                         | Unknown                                               |
|----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-------------------------------------------------------|
| D081BC00001 Japan Phase I study (Part B only) N=23/23 (19 in pooled dataset)                 | 34 to 77 years (mean age 54.1 years) 15 (65.2%) Female, 8 (34.8%) Male 23 (100.0%) Asian                                                                     | ECOG PS ≤2 (18 [78.3%] patients were ECOG PS 0)                                                                                          | Patientswith advancedsolid malignancies. The primary tumour locations in most of the patients were breast (5 [21.7%] patients), ovary (4 [17.4%] patients), cervix and uterus (2 [8.7%] patients each).                                                                                                  | The median number of previous chemotherapy regimens at baseline was 3.                  |                                                       |
| D081CC00001: Anti-hormonal PK interaction study (Part B only) N=79/79 (69 in pooled dataset) | 29 to 79 years (mean age 58.3 years) 64 (81.0%) Female, 15 (19.0%) Male 73 (92.4%) White, 2 (2.5%) Asian, 2 (2.5%) Black or African American, 2 (2.5%) other | ECOG PS ≤2 (78[98.7%] patients were ECOG PS ≤1; 1 patient was PS 2)                                                                      | Patients with advanced solid cancer. The most common primary tumour locations were: ovary (36 patients [45.6%]), and breast (16 patients [20.3%]).                                                                                                                                                       | All pre-treated                                                                         | 21 BRCAm, 9 BRCAwt, 46 patients not tested, 3 missing |
| D0816C00005 Hepatic impairment study N=31/31 (30 in pooled dataset)                          | 41 to 78 years (mean age 59.7 years) 14 (45.2%) Female, 17 (54.8%) Male 30 (96.8%) White, 1 (3.2%) Asian.                                                    | ECOG PS≤2 (12[38.7%] patients were ECOG PS 0; 17 [54.8%] patients were PS1 and 2 patients were PS 2 at the start of Part B of the study) | Patients with advanced solid cancer. Themost common primarytumour locations were: liver (8 patients); ovary, colon and pancreas were also commonsites(each in 4patients) Hepaticfunctionwasnormal in 13 (41.9%) patients; mild impairment in 10 (32.3%) patients; moderate impairmentin8(25.8%)patients. | All pre-treated                                                                         | BRCA status was not a requirement for study entry     |
| D081BC00002 China PK study; N=47/36 (20 in pooled dataset)                                   | 32 to 67 years (mean age 48.4 years). 8 (22.2% male, 28 (77.8%) female. 36 (100%) Asian                                                                      | 35 [97.2%] patients were ECOG PS ≤1; 1 patient was PS 2                                                                                  | Patientswith advanced solid tumours. Mostcommonlocationswerebreast (21 [58.3%] patients) ovary (6 [16.7%] patients), and gastric (5 [13.9%] patients).                                                                                                                                                   | All pre-treated. Median number of regimens of previous chemotherapy at baseline was 4.0 | Patientswerenot tested for BRCA mutation status.      |

<div style=\"page-break-after: always\"></div>

## Adverse events

## Overview of AE

Table 43: PAOLA-1: Number (%) of patients who had at least 1 AE in any category (SAS)

|                                                            | Nunber (%) of patients      | Nunber (%) of patients     | Nunber (%) of patients           | Nunber (%) of patients           |
|------------------------------------------------------------|-----------------------------|----------------------------|----------------------------------|----------------------------------|
| AE categorya                                               | Overall study duration      | Overall study duration     | Combination treatment phase only | Combination treatment phase only |
|                                                            | Olaparib/ bevacizumab N=535 | Placebo/ bevacizunab N=267 | Olaparib/ bevacizumab N=534b     | Placebo/ bevacizumab N=267       |
| Any AE                                                     | 531 (99.3)                  | 256 (95.9)                 | 523 (97.9)                       | 255 (95.5)                       |
| Any AE of CTCAE Grade3 or higher                           | 308 (57.6)                  | 136 (50.9)                 | 267 (50.0)                       | 116 (43.4)                       |
| Any AE with outcome = death                                | 1 (0.2)                     | 4 (1.5)                    | 0                                | 2 (0.7)                          |
| Any SAE (including events with outcome = death)            | 167 (31.2)                  | 83 (31.1)                  | 130 (24.3)                       | 67 (25.1)                        |
| Any AE leading to discontinuation of olaparib or placebo   | 109 (20.4)                  | 15 (5.6)                   | 86 (16.1)                        | 10 (3.7)                         |
| Any AE leading to dose reduction of olaparib or placebo    | 220 (41.1)                  | 20 (7.5)                   | 210 (39.3)                       | 16 (6.0)                         |
| Any AE leading to dose interruption of olaparib or placebo | 291 (54.4)                  | 65 (24.3)                  | 272 (50.9)                       | 51 (19.1)                        |

The majority  of  AE  were  reported  during  the  combination  period,  with  most  events  occurring  early  in treatment. In the olaparib/bevacizumab arm, 531 (99.3%) patients reported a total of 5970 AEs across the overall study duration, 4719 of these 5970 (79.0%) AEs were reported during the combination period. For the placebo/bevacizumab arm, 256 (95.9%) patients reported a total of 2304 AEs, with 1812 of 2304 (78.6%) AEs reported during the combination period.

The safety profile of olaparib/bevacizumab in non-tBRCAm and tBRCAm patients was similar to that of the SAS (data not shown).

## Comparison with olaparib 300mg bd pool

As shown in the table below, the proportions of patients with SAEs, AEs leading to treatment (olaparib) discontinuation, CTCAE Grade ≥3 AEs, DAEs, AEs leading to dose reduction and AEs leading to treatment interruption were higher for the olaparib/bevacizumab arm of PAOLA-1 compared with the 300 mg bd pool.

<div style=\"page-break-after: always\"></div>

Table 44: Number (%) of patients who had at least 1 AE in any category (olaparib treatment groups) in PAOLA-1 and the 300 mg bd pool

|                                                         | Number (%) of patients             | Number (%) of patients             | Number (%) of patients   |
|---------------------------------------------------------|------------------------------------|------------------------------------|--------------------------|
|                                                         | PAOLA-1 SAS,overall study duration | PAOLA-1 SAS,overall study duration | Olaparib 300 mg bd pool  |
|                                                         | Olaparib/ bevacizumab N=535        | Placebo/ bevacizumab N=267         | (N=1585)                 |
| AE categorya                                            |                                    |                                    |                          |
| Any AE                                                  | 531 (99.3)                         | 256 (95.9)                         | 1542 (97.3)              |
| Any AE of CTCAE Grade 3 or higher                       | 308 (57.6)                         | 136 (50.9)                         | 659 (41.6)               |
| AnyAEwithoutcome=Death                                  | 1 (0.2)                            | 4 (1.5)                            | 19 (1.2)                 |
| Any SAE (including events with outcome = death)         | 167 (31.2)                         | 83 (31.1)                          | 365 (23.0)               |
| AnyAE leadingtodiscontinuation of olaparib or placebo   | 109 (20.4)                         | 15 (5.6)                           | 148 (9.3)                |
| Any AE leading to dose reduction of olaparib or placebo | 220 (41.1)                         | 20 (7.5)                           | 339 (21.4)               |
| Any AE leading to interruption of olaparib or placebo   | 291 (54.4)                         | 65 (24.3)                          | 630 (39.7)               |

Table 45: PAOLA-1: Most commonly reported AEs (occurring in &gt;10%) of patients in either treatment group (SAS)

|                         | Nunber (%) of patients      | Nunber (%) of patients     | Nunber (%) of patients           | Nunber (%) of patients           |
|-------------------------|-----------------------------|----------------------------|----------------------------------|----------------------------------|
|                         | Overall study duration      | Overall study duration     | Combination treatment phase only | Combination treatment phase only |
| MedDRA preferred termb  | Olaparib/ bevacizumab N=535 | Placebo/ bevacizumab N=267 | Olaparib/ bevacizumab N=534      | Placebo/ bevacizumab N=267       |
| Patients with any AE    | 531 (99.3)                  | 256 (95.9)                 | 523 (97.9)                       | 255 (95.5)                       |
| Nausea                  | 285 (53.3)                  | 58 (21.7)                  | 277 (51.9)                       | 51 (19.1)                        |
| Fatigue                 | 283 (52.9)                  | 86 (32.2)                  | 264 (49.4)                       | 80 (30.0)                        |
| Hypertension            | 245 (45.8)                  | 160 (59.9)                 | 223 (41.8)                       | 153 (57.3)                       |
| Anaemia                 | 219 (40.9)                  | 27 (10.1)                  | 193 (36.1)                       | 16 (6.0)                         |
| Lymphopenia             | 120 (22.4)                  | 24 (9.0)                   | 97 (18.2)                        | 20 (7.5)                         |
| Vomiting                | 117 (21.9)                  | 29 (10.9)                  | 105 (19.7)                       | 26 (9.7)                         |
| Arthralgia              | 116 (21.7)                  | 64 (24.0)                  | 99 (18.5)                        | 58 (21.7)                        |
| Abdominal pain          | 103 (19.3)                  | 53 (19.9)                  | 89 (16.7)                        | 39 (14.6)                        |
| Diarrhoea               | 98 (18.3)                   | 45 (16.9)                  | 93 (17.4)                        | 39 (14.6)                        |
| Leukopenia              | 87 (16.3)                   | 26 (9.7)                   | 75 (14.0)                        | 24 (9.0)                         |
| Urinary tract infection | 79 (14.8)                   | 27 (10.1)                  | 65 (12.2)                        | 24 (9.0)                         |
| Headache                | 73 (13.6)                   | 36 (13.5)                  | 68 (12.7)                        | 34 (12.7)                        |
| Neutropenia             | 62 (11.6)                   | 33 (12.4)                  | 55 (10.3)                        | 28 (10.5)                        |
| Constipation            | 53 (9.9)                    | 28 (10.5)                  | 34 (6.4)                         | 22 (8.2)                         |
| Proteinuria             | 31 (5.8)                    | 40 (15.0)                  | 26 (4.9)                         | 36 (13.5)                        |

The largest differences in incidence between the two arms for the overall study duration were for the AEs of  nausea  and  anaemia  (incidence difference  of  31.6  and 30.8  percentage points  respectively).  AEs  of fatigue, lymphopenia and vomiting were also reported at a higher incidence (an incidence difference of ≥10 percentage points) for patients in the olaparib/bevacizumab arm compared with the placebo/bevacizumab arm. All of the AEs reported with a higher incidence of ≥10% for patients in the olaparib/bevacizumab arm, compared with the placebo/bevacizumab arm are known ADRs for olaparib.

<div style=\"page-break-after: always\"></div>

Other AEs which occurred more frequently i n the olaparib/bevacizumab arm (a higher incidence of ≥5 to 10  percentage  points  in  the  olaparib/bevacizumab  arm  compared  with  the  placebo/bevacizumab  arm; overall  study  duration)  were:  dysgeusia  and  leukopenia.  Dysgeusia  is  a  known  ADR  for  olaparib  and leukopenia is a known ADR for both olaparib and bevacizumab. There were no AEs which occurred more frequently (a higher incidence of ≥5 percentage points) in the olaparib/bevacizumab arm that are not currently listed as ADRs for either olaparib alone or both olaparib and bevacizumab.

AEs which occurred less frequently in the olaparib/bevacizumab arm (a lower incidence of ≥5 percentage points in the olaparib/bevacizumab arm compared with the placebo/bevacizumab arm) were proteinuria and hypertension (both listed as ADRs for bevacizumab).

## Comparison with olaparib 300mg bd pool

Table 46: Most commonly reported AEs (occurring in &gt;10% of patients) in PAOLA-1 or the 300 mg bd pool

|                         | Nunber (%) of patientsa             | Nunber (%) of patientsa             | Nunber (%) of patientsa        |
|-------------------------|-------------------------------------|-------------------------------------|--------------------------------|
|                         | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration | Olaparib 300 mg bd pool N=1585 |
| Preferred term          | Olaparib/ bevacizumab N=535         | Placebo/ bevacizumab N=267          | Olaparib 300 mg bd pool N=1585 |
| Patients with any AE    | 531 (99.3)                          | 256 (95.9)                          | 1542 (97.3)                    |
| Nausea                  | 285 (53.3)                          | 58 (21.7)                           | 944 (59.6)                     |
| Fatigue                 | 283 (52.9)                          | 86 (32.2)                           | 589 (37.2)                     |
| Hypertension            | 245 (45.8)                          | 160 (59.9)                          | 42 (2.6)                       |
| Anaemia                 | 219 (40.9)                          | 27 (10.1)                           | 632 (39.9)                     |
| Lymphopenia             | 120 (22.4)                          | 24 (9.0)                            | 53 (3.3)                       |
| Vomiting                | 117 (21.9)                          | 29 (10.9)                           | 514 (32.4)                     |
| Arthralgia              | 116 (21.7)                          | 64 (24.0)                           | 201 (12.7)                     |
| Abdominal pain          | 103 (19.3)                          | 53 (19.9)                           | 246 (15.5)                     |
| Diarrhoea               | 98 (18.3)                           | 45 (16.9)                           | 412 (26.0)                     |
| Leukopenia              | 87 (16.3)                           | 26 (9.7)                            | 114 (7.2)                      |
| Urinary tract infection | 79 (14.8)                           | 27 (10.1)                           | 132 (8.3)                      |
| Headache                | 73 (13.6)                           | 36 (13.5)                           | 243 (15.3)                     |
| Neutropenia             | 62 (11.6)                           | 33 (12.4)                           | 200 (12.6)                     |
| Constipation            | 53 (9.9)                            | 28 (10.5)                           | 288 (18.2)                     |
| Dysgeusia               | 42 (7.9)                            | 3 (1.1)                             | 173 (10.9)                     |
| Decreased appetite      | 42 (7.9)                            | 10 (3.7)                            | 371 (23.4)                     |
| Dyspnoea                | 39 (7.3)                            | 8 (3.0)                             | 197 (12.4)                     |
| Back pain               | 33 (6.2)                            | 9 (3.4)                             | 196 (12.4)                     |
| Proteinuria             | 31 (5.8)                            | 40 (15.0)                           | 4 (0.3)                        |
| Pyrexia                 | 28 (5.2)                            | 10 (3.7)                            | 175 (11.0)                     |
| Cough                   | 23 (4.3)                            | 11 (4.1)                            | 207 (13.1)                     |
| Dizzinesss              | 14 (2.6)                            | 5 (1.9)                             | 181 (11.4)                     |
| Asthenia                | 1 (0.2)                             | 1 (0.4)                             | 262 (16.5)                     |

The only common (≥30% of patients) AE reported in PAOLA-1 but not consistently reported in the 300 mg bd pool was hypertension (45.8% of olaparib/bevacizumab patients in PAOLA-1 compared with 2.6% of patients in the 300 mg bd pool); hypertension is a known ADR for bevacizumab.

Of the AEs reported with an incidence of ≥10% in the olaparib/bevacizumab arm of PAOLA -1 or the 300 mg bd pool, AEs of hypertension, lymphopenia, fatigue, leukopenia, arthralgia and urinary tract infection were reported at a higher incidence (≥5 percentage points difference) in the

<div style=\"page-break-after: always\"></div>

olaparib/bevacizumab arm of PAOLA-1 compared with the 300 mg bd pool. All of these terms are either known ADRs for bevacizumab, or are symptoms commonly reported in an ovarian cancer population.

## Adverse events by treatment period

The majority of AEs first o ccurred within the first 3 months of treatment. Data for the most common (≥10% of patients) in the olaparib/bevacizumab arm are presented in the table below.

Table 47: PAOLA-1: onset of AE by months of study treatment (up to D360) for the most common AEs (reported in ≥10% of patients in the olaparib/bevacizumab arm, overall); SAS, overall study duration

<!-- image -->

|                         | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|-------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Preferredterm           | Onset Day 1-90           | Onset Day 1-90           | OnsetDay91-180           | OnsetDay91-180           | OnsetDay181-270          | OnsetDay181-270          | OnsetDay271-360          | OnsetDay271-360          |
| Preferredterm           | Olap/ ber N=535          | Pbo/ bev N=267           | Olap/ bev N=486          | Pbo/ bev N=261           | Olap/ bev N=435          | Pbo/ bev N=224           | Olap/ bev N=382          | Pbo/ bev N=207           |
| Nausea                  | 259 (48.4)               | 36 (13.5)                | 54 (11.1)                | 12 (4.6)                 | 28 (6.4)                 | 7 (3.1)                  | 28 (7.3)                 | 10 (4.8)                 |
| Fatigue                 | 217 (40.6)               | 52 (19.5)                | 61 (12.6)                | 24 (9.2)                 | 37 (8.5)                 | 15 (6.7)                 | 22 (5.8)                 | 11 (5.3)                 |
| Hypertension            | 160 (29.9)               | 105 (39.3)               | 98 (20.2)                | 68 (26.1)                | 56 (12.9)                | 41 (18.3)                | 52 (13.6)                | 44 (21.3)                |
| Anaemia                 | 163 (30.5)               | 12 (4.5)                 | 67 (13.8)                | 3 (1.1)                  | 29 (6.7)                 | 2 (0.9)                  | 20 (5.2)                 | 2 (1.0)                  |
| Lymphopenia             | 72 (13.5)                | 14 (5.2)                 | 36 (7.4)                 | 5 (1.9)                  | 27 (6.2)                 | 3 (1.3)                  | 23 (6.0)                 | 3 (1.4)                  |
| Vomiting                | 81 (15.1)                | 14 (5.2)                 | 33 (6.8)                 | 4 (1.5)                  | 15 (3.4)                 | 5 (2.2)                  | 15 (3.9)                 | 8 (3.9)                  |
| Arthralgia              | 64 (12.0)                | 42 (15.7)                | 23 (4.7)                 | 21 (8.0)                 | 20 (4.6)                 | 10 (4.5)                 | 13 (3.4)                 | 4 (1.9)                  |
| Abdominalpain           | 56 (10.5)                | 26 (9.7)                 | 26 (5.3)                 | 8 (3.1)                  | 15 (3.4)                 | 10 (4.5)                 | 13 (3.4)                 | 10 (4.8)                 |
| Diarrhoea               | 59 (11.0)                | 24 (9.0)                 | 27 (5.6)                 | 8 (3.1)                  | 13 (3.0)                 | 6 (2.7)                  | 15 (3.9)                 | 8 (3.9)                  |
| Leukopenia              | 57 (10.7)                | 19 (7.1)                 | 24 (4.9)                 | 4 (1.5)                  | 15 (3.4)                 | 3 (1.3)                  | 10 (2.6)                 | 2 (1.0)                  |
| Urinary tract infection | 33 (6.2)                 | 8 (3.0)                  | 25 (5.1)                 | 12 (4.6)                 | 15 (3.4)                 | 4 (1.8)                  | 12 (3.1)                 | 5 (2.4)                  |
| Headache                | 48 (9.0)                 | 24 (9.0)                 | 14 (2.9)                 | 10 (3.8)                 | 15 (3.4)                 | 8 (3.6)                  | 7 (1.8)                  | 6 (2.9)                  |

## CTCAE Grade &gt;3 or higher

Adverse events of CTCAE Grade ≥3 (version 4.0) were most commonly reported in the SOC of Blood and lymphatic system disorders. The majority of CTCAE Grade ≥3 AEs were reported during the combination period.

<div style=\"page-break-after: always\"></div>

Table 48: PAOLA1: CTCAE Grade≥3 AEs occurring in ≥1% patients in either treatment arm (SAS)

|                                                       | Number (%) of patientsa     | Number (%) of patientsa    | Number (%) of patientsa           | Number (%) of patientsa           |
|-------------------------------------------------------|-----------------------------|----------------------------|-----------------------------------|-----------------------------------|
| MedDRA SOC                                            | Overall study duration      | Overall study duration     | Combination treatiment phase only | Combination treatiment phase only |
| preferred termb                                       | Olaparib/ bevacizumab N=535 | Placebo/ bevacizumab N=267 | Olaparib/ bevacizumab N=534       | Placebo/ bevacizumab N=267        |
| Patients with any CTCAE Grade ≥3 AE                   | 308 (57.6)                  | 136 (50.9)                 | 267 (50.0)                        | 116 (43.4)                        |
| Blood and lymphatic system disorders                  | 140 (26.2)                  | 13 (4.9)                   | 125 (23.4)                        | 9 (3.4)                           |
| Anaemia                                               | 93 (17.4)                   | 1 (0.4)                    | 87 (16.3)                         | 1 (0.4)                           |
| Lymphopenia                                           | 37 (6.9)                    | 3 (1.1)                    | 31 (5.8)                          | 2 (0.7)                           |
| Neutropenia                                           | 21 (3.9)                    | 6 (2.2)                    | 19 (3.6)                          | 4 (1.5)                           |
| Leukopenia                                            | 9 (1.7)                     | 3 (1.1)                    | 6 (1.1)                           | 2 (0.7)                           |
| Thrombocytopenia                                      | 7 (1.3)                     | 1 (0.4)                    | 6 (1.1)                           | 0                                 |
| Vascular disorders                                    | 108 (20.2)                  | 81 (30.3)                  | 89 (16.7)                         | 74 (27.7)                         |
| Hypertension                                          | 100 (18.7)                  | 81 (30.3)                  | 83 (15.5)                         | 73 (27.3)                         |
| Gastrointestinal disorders                            | 63 (11.8)                   | 25 (9.4)                   | 52 (9.7)                          | 17 (6.4)                          |
| Nausea                                                | 13 (2.4)                    | 2 (0.7)                    | 12 (2.2)                          | 0                                 |
| Dianrhoea                                             | 12 (2.2)                    | 5 (1.9)                    | 12 (2.2)                          | 3 (1.1)                           |
| Vomiting                                              | 9 (1.7)                     | 5 (1.9)                    | 8 (1.5)                           | 1 (0.4)                           |
| Abdominal pain                                        | 8 (1.5)                     | 5 (1.9)                    | 7 (1.3)                           | 3 (1.1)                           |
| Subileus                                              | 7 (1.3)                     | 4 (1.5)                    | 6 (1.1)                           | 2 (0.7)                           |
| Ileus                                                 | 4 (0.7)                     | 3 (1.1)                    | 2 (0.4)                           | 3 (1.1)                           |
| General disorder's and administration site conditions | 34 (6.4)                    | 8 (3.0)                    | 31 (5.8)                          | 4 (1.5)                           |
| Fatigue                                               | 28 (5.2)                    | 4 (1.5)                    | 27 (5.1)                          | 2 (0.7)                           |
| Mucosal inflammation                                  | 6 (1.1)                     | 0                          | 4 (0.7)                           | 0                                 |
| Investigations                                        | 29 (5.4)                    | 10 (3.7)                   | 22 (4.1)                          | 9 (3.4)                           |
| Neutrophil count decreased                            | 10 (1.9)                    | 3 (1.1)                    | 8 (1.5)                           | 3 (1.1)                           |
| Weight increased                                      | 4 (0.7)                     | 4 (1.5)                    | 2 (0.4)                           | 4 (1.5)                           |
| Respiratory, thoracic and mediastinal disorders       | 15 (2.8)                    | 4 (1.5)                    | 5 (0.9)                           | 2 (0.7)                           |
| Pulmonary embolism                                    | 7 (1.3)                     | 1 (0.4)                    | 2 (0.4)                           | 0                                 |
| Musculoskeletal and connective tissue disorders       | 8 (1.5)                     | 7 (2.6)                    | 7 (1.3)                           | 6 (2.2)                           |
| Arthralgia                                            | 3 (0.6)                     | 4 (1.5)                    | 3 (0.6)                           | 4 (1.5)                           |
| Cardiac disorders                                     | 2 (0.4)                     | 7 (2.6)                    | 1 (0.2)                           | 2 (0.7)                           |
| Myocardial infarction                                 | 0                           | 4 (1.5)                    | 0                                 | 2 (0.7)                           |

<div style=\"page-break-after: always\"></div>

## Comparison with olaparib 300mg bd pool

Table 49 : Most common AEs of CTCAE Grade≥3 (reported in ≥1% patients in the olaparib/bevacizumab arm of PAOLA -1 or ≥2% patients in the 300 mg bd pool)

<!-- image -->

|                                                    | Number (%) of patientsa             | Number (%) of patientsa             | Number (%) of patientsa   |
|----------------------------------------------------|-------------------------------------|-------------------------------------|---------------------------|
| System organclass                                  | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration | Olaparib 300 mg bd pool   |
| Preferred term                                     | Olaparib/ bevacizumab N=535         | Placebo/ bevacizumab N=267          | (N=1585)                  |
| Patientswith anyCTCAEGrade≥3AE                     | 308 (57.6)                          | 136 (50.9)                          | 659 (41.6)                |
| Blood and lymphatic system disorder's              | 140 (26.2)                          | 13 (4.9)                            | 347 (21.9)                |
| Anaemia                                            | 93 (17.4)                           | 1 (0.4)                             | 284 (17.9)                |
| Lymphopenia                                        | 37 (6.9)                            | 3 (1.1)                             | 12 (0.8)                  |
| Neutropenia                                        | 21 (3.9)                            | 6 (2.2)                             | 72 (4.5)                  |
| Leukopenia                                         | 9 (1.7)                             | 3 (1.1)                             | 23 (1.5)                  |
| Thrombocytopenia                                   | 7 (1.3)                             | 1 (0.4)                             | 29 (1.8)                  |
| Vasculardisorders                                  | 108 (20.2)                          | 81 (30.3)                           | 24 (1.5)                  |
| Hypertension                                       | 100 (18.7)                          | 81 (30.3)                           | 8 (0.5)                   |
| Gastrointestinal disorder's                        | 63 (11.8)                           | 25 (9.4)                            | 102 (6.4)                 |
| Nausea                                             | 13 (2.4)                            | 2 (0.7)                             | 16 (1.0)                  |
| Diarhoea                                           | 12 (2.2)                            | 5 (1.9)                             | 17 (1.1)                  |
| Vomiting                                           | 9 (1.7)                             | 5 (1.9)                             | 22 (1.4)                  |
| Abdominal pain                                     | 8 (1.5)                             | 5 (1.9)                             | 20 (1.3)                  |
| Subileus                                           | 7 (1.3)                             | 4 (1.5)                             | 0                         |
| General disordersand administrationsite conditions | 34 (6.4)                            | 8 (3.0)                             | 83 (5.2)                  |
| Fatigue                                            | 28 (5.2)                            | 4 (1.5)                             | 41 (2.6)                  |
| Investigations                                     | 29 (5.4)                            | 10 (3.7)                            | 103 (6.5)                 |
| Neutrophil count decreased                         | 10 (1.9)                            | 3 (1.1)                             | 42 (2.6)                  |
| Respiratoryandmediastinaldisorders                 | 15 (2.8)                            | 4 (1.5)                             | 52 (3.3)                  |
| Pulmonary embolism                                 | 7 (1.3)                             | 1 0.4)                              | 18 (1.1)                  |

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Deaths

Table 50: PAOLA-1: all deaths (FAS)

|                                                                                      | Number(%)ofpatients Overallstudyduration   | Number(%)ofpatients Overallstudyduration   |
|--------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|
| Category                                                                             | Olaparib/ bevacizumab N=537                | Placebo/ bevacizumab N=269                 |
| Totalnumberofdeaths                                                                  | 139 (25.9)                                 | 70 (26.0)                                  |
| Deathrelatedtodiseaseunderinvestigationonly                                          | 127 (23.6)                                 | 61 (22.7)                                  |
| AEwith outcome of deathonly                                                          | 1 (0.2)                                    | 4 (1.5)                                    |
| AE with outcome of death (AE start date falling >30 days after last treatment dose)b | 3 (0.6)                                    | 2 (0.7)                                    |
| Other deathsc                                                                        | 7 (1.3)                                    | 2 (0.7)                                    |
| Patientswithunknownreasonfordeath                                                    | 1 (0.2)                                    | 1 (0.4)                                    |

a Deathsonor afterthedateoffirstdoseandupto30daysfollowingthelastdoseofstudymedication

b After the 30-day safety follow-up period, only events that are AESIs were reported as AEs

Patientswhodiedand arenotcapturedinthe earlier categories.

Two of the 4 patients in the placebo/bevacizumab arm who died as a result of an AE were in the combination phase of the study. The remaining 2 patients in the placebo/bevacizumab arm, and the patient in the olaparib/bevacizumab arm who died as a result of an AE were in the monotherapy phase of the study (i.e., after discontinuation of bevacizumab treatment).

For twelve patients in the olaparib/bevacizumab arm, death was not considered due to disease progression only. There was one additional case in the olaparib/bevacizumab arm, the primary cause of death was first reported by the investigator as disease progression due to pancreas carcinoma (second primary tumour), and not due to her underlying cancer.

Comparison with olaparib 300mg bd pool

Table 51: Patients who died in PAOLA-1 and the 300 mg pool

|                                                            | Number (%) of patients              | Number (%) of patients              | Number (%) of patients   |
|------------------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------|
| Category                                                   | PAOLA-1 FAS, overall study duration | PAOLA-1 FAS, overall study duration | Olaparib 300 mg bd pool  |
|                                                            | Olaparib/ bevacizumab N=537         | Placebo/ bevacizumab N=269          | (N=1585)                 |
| Totalnumberofdeaths                                        | 139 (25.9)                          | 70 (26.0)                           | 462 (29.1)               |
| Death related to disease under investigation only          | 127 (23.6)                          | 61 (22.7)                           | 419 (26.4)               |
| AE with outcome = death only                               | 1 (0.2)                             | 4 (1.5)                             | 11 (0.7)                 |
| Deathrelatedtodiseaseand anAEwithoutcome= death            | 0                                   | 0                                   | 8 (0.5)                  |
| AE with outcome of death ≥30 days after last treatmentdose | 3 (0.6)                             | 2 (0.7)                             | 2 (0.1)                  |
| Other deathsa,b                                            | 7 (1.3)                             | 2 (0.7)                             | 22 (1.4)                 |
| Patientswithunknownreasonfordeath                          | 1 (0.2)                             | 1 (0.4)                             | 0                        |

<div style=\"page-break-after: always\"></div>

## Serious adverse event

Table 52: PAOLA1: SAEs occurring in ≥1% patients in either treatment group (SAS)

<!-- image -->

|                                       | Number (%) of patients                | Number (%) of patients                | Number (%) of patients                | Number (%) of patients                |
|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| Category                              | Overall study duration                | Overall study duration                | Combinationtreatment phase only       | Combinationtreatment phase only       |
|                                       | Olaparib/ bevacizumab N=535           | Placebo/ bevacizumab N=267            | Olaparib/ bevacizumab N=534           | Placebo/ bevacizumab N=267            |
| Patientswith anySAE                   | 167 (31.2)                            | 83 (31.1)                             | 130 (24.3)                            | 67 (25.1)                             |
| Vascular disorders                    |                                       |                                       |                                       |                                       |
| Hypertension                          | 48 (9.0)                              | 35 (13.1)                             | 38 (7.1)                              | 32 (12.0)                             |
| Blood and lymphatic system disorder's | Blood and lymphatic system disorder's | Blood and lymphatic system disorder's | Blood and lymphatic system disorder's | Blood and lymphatic system disorder's |
| Anaemia                               | 34 (6.4)                              | 1 (0.4)                               | 30 (5.6)                              | 1 (0.4)                               |
| Gastrointestinal disorders            | Gastrointestinal disorders            | Gastrointestinal disorders            | Gastrointestinal disorders            | Gastrointestinal disorders            |
| Subileus                              | 8 (1.5)                               | 3 (1.1)                               | 6 (1.1)                               | 2 (0.7)                               |
| Intestinal obstruction                | 8 (1.5)                               | 2 (0.7)                               | 4 (0.7)                               | 1 (0.4)                               |
| Ileus                                 | 3 (0.6)                               | 3 (1.1)                               | 3 (0.6)                               | 3 (1.1)                               |
| Cardiac disorders                     |                                       |                                       |                                       |                                       |
| Myocardial infarction                 | 0                                     | 4 (1.5)                               | 0                                     | 2 (0.7)                               |

## Comparison with olaparib 300mg bd pool

There was an increased incidence of SAEs in the olaparib/bevacizumab arm of PAOLA-1, compared with the 300 mg bd pool. This increased incidence appeared to be largely caused by an increased incidence of SAEs of hypertension (which occurred at a frequency of 9.0% in the olaparib/bevacizumab arm of PAOLA-1, compared with no SAEs in the 300 mg bd pool). The most common (≥2% of patients) SAE of anaemia in the olaparib 300 mg bd pool was reported at a similar frequency in the olaparib/bevacizumab arm of PAOLAMost other SAEs were reported in fewer than 2 patients in each arm of PAOLA-1.

Table 53 : Most comment SAEs (reported by ≥1% patients in PAOLA -1 and/or reported by ≥2% patients in the 300 mg bd pool)

|                                    | Nunber (%o) of patients             | Nunber (%o) of patients             | Nunber (%o) of patients   |
|------------------------------------|-------------------------------------|-------------------------------------|---------------------------|
| System organ class Preferred term  | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration | Olaparib 300 mg bd pool   |
|                                    | Olaparib/ bevacizumab N=535         | Placebo/ bevacizumab N=267          | (N=1585)                  |
| Patients with any SAE              | 167 (31.2)                          | 83 (31.1)                           | 365 (23.0)                |
| Vascular disorders                 | 56 (10.5)                           | 35 (13.1)                           | 13 (0.8)                  |
| Hypertension                       | 48 (9.0)                            | 35 (13.1)                           | 0                         |
| Blood and lynphaticsystemdisorders | 40 (7.5)                            | 4 (1.5)                             | 110 (6.9)                 |
| Anaemia                            | 34 (6.4)                            | 1 (0.4)                             | 89 (5.6)                  |
| Gastrointestinaldisorder's         | 31 (5.8)                            | 19 (7.1)                            | 66 (4.2)                  |
| Subileus                           | 8 (1.5)                             | 3 (1.1)                             | 1 (0.1)                   |
| Intestinal obstruction             | 8 (1.5)                             | 2 (0.7)                             | 6 (0.4)                   |
| Ileus                              | 3 (0.6)                             | 3 (1.1)                             | 5 (0.3)                   |
| Cardiac disorders                  | 4 (0.7)                             | 7 (2.6)                             | 14 (0.9)                  |
| Myocardial infarction              | 0                                   | 4 (1.5)                             | 1 (0.1)                   |

<div style=\"page-break-after: always\"></div>

## Adverse drug reactions

Lynparza has been associated with adverse reactions generally of mild or moderate severity (CTCAE grade 1 or 2) and generally not requiring treatment discontinuation. The most frequently observed adverse reactions across clinical trials in patients receiving Lynp arza monotherapy (≥ 10%) were nausea, vomiting, diarrhoea, dyspepsia, fatigue, headache, dysgeusia, decreased appetite, dizziness, cough, dyspnoea, anaemia, neutropenia, thrombocytopenia and leukopenia.

The Grade ≥ 3 adverse reactions occurring in &gt; 2% of patients were anaemia (17%), neutropenia (6%), fatigue/asthenia (5%), leukopenia (3%), thrombocytopenia (3%) and vomiting (2%).

Adverse reactions that most commonly led to dose interruptions and/ or reductions in monotherapy were anaemia (16.2%), vomiting (6.8%), nausea (6.2%), neutropenia (6.2%) and fatigue/asthenia (6.0%). Adverse reactions that most commonly led to permanent discontinuation were anaemia (1.8%), fatigue/asthenia (0.7%), nausea (0.7%) and thrombocytopenia (0.7%).

When Lynparza is used in combination with bevacizumab the safety profile is generally consistent with that of the individual therapies.

Adverse events led to dose interruption and/ or reduction of olaparib in 57.4% of patients when used in combination with bevacizumab and led to permanent discontinuation of treatment with olaparib/bevacizumab and placebo/bevacizumab in 20.4% and 5.6% of patients, respectively. The adverse reactions that most commonly led to dose interruption and/or reduction were anaemia (20.6%) and nausea (7.5%). The adverse reactions that most commonly led to permanent discontinuation were anaemia (3.6%), nausea (3.4%) and fatigue/asthenia (1.5%).

The safety profile is based on pooled data from 2351 patients with solid tumours treated with Lynparza monotherapy in clinical trials at the recommended dose.

Table 54: Tabulated list of adverse reactions in clinical trials with Lynparza

|                                      | Adverse reactions                                                                              | Adverse reactions                                                                                     |
|--------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| MedDRA System Organ Class            | Frequency of All CTCAE grades                                                                  | Frequency of CTCAE grade 3 and above                                                                  |
| Blood and lymphatic system disorders | Very common Anaemia a , Neutropenia a , Thrombocytopenia a , Leukopenia a Common Lymphopenia a | Very common Anaemia a Common Neutropenia a , Thrombocytopenia a , Leukopenia a Uncommon Lymphopenia a |
| Immune system disorders              | Common Rash a Uncommon Hypersensitivity a , Dermatitis a                                       | Rare Rash a , Hypersensitivity a                                                                      |
| Metabolism and nutrition disorders   | Very common Decreased appetite                                                                 | Uncommon Decreased appetite                                                                           |
| Nervous system disorders             | Very common Dizziness, Headache, Dysgeusia                                                     | Uncommon Dizziness, Headache                                                                          |

<div style=\"page-break-after: always\"></div>

|                                                      | Adverse reactions                                                                             | Adverse reactions                                                               |
|------------------------------------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| MedDRA System Organ Class                            | Frequency of All CTCAE grades                                                                 | Frequency of CTCAE grade 3 and above                                            |
| Respiratory, thoracic and mediastinal disorders      | Very common Cough a , Dyspnoea a                                                              | Common Dyspnoea a Uncommon Cough a                                              |
| Gastrointestinal disorders                           | Very common Vomiting, Diarrhoea, Nausea, Dyspepsia Common Stomatitis a , Upper abdominal pain | Common Vomiting, Diarrhoea, Nausea Uncommon Stomatitis a , Upper abdominal pain |
| General disorders and administration site conditions | Very common Fatigue (including asthenia)                                                      | Common Fatigue (including asthenia)                                             |
| Investigations                                       | Common Increase in blood creatinine Uncommon Mean corpuscular volume elevation                | Uncommon Increase in blood creatinine                                           |

a Anaemia includes preferred terms (PTs) of anaemia, anaemia macrocytic, erythropenia, haematocrit decreased, haemoglobin decreased, normochromic anaemia, normochromic normocytic anaemia, normocytic anaemia and red blood cell count decreased; Neutropenia includes PTs of agranulocytosis, febrile neutropenia, granulocyte count decreased, granulocytopenia, idiopathic neutropenia, neutropenia, neutropenic infection,  neutropenic sepsis and neutrophil count decreased; Thrombocytopenia includes PTs of platelet count decreased, platelet production decreased, plateletcrit decreased and thrombocytopenia; Leukopenia includes PTs of leukopenia and white blood cell count decreased; Lymphopenia includes PTs of B-lymphocyte count decreased, lymphocyte count decreased, lymphopenia and T-lymphocyte count decreased; Cough includes PTs of cough and productive cough; Rash includes PTs of exfoliative rash, generalised erythema, rash, rash erythematous, rash generalised, rash macular, rash maculo-papular, rash papular and rash pruritic; Hypersensitivity includes PTs of drug hypersensitivity and hypersensitivity; Dermatitis includes PTs of dermatitis, dermatitis allergic and dermatitis exfoliative. Dyspnoea includes PTs of dyspnoea and dyspnoea exertional; Stomatitis includes PTs of aphthous ulcer, mouth ulceration and stomatitis.

## Haematological toxicity

In clinical studies with the tablet formulation, the incidence of anaemia adverse reactions was 40.8% (CTCAE grade ≥3 18.1%) and the incidences of dose interruptions, reductions and discontinuations for anaemia were 17.7%, 12.2% and 2.5%, respectively; 22.6% of patients treated with olaparib needed one or more blood transfusions. An exposure-response relationship between olaparib and decreases in haemoglobin has been demonstrated. In clinical studies with Lynparza the incidence of CTCAE grade ≥ 2 shifts (decreases) from baseline in haemoglobin was 23%, absolute neutrophils 19%, platelets 6%, lymphocytes 29% and leucocytes 20% (all % approximate).

<div style=\"page-break-after: always\"></div>

The incidence of elevations in mean corpuscular volume from low or normal at baseline to above the ULN was approximately 58%.

## Anaemia

Table 55: PAOLA-1 and the 300 mg bd pool: patients who had at least one AE of anaemia (grouped term) reported in any category

|              | Nunber(%)ofpatients                 | Nunber(%)ofpatients                 | Nunber(%)ofpatients     |
|--------------|-------------------------------------|-------------------------------------|-------------------------|
| AE categorya | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration | Olaparib 300 mg bd pool |
|              | Olaparib/ bevacizumab N=535         | Placebo/ bevacizumab N=267          | (N=1585)                |
| Any AE       | 219 (40.9)                          | 27 (10.1)                           | 646 (40.8)              |

| Any AE of CTCAE Grade 3 or higher                           | 93 (17.4)   | 1 (0.4)   | 287 (18.1)   |
|-------------------------------------------------------------|-------------|-----------|--------------|
| Any AE with outcome = death                                 | 0           | 0         | 0            |
| Any SAE                                                     | 34 (6.4)    | 1 (0.4)   | 93 (5.9)     |
| AEs leading to dose reduction of olaparib or placebo        | 99 (18.5)   | 0         | 194 (12.2)   |
| AEsleading to treatment interruption of olaparib or placebo | 110 (20.6)  | 1 (0.4)   | 285 (18.0)   |
| AnyAEleadingtodiscontinuationof olaparib or placebo         | 19 (3.6)    | 0         | 40 (2.5)     |

In more than half of cases, anaemia events were Grade 1 or 2 in severity. Events rarely led to permanent discontinuation of treatment. In the olaparib/bevacizumab arm, 28 of the 93 patients with CTCAE Grade ≥ 3 AEs of anaemia (single PT) were SAEs and 3 patients had a CTCAE Grade 4 AE that were SAEs. Olaparib treatment was interrupted and the dose subsequently reduced in 2 of the 3 patients with CTCAE Grade 4 AEs of anaemia, treatment was permanently discontinued in the remaining patient. All 3 patients with CTCAE Grade 4 AE received treatment for the AEs, and AEs in all 3 patients were reported as recovered, with durations ranging from 7 days to 48 days.

Onset of anaemia was early, generally in the first 3 months of starting olaparib (median time to first onset was 1.54 months), although the risk of developing anaemia remained fairly constant throughout exposure with no evidence of cumulative effect.

The majority (209 of 219 patients) of first events with olaparib/bevacizumab resolved (median time to resolution 1.41 months for first event.)

Regarding  laboratory  abnormalities  for  haemoglobin,  no  patients  in  PAOLA-1  had  CTCAE  Grade  4 haemoglobin values during the study; 12.5% of olaparib/bevacizumab-treated patients had reductions to CTCAE Grade 3 haemoglobin values.

In the olaparib/bevacizumab arm, 112 (51.1%) of 219 patients with AEs of anaemia (grouped term) were treated for the AE compared with 3 (11.1%) of 27 patients in the placebo/bevacizumab arm.

In the olaparib/bevacizumab arm of PAOLA-1, 94 (17.6%) patients received a blood transfusion. A total of 26 (4.9%) patients in the olaparib/bevacizumab arm had more than 1 transfusion of either whole blood or packed red blood cells (PRBCs) after the start of study treatment; the majority of these occurred in the first 4 months on study treatment. Thirty (5.6%) olaparib/bevacizumab-treated patients had an erythropoiesis stimulating agent.

<div style=\"page-break-after: always\"></div>

## Neutropenia

Table 56: PAOLA-1 and the 300 mg bd pool: patients who had at least one AE of neutropenia (grouped term) reported in any category

|                                                             | Nunber (%) of patients             | Nunber (%) of patients             | Nunber (%) of patients   |
|-------------------------------------------------------------|------------------------------------|------------------------------------|--------------------------|
| AE category\"                                                | PAOLA-1 SAS,overall study duration | PAOLA-1 SAS,overall study duration | Olaparib                 |
|                                                             | Olaparib/ bevacizumab              | Placebo/ bevacizumab N=267         | 300 mg bd pool           |
|                                                             | N=535                              |                                    | (N=1585)                 |
| Any AE                                                      | 97 (18.1)                          | 42 (15.7)                          | 293 (18.5)               |
| Any AE of CTCAE Grade 3 or higher                           | 34 (6.4)                           | 8 (3.0)                            | 114 (7.2)                |
| Any AE with outcome = death                                 | 0                                  | 0                                  | 1 (0.1)                  |
| Any SAE                                                     | 5 (0.9)                            | 1 (0.4)                            | 18 (1.1)                 |
| AEsleadingtodosereduction of olaparib or placebo            | 7 (1.3)                            | 1 (0.4)                            | 44 (2.8)                 |
| AEsleading to treatment interruption of olaparib or placebo | 19 (3.6)                           | 4 (1.5)                            | 117 (7.4)                |
| AnyAEleadingtodiscontinuationofolaparibor placebo           | 3 (0.6)                            | 0                                  | 10 (0.6)                 |

Grouped term consisting of: agranulocytosis, febrile neutropenia, granulocyte count decreased, granulocytopenia, idiopathic neutropenia, neutropenia, neutropenic infection, neutropenic sepsis, and neutrophil count decreased

These events were predominantly Grade 1 or 2 in severity and rarely led to permanent discontinuation of treatment. No patients in either treatment arm had AEs of febrile neutropenia occurring on treatment. In the follow-up period, 4 (0.7%) patients in the olaparib/bevacizumab arm had AEs of febrile neutropenia 3 of the 4 patients had CTCAE Grade 3 AEs, 1 patient had a CTCAE Grade 4 AE. All 4 patients were treated for the event.

Onset of AEs was 5 to 18 days after the last dose of olaparib. Five patients in the olaparib/bevacizumab arm and 2 patients in the placebo/bevacizumab arm had AEs of febrile neutropenia that occurred in the post follow-up period. There were no patients with AEs of neutropenic infection or neutropenic sepsis in PAOLA-1.

In the olaparib/bevacizumab arm, 5 of the 34 patients with CTCAE Grade ≥3 AEs of neutropenia were SAEs.

There  was  no  association  between  the  development  of  neutropenia  and  the  length  of  time  on olaparib/bevacizumab treatment; AEs of neutropenia were reported throughout the study period in the olaparib/bevacizumab-treated arm (median time to onset of first event was 1.31 months); the majority (94 of 97 patients) of events with olaparib/bevacizumab resolved (median time to resolution of 0.72 months for first event). A small proportion of patients in each treatment arm received colony stimulating factors (4 patients [0.7%] in the olaparib/bevacizumab arm and 3 patients [1.1%] in the placebo/bevacizumab arm). The AE category table for the 300 mg bd pool showed a consistent pattern of AEs when compared with olaparib/bevacizumab data from PAOLA-1.

Regarding abnormalities data of neutrophils, the majority (534 [93.6 %] patients) of olaparib/bevacizumabtreated patients in PAOLA1 had a maximum CTCAE Grade ≤2 reported for absolute neutrophil count (ANC) values; 97.4% (260 of 267 patients) of patients in the placebo/bevacizumab arm also had CTCAE Grade ≤2 ANC during the PAOLA -1 study.

Of the patients in the olaparib/bevacizumab arm with AEs of neutropenia, 8 (8.2%) of 97 patients were treated for the AE compared with 4 (9.5%) of 42 patients in the placebo/bevacizumab arm.

Colony  stimulating  factor  use  in  the  olaparib/bevacizumab  arm  was  rare  (4  patients  [0.7%]  in  the olaparib/bevacizumab  arm  and  3  patients  [1.1%]  in  the  placebo/bevacizumab  arm  received  colony stimulating factors.

<div style=\"page-break-after: always\"></div>

## Thrombocytopenia

AEs of thrombocytopenia were reported for a higher percentage of patients in the olaparib/bevacizumab arm compared with the placebo/bevacizumab arm. These events were predominantly Grade 1 or 2 in severity and none led to permanent discontinuation of treatment. The proportion of patients with AEs in the grouped term of haemorrhagic events and wound healing complications were similar between the 2 treatment arms in PAOLA-1.

A grouped term analysis of haemorrhage events in PAOLA-1 showed that 52 (9.7%) of 535 patients in the olaparib/bevacizumab arm had a total of 65 AEs. In the placebo/bevacizumab arm 28 (10.5%) of 267 patients had a total of 36 AEs. The majority of these AEs were CTCAE Grade ≤2 AEs; only 3 (0.6%) olaparib/bevacizumab-treated patients and 2 (0.7%) placebo/bevacizumab-treated patients had CTCAE Grade ≥3 AEs.

Three (0.6%) patients in the olaparib/bevacizumab arm and 2 (0.7%) patients in the placebo/bevacizumab arm had haemorrhage events that were SAEs. The SAEs in olaparib/bevacizumab arm were all CTCAE Grade 3 and none were considered related to olaparib by the investigator.

There  was  no  association  between  the  development  of  thrombocytopenia  and  the  length  of  time  on olaparib/bevacizumab treatment. First onset of AEs of thrombocytopenia were reported throughout the first 12 months of study period in the olaparib/bevacizumab-treated arm (median time to first onset was 1.41 months); the majority (42 of 43 patients) of events with olaparib resolved (median time to resolution of first event of 0.82 month).

Table 57: PAOLA-1 and the 300 mg bd pool: patients who had at least one AE of thrombocytopenia (grouped term) reported in any category

|                                                         | Number (%) of patients              | Number (%) of patients              | Number (%) of patients   |
|---------------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------|
| AE categorya                                            | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration | Olaparib 300 mg          |
|                                                         | Olaparib/ bevacizumab N=535         | Placebo/ bevacizumab N=267          | bd pool (N=1585)         |
| Any AE                                                  | 43 (8.0)                            | 9 (3.4)                             | 197 (12.4)               |
| Any AE of CTCAE Grade 3or higher                        | 10 (1.9)                            | 1 (0.4)                             | 47 (3.0)                 |
| AnyAE with outcome=death                                | 0                                   | 0                                   | 0                        |
| Any SAE                                                 | 4 (0.7)                             | 1 (0.4)                             | 14 (0.9)                 |
| AEs leading todosereduction of olaparib or placebo      | 11 (2.1)                            | 0                                   | 22 (1.4)                 |
| AEsleadingtotreatmentinterruptionof olaparib or placebo | 16 (3.0)                            | 1 (0.4)                             | 61 (3.8)                 |
| AnyAEleadingtodiscontinuationofolaparib or placebo      | 0                                   | 0                                   | 14 (0.9)                 |

Grouped term consisting of thrombocytopenia, platelet production decreased, platelet count decreased and plateletcrit decreased.

Regarding abnormalities data of decreased platelet count, the majority of patients had a maximum CTCAE Grade of ≤2 reported for platelet values throughout treatment. A low proportion of olaparib/bevacizumab -treated patients (12 patients [2.2%]) had CTCAE Grade ≥3 reductions in platelet count during the study; no patients in the placebo/bevacizuma b arm had a CTCAE Grade ≥3 reduction in platelet count.

A similar proportion of patients in each arm (5 [11.6%] of 43 olaparib/bevacizumab-treated patients and 1 [11.1%]  of  9  placebo/bevacizumab-treated  patients)  were  treated  for  AEs  of  thrombocytopenia.  Five olaparib/bevacizumab-treated patients (0.9%) received a platelet transfusion, compared with 1 (0.4%) patient in the placebo/bevacizumab arm.

<div style=\"page-break-after: always\"></div>

## Lymphopenia

Table 58: PAOLA-1 and the 300 mg bd pool: patients who had at least one AE of lymphopenia (grouped term) reported in any category

|                                                           | Number (%) of patients              | Number (%) of patients              | Number (%) of patients   |
|-----------------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------|
| AE categorya                                              | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration | Olaparib 300 mg bd pool  |
|                                                           | Olaparib/ bevacizumab N=535         | Placebo/ bevacizumab N=267          | (N=1585)                 |
| Any AE                                                    | 126 (23.6)                          | 25 (9.4)                            | 82 (5.2)                 |
| Any AE of CTCAE Grade 3 or higher                         | 38 (7.1)                            | 3 (1.1)                             | 21 (1.3)                 |
| Any AE with outcome = death                               | 0                                   | 0                                   | 0                        |
| Any SAE                                                   | 0                                   | 0                                   | 0                        |
| AEsleading to dosereductionof olaparib or placebo         | 1 (0.2)                             | 0                                   | 3 (0.2)                  |
| AEsleadingtotreatment interruption of olaparib or placebo | 2 (0.4)                             | 0                                   | 11 (0.7)                 |
| Any AE leading to discontinuation of olaparib or placebo  | 0                                   | 0                                   | 1 (0.1)                  |

Grouped term consisting of the PTs of: B-lymphocyte count decreased, lymphocyte count decreased, lymphopenia and T-lymphocyte count decreased.

T he incidence of all AEs and CTCAE Grade ≥3 AEs of lymphopenia in the 300 mg bd pool was lower when compared with olaparib/bevacizumab data from PAOLA-1. The proportion of patients with AEs and CTCAE Grade ≥3 AEs of lymphocyte count reductions were higher for the olaparib/bevacizumab arm of PAOLA -1 compared with the 300 mg bd pool; however, the proportion of patients with laboratory values showing grade changes to CTCAE Grade ≥3 in lymphocyte cou nt  in  the  olaparib/bevacizumab  arm  of  PAOLA-1 (9.4%) was lower than that observed in the 300 mg bd pool (261 [16.7%] of 1563 patients and similar to that observed in SOLO1 (15 of 231 patients [6.5%]). When compared with the tablet pool, the incidence of  ly mphopenia was higher (grouped terms: any AE, 23.6%; any AE of  CTCAE,  ≥3, 7.1%); however, laboratory values for lymphocytes were consistent between PAOLA-1 and the tablet pool.

There  was  no  association  between  the  development  of  lymphopenia  and  the  length  of  time  on olaparib/bevacizumab treatment (median time to first onset was 2.64 months); the majority (116 of 126 patients) of events with olaparib/bevacizumab resolved (median time to resolution of first event of 0.9 months). Two (1.6%) of the 126 olaparib/bevacizumab-treated patients with lymphopenia were treated for the AE, compared with 2 (8.0%) of the 25 placebo/bevacizumab-treated patients.

Regarding  laboratory  data,  the  majority  of  patients  in  PAOLA1 had a maximum CTCAE Grade of ≤2 reported for low lymphocyte laboratory values throughout treatment. The proportion of patients with CTCAE Grade ≥3 lymphocyte count reductions was higher for olaparib/bevacizumab -treated patients (50 of 533 patients [9.4%]) than for the placebo/bevacizumab arm (6 of 267 patients [2.2%]).

<div style=\"page-break-after: always\"></div>

## Leukopenia

Table 59: PAOLA-1 and the 300 mg bd pool: patients who had at least one AE of leukopenia (grouped term) reported in any category

|                                                              | Number (%) of patients              | Number (%) of patients              | Number (%) of patients   |
|--------------------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------|
| AE categorya                                                 | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration | Olaparib 300 mg bd pool  |
|                                                              | Olaparib/ bevacizumab N=535         | Placebo/ bevacizumab N=267          | (N=1585)                 |
| Any AE                                                       | 95 (17.8)                           | 26 (9.7)                            | 221 (13.9)               |
| Any AE of CTCAE Grade 3 or higher                            | 10 (1.9)                            | 4 (1.5)                             | 49 (3.1)                 |
| Any AE with outcome = death                                  | 0                                   | 0                                   | 0                        |
| Any SAE                                                      | 0                                   | 1 (0.4)                             | 4 (0.3)                  |
| AEsleadingtodosereductionofolaparibor placebo                | 1 (0.2)                             | 1 (0.4)                             | 25 (1.6)                 |
| AEs leading to treatment interruption of olaparib or placebo | 2 (0.4)                             | 1 (0.4)                             | 66 (4.2)                 |
| AnyAEleading todiscontinuation ofolaparib or placebo         | 0                                   | 0                                   | 4 (0.3)                  |

Grouped term consisting of. agranulocytosis, granulocyte count decreased, granulocytopenia, leukopenia and white blood cell count decreased

There was no association between the development of leukopenia and the length of time on olaparib/bevacizumab treatment (median time to onset was 2.10 months); all (95 of 95 patients) patients with events of leukopenia in the olaparib/bevacizumab arm resolved (median time to resolution of first event was 0.95 months). One patient in each arm with AEs of leukopenia were treated for the AE (1 [1.1%] of 95 patients in the olaparib/bevacizumab arm and 1 [3.8%] of 26 patients in the placebo/bevacizumab arm).

## Fatigue/asthenia

Table 60: PAOLA-1 and the 300 mg bd pool: patients who had at least one AE of fatigue or asthenia reported in any category

|                                                        | Number(%o)ofpatients              | Number(%o)ofpatients              | Number(%o)ofpatients             |
|--------------------------------------------------------|-----------------------------------|-----------------------------------|----------------------------------|
| AE categorya                                           | PAOLA-1SAS,overall study duration | PAOLA-1SAS,overall study duration |                                  |
|                                                        | Olaparib/ bevacizumab (N=535)     | Placebo/ bevacizumab (N=267)      | Olaparib 300 mg bd pool (N=1585) |
| Any AE                                                 | 283 (52.9)                        | 86 (32.2)                         | 822 (51.9)                       |
| AnyAEof CTCAE Grade 3 orhigher                         | 28 (5.2)                          | 4 (1.5)                           | 67 (4.2)                         |
| Any AE with outcome = death                            | 0                                 | 0                                 | 0                                |
| Any SAE                                                | 0                                 | 0                                 | 10 (0.6)                         |
| AEsleadingtodosereductionofolapariborplacebo           | 21 (3.9)                          | 2 (0.7)                           | 58 (3.7)                         |
| AEsleading totreatmentinterruptionofolaparibor placebo | 17 (3.2)                          | 2 (0.7)                           | 58 (3.7)                         |
| AnyAEleadingtodiscontinuationofolaparibor placebo      | 8 (1.5)                           | 0                                 | 15 (0.9)                         |

Patients with multiple events reported in the same category are counted only once in that category.Patients with events in more than 1 category are counted once in each of those categories.

Fatigue and asthenia on olaparib/bevacizumab treatment were generally reported early, with the majority of first events with olaparib/bevacizumab reported within the first 3 months of treatment. Median time to

<div style=\"page-break-after: always\"></div>

onset was 0.72 months. The incidence plateaued at around 1 month, suggesting that few first instances were reported after these times.

The majority (220 [77.7%] of 283 patients) of events of fatigue and asthenia with olaparib/bevacizumab resolved (median time to resolution of first event of 2.10 months). A low proportion of olaparib/bevacizumab-treated patients with fatigue and asthenia (6 [2.1%] of 283 patients) were reported by the investigator to have received treatment for the event compared with 3 ([3.5%] of 86 patients) in the placebo/bevacizumab arm).

## Nausea and vomiting

Table 61: PAOLA-1 and the 300 mg bd pool: patients who had at least one AE of nausea or vomiting reported in any category

|                                                            | Nunber (%) of patients           | Nunber (%) of patients           | Nunber (%) of patients   | Nunber (%) of patients            | Nunber (%) of patients            | Nunber (%) of patients   |
|------------------------------------------------------------|----------------------------------|----------------------------------|--------------------------|-----------------------------------|-----------------------------------|--------------------------|
|                                                            | Nausea                           | Nausea                           | Nausea                   | Vomiting                          | Vomiting                          | Vomiting                 |
| AE categorya                                               | PAOLA-1SAS,overall studyduration | PAOLA-1SAS,overall studyduration | Olaparib300mg bd pool    | PAOLA-1SAS,overall study duration | PAOLA-1SAS,overall study duration | Olaparib300mg bd pool    |
|                                                            | Olaparib/ bevacizumab (N=535)    | Placebo/ bevacizumab             |                          | Olaparib/ bevacizumab (N=535)     | Placebo/ bevacizumab (N=267)      | (N=1585)                 |
|                                                            |                                  | (N=267)                          | (N=1585)                 |                                   |                                   |                          |
| Any AE                                                     | 285 (53.3)                       | 58 (21.7)                        | 944 (59.6)               | 117 (21.9)                        | 29 (10.9)                         | 514 (32.4)               |
| Any AE of CTCAE Grade 3or higher                           | 13 (2.4)                         | 2 (0.7)                          | 16 (1.0)                 | 9 (1.7)                           | 5 (1.9)                           | 22 (1.4)                 |
| AnyAEwith outcome=death                                    | 0                                | 0                                | 0                        | 0                                 | 0                                 | 0                        |
| Any SAE                                                    | 0                                | 0                                | 6 (0.4)                  | 2 (0.4)                           | 0                                 | 12 (0.8)                 |
| AnyAEleadingto adosereduction of olapariborplacebo         | 40 (7.5)                         | 2 (0.7)                          | 31 (2.0)                 | 4 (0.7)                           | 0                                 | 15 (0.9)                 |
| Any AE leading to a dose interruption of olapariborplacebo | 39 (7.3)                         | 4 (1.5)                          | 74 (4.7)                 | 18 (3.4)                          | 3 (1.1)                           | 86 (5.4)                 |
| Any AE leading to discontinuation of olaparib or placebo   | 18 (3.4)                         | 1 (0.4)                          | 12 (0.8)                 | 5 (0.9)                           | 0                                 | 10 (0.6)                 |

Events of nausea and vomiting were generally reported early in the treatment period (median time to onset was 0.16 months and 1.38 months, respectively). The majority (263 of 285 AEs of nausea and 110 of 117 AEs of vomiting) of events with olaparib/bevacizumab resolved (median time to resolution of first event of 1.28 months and 0.10 months, respectively). First reports of nausea tended to occur early in treatment and prevalence  of  nausea  events  reduced  from  approximately  0.3%  to  0.2%  in  the  first  6  months  of treatment,  to  approximately  0.2%  to  0.1%  from  6  months  onwards.  The  prevalence  of  vomiting  was approximately 0.05% for the duration of the study.

A  total  of  104  (19.4%)  olaparib/bevacizumab-treated  patients  reported  both  nausea  and  vomiting. Approximately  half  of  the  olaparib/bevacizumab-treated  patients  with  nausea  (158  [55.4%]  of  285 patients) were treated for the AE and 58 (49.6%) of 117 patients with vomiting received treatment; lower proportions of patients received treatment for nausea and vomiting in the placebo/bevacizumab arm (24 [41.4%] of 58 patients and 10 [34.5%] of 29 patients, respectively.

<div style=\"page-break-after: always\"></div>

## Diarrhoea

Table 62: PAOLA-1 and the 300 mg bd pool: patients who had at least one AE of diarrhoea reported in any category

|                                                              | Nunber (%) of patients              | Nunber (%) of patients              | Nunber (%) of patients   |
|--------------------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------|
|                                                              | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration | Olaparib 300 mg          |
| AE categorya                                                 | Olaparib/ bevacizumab (N=535)       | Placebo/ bevacizumab (N=267)        | bd pool (N=1585)         |
| Any AE                                                       | 98 (18.3)                           | 45 (16.9)                           | 412 (26.0)               |
| AnyAEofCTCAEGrade3orhigher                                   | 12 (2.2)                            | 5 (1.9)                             | 17 (1.1)                 |
| Any AE with outcome = death                                  | 0                                   | 0                                   | 0                        |
| Any SAE                                                      | 2 (0.4)                             | 2 (0.7)                             | 2 (0.1)                  |
| AEsleading to dosereduction of olaparib or placebo           | 8 (1.5)                             | 4 (1.5)                             | 3 (0.2)                  |
| AEs leading to treatment interruption of olaparib or placebo | 12 (2.2)                            | 4 (1.5)                             | 39 (2.5)                 |
| AnyAEleadingtodiscontinuationofolaparib or placebo           | 3 (0.6)                             | 0                                   | 1 (0.1)                  |

Patients with multiple events reported in the same category are counted only once in that category. Patients witheventsinmore than1category arecountedonceineachof thosecategories.

Events of diarrhoea were generally reported early in the treatment period (median time to onset was 2.25 months) and the majority (83 of 98 patients) of first events with olaparib/bevacizumab resolved (median time to resolution of first event of 0.44 months). A similar proportion of patients in the olaparib/bevacizumab arm with diarrhoea were treated for the AE (44 [44.9%] of 98 patients) compared with the placebo/bevacizumab arm (23 [51.1%] of 45 patients). The AE category table for the 300 mg bd pool showed a consistent pattern of AEs when compared with olaparib/bevacizumab data from PAOLA-1.

## Increase in creatinine

The biochemical observations of elevated serum creatinine for olaparib monotherapy treatment were not associated  with  renal  impairment  and  without  any  apparent  clinical  sequelae.  The  small  increases  in creatinine  observed  with  olaparib  and  the  rapid  onset  of  the  mild  changes  observed,  with  a  return  to baseline  after  olaparib  discontinuation  are  consistent  with  the  finding  that  olaparib  is  known  to  be  an inhibitor of OCT2 and MATE1.

In clinical studies with Lynparza the incidence of CTCAE grade ≥ 2 shifts (elevations) from baseline in blood creatinine was approximately 11%.

<div style=\"page-break-after: always\"></div>

Table 63: PAOLA-1 and the 300 mg bd pool: patients who had at least one AE of increased creatinine reported in any category

|                                                             | Number (9o) of patients            | Number (9o) of patients            | Number (9o) of patients   |
|-------------------------------------------------------------|------------------------------------|------------------------------------|---------------------------|
| AE category\"                                                | PAOLA-1 SAS,overall study duration | PAOLA-1 SAS,overall study duration | Olaparib300mg             |
|                                                             | Olaparib/ bevacizumab N=535        | Placebo! bevacizumab N=267         | bd pool (N=1585)          |
| Auy AE                                                      | 25 (4.7)                           | 3 (1.1)                            | 87 (5.5)                  |
| Any AE of CTCAE Grade 3 or higher                           | 0                                  | 0                                  | 1 (0.1)                   |
| Any AE with outcome = death                                 |                                    | 0                                  | 0                         |
| Any SAE                                                     |                                    | 0                                  | 2 (0.1)                   |
| AEs leading to dose reduction of olaparib or placebo        | 1 (0.2)                            | 0                                  | 2 (0.1)                   |
| AEs leading to teatment intermuption of olapanib or placebo | 3 (0.6)                            | 0                                  | 5 (0.3)                   |
| Any AE leading to discoutinuation of olapanb or placebo     | 3 (0.6)                            | 0                                  | 0                         |

## Decreased appetite

Table 64:PAOLA-1 and the 300 mg bd pool: Patients who had at least one AE of decreased appetite reported in any category

|                                                              | Number (%) of patients        | Number (%) of patients       | Number (%) of patients   |
|--------------------------------------------------------------|-------------------------------|------------------------------|--------------------------|
| AE category a                                                | PAOLA-1 SAS, duration         | overall study                | Olaparib 300 mg          |
|                                                              | Olaparib/ bevacizumab (N=535) | Placebo/ bevacizumab (N=267) | bd pool (N=1585)         |
| Any AE                                                       | 42 (7.9)                      | 10 (3.7)                     | 371 (23.4)               |
| Any AE of CTCAE Grade 3 or higher                            | 2 (0.4)                       | 1 (0.4)                      | 12 (0.8)                 |
| Any AE with outcome = death                                  | 0                             | 0                            | 0                        |
| Any SAE                                                      | 0                             | 0                            | 4 (0.3)                  |
| AEs leading to dose reduction of olaparib or placebo         | 0                             | 0                            | 6 (0.4)                  |
| AEs leading to treatment interruption of olaparib or placebo | 0                             | 0                            | 6 (0.4)                  |
| Any AE leading to discontinuation of olaparib or placebo     | 0                             | 0                            | 4 (0.3)                  |

a Patients with multiple events reported in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE Adverse event; bd Twice daily; CTCAE Common Terminology Criteria for Adverse Events; DCO Data cut-off; N Total number of patients; SAE Serious adverse event; SAS Safety Analysis Set. (DCO: 22 March 2019).

<div style=\"page-break-after: always\"></div>

## Headache

## Table 65: PAOLA-1 and the 300 mg bd pool: Patients who had at least one AE of headache reported in any category

|                                                              | Number (%) of patients      | Number (%) of patients     | Number (%) of patients           |
|--------------------------------------------------------------|-----------------------------|----------------------------|----------------------------------|
| AE category a                                                | PAOLA-1 SAS, duration       | overall study              |                                  |
|                                                              | Olaparib/ bevacizumab N=535 | Placebo/ bevacizumab N=267 | Olaparib 300 mg bd pool (N=1585) |
| Any AE                                                       | 73 (13.6)                   | 36 (13.5)                  | 243 (15.3)                       |
| Any AE of CTCAE Grade 3 or higher                            | 2 (0.4)                     | 2 (0.7)                    | 4 (0.3)                          |
| Any AE with outcome = death                                  | 0                           | 0                          | 0                                |
| Any SAE                                                      | 0                           | 0                          | 2 (0.1)                          |
| AEs leading to dose reduction of olaparib or placebo         | 3 (0.6)                     | 1 (0.4)                    | 1 (0.1)                          |
| AEs leading to treatment interruption of olaparib or placebo | 3 (0.6)                     | 5 (1.9)                    | 9 (0.6)                          |
| Any AE leading to discontinuation of olaparib or placebo     | 1 (0.2)                     | 1 (0.4)                    | 0                                |

b Patients with multiple events reported in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE Adverse event; bd Twice daily; CTCAE Common Terminology Criteria for Adverse Events; DCO Data cut-off; N Total number of patients; SAE Serious adverse event; SAS Safety Analysis Set. (DCO: 22 March 2019).

## Dizziness

## Table 66: PAOLA1 and the 300 mg bd pool: Patients who had at least one AE of dizziness reported in any category

|                                                              | Number (%) of patients              | Number (%) of patients              | Number (%) of patients   |
|--------------------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------|
| AE category a                                                | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration | Olaparib 300 mg          |
|                                                              | Olaparib/ bevacizumab (N=535)       | Placebo/ bevacizumab (N=267)        | bd pool (N=1585)         |
| Any AE                                                       | 14 (2.6)                            | 5 (1.9)                             | 181 (11.4)               |
| Any AE of CTCAE Grade 3 or higher                            | 2 (0.4)                             | 1 (0.4)                             | 1 (0.1)                  |
| Any AE with outcome = death                                  | 0                                   | 0                                   | 0                        |
| Any SAE                                                      | 0                                   | 0                                   | 1 (0.1)                  |
| AEs leading to dose reduction of olaparib or placebo         | 0                                   | 1 (0.4)                             | 2 (0.1)                  |
| AEs leading to treatment interruption of olaparib or placebo | 0                                   | 1 (0.4)                             | 8 (0.5)                  |
| Any AE leading to discontinuation of olaparib or placebo     | 1 (0.2)                             | 0                                   | 1 (0.1)                  |

c Patients with multiple events reported in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE Adverse event; bd Twice daily; CTCAE Common Terminology Criteria for Adverse Events; DCO Data cut-off; N Total number of patients; SAE Serious adverse event; SAS Safety Analysis Set. (DCO: 22 March 2019).

<div style=\"page-break-after: always\"></div>

## Dysgeusia

## Table 67:PAOLA-1 and the 300 mg bd pool: Patients who had at least one AE of dysgeusia reported in any category

| a                                                            | Number (%) of patients              | Number (%) of patients              | Number (%) of patients           |
|--------------------------------------------------------------|-------------------------------------|-------------------------------------|----------------------------------|
|                                                              | PAOLA-1 SAS, overall study duration | PAOLA-1 SAS, overall study duration |                                  |
| AE category                                                  | Olaparib/ bevacizumab N=535         | Placebo/ bevacizumab N=267          | Olaparib 300 mg bd pool (N=1585) |
| Any AE                                                       | 42 (7.9)                            | 3 (1.1)                             | 236 (14.9)                       |
| Any AE of CTCAE Grade 3 or higher                            | 1 (0.2)                             | 0                                   | 0                                |
| Any AE with outcome = death                                  | 0                                   | 0                                   | 0                                |
| Any SAE                                                      | 0                                   | 0                                   | 0                                |
| AEs leading to dose reduction of olaparib or placebo         | 1 (0.2)                             | 0                                   | 3 (0.2)                          |
| AEs leading to treatment interruption of olaparib or placebo | 2 (0.4)                             | 0                                   | 0                                |
| Any AE leading to discontinuation of olaparib or placebo     | 1 (0.2)                             | 0                                   | 0                                |

d Patients with multiple events reported in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE Adverse event; bd Twice daily; CTCAE Common Terminology Criteria for Adverse Events; DCO Data cut-off; N Total number of patients; SAE Serious adverse event; SAS Safety Analysis Set. (DCO: 22 March 2019).

## Cough

## Table 68: PAOLA-1 and the 300 mg bd pool: Patients who had at least one AE of cough (grouped term analysis) reported in any category

|                                                              | Number (%) of patients      | Number (%) of patients   | Number (%) of patients   |
|--------------------------------------------------------------|-----------------------------|--------------------------|--------------------------|
| AE category a                                                | PAOLA-1 SAS, duration       | overall study Placebo/   | Olaparib 300 mg bd pool  |
|                                                              | Olaparib/ bevacizumab N=535 | bevacizumab N=267        | (N=1585)                 |
| Any AE                                                       | 25 (4.7)                    | 11 (4.1)                 | 224 (14.1)               |
| Any AE of CTCAE Grade 3 or higher                            | 0                           | 0                        | 2 (0.1)                  |
| Any AE with outcome = death                                  | 0                           | 0                        | 0                        |
| Any SAE                                                      | 0                           | 0                        | 1 (0.1)                  |
| AEs leading to dose reduction of olaparib or placebo         | 0                           | 0                        | 0                        |
| AEs leading to treatment interruption of olaparib or placebo | 2 (0.4)                     | 0                        | 9 (0.6)                  |
| Any AE leading to discontinuation of olaparib or placebo     | 0                           | 0                        | 1 (0.1)                  |

Grouped term consisting of cough and productive cough

e Patients with multiple events reported in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes  AEs  with  an  onset  date  between  the  date  of  first  dose  and  30  days  following  the  date  of  last  dose  of  study  treatment. Hypersensitivity grouped term consisting of hypersensitivity and drug hypersensitivity.

AE Adverse event; bd Twice daily; CTCAE Common Terminology Criteria for Adverse Events; DCO Data cut-off; N Total number of patients; SAE Serious adverse event; SAS Safety Analysis Set. (DCO: 22 March 2019).

<div style=\"page-break-after: always\"></div>

## Dyspnoea

Table 69: PAOLA-1 and the 300 mg bd pool: Patients who had at least one AE of dyspnoea (grouped term analysis) reported in any category

|                                                              | Number (%) of patients      | Number (%) of patients   | Number (%) of patients   |
|--------------------------------------------------------------|-----------------------------|--------------------------|--------------------------|
| AE category a                                                | PAOLA-1 SAS, duration       | overall study Placebo/   | Olaparib 300 mg bd pool  |
|                                                              | Olaparib/ bevacizumab N=535 | bevacizumab N=267        | (N=1585)                 |
| Any AE                                                       | 42 (7.9)                    | 9 (3.4)                  | 218 (13.8)               |
| Any AE of CTCAE Grade 3 or higher                            | 5 (0.9)                     | 1 (0.4)                  | 18 (1.1)                 |
| Any AE with outcome = death                                  | 0                           | 1 (0.4)                  | 0                        |
| Any SAE                                                      | 2 (0.4)                     | 1 (0.4)                  | 8 (0.5)                  |
| AEs leading to dose reduction of olaparib or placebo         | 2 (0.4)                     | 0                        | 2 (0.1)                  |
| AEs leading to treatment interruption of olaparib or placebo | 3 (0.6)                     | 1 (0.4)                  | 15 (0.9)                 |
| Any AE leading to discontinuation of olaparib or placebo     | 1 (0.2)                     | 2 (0.7)                  | 2 (0.1)                  |

Grouped  term  consisting  of  bendopnoea,  bergman's  triad,  dyspnoea,  dyspnoea  at  rest,  dyspnoea  exertional,  dyspnoea  paroxysmal nocturnal, laryngeal dyspnoea, nocturnal dyspnoea, orthopnoea, platypnoea, transfusion-associated dyspnoea and trepopnoea.

f Patients with multiple events reported in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

AE Adverse event; bd Twice daily; CTCAE Common Terminology Criteria for Adverse Events; DCO Data cut-off; N Total number of patients; SAE Serious adverse event; SAS Safety Analysis Set.  (DCO: 22 March 2019).

## Important potential risks for olaparib

MDS/AML, pneumonitis and new primary malignancies have been classified in the risk management plan as important potential risks. For the majority of studies with olaparib, including PAOLA-1, reports for events of MDS/AML and new primary malignancies continue to be collected beyond 30 days after the last dose of olaparib: investigators are asked during the regular follow up for OS if the patient had developed MDS/AML or a new primary malignancy and prompted to report any cases to the Sponsor. A targeted safety questionnaire is also used to collect specific follow-up information on these cases.

Since MDS/AML, pneumonitis and new primary malignancies occur at low frequency, to improve the sensitivity and precision of estimates to characterise these important potential risks, information has been drawn from larger pools of olaparib studies. For pneumonitis, in addition to cases from PROfound and the 300 mg bd pool, cases from the 400 mg bd capsule pool were also presented (i.e., the olaparib monotherapy combined therapeutic dose pool). For MDS/AML and new primary malignancies, this pool was further extended to include all patients who have received at least 1 dose of olaparib (tablet or capsule formulation) as monotherapy treatment in a monotherapy clinical study, at any dose (the olaparib monotherapy all doses pool). For MDS/AML and new primary malignancies, these pools are supplemented by data from the entire clinical programme to provide a comprehensive assessment of these risks.

Olaparib monotherapy combined therapeutic dose pool (n=2351 patients) consists of all patients who have received olaparib monotherapy at the intended therapeutic dose of 300 mg bd for the tablet formulation or at the therapeutic dose of 400 mg bd for the capsule formulation (as a continuous dose). All patients from the 300 mg bd pool are included in the olaparib monotherapy combined therapeutic dose pool.

<div style=\"page-break-after: always\"></div>

Olaparib monotherapy all doses pool (n=2783 patients) consists of all patients who have received at least 1 dose of olaparib as a monotherapy treatment (tablet or capsule formulation) at any dose. In addition, 66 patients from Study 41 are included (a Phase II, open-label, randomised, comparative, multicentre study to compare the efficacy and tolerability of olaparib [capsule formulation] in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with platinum sensitive advanced serous ovarian cancers). All patients from the olaparib monotherapy combined therapeutic dose pool are included in the olaparib monotherapy all doses pool.

The entire clinical programme pool as of 15 June 2019 (n=11919 patients) includes all the studies shown in any studies where olaparib is given in combination with other anticancer treatments, investigatorsponsored studies (ISSs) and data from the MAP.

## Myelodysplastic syndrome/acute myeloid leukaemia

In  PAOLA-1,  there  were  4  patients  with  events  of  MDS  or  AML  in  the  olaparib/bevacizumab  arm  and 1 patient with an event of AML in the placebo/bevacizumab arm, which occurred on treatment, within the 30-day follow-up or in the post-follow-up period.

Table 70: Events of MDS/AML occurring in PAOLA-1

| Event                    | tBRCA status             | Day of last dose of study treatment in PAOLA- 1   | Reason for treatment discontinuation   | Day of MDS/AML AE onset (from start of study treatment)   | Number of cycles of prior platinum therapy   | AE outcome                                  |                          |
|--------------------------|--------------------------|---------------------------------------------------|----------------------------------------|-----------------------------------------------------------|----------------------------------------------|---------------------------------------------|--------------------------|
| Olaparib/bevacizumab arm | Olaparib/bevacizumab arm | Olaparib/bevacizumab arm                          | Olaparib/bevacizumab arm               | Olaparib/bevacizumab arm                                  | Olaparib/bevacizumab arm                     | Olaparib/bevacizumab arm                    | Olaparib/bevacizumab arm |
| MDS evolving to AML      | Non- tBRCA               | 212                                               | Anaemia                                | 234                                                       | 9 cycles carboplatin/ paclitaxel             | Fatal Possibly related to olaparib*         |                          |
| MDS evolving to AML      | Non- tBRCA               | 378                                               | MDS                                    | 377                                                       | 6 cycles carboplatin/ paclitaxel             | Fatal Possibly related to olaparib*         |                          |
| AML                      | tBRCA ( BRCA1 )          | 627                                               | Neutropenia                            | 652                                                       | 8 cycles carboplatin/ paclitaxel             | Not recovered Possibly related to olaparib* |                          |
| MDS                      | Non- tBRCA               | 196                                               | MDS                                    | 201                                                       | 6 cycles carboplatin/ paclitaxel             | Recovered Possibly related to olaparib*     |                          |
| Placebo/bevacizumab arm  | Placebo/bevacizumab arm  | Placebo/bevacizumab arm                           | Placebo/bevacizumab arm                | Placebo/bevacizumab arm                                   | Placebo/bevacizumab arm                      | Placebo/bevacizumab arm                     | Placebo/bevacizumab arm  |
| Acute leukaemia          | tBRCA ( BRCA1 )          | 340                                               | Disease progression on Day 340         | 554                                                       | 6 cycles carboplatin/ paclitaxel             | Recovered with sequelae                     |                          |

CTCAE Version 4.03.

AE Adverse event; AML Acute myeloid leukaemia; CSR Clinical study report; CTCAE Common Terminology Criteria for Adverse Events; DCO Data cut-off; MDS Myelodysplastic syndrome; tBRCA Tumour breast cancer susceptibility gene.

(DCO: 22 March 2019)

* As assessed by the investigator.

The incidence in the olaparib/bevacizumab arm of PAOLA-1 (0.7%) was lower than that seen for olaparib in studies in ovarian cancer (SOLO1 [1.2%], SOLO2 [2.1%], Study 19 [1.5%]) and consistent with the incidence  in  the  larger  monotherapy  pool  population  for  the  olaparib  clinical  programme  (1.1%).  The incidence  of  MDS/AML  cases  was  similar  among  g BRCA1m and  g BRCA2m patients  (1.6%  and  1.0%, respectively) in patients treated in clinical trials with Lynparza monotherapy.

Including all patients exposed to olaparib during clinical development provides data for 11919 patients (as of 15 June 2019). In this population, largely composed of ovarian and breast cancer patients, there have

<div style=\"page-break-after: always\"></div>

been 70 reports of MDS/AML out of a total of 11919 patients estimated to have received olaparib in the clinical study programme, giving an estimated cumulative incidence of 0.6% for MDS/AML. The 70 reports of MDS/AML comprise the 30 reports from the olaparib monotherapy all doses pool, plus reports from 191 days). In 4 of the 30 cases, patients died due to other causes (progressive disease [2 patients], bone marrow transplant complications [1 patient], and disseminated intravascular coagulation [1 patient]). In 6 cases, MDS/AML was ongoing at the time of reporting and in 2 cases outcome was reported as recovered.

There  have  also  been  reports  of  MDS/AML  from  post  marketing  surveillance,  consistent  with  the characterisation  of  the  events  reported  from  monotherapy  clinical  studies,  the  ongoing  open-label monotherapy studies, the ongoing MAP programme, combination studies with olaparib and events from placebo-controlled, blinded monotherapy studies.

Most of the 30 patients with events of MDS/AML in the olaparib monotherapy all doses pool were receiving treatment for ovarian, peritoneal or fallopian tube cancer (n=28), with 2 other events occurring in patients with breast cancer. Twenty-six patients had a documented BRCA mutation, 2 patients were gBRCA wildtype and in 2 patients, the BRCA mutation status was unknown.

In 18 of the 30 cases of MDS/AML in the monotherapy pool a fatal outcome was reported, with MDS/AML noted as the primary or secondary cause of death. The duration of therapy with olaparib in patients who developed  MDS/AML  varied  from  &lt;4.2  months  to  &gt;4.9  years.  The  time  to  death  after  olaparib  was discontinued ranged from 17 to 667 days (median 191 days). In 4 of the 30 cases, patients died due to other causes (progressive disease [2 patients], bone marrow transplant complications [1 patient], and disseminated  intravascular  coagulation  [1  patient]).  In  6  cases,  MDS/AML  was  ongoing  at  the  time  of reporting and in 2 cases outcome was reported as recovered.

There  have  also  been  reports  of  MDS/AML  from  post  marketing  surveillance,  consistent  with  the characterisation of the events reported from monotherapy clinical studies.

## New primary malignancies

A review of the SOC of 'Neoplasms benign, malignant and unspecified' showed that during treatment, 9 patients (1.7%) in the olaparib/bevacizumab arm and 3 (1.1%) patients in the placebo/bevacizumab arm had events in this SOC. In the post-follow-up period, there were 5 (0.9%) patients in the olaparib/bevacizumab arm and 2 (0.2%) patients in the placebo/bevacizumab arm who had events in this SOC.

The following events were excluded for the reasons described below:

- AEs of MDS/AML were considered separately

- In the olaparib/bevacizumab arm, 1 patient with a squamous cell carcinoma was excluded as this was a non-melanoma skin cancer; 1 patient with liver metastases and 1 patient with tumour pain were excluded as these were considered disease progression AEs.

- In the placebo/bevacizumab arm, 1 patient with an AE of paraganglion neoplasm was excluded as this was a benign tumour.

Therefore, there were 6 (1.1%) patients in the olaparib/bevacizumab arm and 3 (1.1%) patients in the placebo/bevacizumab arm with new primary malignancies. The AEs of new primary malignancies in PAOLA1  compared  with other  studies  in  the  clinical  programme.  When  larger  populations  of  olaparib-treated patients are considered the incidence remains below 1.5%.

All patients in the 300 mg bd pool had other potential factors that offer alternative explanations for the development of the new primary tumour, such as: a history of smoking, alcohol consumption or exposure to strong sunlight; a documented breast cancer gene (BRCA1 or 2) mutation; a medical history of previous

<div style=\"page-break-after: always\"></div>

cancers;  exposure  to  previous  chemotherapy  agents  including  multiple  cycles  of  platinum  containing chemotherapies that are known DNA-damaging agents and taxanes, anthracyclines and other alkylating and DNA-damaging agents; and prior radiotherapy.

Table 71: Summary of AEs of new primary malignancies occurring across the olaparib programme

<!-- image -->

|                                                              |                                                      | Olaparib      | Olaparib   | Comparator*   | Comparator*   |
|--------------------------------------------------------------|------------------------------------------------------|---------------|------------|---------------|---------------|
|                                                              |                                                      | Number of AEs | Incidence  | Nunber of AEs | Incidence     |
| PAOLA-1 N=535 olaparib/bevacizumab N=267 placebo/bevacizumab | Ovarian                                              | 6             | 1.1%       | 3             | 1.1%          |
| SOL03 N=178 olapanb N=76 chemotherapy                        | Ovarian                                              | 3             | 1.7%       | 0             | 0             |
| SOL01 N=260 olapanb N=130 placebo                            | Ovarian                                              | 5             | 1.9%       | 3             | 2.3%          |
| SOLO2 N=195 olapanb N=99 placebo                             | Ovarian                                              | 1             | 1.5%       | 1             | 1.0%          |
| Study 19 N=136 olapanb N=128 placebo                         | Ovarian                                              | 4             | 2.9%       | 1             | 0.8%          |
| PROfouund N=256 olapanb N=130 investigators choice ofNHA     | Prostate cancer                                      | 1             | 0.4%       | 2             | 1.5%          |
| POLO N=91 olaparib N=60 placebo                              | Pancreatic cancer, prior platinum                    | 0             | 0          | 0             | NA            |
| OlympiAD N=205 olapanb N=91 physician's choice               | Breast cancer, prior platinum                        | 1             | 0.5%       | 0             | 0             |
| Olaparib monotherapy, all doses pool N=2783 olapanib         | Olaparib monotherapy, all doses pool N=2783 olapanib | 36            | 1.3%       | NA            | NA            |
| Entire clinical programme pool N=11919 olaparib              | Entire clinical programme pool N=11919 olaparib      | 96            | 0.8%       | NA            | NA            |

Of the 36 AEs in the olaparib monotherapy all doses pool, 12 patients had skin cancers as follows: basal cell carcinoma (n=6), Skin cancer (n=2), Malignant melanoma (n=2), one patient reported both a basal cell carcinoma and squamous cell carcinoma and one patient reported squamous cell carcinoma unspecified. The non-skin cancer events were: breast cancers (n=9), GI cancers (n=5), thyroid cancer (n=2), plasma cell myeloma (n=2), lung cancer (n=2), bladder cancer, glioma, squamous cell carcinoma of the oral cavity, lip and/or oral cavity cancer (n=1 of each). Of the 36 patients in the olaparib monotherapy all doses pool with  new  primary  malignancies,  31  patients  had  a  documented  BRCA  mutation,  1  patient  was  gBRCA wildtype and in 4 patients, the BRCA mutation status was unknown.

Including all patients exposed to olaparib during clinical development (i.e., including data from ongoing studies, blinded studies, combination studies, ESRs and the MAP) provides data for 11919 patients (as of 15 June 2019). In this population, there have been 96 reports of new primary malignancies out of a total of 11919 patients estimated to have received olaparib in the clinical study programme, giving an estimated cumulative  incidence  of  0.8%.  There  have  also  been  reports  of  new  primary  malignancies  from  post marketing  surveillance,  consistent  with  the  characterisation  of  the  events  reported  from  monotherapy clinical studies.

<div style=\"page-break-after: always\"></div>

## Pneumonitis

At  the  time  of  the  DCO  for  PAOLA-1  (22  March  2019),  it  was  reported  that  6  (1.1%)  patients  in  the olaparib/bevacizumab arm (3 AE of interstitial lung disease, 2 AEs of pneumonitis and 1 AE of bronchiolitis) and no patients in the placebo/bevacizumab arm had an AE of pneumonitis.

The pneumonitis AEs reported with olaparib in PAOLA-1 were generally mild or moderate; all of the 6 AEs were CTCAE Grade 1 or 2 and 2 of the 6 cases were non-serious. There were no AEs of CTCAE Grade 3 severity and 4 SAEs. In 4 of the 6 patients, treatment was interrupted and the pneumonitis AE resolved; no  re-occurrence  or  worsening  of  pneumonitis  was  reported  following  treatment  restart  (negative  rechallenge). Olaparib treatment was continued in 1 patient and in 1 patient, the pneumonitis AEs led to treatment discontinuation.

In  the  larger  pool  (therapeutic  dose  pool),  the  incidence  of  pneumonitis  events  was  0.9%  (20  cases reported). Of the 20 pneumonitis AEs in the olaparib monotherapy combined therapeutic dose pool (n = 2351), 15 were CTCAE Grade 1 or 2 and the remaining 5 AEs were CTCAE Grade 3. Thirteen of the 20 pneumonitis  AEs  were  non-serious  and  7  were  SAEs.  Twelve  of  the  20  AEs  were  reported  to  have recovered/resolved or recovering/resolving and the remaining 8 AEs did not resolve. In 8 of the 20 patients with pneumonitis AEs, treatment was continued without interruption, in a further 6 patients the dose of olaparib was interrupted or reduced and in the remaining 6 patients, olaparib treatment was permanently discontinued. Overall, the majority of pneumonitis AEs reported in the olaparib monotherapy therapeutic dose pool were mild or moderate, non-serious and resolved without treatment discontinuation. None of the 20 pneumonitis AEs in the pool had a fatal outcome.

AstraZeneca's  global  Patient  Safety  database  contains  all  AE  reports,  from  spontaneous  sources  (eg, healthcare professionals, Regulatory Authorities, literature, consumers, and others), whether or not they meet regulatory authorities' definition of SAE, and reports from clinical study use that are defined as SAEs. Non-SAE reports from clinical study use are usually only entered onto the clinical study database, but in some (but not all) olaparib studies, non-serious pneumonitis events were also entered into the safety database. A search of the AstraZeneca safety database up to 15 June 2019, retrieved 161 case reports; 75 case reports from clinical studies, 49 case reports from the post-marketing setting and the remaining 37 case  reports  from  other  solicited  sources  (e.g.,  post  marketing  non-interventional  studies  or  patient assistance programmes). Of the 75 case reports from clinical studies (including PROfound), 66 reported a pneumonitis SAE and 9 reported a non-serious pneumonitis event.

Five of the events in these 161 case reports had a fatal outcome; all of these patients were receiving olaparib in combination with other therapies (including other chemotherapies and/or radiation) and 2 of these 5 were being treated for non-small cell lung cancer. In addition, 2 events in the 86 case reports from the post-marketing setting and other solicited sources had a fatal outcome. One patient had a history of interstitial lung changes before starting olaparib therapy and was receiving concomitant simvastatin and had a recent cycle of carboplatin, which are potential confounders. The patient discontinued olaparib 25 days before the onset of the event. The other patient who developed fatal pneumonitis had lung metastases, pleural effusion and bronchitis, as potential confounders before starting olaparib treatment.

## Main adverse drug reactions related to bevacizumab

The purpose of this section is to provide a more detailed assessment of the AEs for bevacizumab that are listed in the product label as ADRs and are considered to be AESIs. This summary focuses only on data from the PAOLA-1 SAS (overall study duration). The section does not discuss hematologic toxicity which is also known for bevacizumab but is discussed above in the subsection on ADR related to olaparib.

<div style=\"page-break-after: always\"></div>

## Hypertension

Hypertension is reported as a very common ADR for bevacizumab treatment (AEs and clinically significant/severe AEs of hypertension are reported to occur at an incidence of more than ≥1/10 patients).

AEs of hypertension were reported for a lower percentage of patients in the olaparib/bevacizumab arm (45.8%) and the placebo/bevacizumab arm (59.9%). More than half of the hypertension AEs were mild or moderate in severity and the majority of patients with hypertension AEs had events in the combination period in both treatment arms, (223 [91.0%] of 245 patients in the olaparib/bevacizumab arm and 153 [95.6%] of 160 patients in the placebo/bevacizumab arm).

The proportion of patients with CTCAE Grade 3 AEs of hypertension was lower in the olaparib/bevacizumab arm, compared with the placebo/bevacizumab arm of PAOLA-1. There were no Grade 4 AEs of hypertension. SAEs of hypertension were reported in a slightly lower proportion of patients in olaparib/bevacizumab arm (9.0% of patients) compared with the placebo/bevacizumab arm (13.1% of patients).

AE onset data for PAOLA-1 showed that the majority of first AEs of hypertension in both treatment arms of PAOLA-1 occurred in the first 360 days of study treatment. This corresponds with the median duration of bevacizumab treatment in each treatment arm (11.0 months [approximately 336 days] in the olaparib/bevacizumab arm and 10.4 months [approximately 316 days] in the placebo/bevacizumab arm; consistent with most of the AEs of hypertension being associated with bevacizumab treatment. A similar number of patients in each arm had a first AE of hypertension in the first month of treatment with rates of 17.8% and 20.2%, for olaparib/bevacizumab and placebo/bevacizumab treated patients, respectively.

Despite the incidence of AEs, CTCAE Grade ≥3 AEs and SAEs of hypertension, AEs of hypertension rarely led to dose modification of olaparib or placebo treatment in PAOLA-1 and none led to discontinuation of olaparib or placebo treatment.

## Proteinuria

Proteinuria is reported as a very common ADR for bevacizumab treatment (AEs of proteinuria are reported to occur at an incidence of more than ≥1/10 patients and clinically significant/severe AEs of proteinuria are reported to occur at an incidence of between ≥1/ 100 and &lt;1/10 patients). Proteinuria was reported as an AE  for  a  lower  proportion  of  patients  in  the  olaparib/bevacizumab  arm  (5.8%),  compared  the placebo/bevacizumab arm (15.4%). AEs of proteinuria were predominantly Grade 1 or 2 in severity and none led to permanent discontinuation of treatment.

The majority of patients with proteinuria AEs had events in the combination period in both treatment arms, (26  [83.9%]  of  31  patients  in  the  olaparib/bevacizumab  arm  and  37  [90.2%]  of  41  patients  in  the placebo/bevacizumab arm).

The  time  to  first  AE  of  proteinuria  was  similar  in  the  two  arms.  All  of  the  AEs  of  proteinuria  in  the olaparib/bevacizumab arm, and the majority in the placebo/bevacizumab arm, had a first onset in the first 450 days of study (only 2 patients in the placebo/bevacizumab arm had AEs of proteinuria in the period from Day 451 to Day 540 and no patients in either arm had AEs after Day 541. This corresponds with the median duration of bevacizumab treatment in each treatment arm (11.0 months [approximately 336 days] in the olaparib/bevacizumab arm and 10.4 months [approximately 316 days] in the placebo/bevacizumab arm consistent with most of the AEs of proteinuria being associated with bevacizumab treatment.

An analysis of urinary protein values showed that the majority of patients in both treatment arms had values that were normal or showed a trace of urinary protein at each visit.

<div style=\"page-break-after: always\"></div>

## GI perforation, abscesses and fistulae (any grade)

AEs of GI perforation, abscesses and fistulae are reported as common ADRs for bevacizumab treatment (AEs and clinically significant/severe AEs are reported to occur at an incidence of between ≥1/100 and &lt;1/10  patients).  AEs  of  GI  perforation,  abscesses  and  fistulae  were  reported  for  a  low  percentage  of patients  in  the  olaparib/bevacizumab  arm  (2  patients  [0.4%])  and  the  placebo/bevacizumab  arm (2 patients [0.7%]). All AEs were reported during the combination phase. All events were Grade ≥3 in severity and 1 event (intestinal perforation) was reported as fatal in a patient in the placebo/bevacizumab arm.  One  patient  on  each  arm  reported  an  SAE.  AEs  of  GI  perforation,  abscesses  and  fistulae  led  to treatment interruption of olaparib in 0.4% of the olaparib/bevacizumab arm. There were no dose reductions or discontinuation of olaparib or placebo treatment.

## Haemorrhagic events (including wound healing complication)

Wound healing complications are reported as common/very common ADRs for bevacizumab treatment (AEs of wound healing complications are reported to occur at an incidence of more than ≥1/10 patients and clinically significant/severe AEs of wound healing complications are reported to occur at an incidence of between ≥1/100 and &lt;1/10 patients).

AEs of haemorrhagic events (reported terms: cerebral haemorrhage, contusion, epistaxis, gastric haemorrhage, gingival bleeding, haemorrhagic disorder, intestinal haemorrhage, melaena, petechiae, rectal haemorrhage and vaginal haemorrhage) were reported for a similar percentage of patients in the olaparib/bevacizumab arm (9.7%) and the placebo/bevacizumab arm (10.5%). These events were predominantly Grade 1 or 2 in severity and none of the AEs in the olaparib/bevacizumab arm led to permanent discontinuation of treatment. The majority of patients with haemorrhage AEs had events in the combination period in both treatment arms, (48 [92.3%] of 52 patients in the olaparib/bevacizumab arm and 24 [85.7%] of 28 patients in the placebo/bevacizumab arm).

A low number of patients had AEs of wound healing complications. In the olaparib/bevacizumab arm 3 (0.6%) patients, had AEs, all of which occurred during the combination phase; in the placebo/bevacizumab arm, 5 (1.9%) patients had 6 AEs (only 1 patient had 1 AE during the combination phase). One AE in each arm was CTCAE Grade 3 (an AE of wound dehiscence in the olaparib/bevacizumab arm and an AE of wound complication in the placebo/bevacizumab arm), all other events were mild or moderate in severity. One placebo/bevacizumab-treated patient reported an SAE (of impaired healing, CTCAE Grade 2) on Day 362 of study. There were no AEs of wound healing that led to treatment interruption in the olaparib/bevacizumab arm and 0.7% AEs of wound healing led to treatment interruption of placebo in the placebo/bevacizumab arm. There were no dose reductions or discontinuations of olaparib or placebo due to AEs of wound healing.

In addition, there were 6 patients who had AEs of wound evisceration, which were not included in the grouped term for wound healing complications. Four (0.7%) patients were in the olaparib/bevacizumab arm and 2 (0.7%) patients were in the placebo/bevacizumab arm; none of the AEs in the olaparib/bevacizumab arm and 1 of the 2 AEs in the placebo/bevacizumab arm occurred during the combination phase. Of the 4 AEs in the olaparib/bevacizumab arm, 1 patient had a CTCAE Grade 3 SAE which was considered related to olaparib and also led to treatment discontinuation; this event recovered after 6 days. Of the 3 remaining events, 2 were CTCAE Grade 2 (1 event was an SAE and 1 event led to dose interruption; both events were reported as resolved) and 1 was CTCAE Grade 1 (this event occurred in follow-up and a resolution date was not provided). In the placebo/bevacizumab arm, 1 patient had a CTCAE Grade 2 SAE which led to discontinuation and 1 patient had a CTCAE Grade 1 AE. None of the CTCAE Grade ≤2 AEs were considered related to olaparib and none of the patients with AEs of wound evisceration had other AEs that were included in the grouped term for wound healing complications.

<div style=\"page-break-after: always\"></div>

## Thromboembolic events

Thromboembolic events are reported as common/very common ADR for bevacizumab treatment (AEs of venous thromboembolic events are reported to occur at an incidence of more than ≥1/10 patients and clinically significant/severe AEs of arterial thromboembolic events are reported to occur at an incidence of between ≥1/100 and &lt;1/10 patients). AEs of arterial thromboembolic events (reported terms of acute myocardial infarction, cerebrovascular accident, embolism, myocardial infarction, thrombosis and transient ischaemic attack) were reported for 9 (1.7%) patients in the olaparib/bevacizumab arm and 8 (3.0%) patients in the placebo/bevacizumab arm.

The majority of patients with AEs in the grouped term of arterial thromboembolic events occurred in the combination period in both treatment arms, (6 [66.7%] of 9 patients in the olaparib/bevacizumab arm and 5 [62.5%] of 8 patients in the placebo/bevacizumab arm).

In the olaparib/bevacizumab arm 0.6% of patients reported CTCAE Grade 3 events, no patients reported Grade 4 events. In the placebo/bevacizumab arm 2.6% of patients reported CTCAE Grade ≥3 events, of which 2 patient (0.7%) reported Grade 4 events and 1 patient (0.4%) reported a fatal event. All Grade 4 and 5 events were myocardial infarction. Two patients in the olaparib/bevacizumab arm had SAEs (both SAEs of embolism), compared with 6 patients in the placebo/bevacizumab arm (4 patients with myocardial infarction, 1 patient with an acute myocardial infarction and 1 patient with a cerebrovascular accident). Two of the myocardial  infarction  AEs  in  the  placebo/bevacizumab  arm  were  fatal.  Two  patients  in  the placebo/bevacizumab arm discontinued study treatment due to AEs of myocardial infarction.

AEs  of  venous  thromboembolic  events  (grouped  term  consisting  of  the  PTs  of  deep  vein  thrombosis, pulmonary embolism, thrombophlebitis and venous thrombosis) were reported for 17 (3.2%) of patients in the olaparib/bevacizumab arm and 4 (1.5%) of patients in the placebo/bevacizumab arm. The majority of patients with AEs in the grouped term of venous thromboembolic events occurred in the combination period in  both treatment arms, (10 [58.8%] of 17 patients in olaparib/bevacizumab arm and 3 [75.0%] of 4 patients  in  the  placebo/bevacizumab  arm).  At  the  event  level,  10  (52.6%)  of  19  AEs  in  the  venous thromboembolic events grouped term in the olaparib/bevacizumab arm and 3 (75.0%) of 4 AEs in the placebo/bevacizumab arm occurred in the combination period.

On the olaparib/bevacizumab arm, 8 (1.5%) of patients reported CTCAE Grade ≥3 events, 2 patients reported CTCAE Grade 4 events (both had pulmonary embolism SAEs). In the placebo/bevacizumab arm, 1  (0.4%) patient a reported CTCAE Grade 3 AE (pulmonary embolism); no patients reported Grade 4 events.  Six  patients  in  the  olaparib/bevacizumab  arm  had  SAEs  (5  patients  with  SAEs  of  pulmonary embolism  and  1  patient  with  an  SAE  of  venous  thrombosis),  compared  with  1  patient  in  the placebo/bevacizumab arm (1 patient with an SAE of pulmonary embolism). None of the events were fatal or led to discontinuation of olaparib or placebo treatment.

## Posterior reversible encephalopathy syndrome (PRES)

AEs of PRES are reported rare AEs for bevacizumab treatment (AEs of PRES are reported to occur at an incidence of between ≥1/10,000 and &lt;1/1,000 patients). An AE of PRES was reported for 1 patient in the placebo/bevacizumab arm, which occurred during the combination phase. This AE was CTCAE Grade 2, non-serious, and did not lead to death, discontinuation, dose reduction or modification.

## Congestive heart failure (CHF)

Congestive  heart  failure  is  reported  as  a  common  ADR  for  bevacizumab  treatment  (AEs  and  clinically significant/severe AEs of congestive heart failure [reported term: cardiac failure chronic] are reported to occur at an incidence of between ≥1/100 and &lt;1/10 patients). An AE of cardiac failure chronic was reported

<div style=\"page-break-after: always\"></div>

for 1 patient in the olaparib/bevacizumab arm, which occurred outside of the combination phase. The AE was CTCAE Grade 3, non-serious, and did not lead to death, discontinuation, dose reduction or modification.

## Non-GI fistula or abscess (any grade)

AEs of fistula in the SOC of musculoskeletal and connective tissue disorders are reported as common AEs for bevacizumab treatment (AEs and clinically significant/severe AEs of fistula [grouped term] are reported to occur at an incidence of between ≥1/100 and &lt;1/10 patients). Two AEs of non-GI fistula or abscess (reported terms of abscess, fistula, nasal septum perforation and urogenital fistula) were reported in the olaparib/bevacizumab arm (urogenital fistula [1 patient, 0.2%] and fistula [1 patient, 0.2%]) and 2 AEs in the placebo/bevacizumab arm (nasal septum perforation [1 patient, 0.4%] and abscess [1 patient, 0.4%]). One AE in each arm was CTCAE Grade 3: urogenital fistula in the olaparib/bevacizumab arm (also an SAE), and the event of nasal septum perforation in the placebo/bevacizumab arm. Only the AE of abscess in the placebo/bevacizumab arm led to dose interruption.

## Laboratory findings

## Haematology

The proportion of olaparib/bevacizumab-treated patients with a decrease in haemoglobin of CTCAE Grade ≥3 during the study was 12.5%; the proportion of olaparib/bevacizumab-treated patients with abnormal CTCAE Grade of 3 or 4 values for other haematological parameters was generally ≤10%. Anaemia was the second most frequently reported CTCAE Grade ≥3 AE and SAE, and the most frequently reported DAE.

In the olaparib/bevacizumab treatment arm, the proportion of patients with abnormal haematology values of CTCAE Grade ≥3 was similar for each parameter for the overall study period and the combination only phase, when corrected for duration of exposure (Table 72).

<div style=\"page-break-after: always\"></div>

Table 72: PAOLA-1: Number (%) of patients with maximum overall CTCAE grades during treatment for key haematological parameters (SAS)

<!-- image -->

|                                               | Grade 0         | Grade 1         | Grade 2         | Grade 3        | Grade 4       |
|-----------------------------------------------|-----------------|-----------------|-----------------|----------------|---------------|
| Haemoglobin (low)                             |                 |                 |                 |                |               |
| Olaparib/bevacizumab (overall study duation)  | 114/534 (21.3%) | 246/534 (46.1%) | 107/534 (20.0%) | 67/534 (12.5%) | 0             |
| Olaparib/bevacizumab (combination phase only) | 138/530 (26.0%) | 238/530 (44.9%) | 95/530 (17.9%)  | 59/530 (11.1%) | 0             |
| Placebo/bevacizumab                           | 131/267 (49.1%) | 120/267 (44.9%) | 16/267 (6.0%)   | 0              | 0             |
| Platelets                                     |                 |                 |                 |                |               |
| Olaparib/bevacizumab (overall study duation)  | 354/534 (66.3%) | 155/534 (29.0%) | 13/534 (2.4%)   | 8/534 (1.5%)   | 4/534 (0.7%)  |
| Olaparib/bevacizumab (combination phase only) | 370/530 (69.8%) | 141/530 (26.6%) | 12/530 (2.3%)   | 6/530 (1.1%)   | 1/530 (0.2%)  |
| Placebo/bevacizumab                           | 197/267 (73.8%) | 69/267 (25.8%)  | 1/267 (0.4%)    | 0              | 0             |
| Leukocytes                                    |                 |                 |                 |                |               |
| Olaparib/bevacizumab (overall study duation)  | 220/534 (41.2%) | 190/534 (35.6%) | 107/534 (20.0%) | 14/534 (2.6%)  | 3/534 (0.6%)  |
| Olapanib/bevacizumab (combination phase only) | 242/530 (45.7%) | 184/530 (34.7%) | 93/530 (17.5%)  | 11/530 (2.1%)  | 0             |
| Placebo/bevacizumab                           | 152/267 (56.9%) | 83/267 (31.1%)  | 29/267 (10.9%)  | 2/267 (0.7%)   | 1/267 (0.4%)  |
| Neutrophils                                   |                 |                 |                 |                |               |
| Olaparib/bevacizumab (overall study duation)  | 346/534 (64.8%) | 71/534 (13.3)   | 83/534 (15.5%)  | 24/534 (4.5%)  | 10/534 (1.9%) |
| Olaparib/bevacizumab (combination phase only) | 360/530 (67.9%) | 72/530 (13.6%)  | 73/530 (13.8%)  | 21/530 (4.0%)  | 4/530 (0.8%)  |
| Placebo/bevacizuwab                           | 191/267 (71.5%) | 31/267 (11.6%)  | 38/267 (14.2%)  | 7/267 (2.6%)   | 0             |

|                                              | Grade 0         | Grade 1         | Grade 2         | Grade 3       |              |
|----------------------------------------------|-----------------|-----------------|-----------------|---------------|--------------|
| Lymphocytes (low)                            |                 |                 |                 |               |              |
| Olapanib/bevacizumab(overall shudy duation)  | 199/533 (37.3%) | 149/533 (28.0%) | 135/533 (25.3%) | 47/533 (8.8%) | 3/533 (0.6%) |
| Olapanib/bevacizumab(combination phase only) | 238/529 (45.0%) | 146/529 (27.6%) | 111/529 (21.0%) | 33/529 (6.2%) | 1/529 (0.2%) |
| Placebo/bevacizumab                          | 161/267 (60.3%) | 69/267 (25.8%)  | 31/267 (11.6%)  | 5/267 (1.9%)  | 1/267 (0.4%) |

CSR Clinical study report; CTCAE Common Terminology Criteria for Adverse Events; DCO Data cut-off; SAS Safety Analysis Set.

Derived from laboratory assessments using local reference ranges after start of treatment up to the last dose of study medication.

Data derived from Table 14.3.7.1.2.1.1, PAOLA-1 CSR, Module 5.3.5.1 (DCO: 22 March 2019).

<div style=\"page-break-after: always\"></div>

## Clinical chemistry

Table 73: PAOLA-1: Number (%) of patients with maximum overall CTCAE grades during treatment for key clinical chemistry parameters (SAS)

|                                               | Grade 0         | Grade 1         | Grade 1       | Grade 3      | Grade 4   |
|-----------------------------------------------|-----------------|-----------------|---------------|--------------|-----------|
| ALT elevated                                  |                 |                 |               |              |           |
| Olaparib/bevacizumab (overall study duration) | 408/534 (76.4%) | 119/534 (22.3%) | 6/534 (1.1%)  | 1/534 (0.2%) | 0         |
| Olaparib/bevacizumab (combination phase only) | 434/530 (81.9%) | 92/530 (17.4%)  | 4/530 (0.8%)  | 0            | 0         |
| Placebo/bevacizumab                           | 191/267 (71.5%) | 71/267 (26.6%)  | 3/267 (1.1%)  | 2/267 (0.7%) | 0         |
| AST elevated                                  |                 |                 |               |              |           |
| Olaparib/bevacizumab (overall study duration) | 369/534 (69.1%) | 154/534 (28.8%) | 8/534 (1.5%)  | 3/534 (0.6%) | 0         |
| Olapanib/bevacizumab (combination phase only) | 399/530 (75.3%) | 125/530 (23.6%) | 5/530 (0.9%)  | 1/530 (0.2%) | 0         |
| Placebo/bevacizumab                           | 179/267 (67.0%) | 85/267 (31.8%)  | 1/267 (0.4%)  | 2/267 (0.7%) | 0         |
| ALP elevated                                  |                 |                 |               |              |           |
| Olaparib/bevacizumab (overall study duration) | 423/531 (79.7)  | 97/531 (18.3%)  | 8/531 (1.5%)  | 3/531 (0.6%) | 0         |
| Olapanib/bevacizumab (combination phase only) | 463/527 (87.9%) | 56/527 (10.6%)  | 5/527 (0.9%)  | 3/527 (0.6%) | 0         |
| Placebo/bevacizumab                           | 208/263 (79.1)  | 53/263 (20.2%)  | 1/263 (0.4%)  | 1/263 (0.4%) | 0         |
| Bilirubin elevated                            |                 |                 |               |              |           |
| Olaparib/bevacizumab (overall study duration) | 481/534 (90.1%) | 40/534 (7.5%)   | 10/534 (1.9%) | 3/534 (0.6%) | 0         |
| Olapanib/bevacizumab (combination phase only) | 489/529 (92.4%) | 31/529 (5.9%)   | 7/529 (1.3%)  | 2/529 (0.4%) | 0         |
| Placebo/bevacizumab                           | 253/267 (94.8%) | 12/267 (4.5%)   | 1/267 (0.4%)  | 1/267 (0.4%) | 0         |

|                                              | Grade 0         | Grade 1         | Grade 2         | Grade 3      | Grade 4      |
|----------------------------------------------|-----------------|-----------------|-----------------|--------------|--------------|
| Creatinineincreased                          |                 |                 |                 |              |              |
| Olapanib/bevacizumab(overall study duration) | 210/533 (39.4%) | 173/533 (32.5%) | 148/533 (27.8%) | 口            | 2/533 (0.4%) |
| Olapanib/bevacizumab (combinationphaseonly)  | 233/529 (44.0%) | 184/529 (34.8%) | 110/529 (20.8%) | 0            | 2/529 (0.4%) |
| Placebo/bevacizumab                          | 168/266 (63.2%) | 79/266 (29.7%)  | 17/266 (6.4%)   | 1/266 (0.4%) | 1/266 (0.4%) |

ALP Allkaline phosphatase; ALT Alanine aminotansferase; AST Aspartate aminotransferase; CSR Clinical study report; CTCAE Common Terminology Criteria for AdverseEvents; DCO Data cut-off, SAS Safety Analysis Set.

Derived from laboratory assessments using local reference ranges after start of treatment up to the last dose of study medication

Data derived from Table 14.3.7.1.2.1.1, PA0LA-1 CSR, Module 5.3.5.1 (DCO: 22 March 2019).

## Assessment of the potential for drug-induced liver injury

Based on all  available  data  there  is  no  evidence  to  suggest  that  olaparib  causes  DILI.  There  were  no confirmed  or  suspected  Hy's  Law  cases.  No  olaparib/bevacizumab-treated  patients  in  PAOLA-1  had concurrent elevations of bilirubin and ALT/AST.

In PAOLA-1, the majority of patients in the olaparib/bevacizumab arm and placebo/bevacizumab arms had a maximum on-treatment AST (522/534 [97.8%] and 262/267 [98.1%] patients, respectively) and ALT (523/534 [97.9%] and 261/267 [97.7%] patients, respectively) below 3 × ULN.

Of the few patients with AST or ALT values above 3 × ULN in PAOLA-1, 3 olaparib/bevacizumab-treated patients and 1 placebo/bevacizumabtreated patient had AST or ALT values in the range ≥10 × ULN to &lt;20 × ULN. No patients in either treatment arm had an AST or ALT value of ≥20 × ULN.

<div style=\"page-break-after: always\"></div>

In  PAOLA-1,  there  were  no  patients  who  had  CTCAE  Grade  4  laboratory  values  for  ALT  and  AST;  the proportion of patients with CTCAE Grade 3 elevations was low in both treatment arms.

An assessment of ALT, AST maximal elevations during treatment by maximal total bilirubin elevations showed that no patients in the either treatment arm had concurrent elevation of bilirubin and either ALT or AST.  A  similar  proportion  of  olaparib/bevacizumab-treated  patients  in  the  PAOLA-1  study  had  hepatic metastases (6.0% of patients) at baseline, compared with SOLO1 (5.0% patients) and PROfound (9.8% of patients);  the  proportion  of  olaparib/bevacizumab-treated  patients  in  the  PAOLA-1  study  with  hepatic metastases  was  lower  than  for  SOLO2  (13.8%  patients),  SOLO3  (12.4%  patients);  OlympiAD  (38.5% patients) and POLO (66.3%).

In the 300 mg bd pool, the majority (1469/1572 [93.4%] patients) had combined AST or ALT below 3 × ULN. In the 300 mg bd pool, 26 (1.7%) patients had an ALT increased laboratory value (worst grade) of CTCAE Grade 3 and 2 patients (0.1%) had an ALT increased laboratory value of CTCAE Grade 4; 36 (2.3%) patients  had  a  CTCAE  Grade  3  laboratory  value  of  AST  increased;  no  patients  had  an  AST  increased laboratory value of CTCAE Grade 4. The proportion of patients with CTCAE Grade ≥3 laboratory values of ALT or AST in the 300 mg bd pool was higher than that in the olaparib/bevacizumab arm of the PAOLA-1 study (0.2% and 0.6%, respectively)

The proportion of olaparib/bevacizumab-treated patients with CTCAE Grade 3 AEs in the PAOLA-1 study and in the 300 mg bd pool was low and similar to the proportion of patients with CTCAE Grade 3 abnormal laboratory values. In PAOLA-1, 1 (0.2%) olaparib/bevacizumab-treated patient had CTCAE Grade 3 AE report of AST increased (there were no CTCAE Grade 3 AE reports of ALT increased). In the 300 mg bd pool, 11 (0.7%) patients had a CTCAE Grade 3 AE report of AST increased and 10 (0.6%) patients had a CTCAE Grade 3 AE report of ALT increased;

An assessment of combined elevations of ALT and bilirubin was conducted for all patients in the 300 mg bd pool. Of these 1585 patients, 23 patients reported elevations of both AST or ALT &gt;3 × ULN and total bilirubin &gt;2 × ULN, irrespective of ALP, at any point during their study treatment. A detailed evaluation of medical history, progression of disease, temporal association for the 23 patients with elevated ALP (&gt;2 × ULN for  21  patients  and  &lt;1  ×  ULN  for  2  patients)  and  other  factors  showed  that  all  23  patients  had alternative explanations for elevations of ALT and bilirubin, generally suggestive of obstructive causes, or cancer disease progression, including disease progression in the liver.

The  evaluation  of  hepatic  function  laboratory  data,  in  conjunction  with  an  assessment  of  reported hepatobiliary/abnormal hepatic biochemistry AEs did not identify risk of DILI in the olaparib/bevacizumabtreated patient population.

## Assessment of potential for renal impairment

Mild  elevations  in  creatinine  have  been  observed  with  no  apparent  sequelae  and  with  resolution  on discontinuing olaparib, with no change in other renal function biochemistry tests (urea/blood urea nitrogen [BUN]). The small increases in creatinine observed with olaparib and the rapid onset of the mild changes observed,  with  a  return  to  baseline  after  olaparib  discontinuation  are  consistent  with  the  finding  that olaparib is known to be an inhibitor of OCT2 and MATE1.

In the olaparib/bevacizumab arm of PAOLA-1, 94.2% of olaparib/bevacizumab-treated patients had normal creatinine levels at baseline, 5.8% had CTCAE Grade 1 at baseline and no patients had CTCAE Grade ≥2 at baseline. A total of 170/533 (31.9%) patients had a single worsening change in CTCAE Grade (most changes were normal to Grade 1) and 134/533 (25.1%) patients had worsening 2 grade shifts in CTCAE Grade for creatinine;  2  patients  had  a  shift  from  normal  at  baseline  to  CTCAE  Grade  4  on  treatment.  In  the placebo/bevacizumab arm of PAOLA-1, 93.2% of patients had normal creatinine at baseline and 6.8% had CTCAE Grade 1 at baseline; of these patients, 63/266 (23.7%) patients had a single change in CTCAE Grade

<div style=\"page-break-after: always\"></div>

(all except 1 patient had changes from normal to Grade 1); 16/266 (6.0%) patients had worsening 2 grade shifts in CTCAE Grade for creatinine and 2 patients had a shift from normal at baseline to CTCAE Grade 3 or 4 on treatment.

Data from all patients in the 300 mg bd pool showed that a higher proportion of patients in the 300 mg bd pool had CTCAE grade shifts in creatinine, compared with PAOLA-1. In the 300 mg bd pool, 92.4% of olaparib-treated patients had normal creatinine at baseline, 6.9% had CTCAE Grade 1 at baseline and 0.5% had CTCAE Grade 2 at baseline. A total of 1205/1573 (76.6%) patients had a single change in CTCAE Grade (changes were normal to Grade 1 in 1165/1573 [74.1%] patients); 243/1573 (15.4%) had 2 CTCAE grade shifts (all were normal to Grade 2) and 7/1573 (0.4%) patient had a 3 grade shift in creatinine (all were Grade 0 to Grade 3).

## Safety in special populations

## Intrinsic factors

## Effect of gender

As all patients in the PAOLA-1 study were female, an analysis of the effects of gender has been conducted in the 300 mg bd pool.

Table 74: 300 mg bd pool: Number of patients reporting at least one adverse event by gender (SAS)

|                                                  | Number (%) of patientsa Olaparib300mgbdtablet   | Number (%) of patientsa Olaparib300mgbdtablet   |
|--------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| AE category                                      | Male (N = 408)                                  | Female (N = 1177)                               |
| Any AE                                           | 392 (96.1)                                      | 1150 (97.7)                                     |
| Any AE CTCAE grade 3 or higher                   | 184 (45.1)                                      | 475 (40.4)                                      |
| Any AE with outcome = death                      | 12 (2.9)                                        | 7 (0.6)                                         |
| Any SAE (including events with outcome = death)  | 124 (30.4)                                      | 241 (20.5)                                      |
| Any AE leading to dose interruption of treatment | 158 (38.7)                                      | 472 (40.1)                                      |
| AnyAEleadingtodosereduction of treatment         | 73 (17.9)                                       | 266 (22.6)                                      |
| AnyAEleadingtodiscontinuation of treatment       | 55 (13.5)                                       | 93 (7.9)                                        |

Patients with multiple events in the same category were counted only once in that category. Patients with

Includes AEs with an onset date between the first dose of continuous treatment and 30 days following the last dose of continuous treatment (excludes 8 patients[10AEs] from D0816C00010 with pre-treatment AEs defined as treatment-emergentperCSR).

<div style=\"page-break-after: always\"></div>

## Effect of age

Table 75: 300 mg bd pool: number of patients reporting at least one adverse event by age group

|                                                  | Number (%o) of patientsa   | Number (%o) of patientsa   | Number (%o) of patientsa   | Number (%o) of patientsa   |
|--------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| MedDRA term                                      | Age ~65 years (N=1145)     | Age 65 to 74 yea1s (N=334) | Age 75 to (N=103)          | Age ≥85 year's (N=6)       |
| Total AEs                                        | 1111 (97.3)                | 326 (97.6)                 | 99 (96.1)                  | 6 (100)                    |
| Total SAEs\"                                      | 233 (20.4)                 | 94 (28.1)                  | 34 (33|0)                  | 4 (66.7)                   |
| Fatal                                            | 6 (0.5)c                   | 9 (2.7)                    | 3 (2.9)                    | 0                          |
| Hospitalisation'prolong existing hospitalisation | 215 (18.8)                 | 86 (25.7)                  | 33 (32.0)                  | 4 (66.7)                   |
| Life-threatening                                 | 28 (2.5)                   | 17 (5.1)                   | 3 (2.9)                    | 1 (16.7)                   |
| Other (disability incapacity)                    | 5 (0.4)                    | 4 (1.2)                    | 1 (1.0)                    | 0                          |
| Other (medically significant)                    | 63 (5.5)                   | 24 (7.2)                   | 9 (8.7)                    | 2 (33.3)                   |
| Total DAEs                                       | 85 (7.4)                   | 39 (11.7)                  | 22 (21.4)                  | 2 (33.3)                   |

For the majority of the AEs, there were no differences in frequency of AEs by PT in patients aged &lt;65 years when compared with patients aged 65 to 74 years, 75 to 84 years and ≥85 years. Nausea and vomiting were the only AEs that occurred at a higher incidence (≥5 percentage points difference) in t he &lt;65 years category compared with 65 to 74, 75 to 84 and ≥85 years age categories.

For  the  65  to  74  years  age  category,  AEs  that  occurred  at  a  higher  incidence  (≥5  percentage  points difference) when compared with &lt;65 years age category was: oedema peripheral. AEs that occurred at a lower incidence (≥5% difference) when compared with &lt;65 years age category were: nausea and vomiting.

For  the  75  to  84  years  age  category,  AEs  that  occurred  at  a  higher  incidence  (≥5  percentage  points difference) when compared with &lt;65 years were: anaemia, decreased appetite, dyspnoea, hypotension, muscular weakness, oedema peripheral and pneumonia. AEs that occurred at a lower incidence (≥5% difference) when compared with &lt;65 years age category were: abdominal pain, abdominal pain upper, dysgeusia, headache, leukopenia, nasopharyngitis, nausea and vomiting.

An analysis of AEs by the SOCs/SMQs most relevant to elderly patients, and age did not reveal major differences.

## Effect of race

The majority of these patients 331 (85.8%) were of Asian origin, 19 (4.9%) patients were of Black or African-American origin, 9 (2.3%) were of American Indian or Alaska Native origin, 1 (0.3%) was of Native Hawaiian or Other Pacific Islander origin and 11 (2.8%) were of other racial origin. Numbers of Asian and other  non-White  patients  represent  20.9%  of  patients  and  2.5%  of  patients  (331/1585  and  40/1585 patients) in the 300 mg bd pool, respectively.

<div style=\"page-break-after: always\"></div>

Table 76: 300 mg bd pool: Number (%) of patients who had at least 1 AE in any category by race (White patients, Asian patients and other non -White patients)

<!-- image -->

|                                                    | Number (%)of patients   | Number (%)of patients   | Number (%)of patients   |
|----------------------------------------------------|-------------------------|-------------------------|-------------------------|
| AE categorya                                       |                         | Non-White patients      | Non-White patients      |
|                                                    | White patients (N=1199) | Asian patients (N=331)  | Other patientsb (N=40)  |
| Any AE                                             | 1172 (97.7)             | 317 (95.8)              | 38 (95.0)               |
| Any AE of CTCAE Grade 3 or higher                  | 477 (39.8)              | 156 (47.1)              | 17 (42.5)               |
| AnyAEwithoutcome=death                             | 15 (1.3)                | 4 (1.2)                 | 0                       |
| AnySAE(includingeventswith outcome = death)        | 274 (22.9)              | 79 (23.9)               | 7 (17.5)                |
| Any AE leading to dose reduction of studytreatment | 264 (22.0)              | 62 (18.7)               | 10 (25.0)               |
| Any AE leading to interruption of study treatment  | 468 (39.0)              | 138 (41.7)              | 16 (40.0)               |
| AnyAEleadingtodiscontinuationof studytreatment     | 115 (9.6)               | 26 (7.9)                | 3 (7.5)                 |

AEs that occurred at a higher incidence in Asian patients (≥5 percentage points difference) compared with White patients were: ALT increased, anaemia, AST increased, decreased appetite, malaise, muscle spasms, neutrophil  count  decreased,  platelet  count  decreased,  upper  respiratory  tract  infection  and  WBC  count decreased. AEs that occurred at a lower incidence in Asian patients (≥5 percentage points difference) compared with White patients were: abdominal pain, abdominal pain upper, arthralgia, asthenia, back pain, constipation,  diarrhoea,  dyspnoea,  fatigue,  headache,  nausea,  oedema  peripheral  and  urinary  tract infection.

AEs that occurred at a higher incidence in other non-W hite  patients  (≥5 percentage points difference) compared  with  White  patients  were:  anaemia,  decreased  appetite,  hyperglycaemia,  hypertension, hypokalaemia,  leukopenia,  neutropenia,  upper  respiratory  tract  infection,  vertigo  and  WBC  count decreased.  AEs  that  occurred  at  a  lower  incidence  in  other  nonWhite patients  (≥5  percentage  points difference) compared with White patients were: asthenia, dyspepsia, fatigue, nausea, pyrexia, rash and vomiting.

AEs with a CTCAE Grade ≥3 that occurred at a higher incidence in Asian patients (≥5 percentage points difference)  compared  with  White  patients  were:  anaemia,  neutrophil  count  decreased  and  WBC  count decreased.  The  only  CTCAE  Grade  ≥3  AE  that  occurred  at  a  higher  incidence  (≥5  percentage  points difference) in other non-White patients compared with White patients was anaemia.

Anaemia, neutrophil count decreased and WBC count decreased were the only AEs that resulted in a dose modification  that  occurred  at  a  higher  incidence  in  Asian  patients  (≥5  percentage  points  diffe rence) compared with White patients. Anaemia was the only AE that resulted in a dose modification that occurred at a higher incidence (≥5 percentage points difference) in other non -White patients compared with White patients.

There were no AEs leading to treatment discontinuation that occurred at a higher incidence in Asian patients (≥5 percentage points difference) compared with White patients. Anaemia was the only AE leading to treatment discontinuation that occurred at a higher incidence (≥5 percentage p oints difference) in other non-White patients compared with White patients.

## Safety related to drug-drug interactions and other interactions

No new data were submitted in the context of this procedure

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

## Adverse events leading to discontinuation

An assessment of the olaparib or placebo exposure over time (figure below) and the reasons for treatment discontinuation  by  time  to  treatment  discontinuation  (table  below)  showed  that  the  higher  rate  of discontinuation rate from olaparib versus placebo was driven by AEs in the olaparib/bevacizumab arm in the first 3 months of treatment. Between 3 and 9 months, the overall rate of discontinuation was similar between the olaparib/bevacizumab arm and placebo/bevacizumab arm. Following completion of bevacizumab treatment at approximately 10 months, the rate of discontinuation of olaparib was reduced, in contrast to discontinuations due to progression or death occurring in a higher proportion of patients in the placebo arm.

<!-- image -->

Data derived fromFigure14.3.1.1,PAOLA-1CSR,Module 5.3.5.1(DCO:22March 2019). CSRClinical studyreport;DCOData cut-off;SASSafety analysis set.

Figure 29 : PAOLA-1: Olaparib or placebo exposure over time (SAS)

<div style=\"page-break-after: always\"></div>

Table 77: PAOLA-1: Reason for discontinuation over time-period (FAS)

| Time period   | Olaparib 300 mg bd (N=537)   | Olaparib 300 mg bd (N=537)   | Olaparib 300 mg bd (N=537)   | Olaparib 300 mg bd (N=537)   | Placebo bd (N=269)      | Placebo bd (N=269)   | Placebo bd (N=269)   | Placebo bd (N=269)   |
|---------------|------------------------------|------------------------------|------------------------------|------------------------------|-------------------------|----------------------|----------------------|----------------------|
| Time period   | Progres sion or Death a      | AE b                         | Other                        | Total                        | Progressi on or Death a | AE b                 | Other                | Total                |
| <3 months     | 8 (1.5)                      | 51 (9.5)                     | 10 (1.9)                     | 69 (12.8)                    | 14 (5.2)                | 3 (1.1)              | 5 (1.9)              | 22 (8.2)             |
| 3-6 months    | 33 (6.1)                     | 17 (3.2)                     | 2 (0.4)                      | 52 (9.7)                     | 21 (7.8)                | 4 (1.5)              | 2 (0.7)              | 27 (10.0)            |
| 6-9 months    | 30 (5.6)                     | 18 (3.4)                     | 5 (0.9)                      | 53 (9.9)                     | 20 (7.4)                | 2 (0.7)              | 0                    | 22 (8.2)             |
| 9-12 months   | 20 (3.7)                     | 8 (1.5)                      | 3 (0.6)                      | 31 (5.8)                     | 28 (10.4)               | 1 (0.4)              | 3 (1.1)              | 32 (11.9)            |
| 12-15 months  | 18 (3.4)                     | 6 (1.1)                      | 4 (0.7)                      | 28 (5.2)                     | 24 (8.9)                | 2 (0.7)              | 1 (0.4)              | 27 (10.0)            |
| 15-18 months  | 37 (6.9)                     | 4 (0.7)                      | 1 (0.2)                      | 42 (7.8)                     | 24 (8.9)                | 0                    | 2 (0.7)              | 26 (9.7)             |
| ≥18 months    | 46 (8.6)                     | 5 (0.9)                      | 7 (1.3)                      | 58 (10.8)                    | 37 (13.8)               | 1 (0.4)              | 2 (0.7)              | 40 (14.9)            |

g Includes the terms 'disease progression as other reason as RECIST criteria', 'disease progression as per RECIST criteria', and 'death'

h Includes the terms 'toxicity of interest', 'Other unacceptable toxcity or AE'

AE Adverse event; FAS Full analysis set; RECIST Response evaluation criteria in solid tumors.

Data derived from Table 1409, Module 5.3.5.3 (DCO: 22 March 2019).

In PAOLA-1, a higher proportion of patients had DAEs (from olaparib or placebo) in the olaparib/bevacizumab arm (20.4%), compared with the placebo/bevacizumab arm (5.6%). The majority of DAEs were reported during the combination period.

In the olaparib/bevacizumab arm, 34 (6.4%) patients discontinued treatment within the first month on study. The most common DAE in the first month on study was nausea, which resulted in olaparib discontinuation in 11 (2.1%) patients; DAEs of blood creatinine increased, fatigue and vomiting each occurred in 3 (0.6%) patients in the olaparib/bevacizumab arm. The only AEs leading to discontinuation of olaparib that were reported in &gt;3 olaparib/bevacizumab-treated patients were: anaemia, fatigue, nausea and vomiting.

<div style=\"page-break-after: always\"></div>

Table 78: PAOLA1: AEs leading to olaparib or placebo discontinuation occurring in ≥ 2 patients in either treatment group (SAS).

<!-- image -->

|                                                                     | Number (%o) of patients\"    | Number (%o) of patients\"   | Number (%o) of patients\"         | Number (%o) of patients\"         |
|---------------------------------------------------------------------|-----------------------------|----------------------------|----------------------------------|----------------------------------|
| MIedDRA SOC                                                         | Orerall study duration      | Orerall study duration     | Combination treahnent phase only | Combination treahnent phase only |
| preferred term                                                      | Olaparih! bevacizumab N=535 | Placebo! bevacizumab N=267 | Olaparib. bevacizumab N=534      | Placebo! bevacizumab N=267       |
| Patients with any AE leading to discontinuation                     | 109 (20.4)                  | 15 (5.6)                   | 86 (16.1)                        | 10 (3.7)                         |
| Gastrointestinal disorders                                          | 33 (6.2)                    | 4 (1.5)                    | 30 (5.6)                         | 2 (0.7)                          |
| Nausea                                                              | 18 (3.4)                    | 1 (0.4)                    | 16 (3.0)                         | 1 (0.4)                          |
| Vomiting                                                            | 5 (0.9)                     | 0                          | 5 (0.9)                          | 0                                |
| Abdominal pain                                                      | 3 (0.6)                     | 0                          | 3 (0.6)                          | 0                                |
| Diamhoea                                                            | 3 (0.6)                     | 0                          | 3 (0.6)                          | 0                                |
| Blood and lymphatic system disorders                                | 23 (4.3)                    | 0                          | 17 (3.2)                         | 0                                |
| Anaemia                                                             | 19 (3.6)                    | 0                          | 15 (2.8)                         | 0                                |
| Neutropenia                                                         | 2 (0.4)                     | 0                          | 1 (0.2)                          | 0                                |
| General disorders and administration site conditions                | 13 (2.4)                    | 0                          | 9 (1.7)                          | 0                                |
| Fatigue                                                             | 8 (1.5)                     | 0                          | 6 (1.1)                          | 0                                |
| Mucosal inflammation                                                | 2 (0.4)                     | 0                          | 1 (0.2)                          | 0                                |
| Investigations                                                      | 8 (1.5)                     | 0                          | 8 (1.5)                          | 0                                |
| Blood creatinine increased                                          | 3 (0.6)                     | 0                          | 3 (0.6)                          | 0                                |
| Gamma-glutamylhransferase increased                                 | 2 (0.4)                     | 0                          | 2 (0.4)                          | 0                                |
| Infections and infestations                                         | 5 (0.9)                     | 2 (0.7)                    | 3 (0.6)                          | 1 (0.4)                          |
| Cytomegalovinus infection                                           | 2 (0.4)                     | 0                          | 1 (0.2)                          | 0                                |
| Neoplasms benign, maliguant and umspecified (incl cysts and polyps) | 5 (0.9)                     | 1 (0.4)                    | 0                                | 1 (0.4)                          |
| Myelodysplashic syndrome                                            | 2 (0.4)                     | 0                          | 0                                | 0                                |
| Mfusculoskeletal and connective tissue disorders                    | 4 (0.7)                     | 2 (0.7)                    | 4 (0.7)                          | 2 (0.7)                          |
| Arthualgia                                                          | 3 (0.6)                     | 1 (0.4)                    | 3 (0.6)                          | 1 (0.4)                          |
| Respiratory, thoracic and mediastinal disorders                     | 3 (0.6)                     | 2 (0.7)                    | 2 (0.4)                          | 2 (0.7)                          |
| Dyspnoea                                                            | 1 (0.2)                     | 2 (0.7)                    | 0                                | 2 (0.7)                          |
| Pneumonitis                                                         | 2 (0.4)                     | 0                          | 2 (0.4)                          | 0                                |
| Renal and urinary disorders                                         | 3 (0.6)                     | 0                          | 2 (0.4)                          | 0                                |
| Acute kidney injuy                                                  | 2 (0.4)                     | 0                          | 2 (0.4)                          | 0                                |
| Cardiac disorders                                                   | 2 (0.4)                     | 2 (0.7)                    | 2 (0.4)                          | 1 (0.4)                          |
| Myocardial infarction                                               | 0                           | 2 (0.7)                    | 0                                | 1 (0.4)                          |

Table 79: Most common AEs leading to discontinuation (reported by ≥1% patients in PAOLA -1 and/or reported by ≥2% patients in the 300 mg bd pool)

<!-- image -->

|                                                 | Number (%o) of patients             | Number (%o) of patients             | Number (%o) of patients          |
|-------------------------------------------------|-------------------------------------|-------------------------------------|----------------------------------|
| Preferred term                                  | PAOLA-l SAS, overall study duration | PAOLA-l SAS, overall study duration | Olaparib 300 mg bd pool (N=1585) |
|                                                 | Olaparib/ bevacizumab N=535         | Placebo/ bevacizumab N=267          |                                  |
| Patients with any AE leading to discontinuation | 109 (20.4)                          | 15 (5.6)                            | 148 (9.3)                        |
| Anaemia                                         | 19 (3.6)                            | 0                                   | 40 (2.5)                         |
| Nausea                                          | 18 (3.4)                            | 1 (0.4)                             | 12 (0.8)                         |
| Fatigue                                         | 8 (1.5)                             | 0                                   | 11 (0.7)                         |

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

<div style=\"page-break-after: always\"></div>

Table 80:Olaparib 300 mg bd pool: Non-progression reasons for discontinuation across the Phase III studies included in the pool

<!-- image -->

| Studynumber/name     | Tumourtype                    |   0ofpatients with DAEs |   0 of patients discontinuing due topatient decision/withdrawn consent |   0ofpatients discontinuing forother reasonsa |
|----------------------|-------------------------------|-------------------------|------------------------------------------------------------------------|-----------------------------------------------|
| D0817C00003/PAOLA-1  | Ovarian(newly diagnosed)      |                    20.4 |                                                                    0.7 |                                           3.6 |
| D0818C00001/SOLO1    | Ovarian (mewly diagnosed)     |                    11.5 |                                                                    8.5 |                                           4.2 |
| D0816C00002/SOLO2    | Ovarian (relapsed/refractory) |                    11.3 |                                                                    2.6 |                                           5.1 |
| D0816C00010/SOLO3    | Ovarian (relapsed/refractory) |                     7.3 |                                                                    2.8 |                                           2.2 |
| D0819C00003/OlympiAD | Breast (metastatic)           |                     4.9 |                                                                    3.4 |                                           2.4 |
| D081FC00001/P0LO     | Pancreatic                    |                     5.4 |                                                                    1.1 |                                           1.1 |
| D081DC00007/PROfouud | Prostate(hormone- resistant)  |                    11.7 |                                                                    6.8 |                                           8   |

Note,PAOLA-1andSOLO1bothhadapre-specifiedmaximumtreatmentperiodforolaparibof2years;patients whodiscontinuedtreatmentastheyhadreachedthismaximumperiodarenotincludedinthereasonsfor discontinuationshowninthistable.

Note; other reasons exclude diseaseprogression or symptomatic deterioration.

## AEs leading to treatment interruption

Table 81: PAOLA1: AEs leading to treatment interruption occurring in ≥2% patients in either treatment group (SAS)

| MfedDRAPreferredterm                              | Number (9o) of patientsa Overall study duration   | Number (9o) of patientsa Overall study duration   |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                   | Olaparib/ bevacizumab N=535                       | Placebo/ bevacizumab N=267                        |
| Patients with any AE leading to dose interruption | 291 (54.4)                                        | 65 (24.3)                                         |
| Anaemia                                           | 110 (20.6)                                        | 1 (0.4)                                           |
| Nausea                                            | 39 (7.3)                                          | 4 (1.5)                                           |
| Vomiting                                          | 18 (3.4)                                          | 3 (1.1)                                           |
| Fatigue                                           | 17 (3.2)                                          | 2 (0.7)                                           |
| Neuhropenia                                       | 14 (2.6)                                          | 2 (0.7)                                           |
| Dianhoea                                          | 12 (2.2)                                          | 4 (1.5)                                           |
| Thrombocytopenia                                  | 12 (2.2)                                          | 1 (0.4)                                           |
| Abdominal pain                                    | 11 (2.1)                                          | 2 (0.7)                                           |

Multiple occurences of a SOC /PT for a patient are coumted only once for the patient.

Sorted by decreasing order of frequency in the olapamib/bevacizummab aum and then by order of fiequency in theplacebo/bevacizumabarm.

<div style=\"page-break-after: always\"></div>

Table 82: PAOLA1: AEs leading to treatment interruption occurring in ≥2% patients in the olaparib/bevacizumab arm of PAOLA -1 (SAS) or the 300 mg bd pool.

| MfedDRA Preferred term                            | Number (%6) of patientsa    | Number (%6) of patientsa   | Number (%6) of patientsa   |
|---------------------------------------------------|-----------------------------|----------------------------|----------------------------|
|                                                   | Overall study duration      | Overall study duration     | Olaparib 300 mg bd pool    |
|                                                   | Olaparib/ bevacizumab N=535 | Placebo! bevacizumab N=267 | (N=1585)                   |
| Patients with any AE leading to dose interruption | 291 (54.4)                  | 65 (24.3)                  | 630 (39.7)                 |
| Anaemia                                           | 110 (20.6)                  | 1 (0.4)                    | 280 (17.7)                 |
| Nausea                                            | 39 (7.3)                    | 4 (1.5)                    | 74 (4.7)                   |
| Vomiting                                          | 18 (3.4)                    | 3 (1.1)                    | 86 (5.4)                   |
| Fatigue                                           | 17 (3.2)                    | 2 (0.7)                    | 36 (2.3)                   |
| Neuhropenia                                       | 14 (2.6)                    | 2 (0.7)                    | 82 (5.2)                   |
| Dianho ea                                         | 12 (2.2)                    | 4 (1.5)                    | 39 (2.5)                   |
| Thrombocytopenia                                  | 12 (2.2)                    | 1 (0.4)                    | 41 (2.6)                   |
| Abdominal pain                                    | 11 (2.1)                    | 2 (0.7)                    | 21 (1.3)                   |
| Neuhrophil coumt decreased                        | 5 (0.9)                     | 2 (0.7)                    | 36 (2.3)                   |

| MfedDRAPreferred term   | Number (9o) of patients     | Number (9o) of patients    | Number (9o) of patients        |
|-------------------------|-----------------------------|----------------------------|--------------------------------|
|                         | Overall study duration      | Overall study duration     | Olaparib 300 mgbdpool (N=1585) |
|                         | Olaparib/ beracizumab N=536 | Placebo/ beracizumab N=267 |                                |
| Leukopenia              | 1 (0.2)                     | 1 (0.4)                    | 39 (2.5)                       |

Sorted by decreasing order of frequency in the olapanb/bevacizummab aim and then by order of frequency in the placebo/bevacizumab arm.

Mfultiple occuumences of a SOC/PT for a patient are coumted only once for the patient.

## AEs leading to dose reduction

In PAOLA-1, a higher proportion of patients had AE leading to dose reduction (from olaparib or placebo) in the olaparib/bevacizumab arm (41.1%), compared with the placebo/bevacizumab arm (7.5%). The most common (≥5% patients) AEs leading to dose reduction of olaparib or placebo were: anaemia and nausea. The majority of AEs leading to dose reduction occurred during the combination phase. About one third of dose reductions occurred in the initial treatment period of up to 3 months.

Table 83: PAOLA-1: Dose reductions of olaparib by time period (safety analysis set) (DCO 22 March 2019)

|                                | Number (%) of patients by time period   | Number (%) of patients by time period   | Number (%) of patients by time period   | Number (%) of patients by time period   | Number (%) of patients by time period   |
|--------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| Olaparib total daily dose (mg) | Up to 3 months                          | >3 to ≤6 months                         | >6 to ≤9 months                         | >9 to ≤12 months                        | >12 months                              |
|                                | (N=535)                                 | (N=460)                                 | (N=402)                                 | (N=356)                                 | (N=324)                                 |
| First dose reduction           | 183 (34.2)                              | 40 (8.7)                                | 4 (1.0)                                 | 2 (0.6)                                 | 1 (0.3)                                 |
| Second dose reduction          | 72 (13.5)                               | 56 (12.2)                               | 11 (2.7)                                | 10 (2.8)                                | 11 (3.4)                                |

Patients can be included more than once in each relevant time period.

<div style=\"page-break-after: always\"></div>

Table 84: PAOLA1: AEs leading to dose reduction occurring in ≥2 patients in either treatment group (SAS)

| MfedDRAPreferred term                          | Number (96) of patientsa Orerall studyduration   | Number (96) of patientsa Orerall studyduration   |
|------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                                                | Olaparib/ bevacizumab N=535                      | Placebo! bevacizumab N=267                       |
| Patients with any AE leading to dose reduction | 220 (41.1)                                       | 20 (7.5)                                         |
| Anaemia                                        | 99 (18.5)                                        | 0                                                |
| Nausea                                         | 40 (7.5)                                         | 2 (0.7)                                          |
| Fatigue                                        | 21 (3.9)                                         | 2 (0.7)                                          |
| Dianhoea                                       | 8 (1.5)                                          | 4 (1.5)                                          |
| Thrombocytopenia                               | 8 (1.5)                                          | 0                                                |
| Neuhrophil coumt decreased                     | 4 (0.7)                                          | 0                                                |
| Platelet coumt decreased                       | 4 (0.7)                                          | 0                                                |
| Stomatitis                                     | 4 (0.7)                                          | 0                                                |
| Vomiting                                       | 4 (0.7)                                          | 0                                                |
| Abdominal pain                                 | 3 (0.6)                                          | 1 (0.4)                                          |
| Headache                                       | 3 (0.6)                                          | 1 (0.4)                                          |
| Myalgia                                        | 3 (0.6)                                          | 1 (0.4)                                          |
| Neutropenia                                    | 3 (0.6)                                          | 1 (0.4)                                          |
| Arthralgia                                     | 2 (0.4)                                          | 1 (0.4)                                          |
| Aphthous ulcer                                 | 2 (0.4)                                          | 0                                                |
| Dyspnoea                                       | 2 (0.4)                                          | 0                                                |
| Oedema peripheral                              | 2 (0.4)                                          | 0                                                |

## Post marketing experience

The safety signal detection activities include review of reported AEs from post-marketed sources, and a review of the published literature relevant to Olaparib. The reports received do not change the benefit-risk profile of Olaparib (PBRER DCO 15 June 2019).

## 2.5.1. Discussion on clinical safety

## Patient exposure

The clinical safety analysis is mainly based on data from the Phase III PAOLA-1 study in 806 randomised patients with newly-diagnosed advanced (FIGO Stage IIIB-IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in response following first line treatment, with platinumtaxane chemotherapy and bevacizumab. Combination therapy of olaparib and bevacizumab was compared to bevacizumab and placebo, followed by monotherapy of olaparib or placebo (535 patients versus 267 patients respectively) (DCO: 22 March 2019). Supportive data with a large pool of 1585 patients which received the same dose of olaparib as monotherapy in other indications were also provided and allow to better characterize the safety profile of the combination therapy.

The methodology used is acceptable and available data are considered sufficient to ensure an effective analysis of the safety profile of olaparib in association with bevacizumab in the scope of the requested indication.

Median duration of treatment was slightly higher in olaparib/bevacizumab arm compared to placebo/bevacizumab group (17.3 months vs 15.6 months) with similar duration of the combination period (10.6 months) which means that combination with olaparib does not impact bevacizumab

<div style=\"page-break-after: always\"></div>

treatment duration as maintenance therapy. Most patients randomized in olaparib/bevacizumab arm received olaparib for a period of &gt;12 months.

The percentage of patients remaining on treatment at 1 year was similar in the olaparib/bevacizumab and placebo/bevacizumab arms (61.9% and 61.8%, respectively); the percentage of patients remaining on treatment at 2 years was greater in the olaparib/bevacizumab arm (20.4%) than in the placebo/bevacizumab arm (13.9%). Note that in PAOLA-1 patients could continue treatment for 2 years or until disease progression. Patients who in the opinion of the treating physician could derive further benefit from continuous treatment, could be treated beyond 2 years.

However, long-term data of the combination therapy are limited since median duration of treatment was 10.6 months with range from 0.3 to 20.2 months and the MAH is recommended to submit the long-term safety data analysis of the clinical study PAOLA-1 at the time of the final OS analysis (REC).

Disease progression was the main reason for study discontinuation with a lower rate in the combination treatment group compared bevacizumab alone (34.0% vs 58.1%).

In PAOLA-1 study, patient's demographics were consistent across treatment groups and reflect the population of the proposed indication. All patients were women with mean age of 60 years old and primary tumour location was mostly ovary.

## Safety monitoring and protocol amendment

No dose-finding study has been conducted for the combination of olaparib with bevacizumab to determine an optimal combination dose in maintenance setting. An interim safety analysis have been conducted on 26 April 2016 to evaluate the tolerability profile in the 42 first randomised and followed for two 3-week cycles patients that received continuous twice daily oral olaparib (300 mg twice) or placebo in patient treated in maintenance with intravenous bevacizumab at a fixed dose (15 mg/kg) administered every 21 days. The data of the interim analysis has been reviewed by the IDMC which has recommended to continue the enrolment as planned to the sponsor ARCAGY Research. IDMC was reviewing the emerging safety data during the whole duration of the trial.

To ensure robust safety monitoring, additional safety measures have been incorporated into this phase III protocol. Patients with history of MDS/AML and having experienced prolonged haematotoxicity (&gt; 2 weeks) to first-line chemotherapy were excluded. While on treatment, regular blood tests were required to detect early haematological abnormality and the frequency of tests was increased under the protocol version 5 between 6 and 12 months of treatment to every 3 weeks instead of every 6 weeks. In case of prolonged cytopenia, patients were to be referred to an haematologist and bone marrow analysis was to be considered, with discontinuation of treatment in case of confirmed MDS or AML.

Moreover, in the protocol version 4.0 (06 January 2017), the following exploratory objective was added: 'Explore the time to next severe toxicity (grade 4 neutropenia lasting &gt; 7 days, grade ≥ 3 febrile neutropenia, grade 4 thrombocytopenia with bleeding or platelet transfusion, grade ≥ 3 non -haematological toxicity) in both arms'. The objective was to explore the ability of olaparib, compared to placebo, to postpone the occurrence of a severe toxicity during the whole course of the study including study treatment and next subsequent treatments. The analysis of this exploratory endpoint has not been performed to date. This exploratory objective was planned not earlier than when final PFS2 results would be available (in order to have as much information as possible available on subsequent treatments) and will be reported separately in the CSR (REC).

Safety analyses were performed on the overall study duration (SAS) and on the population of patients in the two study arms from initiation of olaparib or placebo until the last dose of olaparib or placebo and bevacizumab given concurrently plus 21 day (Combination Phase only). Four patients were excluded from the SAS (2 patients each arm) as they did not start olaparib or placebo. One patient

<div style=\"page-break-after: always\"></div>

olaparib/bevacizumab was excluded from the combination phase because patient discontinued bevacizumab prior to the first dose of olaparib.

## Adverse events (AE)

Overall, the safety profile of olaparib in combination with bevacizumab is considered to be consistent with the known safety profiles of the combined olaparib and bevacizumab monotherapies.

The incidence and severity of the ADR identified with olaparib monotherapy treatment (300 mg bd pool data) and identified with olaparib/bevacizumab in PAOLA-1 were compared. Several ADRs had similar incidences with monotherapy and combination treatment. However, some ADRs had different incidences with monotherapy or combination treatment. The frequency was lower with combination treatment (common) than observed with monotherapy (very common) for the following ADR: thrombocytopenia, decreased appetite, dizziness, dysgeusia, cough, and dyspnoea (all grade). The frequency was higher with combination treatment (very common) than observed with monotherapy (common) for lymphopenia (all grade).

Although some differences of incidence have been noted the larger patient exposure (n=2351) from the olaparib therapeutic dose pool provides the most robust estimates of the ADR frequencies for olaparib, a separated ADR table for the combination is not warranted. The statement in section 4.8 of the SmPC 'When Lynparza is used in combination with bevacizumab the safety profile is generally consistent with that of the individual therapies' is considered sufficient. For overlapping toxicities, no notable increase in severity of events has been observed.

The majority of AEs were reported during the combination treatment phase and mostly within the first 3 months of treatment.

Most commonly AEs reported were consistent with the safety of olaparib with AEs pertaining to the SOC Hematologic disorders (anaemia, 40.9%; neutropenia, 18.1%; lymphopenia, 23.6%; leukopenia, 17.8%), SOC Gastro-intestinal disorders (nausea, 53.3%; vomiting, 21.9%) and SOC General disorders (fatigue, 52.9%) as well as known AEs of bevacizumab with hypertension (45.8%) and proteinuria (5.8%). Other known AE of olaparib were reported with a lower frequency such as cough (4.7%), dyspnoea (7.9%), dizziness (2.6%) and headache (13.6%) as well as known AE of bevacizumab such as haemorrhagic events (9.7%) and thromboembolic events (1.7%).

AE were mainly manageable by treatment interruption or dose reduction and supportive treatment. There was no evidence of overlapping toxicities, although such effects are not excluded as the mechanism of action of PARP inhibitors, including olaparib, is not fully elucidated.

Most deaths reported in PAOLA-1 study were related to the disease under investigation. Four fatal cases might be related to the combination treatment including one case of aplastic anaemia and pneumonia. Appropriate warnings are mentioned in the SmPC to closely monitor haematotoxicity during olaparib treatment.

Five deaths associated with treatment emergent AEs were also reported &gt;30 days after last treatment dose: 3 olaparib/bevacizumab-treated patients (2 from acute myeloid leukaemia - AML and 1 from acute lymphoblastic leukaemia type B - ALL, all events possibly related to olaparib) and 2 placebo/bevacizumabtreated  patient.  The  number  of  patients  who  died  post  follow-up  was  numerically  higher  with  the combination:  7  olaparib/bevacizumab-treated  patients  (various  causes)  and  2  placebo/bevacizumabtreated patients.

Compared to placebo/bevacizumab group, the proportion of AEs reported was slightly higher in olaparib/bevacizumab group (99.3% vs 95.9%) with similar proportion of SAEs (31.2% vs 31.1%) and slightly higher proportion of AEs of CTCAE Grade≥3 (57.6% vs 50.9%). The rate of treatment discontinuation of olaparib/placebo was higher in olaparib/bevacizumab group compared to

<div style=\"page-break-after: always\"></div>

placebo/bevacizumab group (20.4% vs 5.6%) as well as treatment interruption (54.4% vs 24.3%) and dose reduction of olaparib (41.1% vs 7.5%). Adverse events led to dose interruption and/or reduction of olaparib in 57.4% of patients when used in combination with bevacizumab. The adverse reactions that most commonly led to dose interruption and/or reduction were anaemia (20.6%) and nausea (7.5%). The adverse reactions that most commonly led to permanent discontinuation were anaemia (3.6%), nausea (3.4%) and fatigue/asthenia (1.5%). Data on bevacizumab dose interruption and discontinuation due to AE were not collected in PAOLA-1. Dose reductions of bevacizumab were not permitted.

Discontinuations due to AE were mainly reported during the first 3 months of treatment in the olaparib/bevacizumab combination arm.

Frequencies of AEs leading to dose interruption were similar between SOLO1 (maintenance treatment of newly diagnosed advanced BRCA-mutated high-grade ovarian cancer after first line chemotherapy with olaparib monotherapy) and PAOLA-1. However, the incidence of any AE leading to dose reduction was higher in PAOLA-1 compared to SOLO-1 (41.1% vs. 28.5%, respectively). Likewise, the incidence of any AE leading to discontinuation was higher in PAOLA-1 compared to SOLO-1 (20.4% vs. 11.5%, respectively).

The differences between the two arms in PAOLA-1 were mainly driven by hematologic and gastrointestinal disorders, known ADRs of olaparib, with higher rate of anaemia (40.9% vs 10.1%) nausea (53.3% vs 21.7%) and fatigue (52.9% vs 32.2%) in olaparib/bevacizumab arm.

For non-tBRCAm/unknown patients (approximatively 70% of the patients) and tBRCAm (approximatively 30% of the patients), common adverse events, incidence of AE Grade ≥ 3, discontinuation of olaparib or placebo due to AE and AE with an outcome of death were consistent with the SAS (data not shown).

Compared to olaparib pool, the proportion of AEs reported was slightly higher in olaparib/bevacizumab group (99.3% vs 97.3%) despite shorter median treatment duration in the pool. Higher rates of SAEs and AEs of CTCAE Grade≥3 were also reported (31.2% vs 23% and 57.6% vs 41.6%) which were driven by hypertension, a known AE of bevacizumab. However, rates of discontinuation due to AEs, dose interruption and reduction of olaparib were more reported in olaparib/bevacizumab group than in the olaparib pool (20.4% vs 9.3%; 54.4% vs 39.7%; 41.1% vs 21.4%), mainly due to nausea, anaemia and fatigue. The rate of discontinuation due to AEs was higher than observed in the SOLO1 study (maintenance treatment of newly diagnosed advanced BRCA-mutated high-grade ovarian cancer after first line chemotherapy with olaparib monotherapy), in which it was 11.5% with olaparib monotherapy (and 2.3% in placebo arm). These differences could be explained by the combination therapy rather than a lower median treatment duration in olaparib pool. Hematologic toxicity which is known for both substances, does not appear to increase in terms of incidence and severity with the combination therapy such as anaemia and neutropenia, except for lymphopenia and leukopenia which were more reported in olaparib/bevacizumab arm compared to olaparib pool (23.6% vs 5.2%; 16.3% vs 13.9%).

Incidence of some AE was lower with the combination therapy such as thrombocytopenia, decreased appetite, dizziness, dysgeusia, cough, and dyspnoea (all grade).

Analysis of bevacizumab-related ADRs, including hypertension, proteinuria, haemorrhagic and thromboembolic events, has been provided. Known AEs of bevacizumab were reported with similar rates between olaparib/bevacizumab and placebo/bevacizumab arms, except for hypertension and proteinuria for which lower rates were reported in olaparib/bevacizumab group compared to placebo/bevacizumab group.

The two arms of the PAOLA-1 study were homogeneous in terms of risk factors of hypertension and baseline characteristics  (age,  weight/body  and  mass  index)  except  for  tobacco  use  which  was  not  presented. Relevant medical history reported as current at baseline were well balanced between the two arms as well.

<div style=\"page-break-after: always\"></div>

Hence, the lower proportion of hypertension in the olaparib/bevacizumab arm compared to placebo/bevacizumab arm cannot be explained on the basis of baseline characteristics or medical history. Overall, these findings are quite similar to incidences reported for bevacizumab monotherapy in clinical studies. The incidence of hypertension in PAOLA-1 was 45% for all grades and 18.7% for grade ≥3 on and it was up to 42% for all grades and 17,9% for grade ≥3 in clinical studies for bevacizumab according to its SmPC.

Relevant  medical  history  reported  as  current  at  baseline  associated  with  AEs  proteinuria  and  baseline characteristics were well balanced between both groups in PAOLA-1 study and thus cannot explain the reported incidence differences in proteinuria. However, the incidence of proteinuria in olaparib/bevacizumab arm were in the range of incidence reported in clinical studies of bevacizumab according to its SmPC (0.7 to 38 %).

Regarding potential important risks, 4 cases of MDS/AML (0.7%) were reported in olaparib/bevacizumab group including two fatal events. All patients had risk factors such as several previous cycles of platinum agents or BRCA mutation and similar rates were reported in SOLO studies (between 1.2% and 2.1%) which involved similar patient population. In addition, 6 cases of new primary malignancies were reported (1.1%) including 4 in patients with documented mutations in BRCA1/2 genes. However, despite similar and consistent rates reported for both safety concerns compared to olaparib entire program (0.6% and 0.8% respectively), low rates reported make the interpretation of differences observed difficult between groups. Due to mechanism of action of PARP inhibitors which lead to genome instability, causal role of olaparib cannot be excluded for these two risks and a close monitoring will be maintained in postmarketing setting.

MDS/AML remain as important potential risks in the RMP. Appropriate warnings are mentioned in the product information to monitor blood count and to discontinue treatment in case of MDS/AML occurrence. In addition, a targeted questionnaire has been implemented to better document cases reported.

Six cases of pneumonitis (1.1%) were reported in olaparib/bevacizumab group. Despite similar and consistent rates observed compared to olaparib 300mg bd pool (0.9%), interpretation of differences is challenging. A close monitoring will be maintained in post-marketing setting. All 6 patients who reported pneumonitis received previously platinum chemotherapy treatment which is a risk factor. Moreover, the mechanisms of drug-induced interstitial lung disease/pneumonitis is still not well understood. All AEs of pneumonitis were mild or moderate in severity, two cases were non-serious and all of them had a favourable outcome. The management of pneumonitis required dose modifications and corrective treatment and two patients had permanent treatment discontinuation. Overall, the causality of olaparib for pneumonitis remains uncertain. Pneumonitis is an important potential risks (RMP) and adequate information is included in the SmPC in this regard. The MAH will continue to closely monitor pneumonitis cases in post-marketing setting.

In PAOLA1, a higher proportion of patients in the olaparib/bevacizumab arm had ≥2 grade changes in haematological laboratory parameters, compared with patients in the placebo/bevacizumab arm. Anaemia was the most frequently reported CTCAE Grade ≥3 AE. The only significant changes in clinical chemistry parameters occurred for blood creatinine and proteinuria. Creatinine increases are a recognised ADR for olaparib. Proteinuria is a recognised ADR for bevacizumab.

Assessment of potential for hepatic and renal impairment was consistent with data reported from olaparib monotherapy clinical studies.

Overall, the laboratory findings were consistent with available data from the olaparib pool.

Safety data in special populations did not identify any differential effects by gender despite low number of men included and slight differences observed, which might rather be related to underlying diseases. In

<div style=\"page-break-after: always\"></div>

addition, similar proportion of AE was reported among the different age population with an increase of seriousness and discontinuation of treatment from younger to older groups.

Consistent data were reported by race but these data should be interpreted with caution due to over representation of white patients compared to non-white patients. With regards to safety in Japanese participants, although the proportions of patients with any treatment emergent adverse events were similar between the Japan cohort and the overall safety analysis set, the incidence of treatment-emergent grade 3 and above adverse was higher in the Japan cohort than in the Safety Analysis in the olaparib/bevacizumab arm 73% and 58%, respectively. There is a higher incidence of haematologyrelated adverse events in Japanese cohort compared with the overall safety analysis set. The higher haematology toxicity in Asian population compared with White populations was also observed in previous studies (SOLO1). It is unknown why Japanese participants have an increased haematological toxicity. The MAH provided one exposure-safety analysis in Asian/Japanese population based on pooled data from capsule and tablet monotherapy studies (Olaparib-MS-07) and another based on pooled data from tablet monotherapy studies (Olaparib-MS-08) (data not shown). The population pooled in these data set includes patients with various cancers (ovarian, breast, prostate or other advanced malignancies) possibly in different line of therapy. However, it remains unknown whether the differences in AEs between Japanese patients and the overall population in PAOLA-1 study were due to bevacizumab potentiation, disease setting or other factors.

## 2.5.2. Conclusions on clinical safety

Overall  the  safety  profile  of  olaparib  in  combination  with  bevacizumab  as  maintenance  treatment  is considered acceptable for the intended population and is generally consistent with the safety profile of the individual therapies.

The results from study PAOLA-1 showed that there were no high differences in risk of the combination therapy compared to placebo/bevacizumab group and compared to olaparib pooled safety data, except for lymphopenia and leukopenia. However, slightly more AE ≥ Grade 3 and more AE leading to dose adjustment of olaparib were reported with the combination compared to monotherapy.

Nevertheless, patients experiencing ADRs need to be carefully followed by physicians as indicated in the SmPC. Furthermore, more information is needed to assess the causal relationship between olaparib and the potential risks as identified in the RMP.

Overall, no new safety signals were identified from the analyses of safety data from both treatment arms of  PAOLA-1.  AEs  that  occurred  more  frequently  on  the  olaparib/bevacizumab  arm  than  in  the placebo/bevacizumab arm were consistent with the known safety profile of olaparib.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 20.3 is acceptable.

<div style=\"page-break-after: always\"></div>

The CHMP endorsed the Risk Management Plan version 20.3 with the following content:

## Safety concerns

The PRAC agrees that the safety concerns listed by the MAH are appropriate.

Table 85: Safety concerns

| Important identified risks   | None                                                                                                                                                                                                                        |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Myelodysplastic syndrome/acute myeloid leukaemia New primary malignancies Pneumonitis Medication errors associated with dual availability of capsules and tablets Effects on embryofoetal survival and abnormal development |
| Missing information          | Long term exposure to/potential toxicity to olaparib                                                                                                                                                                        |

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance activities for olaparib.

The PRAC, having considered the data submitted, is of the opinion that routine pharmacovigilance is sufficient to identify and characterise the risks of the product.

## Risk minimisation measures

The PRAC having considered the data submitted, is of the opinion that the proposed risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication.

Table 86: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern   | Risk minimisation measures                                                                                                                                                                                      | Pharmacovigilance activities                                                                                                                                                                         |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MDS/AML          | Routine risk communication in: SmPC Section 4.4 PL Section 2 and 4 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.4 PL Section 2 PL Section 4 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Follow-up targeted safety questionnaire Cumulative review (provided concurrent with each annual PBRER) |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                              | Risk minimisation measures                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance activities                                                                                                          |
|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| New primary malignancy                                                      | None                                                                                                                                                                                                                                                                                                                                          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Follow-up targeted safety questionnaire |
| Pneumonitis                                                                 | Routine risk communication in: SmPC Section 4.4 PL Section 2 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.4: PL Section 2                                                                                                                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Follow-up targeted safety questionnaire |
| Medication errors associated with dual availability of capsules and tablets | Routine risk communication in: SmPC Section 4.2 PL Section 3 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.2: PL Section 3 Additional risk minimisation measures: Distribution of a DHPC to prescribers and pharmacists providing clear information on the 2 formulations. | Routine                                                                                                                               |
| Effects on embryofoetal survival and abnormal development                   | Routine risk communication in: SmPC Sections 4.4, 4.6 PL Section 2 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.4, 4.6 PL Section 2:                                                                                                                                      | Routine                                                                                                                               |
| Long term exposure to/potential toxicity to olaparib                        | None                                                                                                                                                                                                                                                                                                                                          | Routine                                                                                                                               |

## Overall conclusion on the RMP

The changes to the RMP and the changes to the conditions and obligations of the MA are acceptable.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, and 5.1of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other relevant guideline(s) which were reviewed by QRD and accepted by the CHMP.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

<div style=\"page-break-after: always\"></div>

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons: Overall, the wording in the PL is similar to that already tested previously during the MA applications. Therefore, it is justified to consider the Package Leaflet User Testing report provided during review of the MA application procedure as relevant for this application, and that no updated document is needed for this submission.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The proposed indication is for Lynparza (tablet) in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of firstline platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

## 3.1.2. Available therapies and unmet medical need

Cytoreductive surgery and platinum-based chemotherapy are considered treatments of choice for patients with newly diagnosed advanced ovarian cancer (NCCN Ovarian 2020, Karam et al 2017, Ledermann et al 2013). For patients for whom upfront surgery is unlikely to achieve a complete resection, treatment consists of neoadjuvant chemotherapy followed by interval debulking surgery and adjuvant chemotherapy (NCCN Ovarian 2020). Even though most newly diagnosed advanced ovarian cancer patients achieve complete response at the end of first line  treatment,  approximately  70% relapse within the first  three  years  of diagnosis (Ledermann et al 2013). Once ovarian cancer relapses, the disease becomes largely incurable. There is a need for treatments that can delay relapse, offering the possibility to improve the long-term outcome for these patients.

Targeted treatments approved in the first line maintenance setting include olaparib for BRCAm patients (SOLO-1 study) and bevacizumab for frontline and maintenance therapy which can be given regardless of BRCAm status (study GOG-218).

## 3.1.3. Main clinical studies

PAOLA-1 was a phase III, randomised, double-blind, placebo-controlled trial of olaparib vs placebo added to bevacizumab for the maintenance treatment of newly diagnosed advanced ovarian cancer patients who were  in  response  following  first  line  platinum-based  chemotherapy  and  bevacizumab.  Patients  were randomised in a 2:1 ratio to receive either olaparib 300 mg bd plus bevacizumab 15 mg/kg Q3W (N=537) or matching placebo bd plus bevacizumab 15 mg/kg Q3W (N=269). Patients were enrolled regardless of the BRCAm status, but were stratified by tBRCAm status, based on the prospectively conducted tumour tissue  testing.  The  primary  analysis  was  based  on  investigator  assessment  of  disease  progression  by RECIST; a sensitivity analysis was also performed using the BICR assessment. Key secondary objectives

<div style=\"page-break-after: always\"></div>

included PFS2, OS (adjusted for multiplicity) TFST, TSST, time to earliest progression by RECIST or CA-125 or death, TDT and HRQoL.

## 3.2. Favourable effects

At DCO (22 March 2019), the main analysis of investigator-assessed PFS showed a statistically significant improvement in PFS in the ITT population. Median PFS was 22.1 months in the olaparib/bevacizumab arm vs 16.6 months in the placebo/bevacizumab arm, with HR=0.59 (95%CI 0.49, 0.72), p&lt;0.0001.

Analysis of PFS by BICR and all other sensitivity analyses were consistent with the investigator assessment of PFS. Consistent results were also shown in the subgroup analyses by stratification factors (first line treatment outcome and local tBRCAm status) and clinical characteristics.

The interim PFS 2 data with 36.5% and 44.2% of events in olaparib/bevacizumab and placebo/bevacizumab arms respectively, showed a HR of 0.86 [0.69, 1.09], p=0.2097.

The interim OS data were 25.9% mature and showed a HR of 1.01 [0.76 to 1.36] with a similar proportion of deaths occurring in each arm. At the DCO of 30 September 2019, the updated OS analysis showed a HR of 0.94; (95% CI 0.73 to 1.21) in the ITT population.

In the subgroup of patients with deleterious tBRCA1/2m (based on local test results at randomisation), the PFS HR was 0.34 (0.23, 0.51). The median PFS was 37.2 months in olaparib/bevacizumab arm versus 22 months in placebo/bevacizumab arms. The OS HR point estimate was reported as 0.66 (95% CI 0.37 to 1.21) at DCO 30 September 2019. The subgroup analysis by tBRCA status by Myriad based on retrospective analysis of tumour sample was consistent with this analysis, with the OS HR point estimate of 0.61 (95% CI 0.34 to 1.09) at the same DCO.

In the subgroup of patients whose tumours were classified as Myriad HRD positive based on combined measurement of HR deficiency-associated biomarkers (either tBRCAm or HR deficiency-associated genomic instability) in retrospectively analysed tumour samples, the PFS HR was 0.33 (95% CI 0.25, 0.45). The median PFS was 37.2 months in olaparib/bevacizumab arm versus 17.7 months in placebo/bevacizumab arms. The OS HR point estimate was reported as 0.71 (95% CI 0.47 to 1.10) at DCO 30 September 2019.

Additional analyses in subgroups of patients identified by genomic instability biomarker were consistent with results of combined biomarker measurements.

## 3.3. Uncertainties and limitations about favourable effects

Due to the absence of olaparib monotherapy arm, it remains currently unknown what is the contribution of components  of  such  VEGFi-PARPi  combination  therapy  in  maintenance  phase  and  whether  they  have additive, synergistic or potentially a detrimental effect in different biomarker-defined subpopulations of patients, according to known mechanisms of action. Bevacizumab is indicated in the first-line maintenance setting only  after  prior  concomitant  treatment  with  platinum-based  chemotherapy,  whereas  olaparib is indicated  in  first-line  maintenance  after  platinum-based  chemotherapy  in  the  subgroup  of  BRCA1/2mutated (germline and/or somatic) patients. The contribution of olaparib could only be assessed as add-on therapy to bevacizumab used in both arms concurrently with chemotherapy and in maintenance setting for the total duration of treatment up to 15 months.

In the subgroup of patients without prospectively detected tBRCAm by local test (non-tBRCAm subgroup), PFS HR estimate was of 0.7 (95% CI 0.57, 0.86) while OS HR estimate was 1.02 (95% CI 0.77, 1.36). Consistently, in the Myriad non-tBRCAm subgroup HR was 1.04 (95% CI 0.77 to 1.4) at DCO 30 September 2019.

<div style=\"page-break-after: always\"></div>

As observed in the subgroup analyses by tBRCA mutation status, an inconsistency in treatment effect was also  observed  in  pre-specified  subgroup  analyses  by  Myriad  HRD  status  combining  measurements  of tBRCAm and HRD score (GIS, genomic instability score), as well as in subgroups defined using GIS only. Notably, in subgroups defined as negative for biomarkers of HR deficiency, OS HR estimates at relatively low maturity were exceeding 1, although with large 95% CI.

PFS 2 and OS data are still immature and are confounded by exposure to PARP inhibitors outside of the study.  The  MAH  is  recommended to provide updated PFS 2 and OS data including additional analyses adjusting for impact of subsequent PARP inhibitor treatment.

## 3.4. Unfavourable effects

Overall, the safety profile of the combination therapy appears to be the juxtaposition of both safety profiles of  olaparib  and  bevacizumab  with  slight  differences  in  terms  of  frequency  and  severity  compared  to individual treatments and no emergence of new AE.

The majority of AEs were reported during the first 3 months of treatment and included among the most reported  events  known  AE  of  olaparib  (anaemia,  lymphopenia,  leukopenia,  neutropenia,  nausea  and vomiting) as well as known AE of bevacizumab (hypertension, proteinuria and hemorrhagic events).

AE related to olaparib were mainly manageable by treatment interruption (54.4%) or dose modification (41.1%) and supportive treatment. These proportions  were  higher  in  combination  than  for olaparib  in monotherapy (39.7% and 21.4% respectively).

Discontinuation  of  treatment  due  to  AEs  was  reported  in  20.4%  and  5.6%  of  patients  treated  with olaparib/bevacizumab and placebo/bevacizumab, respectively.

Compared  to  olaparib  monotherapy,  two  AE,  lymphopenia  and  leukopenia,  were  more  reported  in combination with bevacizumab.

## 3.5. Uncertainties and limitations about unfavourable effects

Long-term  safety  data  of  the  combination  therapy  are  limited  with  only  10-months  data.  Long-term exposure to/potential toxicity to olaparib is included in the list of safety concerns under missing information in the risk management plan.

Uncertainties  remain  for  olaparib  on  potential  risks  of  AML/MDS,  new  primary  malignancies  and pneumonitis. The causality of olaparib in occurrence of rare cases of AML/MDS, new primary malignancies and pneumonitis could not be firmly established in the context of previous courses of chemotherapy. These safety issues will continue to be closely monitored in the post-marketing setting.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table  39.  Effects  Table  for  olaparib  in combination  with  bevacizumab  for  the  maintenance treatment  of  adult  patients  with  advanced  high-grade  epithelial  ovarian  cancer  who  are  in response  following  completion  of  first-line  platinumbased  chemotherapy  with  bevacizumab (data cut-off: 22 March 2019)

| Effect                                                           | Short description                                                                      | Unit                                                             | Treatment (olaparib/ bevacizu mab)                               | Control (placebo/ bevacizu mab)                                  | Uncertainties / Strength of evidence                                                                                                                                 | References                                                       |
|------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| Favourable Effects- DCO 22 March 2019 unless otherwise indicated | Favourable Effects- DCO 22 March 2019 unless otherwise indicated                       | Favourable Effects- DCO 22 March 2019 unless otherwise indicated | Favourable Effects- DCO 22 March 2019 unless otherwise indicated | Favourable Effects- DCO 22 March 2019 unless otherwise indicated | Favourable Effects- DCO 22 March 2019 unless otherwise indicated                                                                                                     | Favourable Effects- DCO 22 March 2019 unless otherwise indicated |
| tBRCAm at randomisation                                          | tBRCAm at randomisation                                                                | tBRCAm at randomisation                                          | tBRCAm at randomisation                                          | tBRCAm at randomisation                                          | tBRCAm at randomisation                                                                                                                                              | tBRCAm at randomisation                                          |
| Number of patients                                               | Number of patients                                                                     | Number of patients                                               | N=161                                                            | N=80                                                             |                                                                                                                                                                      |                                                                  |
| PFS by investigator in tBRCAm at randomisation                   | Time from randomisation to progression or death                                        | months                                                           | 37.2                                                             | 22.0                                                             | Subgroup analysis HR 0.34 (0.23, 0.51) Consistent results in Myriad tBRCAm subgroup                                                                                  | PAOLA-1 study                                                    |
| Interim OS in tBRCAm at randomisation                            | Time from randomisation until death                                                    | months                                                           | NR                                                               | NR                                                               | Subgroup analysis HR 0.66 (95% CI 0.37 to 1.21) at DCO 30 sept 2019, updated interim analysis                                                                        | PAOLA-1 study                                                    |
| HRD positive*                                                    | HRD positive*                                                                          | HRD positive*                                                    | HRD positive*                                                    | HRD positive*                                                    | HRD positive*                                                                                                                                                        | HRD positive*                                                    |
| Number of patients                                               | Number of patients                                                                     | Number of patients                                               | N=255                                                            | N=132                                                            |                                                                                                                                                                      |                                                                  |
| PFS by investigator in HRD positive*                             | Time from randomisation to progression or death                                        | months                                                           | 37.2                                                             | 17.7                                                             | Subgroup analysis HR 0.33 (0.25, 0.45) Consistent results in subgroup identified by genomic instability only                                                         | PAOLA-1 study                                                    |
| Interim OS in HRD positive*                                      | Time from randomisation until death                                                    | months                                                           | NR                                                               | NR                                                               | Subgroup analysis HR 0.71 (95% CI 0.47 to 1.10) at DCO 30 sept 2019, updated interim analysis, consistent results in subgroup identified by genomic instability only | PAOLA-1 study                                                    |
| Interim PFS2, by investigator in HRD positive*                   | Time from randomisation to the earliest of the progression subsequent to PFS or death. | months                                                           | NR                                                               | 34.6                                                             | Subgroup analysis HR 0.60 (95%CI 0.41, 0.88)                                                                                                                         | PAOLA-1 study                                                    |
| Unfavourable Effects                                             | Unfavourable Effects                                                                   | Unfavourable Effects                                             | Unfavourable Effects                                             | Unfavourable Effects                                             | Unfavourable Effects                                                                                                                                                 | Unfavourable Effects                                             |
| CTCAE Grade ≥3 AEs                                               |                                                                                        | %                                                                | 57.6                                                             | 50.9                                                             | 41.6% in olaparib 300mg bd pool 1.2% in olaparib 300mg bd pool 23.0% in olaparib 300mg bd pool                                                                       | PAOLA-1 study (overall study duration)                           |
| AE with death outcome                                            |                                                                                        | %                                                                | 0.2                                                              | 1.5                                                              |                                                                                                                                                                      | PAOLA-1 study (overall study duration)                           |
| Serious AEs                                                      |                                                                                        | %                                                                | 31.2                                                             | 31.1                                                             |                                                                                                                                                                      | PAOLA-1 study (overall study duration)                           |
| AEs leading to discontinuation of study treatment                |                                                                                        | %                                                                | 20.4                                                             | 5.6                                                              | 9.3% in olaparib 300mg bd pool                                                                                                                                       | PAOLA-1 study (overall study duration)                           |

Abbreviations: NR: Not reached

<div style=\"page-break-after: always\"></div>

*HRD positive  status  was  defined  in  this  study  by  using  a  combined  measurement  of  two  biomarkers associated with HR deficiency: tBRCAm and HR deficiency-associated genomic instability.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

An improvement of 5.5 months in median PFS, with a HR of 0.59 in the ITT population is considered clinically relevant, keeping however in mind that only patients responding to initial chemotherapy in combination with bevacizumab have been randomised to receive maintenance treatment.

Differential  effects  in  the  subgroups  defined  by  biomarkers  of  HR  deficiency  (tBRCAm,  HR  deficiencyassociated  genomic  instability  or  combination  thereof)  and  insufficient  follow-up  for  key  secondary endpoints (PFS2 and OS) do not allow to exclude for the time being potential detrimental effects in smaller or larger subgroups defined as biomarker-negative.

Absence of effect on PFS is reported in patients whose tumours are not associated with HR deficiency by either biomarker (defined as HRD negative by combining results for both biomarkers used) while a large magnitude of effect is observed in the subgroups defined as biomarker-positive (tBRCAm and/or genomic instability).  Furthermore,  with  the  updated  OS  data,  it  cannot  be  excluded  that  treatment  with  the combination may be associated with poorer OS in patients whose tumours are not associated with HR deficiency. These findings are considered plausible and of relevance based on strong biological plausibility for differential outcomes in the context of newly diagnosed ovarian cancer with subpopulations of patients with  potentially  differential  degree  of  HR  deficiency  and  consequently  different  magnitude  of  benefit following  treatment  with  PARPi.  Besides  biological  rationale,  previously  reported  data  with  olaparib  in relapsed setting support this trend of lower magnitude of benefit or absence of such depending on the definition of subgroups by biomarkers of HRD.

It is noted that an HRD test is not available to date in Europe and different cut-offs are used across different PARPi studies to determine positivity for a genomic instability score. However, a greater treatment effect was consistently observed across several trials using Myriad HRD test at predefined cut-off (42). Post-hoc analyses using only the genomic instability score (GIS) at this cut-off showed comparable results to the one in the HRD subgroups. There is also a biological rational supporting genomic instability as a biomarker predicting magnitude of PARPi activity.

In conclusion, the therapeutic efficacy of combining olaparib and bevacizumab in the first line maintenance setting in patients with ovarian cancer without defined positivity for biomarkers associated with homologous recombination deficiency is not considered demonstrated.

Overall, combination therapy of olaparib and bevacizumab was well-tolerated with a manageable safety profile which is sufficiently characterised. While hematologic, digestive and vascular ADRs occurred at a high  frequency,  they  are  generally  of  low  grade  and  easily  manageable.  More  dose  adjustments (discontinuation, interruption or dose reductions) were reported which is not unexpected for a combination of  2  active  therapies  with  known  safety  profiles  (e.g.  haematological  and  GI  toxicity  for  olaparib  and hypertension  for  bevacizumab).  These  higher  rates  should  be  viewed  in  the  context  of  maintenance treatment which might need for dose optimisation. Discontinuation of treatment due to AEs was reported in  higher  proportion  of  patients  treated  with  olaparib/bevacizumab  than  with  placebo/bevacizumab.  In addition,  data  for  long-term  safety  remain  limited.  Long  term  safety  will  continue  to  be  monitored  as reflected in the RMP.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

The magnitude of the observed effect in the ITT population should be considered in the context of the maintenance setting treatment, current uncertainties on the long-term outcomes and in regard to contribution of components in different subpopulations defined by biomarkers of HR deficiency.

Benefit-risk is considered favourable in the subgroup of patients identified as harbouring tumour BRCA1/2m. In patients without defined positivity for this biomarker (BRCAwt and/or unknown), but with higher degree HR deficiency-associated genomic instability identified based on a validated test, the overall efficacy and safety data support that benefits outweigh risks in line with biological plausibility and results of subgroup analyses. In HRD-negative subgroup of patients, defined as biomarker-negative for both biomarkers used, an additional PFS benefit with olaparib beyond that seen with bevacizumab has not been established. Therefore, the indication is restricted to exclude patients that would not benefit from treatment or with magnitude of benefit that would not outweigh risks.

Safety results of PAOLA-1 study seem to be in line with both safety profile of olaparib and bevacizumab with slight differences in terms of frequency and severity. Measures to minimize the risk are well addressed in the RMP submitted by the MAH.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall B/R of Lynparza in combination with bevacizumab is considered positive for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include the use of Lynparza tablets in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC are updated. The PL is updated accordingly. In addition, sections 4.4 and 4.8 of the SmPC for Lynparza hard capsules are revised based on updated safety data analysis. Furthermore, the PI is brought in line with the latest QRD template version 10.1. The RMP version 20.3 is approved.

The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, II and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Lynparza is not similar to Zejula within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1.